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ABSTRACT 
The development and validation of a respiratory guideline for nurses in 
primary care in South Africa (Dr Rene English; August 2006) 
The Practical A~proach to Lung Health in South Africa (P ALSA) initiative aims to 
improve the diagnosis and management of patients with respiratory diseases in primary 
care. An algorithm-based syndromic guideline integrating common respiratory diseases 
for nurses was developed after review of a generic respiratory guideline, medical 
literature, local policies, and qualitative research. 
The diagnostic performance of the guideline was tested prospectively by comparing 
assessments made by a nurse using the guideline with those of physicians with access to 
special investigations in 1392 consecutive patients attending a primary care clinic in Cape 
Town. Patients ~ 15 years with cough and/or difficult breathing were independently 
assessed (blinded) by (1) a nurse using the guideline (2) a primary care physician with 
access to detailed clinical information, spirometric data and chest radiographs, and (3) a 
respiratory physician who reviewed the data collected by the primary care physician. 
Only patients viewed by the latter who required screening for tuberculosis, underwent 
sputum examination. The subjects, 63% of whom were females, had a mean age of 48 
years; 38% had asthma, 29% chronic obstructive lung disease, 26% acute exacerbation of 
obstructive lung disease, and 37% suspected tuberculosis. The performance of the nurse 
using the guideline was judged as good with sensitivities ranging from 33-90% and 
specificities from 65%-94%. Potential for resulting in harmful incorrect diagnoses was 
limited and outweighed by potential benefits of earlier diagnosis and institution of 
appropriate treatment, and/or appropriate referral to a higher level of care. 
It is concluded that P ALSA, a simplified guideline adapted for local conditions in 
primary care in South Africa, has satisfactory diagnostic accuracy for use by a nurse and 
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Chapter 1 : INTRODUCTION 
1.1 Introduction 
The aims of this thesis are two-fold. The first aim is to present the development methods 
and the final draft of the P ALSA (Practical Approach to Lung Health in South Africa) 
guideline. This guideline is an algorithmic, symptom and sign based document that 
integrates respiratory diseases commonly encountered in primary care. The second aim of 
the thesis is to present the methodology and results of a validation study in which the 
accuracy of the P ALSA guideline in diagnosing these respiratory conditions is assessed. 
To provide a background to the work presented in this thesis, this chapter will briefly 
overview the burden of respiratory diseases both worldwide and locally, as well as the 
role of multipurpose health care workers in providing primary care. Thereafter, the World 
Health Organisation's (WHO) Practical Approach to Lung Health (PAL) strategy will be 
introduced. This will be followed by a description of the South African adaptation of this 
strategy, the P ALSA initiative. Three literature reviews have been undertaken. These will 
provide an overview of primary health care in South Africa and the role of the nurse; the 
origins and evolution of guideline development; and finally; a review of the symptoms 
and signs that best predict obstructive airways disease in patients with respiratory 
symptoms. 
1.2 The global burden of respiratory diseases 
Respiratory diseases constitute about one-fifth of the global burden of disease as 
measured in disability-adjusted life years (DAL Ys), 1 and are among the leading causes 
of deaths. 2 In 2001, the largest contributors in this category in developed countries were 
chronic obstructive pulmonary disease (COPD), respiratory cancers (trachea, bronchial, 
and lung cancers), and asthma3; the first two contributing 7.1 % to the total burden. In 
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contrast, in developing countries, tuberculous and non-tuberculous lower respiratory tract 
infections (LRTIs) are the leading causes of death and disability in both young and old, 
contributing 6% and 2.6%, respectively.3 However, urbanisation and economic transition 
are resulting in a steady rise in non-communicable diseases such as asthma and COPD.4 
By 2020, tuberculosis will account for 31 % of DALY s worldwide, followed by LR TIs 
(28%), and COPD (25%). In that year, LRTIs, COPD, tuberculosis, and respiratory 
cancers will rank among the top ten causes of death worldwide. 5 
1.2.1 Asthma 
Over the last four decades the prevalence of asthma has increased by 50% every ten 
years.6 These increases have been highest (> 10%) in western countries. Although data for 
developing countries are limited, marked increases in Africa, Central and South America, 
Asia and the Pacific regions have been reported. This rise is partly attributable to 
increased exposure to indoor and outdoor pollutants, allergens, and tobacco smoke. 7 
Globally, about 300 million people have asthma, of which 50 million are in Africa In 
parallel to the rise in prevalence is an increase in hospitalisation due to asthma, which 
may reflect an increase in disease severity.8 9 Despite improvements in overall asthma 
mortality rates over the past two decades, asthma still accounts for an estimated 180 000 
deaths each year. Most of these deaths are thought to be preventable and represent 
inadequate or inappropriate care. For the year 1994, the direct global costs of asthma 
surpassed those for tuberculosis and HIV/AIDS combined,10 and most of the economic 
burden of asthma is incurred by the relatively smaller number of severe cases.9 11 12 
1.2.2 Chronic obstructive airways disease 
The prevalence of COPD is estimated to be between 4% and 9% globally, and has been 
rising worldwide.13 14 In men, the prevalence rate is estimated to be 9.33 per 1000 and for 
women, 7.33. 15 It is projected that COPD will rank fifth as a cause of death and disability 
by 2020.5 In the United States, the prevalence of chronic bronchitis rose from 3% to 5% 
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between 1970 and 1993,16 whereas estimates for developing countries suggest much 
higher prevalences (13-27%):7 This rise is partly related to the increase in COPD risk 
factors (such as indoor and outdoor pollution and smoking), and the effects of ageing 
populations. It is greatest in developing countries where women and young people are 
starting to smoke at a younger age and more heavily. IS Estimations suggest that between 
15% and 50% of smokers develop COPD. 19 20 21 Worldwide, the number of deaths 
including COPD attributable to tobacco is expected to increase from 3.0 million in 1990 
to 8.4 million in 2020, and it is predicted to be the leading cause of mortality compared to 
any other single disease.5 
1.2.3 Tuberculosis 
Tuberculosis is the leading potentially curable infectious cause of death worldwide.22 The 
WHO reports that in 2004,9 million (140 per 100000) new cases, 4 million (62 per 100 
000) smear-positive cases, and approximately 2 million deaths were reported.23 More 
than 80% of new cases were from South-East Asia (35%), Africa (24%), and the Western 
pacific (24%). Although the global treatment success rate was excellent (82%; with a 
target of 85%), the case-detection rate was only 53%, falling far short of the 70% target. 
Despite these statistics, global trends indicate that overall the tuberculosis prevalence rate 
has decreased from 297 per 100 000 to 229 per 100 000 between 1990 and 2004. 
Incidence rates have also stabilised or fallen in 6 of the 9 epidemiologically different 
WHO regions (1.2% per year in 1997 to 0.6% per year in 2004). However, this has not 
been the case in sub-Saharan regions, where the HIV epidemic has fuelled a dramatic 
rise, both in tuberculosis and other respiratory diseases.242526 By 2020, HIV and AIDS, 
will be the 9th leading cause of deaths worldwide and will contribute 39.7% to the overall 
global burden of disease. 5 
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1.2.4 Acute respiratory infections 
In total respiratory tract infections account for large numbers of deaths, 27 but the 
contribution made by upper respiratory tract infections (URTIs) to these deaths are much 
smaller owing to their short duration, self-limiting nature and milder morbidity. LRTls 
accounted for 7% of the total deaths in low-and-middle-income countries in 2001, and 
4.4% in high-income countries.3 It ranked third in the former and fourth in the latter. By 
the year 2020, LRTI will contribute 28% to the total burden of disease and will be the 
fourth leading cause of death worldwide.5 
1.3 The burden of respiratory disease in South Africa 
Data on the burden of respiratory diseases in South Africa is limited. But a recent 
comprehensive study reported that the pattern of respiratory diseases in South Africa is 
mixed, comprising poverty-related conditions such as lower respiratory tract infections, 
the effects of HIV I AIDS, and emerging chronic diseases.28 Respiratory diseases rank 
eighth and respiratory tract infections ninth as causes of death, and are exceeded only by 
HIV and AIDS, other infectious conditions, cardiovascular diseases, malignancies, 
injuries, and perinatal conditions. They are also major causes of premature mortality 
(years of life lost). The HIV/AIDS epidemic is expected to more than double the burden 
of premature mortality by 201 0, and is predicted to add to the existing burden of disease 
in all 9 provinces of South Africa (see Appendix 1 for a map of South Africa)?9 In all but 
one province (Kwa-Zulu Natal), COPD is among the top 20 causes. The incidence of 
tuberculosis is amongst the highest in the world (718 per 100 000 population per year) 
with 135 deaths per 100000 population per year,23 and with a tuberculosis and HIV co-
infection rate exceeding 60%.25 
In the National Demographic Household Survey conducted in 1998, it was established 
that approximately 7 million South Africans smoked.3o The prevalence of self-reported 
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asthma for males and females were 3.7% and 3.8%, respectively; for emphysema, they 
were 4.2% and 4.8%, respectively. Asthma symptoms were reported in 6.7% of males 
and in 8.6% of females, and chronic bronchitis symptoms ranged from 2.3% to 2.8% for 
the two sexes. Low socio-economic communities comprising most of the countries' 
population are most affected by respiratory disease. These communities also traditionally 
have less access to health care and other necessary resources. Asthma symptoms, lower 
peak expiratory flow rates, chronic bronchitic symptoms, tobacco smoking, and domestic 
use of biomass fuels were strongly correlated with levels of education and illiteracy. 
Another study of adult medical admissions to a rural South African hospital (1991-2002) 
reported that respiratory diseases are the most common reasons for presentation. 31 
Tuberculosis (37%) and LRTIs (15%) are the most common indications for admissions, 
and the most frequent causes of death. These results reflect the increased burden of 
communicable and non-communicable respiratory diseases encountered in a country 
undergoing epidemiological transition. 
1.4 Respiratory diseases in primary care in developing countries 
Cough, dyspnoea, and sputum production are common symptoms in primary care and are 
often acute.32 33 It is estimated that up to 30% of patients presenting to primary care in 
developing countries have respiratory conditions.34 3S There is however a paucity of data 
on the prevalence of respiratory conditions in primary care in developing countries.34 
Thus, to address this deficiency, a multi-country evaluation of respiratory conditions 
among 29 000 patients age 15 years and older presenting to 76 primary care facilities was 
undertaken by the World Health Organization.34 Respiratory tract infections were shown 
to account for 90% of all presentations, with upper respiratory tract infections being 
much more common than lower respiratory tract infections. Pneumonia accounted for 
only a small percentage. In this survey, the proportion with chronic respiratory diseases 
ranged from 2-25%. Tuberculosis was a consideration in 40%, and sputum examination 
was indicated. However, of these suspects, less than 5% were actually proven to have 
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tuberculosis. Respiratory drug prescription was high (95%) with between 50-75% 
receiving antibiotics, most of which on review were thought to not be indicated. 
1.S The role of multipurpose health care workers 
In most primary health care settings throughout the world, first-level facilities are staffed 
by multipurpose healthcare workers. 36 These deliver a wide range of promotive, 
preventive and curative services, and are also faced with administrative duties like 
completing patient records, overseeing the running of the health facility, and ordering 
supplies. Protocols or standardised treatment policies are often not applicable to the local 
setting or are not integrated, leading to increased variation in care, and unnecessary 
expenditure of available resources due to inappropriate use.37 38 In many countries, like 
South Africa, these facilities are staffed by nurses rather than doctors and the fonner 
often feel ill-equipped to fulfill all the responsibilities required of them.39 Their task is 
made more difficult by limited access to diagnostic tests, financial constraints, and 
inadequate training and support from physicians, mentors and managers. Owing to a 
combination of the increasing burden of respiratory diseases worldwide, the consequent 
increase in the numbers of patients to be seen in primary care, as well as health sector 
reform, interventions aimed at integrating and improving the detection and management 
of respiratory diseases should be targeted at first-level facilities. Multipurpose primary 
health care workers are therefore well positioned to be the recipients of these 
interventions. Despite the obstacles faced by these health care workers, research shows 
that they are able to provide improved health care if trained to do So.4O 41 
1.6 The role of simplified interventions 
Interventions for primary care should be simplified and tailored according to the level of 
training of the healthcare worker. 'Simplified' implies that the intervention promotes 
productivity through ensuring increased consistency of tasks and efficiency, often by 
lower cadres of health workers.36 They should provide comprehensive care through 
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integrating the approach to patients with respiratory complaints, rather than focusing on a 
single disease. Interventions, such as primary care guidelines, should preferably be 
symptom and sign-based (syndromic) given the limited available diagnostic resources 
and capabilities, and should be implemented in as simple a manner as possible without 
interruptions of the daily workload. And finally, they should build on existing 
knowledge, complement existing local policies and guidelines, and should provide 
standardised recommendations based on evidence. 
1.7 Initiatives to provide standardised interventions for respiratory diseases 
In many developing countries the problem of managing respiratory diseases is aggravated 
by reduced quality and delivery of medical care,42 inappropriate antibiotic and inhaled 
corticosteroid prescriptions,43 underdetection of asthma, COPD and tuberculosis, 44 45 and 
non-adherence to guideline recommendations.46 47 48 49 Other aggravating factors are the 
unavailability, or high costs of respiratory medications,50 and the decreased status of 
respiratory diseases as a public health priority.51 Over the past decade there has been a 
growing international interest in global initiatives aimed at standardising the management 
of respiratory conditions. Some like the Global Initiative for Asthma (GINA)52 and the 
Global Initiative for Chronic Obstructive Disease (GOLD)53 have focused on one disease, 
whereas others like the IUATLD54 on several. These international agencies are actively 
engaged in addressing many of the above-mentioned problems, chiefly through technical 
advice and assistance in developing local responses to these needs. Other organisations 
like the World Health Organization (WHO) have emphasised the importance of 
improving and standardising the management of tuberculosis and other respiratory 
conditions worldwide. 55 One of the main identified barriers in achieving these aims 
however is the failure of many countries to adapt their guidelines to suit local health 
systems, practices, and resource availability. 56 57 Other challenges are finding effective 
ways of changing the behaviours of health care professionals. 58 
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1.8 The Practical Approach to Lung Health (PAL) strategy 
The PAL strategy 59 was developed by the WHOs Stop-TB Department to provide a 
comprehensive syndromic approach to adult patients presenting to first-level facilities in 
developing countries with respiratory conditions. A generic guideline that integrated the 
case management of asthma, COPD, tuberculosis, lower respiratory tract infections, and 
accompanying training materials for multipurpose health care workers, usually nurses, 
was developed. The guidelines also contained approaches to the management of malaria 
and HIV/AIDS. It is fully consistent with GINA, GOLD, the WHO Tuberculosis 
guidelines and the WHO Essential Drug List. Special emphasis was placed on including 
the most cost-effective interventions, and on including recommendations based on 
evidence.60 61 62 
PAL was developed to be a component of the Global DOTS Expansion plan63 64 and also 
of the new Stop TB strategy65 in that it was developed to contribute to strengthening 
health systems, and to promote the participation and expansion of tuberculosis care to 
respiratory care. More focused aims are to increase the case detection of tuberculosis, and 
to provide diagnostic and treatment support for further investigation of patients who 
remain symptomatic despite having been shown to not have tuberculosis through 
bacteriological testing of their sputa. The initiative is based on the successes of other 
guideline development and implementation approaches, such as the Directly-Observed 
Therapy Short Course (DOTS) 66 67 programme and the Integrated Management of 
Childhood Illnesses (IMCI)68 initiative. IMCI, a precursor to PAL, will be discussed in 
more detail in Chapter 3. 
Requirements for optimal uptake of PAL are a well-functioning primary healthcare 
sector, a fully implemented national tuberculosis control programme, and governmental 
commitment to adapt, develop and implement the guideline and strategy. PAL has been 
implemented in a number of countries around the world, including South Africa, 
Morocco, Nepal and Chile69 and has now been implemented to varying degrees in more 
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than 14 countries. The South African adaptation of PAL is known as the Practical 
Approach to Lung Health in South Africa (P ALSA). 
1.8.1 The PAL Guideline 
Syndromic diagnoses are offered for patients presenting with cough and/or difficult 
breathing, and/or fever. Diagnostic and treatment algorithms are presented in 7 main 
sections: acute care of the sick adolescent or adult; follow-up care for acute illness; 
chronic care for all ages; laboratory tests; treatments; palliative care, and finally, advice 
and counselling. Guidelines for implementation at a national level were also designed. 
These guidelines were intended to be adapted to match individual countries' 
epidemiological and socio-economic conditions. 
Through the use of the Ask, Look, Listen management plan (Appendix 2), the PAL 
guideline asks questions relating to the assessment of the duration, severity, and 
associated presenting features of the presenting illness. Through the Classify and Identify 
Treatment management plan, disease syndromes are grouped according to (1) the 
presence of wheezing (2) a previous diagnosis of COPD (3) no known history of COPD. 
The Ask section includes questions that cover the following history items: previous 
diagnosis of asthma, COPD, heart failure TB; age; smoking status with or without 
associated loss of weight; and use of medications; duration of the presenting respiratory 
symptoms; severity and frequency of those symptoms; and symptoms that predict asthma 
and COPD. The Look, Listen section includes assessment of the following examination 
variables: mental state of the patient; breath rate; degree of breathlessness; use of 
accessory muscles; inability to speak; ability to walk unaided. Other indicators are: 
wheezing; temperature and the presence of oedema. Many of the questions in the Classify 
section relate to the assessment of the severity of disease. Clinical indicators defining 
very severe, severe, moderate or mild disease are repeated in every section regardless of 
the final disease syndrome. 
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1.9 Development of the Practical Approach to Lung Health in South Africa 
(pALSA) 
In 1999, the Department of Health of the Free State (FS) province of South Africa, 
approached the Medical Research Council's Health Systems Research Unit to request 
assistance with planning for improving services for patients with respiratory diseases in 
their province. PAL was suggested as a potential strategy for this purpose. Upon review, 
the FS province was considered ready for implementation of PAL as it had a functional 
tuberculosis control programme and a well-developed network of primary care clinics as 
well as provincial commitment to strengthen healthcare systems. However, it was evident 
that PAL would require considerable adaptation to make it suitable for local conditions 
and practices, including its use by nurse practitioners rather than by doctors. The fIrst 
phase of implementation was therefore to adapt PAL to a local primary care respiratory 
guideline to be known as P ALSA. 
1.9.1 Objectives of the P ALSA guideline development initiative. 
The P ALSA project team identifIed the following objectives: 
1. To develop the guideline to address priority respiratory diseases in primary care clinics 
where nurse practitioners provide the 'frontline' care for patients with these conditions. 
2. To identify and address perceived and actual barriers to the quality of respiratory 
disease care through brainstorming, focus group discussions, and consultation with 
frontline clinicians, key role-players and stakeholders. 
3. To evaluate in a validation study, the perfonnance of the PALSA guideline as a tool 
for diagnosing respiratory diseases and grading of disease severity; and for directing 
treatment of respiratory diseases. 
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4. To develop interventions aimed at improving the implementation of the P ALSA 
approach, including a programme of in-service training. 
5. To evaluate the effect of implementing the P ALSA guideline and training approach in 
the field setting, by means of a pragmatic randomised controlled trial.70 
1.10 The work reported in this thesis 
This thesis therefore fonus part of the larger P ALSA intervention strategy aimed at 
evaluating the impact of the development and implementation of the guideline and other 
support materials through an in-service training programme (educational outreach) in a 
predominantly rural province, the Free State province, in South Africa. Other components 
of the larger project that are described briefly in the sections that follows are: (1) An 
evaluation of the effectiveness of the P ALSA guideline in improving the way nurses 
identify and manage respiratory conditions in primary care assessed in a pragmatic 
clustered randomised controlled trial. This work fonued part of the doctoral thesis of Dr 
Bosielo Majara (Free State University). (2) A study of the economic, cost-effectiveness, 
and quality of life outcomes of the P ALSA intervention evaluated alongside the Free 
State randomised controlled trial. This fonus the topic of the doctoral thesis of Dr Lara 
Fairall (University of Cape Town) submitted in August 2006. Finally, Mrs Pat Mayers 
(University of Stellenbosch) conducted qualitative research and evaluated the 
acceptability of the intervention to nurses. This work will be presented as part of her 
doctoral thesis. 
Chapter 2 provides an overview of the origins and evolution of primary health care in 
South Africa, and a brief description of the role of the nurse in primary care. Barriers to 
comprehensive primary health care in South Africa will also be explored. 
Chapter 3 of this thesis describes two emerging models of guideline development. The 
evolution of rigorous evidence-based guideline development methods, and then that of 
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more pragmatic syndromic, integrated guidelines, developed specifically for 
implementation in resource-poor settings will be discussed. An aim of this chapter is to 
provide background to the origins and development of the PAL strategy, the forerunner 
of the P ALSA initiative 
Chapter 4 presents a review of studies reporting the accuracy of clinical features 
(history-related infonnation, symptoms and signs) in diagnosing obstructive airways 
disease. 
Chapter 5 details the methods employed in developing the P ALSA guideline, and 
Chapter 6 presents the results of this process 
Chapter 7 details the methods and materials for the validation study, in which the 
accuracy of the P ALSA guideline in a primary care clinic was tested. Chapter 8 presents 
the results of this study. 
In Chapter 9 the above results are discussed, together with the strengths and limitations 
of the study, and implication for primary care policies and future research. 
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Chapter 2 : LITERATURE REVIEW: Primary Health Care in 
South Africa and the role of the nurse. 
2.1 The concept of primary health care 
The concept of primary health care arose as a result of a number of medical and 
political events in the 1960s and 1970s.1 Criticism of vertic ali sed programmes such as 
the malaria eradication programme run jointly by some North American agencies and 
the World Health Organisation (WHO) gave rise to a series of publications 
challenging the model of primarily hospital-based curative health care which excluded 
preventive care, particularly for developing countries. 2 In addition, the success of 
rural medical models which promoted community involvement in the provision of 
health care further served to provide support for a new model of care. 3 4 5 The 
International Conference on Primary Health Care at Alma-Ata in 1978 formalised the 
concept of primary health care and led to its adoption as a global strategy. 6 
2.1.1 The global introduction of the concept of comprehensive primary health: 
The Alma-Ata Declaration 
The primary health care conference held in Alma-Ata, was attended by delegates from 
134 countries and 67 international agencies. I It resulted in the approval of a document 
known as the Declaration of Alma-Ata which detailed the fundamentals of primary 
health care.6 'Health for all by the year 2000' was identified as a primary global target 
and primary health care was considered to be the means to achieving this goal. 
In the Declaration document, primary health care was defined as6: 
essential health care based on practical, scientifically sound and socially 
acceptable methods and technology made universally accessible to individuals 
and families in the community through their full participation and at a cost that 
the community and country can afford to maintain at every stage of their 
development in the spirit of self-reliance and self-determination. It forms an 
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integral part both of the country's health system, of which it is the central 
function and main focus, and of the overall social and economic development 
of the community. It is the first level of contact of individuals, the family and 
community with the national health system bringing health care as close as 
possible to where people live and work, and constitutes the first element of a 
continuing health care process. 
Eight of the ten statements of the Declaration can be summarised as follows: 
• Health inequalities between developed and developing countries and within 
countries were considered to be unacceptable. 
• Socioeconomic development was considered to be vital to the attainment of health 
with health promotion and protection being integral to socioeconomic 
development and improved quality oflife. 
• Community participation in the planning and implementation of their health care 
was considered to be the right and duty of each person. 
• Governments have a responsibility to ensure achievement of the social target of 
health for all by the year 2000, and for ensuring socioeconomic productivity. 
• Governments were to develop policies, and strategies to introduce and implement 
primary health care as part of a comprehensive national health system. This was to 
be done through intersectoral collaboration and mobilisation of internal and 
external resources. 
• Countries should partner to ensure that each country benefits from the 
advancements of the other. 
• World resources should be redirected from the support of wars to initiatives that 
promote peaceful aims, with it rightful share going to primary health care, and to 
the advancement of socioeconomic development. 
2.1.2 Components of a functional primary health care programme 
According to the Alma-Ata declaration, fundamental to the establishment of a 
functional primary health system is the successful integration of the above-mentioned 
factors and active collaboration between the various roleplayers with the formation of 
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a multidisciplinary health team. Health ("a state of complete physical, mental and 
social well-being"), is considered to be a basic human right. Re-organisation of health 
services with a focus on community-based, as opposed to hospital-based care and a 
shift from central to more peripheral services, in particular to the district level is 
fundamental to its success. The components of a successful primary health care 
programme are defined as equity, accessibility, affordability, availability, 
effectiveness, and efficiency. 7 
2.2 The history of primary health care in South Africa 
The political history of South Africa has shaped the health care system, and 
understanding its evolution is integral to understanding why primary health care is 
structured and functions in the way that it does today. The fragmentation and 
inequality so evident during the apartheid years have, and continue to this day, to 
mark health care. In the early 20th century, health care provision in South Africa was 
haphazard and fragmented. The formation of the Union of South Africa in 1910 
further fragmented the health system by creating independently functioning health 
systems in the various provinces. 8 Curative services provided by general hospitals 
dominated. 9 The passing of the Health Act No. 36 of 1919, which led to the 
establishment of the Department of Public Health, were in response to the devastating 
effects of the influenza epidemic in 1918. 10 The main thrusts of this Act were to 
improve health care in general by promulgating hospital-based health care and 
promotive and preventive medicine. But contrary to the intentions of the Union 
government to unite the health authorities through this Act, it merely led to further 
fragmentation of the health system. 
The medical and social problems affecting the poor of all races in South Africa during 
the 1930s and 1940s, and the pro-World War 2 political strategies of the British 
colonists which promised health "benefits for all", II prompted the establishment of 
the National Health Services Commission, under the direction of Dr. Henry 
Gluckman. The commission reviewed international research on preventive medicine, 
and local health units and programmes, and produced the Gluckman Report, 12 13 
which proposed the introduction of health promotion, prevention, curative care and 
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rehabilitative strategies in primary care. Significantly, it also proposed a national 
health system under the control of a minister of health, free health care for all, 
restraints on private practice, a well-functioning referral system, an increase in 
training of health professionals and the need for more governmental concern and 
responsiveness to the needs of the whole population. However with the election of the 
National Party Government in 1952, the South African Health Centre Programme 
came to an end, and so did the promise of health for all. By the mid-1960s all the 
health centres had been closed.14 
The second wave of health care reform with suggestions to adopt a comprehensive 
primary health care approach occurred in the late 1970s in South Africa, mainly in 
response to economic recession.8 The Health Act No. 63 of 1977 IS served to 
emphasise preventive health care and to promote health care. Local authority clinics 
(community-based) were given the task of providing preventive, promotive and 
rehabilitative health care, and provincial administrations were tasked with the 
provision of curative care. Unfortunately the broader aims of this Act were never 
achieved. 16 17 18 More health care plans, 19 20 21 22 intended to reinforce the 
implementation of primary health care were passed in the years that followed. The 
core elements of primary health care were included in these plans with 
decentralization and community-focused training of health professionals. However, 
lack of cooperation and uncertainty about financial resources for both provincial and 
local authority clinics prevented its implementation.16 The Health Act of 1990 also 
proposed that users pay for services and that private health care continue to playa role 
in health service provision in South Africa. 
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2.3 The adoption and implementation of comprehensive health care in South 
Africa: post-1994 
The democratisation of South Africa in 1994 provided scope for the introduction of 
primary health care and active promotion of the formation of the district health 
system. 
2.3.1 Reconstruction and development programme: 1994 
The Reconstruction and Development Programme (RDP) 23 of the new ruling party 
served as a framework for implementing equitable policies to improve socioeconomic 
conditions. The RDP document described how the health system in South Africa was 
to be transformed and contained all the elements of the Alma-Ata declaration. A more 
detailed plan was laid out in the National Health Plan for South Africa.24 It proposed 
that the primary health care approach be adopted nationally and that services be 
brought 'into line with international thinking and practices,.24 Community health 
promotion, prevention, curative and rehabilitative care were to be the focus. Efficient 
and appropriate referral of patients within this coordinated and integrated system was 
to be emphasised. The White Paper for the Transformation of the Health System in 
South Africa 25 and The Primary Health Care Package for South Africa - a set of 
norm and standards: 2000,26 stated that an integrated package of essential primary 
health care services was to be made available to the population at the first point of 
contact. A free health service for children under the age of 5 years, pregnant women, 
and mothers was proposed and implemented. The prevention, early detection, and 
treatment of tuberculosis care was to be prioritised. Cost-effective essential drugs 
were to be made available at all primary care clinics, and an Essential Drugs List 
(EDL) and Standard Treatment Guidelines (STG) were to be established. 
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The role of health care workers was more explicitly defined. 2S Those working at 
primary care level were primarily responsible for providing health care services. The 
policy stated thafs: 
there is a particular need to train existing and new staff in the primary health care 
approach, in management, in primary clinical care, in environmental health, in 
health promotion and advocacy, in occupational health and in the maintenance and 
repair of equipment. 
It was evident that nurses would be expected to provide a wide range of basic services 
and that much of the responsibility for care in this transformed system would fall 
upon the shoulders of nurses - who fonn the backbone of primary health care.27 
2.4 Nurses: the backbone of primary health care in South Africa 
In 1994, nurses fonned the bulk (60%) of health care professionals in South Africa, 
and about two-thirds worked within the public sector.27 In theory, their basic training 
equips them for primary health care service delivery, but is not sufficient to prepare 
them for all the roles they were now expected to play.28 Their training remains largely 
hospital-based and geared towards curative care with insufficient exposure to primary 
care teaching or practice, and with an orientation toward a doctor-driven model of 
care. Nurses are expected to know how to diagnose diseases, to recognise severe 
conditions, to exercise clinical judgment by knowing when to refer, to counsel, and to 
execute administrative tasks such as the recording of statistics and ensuring that 
equipment is fixed.26 The nurse is also expected to seek training where lack of skills 
are identified, and in-service training is to take place on a regular basis.29 26 
The White paper for the transfonnation of the health system in South Africa requires 
nurses to provide the following primary health care services2s : 
• Promotive and preventive services that encompasses health education, family planning, 
immunisation, nutrition, and screening for common diseases. 
• Curative care for minor acute conditions, communicable and chronic diseases, and trauma. 
• Essential drugs. 
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• Basic optometry services, with appropriate referral when indicated. 
• School and other institutional services including oral health, audiology, and optometry. 
• Mental health and substance abuse services. 
• Community nursing, home care, and palliative caring for the terminally ill. 
• Geriatric services. 
The White paper also provides details of the care expected of nurses for individual 
diseases. For example, for asthma, nurses are expected to diagnose, use and interpret 
peak: expiratory flow meter readings, treat acute exacerbations and understand the 
treatment of chronic asthma. They are required to understand the aetiology and nature 
of asthma, educate the patient and family, understand the risk factors associated with 
increased morbidity and mortality of asthma, and to know when to refer patients for 
further acute or chronic care. 
For tuberculosis, nurses are expected to know how to recognise and investigate 
tuberculosis suspects, and to initiate, follow-up and treat those shown to have 
tuberculosis on further investigation. They are also expected to adhere to the 
diagnostic and management protocols, and to complete the tuberculosis register for 
monitoring and evaluation purposes.26 They must also know when to refer ill patients 
to hospital, and/or social services, and what the side effects of anti-tuberculosis 
medications are?6 Contacts of tuberculosis patients are to be screened for tuberculosis 
and the patient, relatives and community appropriately educated. Voluntary 
Counselling and Testing (VCT) should be offered to all patients and the nurse must 
know how to provide education to patients about HIV and AIDS and sexually 
transmitted infections. 
By 1996, 86% of nurses were employed in the public sector, but only a minority was 
in primary care,30 and many were inequitably distributed throughout the health care 
system.31 Currently, there are more nurses per 100000 population than doctors (33.2 
vs 2.5 full time equivalents per 100 000),32 with many working in primary care. Yet, 
about sixty percent of primary care facilities have no nurses with primary health care 
training qualifications. 33 In a survey conducted in 2003, the percentage of nurses 
trained in HIV/AIDS, tuberculosis diagnosis and management, and prevention of 
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mother to child transmission of HIV over a 12-month period was shown to be 30%, 
29%, and 27%, respective1y,31 
2.S Primary care facilities 
By 2003, 35% of existing primary health care facilities were built,31 and with most 
(1345 clinics) having been built between 1994 and 2004.34 According to data from the 
National Primary Care Facilities Survey,35 a typical facility is managed by a nurse 
with a professional nursing qualification degree or higher. It is open for 5 days a 
week, for about 9 hours. Only one third of facilities offer 24 hour services, and staff 
turnover is high.31 A typical rural clinic is staffed by 2 to 3 professional nurses, 2 to 3 
enrolled nurses, and 1 or 2 nursing assistants.36 Although equipment is available in 
most clinics, key items such as thermometers, stethoscopes, baumanometers, and 
otoscopes are not plentiful (Table 1). Most (96%) facilities are stocked with the most 
commonly used medications, but fewer than 10% have regular full supplies of all 25 
essential drugS.31 The EDL and STG are available in almost all clinics. Table 1 lists 
the services provided to or by primary health care facilities in South Africa. 
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Table 1: Services provided to or by primary health care facilities in South Africa. 
Indicator (2003)§ 
Availability of ambulance during working hours* 
Availability of ambulance after working hours* 
Expected time for ambulance to arrive at facility (travel time plus 20 
minutes) * 
Actual time for ambulance to arrive at facility* 




Sexually transmitted infection 
Tuberculosis 
Prevention of mother-to-child treatment 
Voluntary counselling and testing for HIV 
Clinics with access to laboratory services*** 





Sputum microscopy for tuberculosis 
AFB turnaround time*** 




Availability of the following equipment in the consultation room:***** 
Stethoscope 
Otoscope 
Thermometer, stethoscope, baumanometer, and otoscope) 
§ Taken from: The National Primary Health Care Facilities Survey 
*: Page 19 
**: Pages 9-14 
***: Page 18 
****: Page 25 


























2.6 Barriers to delivery of comprehensive primary health care by nurses in South 
Africa 
Skills and knowledge of nurses. Studies on the knowledge and skills of primary care 
nurses working in South Africa indicate, that nurses are not necessarily competent to 
provide quality primary health care. 37 38 39 40 41 42 In-service training curriculae have 
and are being changed. But these changes do not appear to have affected the majority 
of nurses who have already qualified. The decentralisation of nurses from secondary 
and tertiary care to primary care, the integration of previously verticalised 
programmes into an integrated comprehensive primary care package, and the 
predominantly hospital-based training of most qualified nurses have resulted in a 
primary care workforce that is not fully equipped to provide a wide-range of basic 
primary health care services. The National Primary Health Care Facilities Survey5 
concluded that 90% of nurses knew how to treat tuberculosis, 89% of nurses knew 
how to prepare oral rehydration solution, 88% knew how to treat urethral discharge, 
and 69% were able to correctly treat genital ulcers. There was however a wide 
variation in the knowledge of nurses between the provinces. For example, nurses in 
the Free State (72%) and Western Cape (73%) performed worst at prescribing 
treatment for tuberculosis, and this possibly reflects the verticalisation of these 
programmes in these provinces. 
Lack of standardised diagnostic, management and referral protocols. A lack of 
clinical management protocols has been cited as another barrier to the provision of 
comprehensive health care by nurses,43 yet a large number of guidelines and protocols 
can be found in most primary care facilities in South Africa.35 The EDL and STG are 
said to "have the potential to be powerful tools for the improvement of clinic nursing 
services if the knowledge base and scope of practice of nurses is recognised".27 But 
failure to train nurses in their use was said to be a major factor impeding the 
implementation of the first EDL edition, as no formal strategy for dissemination and 
implementation appeared to be in place. 44 A study evaluating barriers to the 
application of diabetes guidelines in primary care suggested that time constraints, 
conflict of guideline recommendations with local practices, and health system 
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problems were common factors influencing their use.45 This confinned findings of 
other studies evaluating the care of diabetes mellitus by nurses and doctors in primary 
care in South Africa.46 47 
Clinic factors. There is a pressing need for more nurses. The availability of 
professional nurses in the public sector declined between 2000 and 2002 but increased 
slightly between 2002 and 2003.34 Factors resulting in a shortage of primary care 
nurses are said to be an increase in the number of patients accessing care in response 
to the free health care policy for children and pregnant women, an increase in the 
number of new or upgraded clinics, loss of nurses to other countries or the private 
sector, a lag in the number of nurses trained, and the HIV/AIDS epidemic that is not 
only placing excessive pressure on nurses and causing them to resign, but also 
resulting in their deaths. 48 49 Increased workloads also prevent many nurses from 
being available for training. Inadequate resources and below standard facilities have 
been reported to prevent nurses from applying their skills because of absence of 
necessary equipment. These deficiencies have also been said to increase their personal 
stress as it emphasises their own lack of skills in managing patients in resource-poor 
settings. 50 Ijumba highlights how the high administrative load and external district or 
provincial 'demands' impact their ability to plan,51 and the negative effects of limited 
managerial supervision. 
Drug policy. Section 38A of the Nursing Act52 defines the schedules and conditions 
under which nurses may prescribe medicines. However, confusion about which 
qualifications a nurse requires in order obtaining a prescribing permit, and failure of 
the EDL to be explicit about exactly which medications nurses can prescribe have 
been cited as real and perceived barriers to care. 53 
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2.7 Summary 
The role of the nurse has evolved over the past 15 years in line with the changes in 
health policy in South Africa towards the goals of Alma Ata. They now playa central 
and defined role in primary health care delivery. However, their numbers and training 
have lagged behind, and are resulting in serious problems in service delivery. 
Strategies to relieve these problems have been devised, but much more needs to be 
done. There is a need for fresh approaches to equipping and training nurses in primary 
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Chapter 3 : LITERATURE REVIEW: Origins and evolution of 
evidence-based and syndromic guideline development methods 
3.1 Introduction 
Literature, in the form of text books, treatment recommendations, immunisation 
schedules and algorithms have been used for many years to guide health care 
practitioners. l But over the last 20 years this literature mainly in the form of clinical 
practice guidelines has evolved and has increasingly focused on providing diagnostic 
and management recommendations that are explicitly linked to evidence. These 
evidence-based guidelines have mostly been developed in and for developed countries 
according to rigorous methodologies. In parallel with, but not in isolation of this 
process, several international bodies began to consider developing guidelines for 
resource-poor settings, many of them symptom and sign based. 
In this chapter the origins of evidence-based guidelines, the evolution of methods used 
to develop them, and pertinent issues relating to their implementation and use in 
clinical practice will be briefly overviewed. Thereafter, the origins of integrated, 
syndromic guidelines, and the first guideline-based programme of its kind will be 
presented. 
3.2 EVIDENCE-BASED GUIDELINES 
3.2.1 The origins of evidence-based clinical practice guidelines 
Clinical practice guidelines originated in the late 1980's, and their use gained 
prominence with federal agencies, medical speciality societies, health care funders, 
legal agencies, and other interest groupS. 2 At the time, the major reasons for the 
increased awareness of the need for clinical guidelines were rising health care costs,2 
wide geographic variations in the way physicians' delivered health care,34 S 6 7 and 
evidence of increasing clinical uncertainty amongst health care professionals.8 Other 
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influencing factors were a rise in the use of unnecessary investigations, and escalating 
provision of inappropriate treatments to patients.9 
3.2.2 The def"mition of clinical practice guidelines 
Clinical practice guidelines are defined as "systematically developed statements to 
assist practitioners and consumer decisions about appropriate health care for specific 
clinical circumstances". 10 They have also been described as being decision-making 
tools intended to minimise disparities between current and best possible practice. II 
Evidence-based guidelines, on the other hand, are defined as clinical practice 
guidelines that have been developed after retrieval and appraisal of the medical 
literature using specified and systematic methods. The evidence included in these 
guidelines are described in terms of its strength, and recommendations are graded and 
linked to the appraised evidence. They are generally considered to be superior to those 
developed using other methodologies. 12 J3 14 
Systematic reviews have shown that guidelines can improve clinical practice,15 as 
well as patient outcomes. 16 They are also said to standardise diagnostic processes and 
management of patients, and reduce practice variations by closing the gap between 
what scientific evidence supports and what clinicians do.17 In settings where resources 
(money, human and physical) are limited, they can improve the efficiency of health 
care services through standardisation of care. 17 Additionally, they also serve as 
educational tools,18 and can influence public policy by highlighting priority health 
problems, areas of poor service delivery, and neglected or high risk patients not 
previously recognised.17 
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3.2.3 The evolution of evidence-based guideline development 
3.2.3.1 Consensus-based guideline del'elopment 
Initially, the only methods used to develop guidelines were consensus-based, and the 
quality of the evidence supporting the guideline recommendations was not always 
considered. 19 Recommendations were made on the basis of consensus achieved after 
open discussion, and the process of decision-making relied on the pooled knowledge 
and collective experience of the experts. This method is often referred to as global 
subjective judgment. 20 
In the late 1970s, more fonnal ways of gaining consensus were introduced. In the first 
method, known as the consensus conference, a clinical question was discussed by a 
panel. 21 22 A group of experts were selected and requested to present the latest 
evidence and practices to the panel and other interested parties, including 
representatives from the public at a 2 or 3 day conference. The panel then met behind 
'closed doors' to fonnulate recommendations based on the presented infonnation. On 
the final day, the recommendations were made public. Major criticisms of this 
technique are that it failed to make explicit how the presented evidence related to the 
final recommendations, and that too short a time was allocated for their development 
(usually one or two days).23 
A second consensus-based development method, the Delphi-technique was introduced 
in the early 1980s,19 24 and was considered to be a more fonnal method of developing 
consensus. This method was initially developed in the 1950s for other non-health 
related purposes?5 The methodological steps are as follows. After selection of a topic 
(usually a medical or surgical procedure), the medical literature was reviewed. A 
panel then reviewed the evidence, for example, how appropriate a procedure was for a 
particular indication and allocated a score. These recommendations were then 
circulated to other clinicians who also scored these recommendations. The scores 




recommendations about which disagreement existed. After discussion, the scoring 
process was repeated and the final ratings (which reflected the degree of disagreement 
between the experts) were used to generate final recommendations. A variation of this 
method used questionnaires to record the views of clinicians on the topic under 
discussion.25 A panel reviewed the questionnaire responses and this process was 
repeated until the final recommendations were made. The strengths of this method are 
that it gathers the opinion of a wide range of specialists and is relatively easy to 
implement. A disadvantage is that it is largely based on opinion with little indication 
of how scientific literature influences the development of the recommendations. 
Because the methods underpinning the Delphi techique are not made explicit it is not 
easy to assess how consensus is reached. 20 
The final method is known as the Nominal Group Technique (NG1),26 27 or the 
'modified-Delphi method'. This technique is also considered to be a form of formal 
consensus guideline development. 25 After a topic is identified, each participant 
records his thoughts. These are then presented in a round-robin fashion to a facilitator 
who records them. Each opinion or idea is discussed, and each member ranks them in 
terms of importance. The ranking is recorded 'anonymously' and presented to the 
facilitator who records each member's ranking for each idea. These rankings are 
tallied, and those with the highest scores are considered to be the final 
recommendations. The advantages of this method are that it encourages discussion 
around each topic and explores each idea or opinion individually. Disadvantages are 
that because of the heavy reliance on decision-making, it is very hard to determine the 
influence of evidence on the final recommendations. A modified version of the NOT, 
the modified-Delphi method, relies on the responses of mailed questionnaires to 
generate ideas. The respondents are invited to attend a session such as the one 
described above in order to determine the final recommendations. 25 
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3.2.3.2 Evidence-based guideline development 
In 1979, the Canadian Task Force on the Periodic Health Examination28 introduced 
the practice of quantitatively assessing the quality of scientific evidence, and proposed 
that guideline recommendations be linked to their supporting evidence.28 This was 
one of the first major moves to developing evidence-based guidelines. After extensive 
and systematic review of the literature, each retrieved study is coded according to the 
quality of its evidence as determined by its study design. Based on the retrieved 
evidence, recommendations are derived. The final recommendations are then graded 
to reflect the quality of the supporting evidence. The limitations of such a rigorous 
approach however is that scientific evidence for the effectiveness of the diagnostic 
and treatment recommendations are often lacking, or are of poor quality.19 Therefore 
evidence-based guideline methods combining this approach with consensus-based 
methods were introduced. 19 29 30 Table 2 outlines the grading system introduced by the 
Canadian Task Force on the Periodic Health Examination. 
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Table 2: An adaptation of the Canadian Task Force Classification of Recommendations 












* Source: Woolf et al2 
Description 
Study designs** 
Evidence obtained from at least 1 properly 
designed randomized controlled trial. 
Evidence obtained from well-designed controlled 
trials without randomisation. 
Evidence obtained from well-designed cohort or 
case-control analytic studies, preferably from 
more than 1 centre or research group. 
Evidence obtained from comparisons between 
times or places with or without intervention; 
dramatic results in uncontrolled experiments 
(such as the results of treatment with penicillin in 
the 1940s) could also be included in this category. 
Opinions of respected authorities, based on 
clinical experience, descriptive studies, or reports 
of expert committees. 
Recommendations 
There is good evidence to support the 
recommendation that the condition be specifically 
considered in the periodic health examination. 
There is fair evidence to support the 
recommendation that the condition be specifically 
considered in the periodic health. 
There is poor evidence regarding the inclusion of 
the condition in a periodic health examination, 
but recommendations may be made on other 
grounds. 
There is fair evidence to support the 
recommendations that the condition be excluded 
from consideration on the periodic health 
examination. 
There is good evidence to support the 
recommendation that the condition be excluded 
from consideration in the periodic health 
examination. 
** Prior to 1984, category II-I was not included in the scoring table. 
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3.2.4 Methods of evidence-based guideline development 
Methods of guideline development according to rigorous methodologies are promoted 
by many specialty societies and guideline development agencies in North AmeriCa.,31 
Europe,32 33 and New Zealand.34 A review of guideline development methodologies 
used by these organisations shows little deviation from those originally published in 
the early 1990s.19 35 The following five methodological steps common to all are1936: 
(1) identification of topic and refining of the subject area (2) formation, convening 
and running of a development group (3) retrieval and assessment of clinical evidence 
(4) derivation and grading of treatment recommendations, and (5) external review of 
the guideline. 
Topic identification and refmement of subject area. The first step of evidence-
based guideline development involves identifying a guideline topic (condition, 
presenting complaint, procedure), and determining whether the guideline will focus 
on disease prevention, diagnosis, or treatment. The guideline development group then 
refines the subject area by determining the level of care (primary, secondary, tertiary) 
at which the guideline will be targeted, and who the end-users will be. 
Formation of the guideline development group. The composition of the guideline 
development group is a major determinant of the guideline's validity.35 The group 
should be multidisciplinary in nature to ensure a wide range of views and reduce bias 
in the final recommendations.35 37 An ideal group consists of between 6 and 15 
members, and each member's role should be clearly defined. The group leader should 
preferably possess clinical and group process skills, 38 but does not necessarily have to 
be an expert in the field. 
Retrieval and assessment of evidence. Members of the development group then 
conduct a systematic review of the medical literature using search strategies that are 
conducted according to specified inclusion and exclusion criteria.39 Information on the 
benefits, harms, and costs are extracted from relevant studies.35 The internal validity 
(''the extent to which the study provides valid information about the type of conditions 
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represented in the study"), and the external validity (''the generalisability of the results 
to conditions outside of the study setting") are assessed. 35 Primary research is when 
the group conducts its own appraisal of the existing evidence and assesses its quality, 
whereas secondary research uses existing systematic reviews.36 The latter may be 
necessary when time or resources limit the undertaking of new research. The strength 
of evidence-based guidelines are said to lie in the next phase, which is when the 
evidence is categorised according to its susceptibility to bias by using schemes similar 
to that presented in Table 2. Several strength of recommendations schemes exist.40 41 
Derivation and grading of treatment recommendations. The categorised evidence 
is made available to the guideline development group who interprets and assesses it 
for relevance to the context in which the guideline will be implemented (clinical, 
public health, policy, or govemment).35 In particular, the generalisability of evidence 
to the population in which the guideline is to be implemented is considered. The aim 
of this process is to derive recommendations based on the opinion of the guideline 
development group. After discussion, the derived recommendations are graded 
according to the groups' confidence that the health outcomes presented in the 
guideline will be achieved if adhere to. It is also during this process that formal 
consensus development methods as discussed above are commonly used to develop 
and grade the recommendations. 
External review of the guideline. The complete guideline is then sent out for review 
by respected professionals in the field of interest. 35 Those consulted should represent a 
wide range of opinions and spheres of practice, but should definitely include a 
majority from the area of clinical practice (representatives) for which the guideline is 
intended. The comments of reviewers are considered and where considered relevant, 
are included in the report. Future revision of the guideline is essential, and this is 
prompted by ongoing systematic review of the medical literature. 
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3.2.4.1 Local adaptation of clinical practice guidelines 
Adaptation (tailoring) of existing clinical guidelines to local practices, resources, and 
barriers to the delivery of effective health care has been shown to be one of the most 
effective strategies to ensure acceptability and use of guidelines. 42 43 44 45 Other 
advantages are that this process facilitates more effective implementation,46 47 and 
increases the use of protocols62 as has been shown by the Scottish Intercollegiate 
Guidelines Network (SIGN) groUp.44 Before deciding to locally adapt national 
guidelines general characteristics such as its generalisability to the local population 
and setting, and its feasibility in terms of local organisational and financial resources 
should be considered. The adaptation process should include relevant roleplayers 
(respected experts and other individuals), the intended target users, and sometimes 
patients.62 Local adaptation is said to increase ownership of the guidelines, local 
innovation, and to engender change in clinical practice. 62 48 49 50 
An important potential disadvantage of local adaptation is that it may reduce the 
validity of the guideline's recommendations, thereby impeding the attainment of its 
intended outcomes. 51 This is of particular consideration if the setting in which the 
guideline is to be implemented is different to the one for which the source guideline 
was originally intended. No formal framework for assessing the impact of the local 
adaptation process on the validity of the guideline's recommendation exists. 52 Up 
until 2006, no validated process for adaptation of guidelines developed in one setting 
for use in another had been proposed. 
This has led a group of researchers, the ADAPTE group, to very recently propose a 
framework for local adaptation (trans-contextual adaptation) of guidelines. 52 An 
outline of the framework mirrors the methods used to develop evidence-based 
guidelines and is as follows. 52 The first step of guideline adaptation is the same as that 
for guideline development (identification of topic and context). Step two involves a 
search of guideline resource databases, and websites of guideline development 
agencies and other search engines. Step three is to assess the content of the source 
guidelines and compare the clinical questions with those questions defined by the 
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guideline adaptation group. The next step is to evaluate the quality of the guideline 
(AGREE instrument53), and to appraise how current, applicable, and acceptable the 
evidence is. Finally, the recommendations are adapted to local conditions and the 
guideline is externally reviewed, and adopted, endorsed and implemented. The group 
states that within the next few years, they wish to further advance knowledge 
regarding how to best adapt guidelines for local settings, and how to evaluate the 
validity of these guidelines. 
3.2.4.2 What makes guidelines work? 
Developing an evidence-based guideline does not guarantee its use in clinical 
practice. Grimshaw et al 54 reviewed 44 systematic reviews on strategies aimed at 
changing medical practitioners' behaviours and reported that passive dissemination of 
guidelines (for example, posting them to practitioners) may be useful at increasing 
physician awareness of the need to change clinical behaviour, but is unlikely to effect 
such a change. By contrast, active implementation which involves the intentional 
introduction of the guideline into clinical practice using a number of strategies, rather 
than merely posting it or assuming that the practitioner will make an effort to retrieve 
and refer to it, is shown to be more effective. However, a second review of 235 
studies published 5 years later concluded that it remains uncertain which guideline 
implementation strategy or combination of strategies is most effective. 55 A list of the 
implementation strategies reviewed in that study is presented in Table 3. 
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Audit and feedback 
Reminders 





Multifaceted interventions (a combination of different strategies)** 
* Adapted from Grimshaw et al.55 
** 56 ,., 
Factors preventing the use of guidelines by practitioners range from personal attitudes 
and personality traits to the guideline itself. 58 Professional barriers include factors 
relating to health professionals' knowledge of guidelines; and their lack of skills in 
locating, using or applying it to practice. 59 Environmental factors relate to whether or 
not colleagues, managers, or opinion leaders (social factors) support the guideline 
recommendations. Finally, economic considerations for the doctor, the patient and the 
health care system are other major barriers to their use by health care professionals. 
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3.2.4.3 Ensuring effective implementation 
To ensure effective implementation, the following are required60 61 62: 
• Knowledge of the target audience and current clinical practice. 
• Knowledge of guideline development methods. 
• Identification of barriers to change, and knowledge of gaps between current and 
ideal practice. 
• A clear statement of key recommendations (messages) from the guideline. 
• Knowledge of the effectiveness of the various dissemination and implementation 
strategies. 
• Logistical support or infonnation (a budget, development and implementation time 
frame). 
• A plan to evaluate the implementation strategy. 
Qualitative research (interviews, direct observation) plays an important role in 
guideline development and implementation, as it can provide infonnation about 
perceived or actual barriers to the delivery of effective clinical practice by health care 
professionals. It also provides infonnation on the best implementation strategy to use, 
gaps in clinical practice, and the acceptability of the proposed guideline and its 
implementation strategy. The use of qualitative evaluation as part of the design of an 
intervention strategy is of particular importance when designing a complex 
intervention (a multicomponent intervention targeting a health professional to ensure 
a change in professional behavior), such as the one presented in this thesis.63 
3.2.5 Summary of evidence-based guideline development 
Methods of guideline development have evolved over the past 20 years with a shift 
from primarily consensus-based development to those incorporating more rigorous 
appraisal of existing scientific literature combined with fonnal consensus. Despite the 
increased emphasis on evidence-based guideline development, evidence is lacking as 
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to what the most effective strategies to disseminate and implement these guidelines 
are. Local adaptation of existing guidelines and implementation strategies to address 
identified local barriers to change, however, is one approach that is said to promote 
their implementation and thereby their uptake and use in clinical practice. 
3.3 INTEGRATED SYNDROMIC GUIDELINES 
3.3.1 Origins of integrated syndromic guidelines 
In parallel to the expansion of the evidence-based guideline development movement 
has been the emergence of integrated syndromic guideline-based programmes. 
Syndromic approaches to disease management have been used for many years. This 
approach was made prominent through the development of protocols for the 
management of sexually transmitted infections (STIs) whereby a genital discharge is 
treated empirically with a range of medications targeting a number of possible 
underlying aetiologies. STI guidelines however target one cluster of diseases. 
Syndromes are defined as "a group of symptoms ~d signs that occur together and 
\ 
characterise a particular abnormality or condition"; integration means ''to incorporate 
[parts] into a larger unit".64 Together these definitions summarise what integrated 
syndromic guidelines do. They incorporate a number of related conditions into one 
document, and group them into disease syndromes according to the correlations 
between their symptoms and signs and the diagnosis (syndromic diagnoses), and/or 
according to their common responses to medications (syndromic management). 6S 66 
Syndromic, integrated guidelines are typically algorithm-based. Clinical algorithms 
are defmed as being "written guider s] to stepwise evaluation and management 
strategies that require observations to be made, decisions to be considered, and actions 
to be taken".67 They have also been reported to accelerate learning, retention of 
information, and results in faster adherence to recommendations than information 
presented in text. 68 69 70 
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For the purpose of this review, strategies based on the development of more 
comprehensive guidelines that integrate a larger number of conditions will be 
discussed. The shift to develop this type of guideline was made prominent by the 
World Health Organization's (WHO) Integrated Management of Childhood lllnesses 
(IMCI) initiative. 71 Other similar programmes are the Practical Approach to Lung 
Health (PAL) strategy,72 the IMAI (Integrated Management of Adolescent and Adult 
lllnesses) pro gramme, 73 and finally, the PALSA (Practical Approach to Lung Health 
in South Africa) initiative on which this thesis is based. 
3.3.2 Integrated Management of Childhood Illness (lMCI) 
The IMCI programme was introduced in the early-1990s.71 It originated in response to 
a number of events. The first being the high mortality rate of children under the age of 
5 years due to diarrhoea, pneumonia, and respiratory tract infections in developing 
countries. The second being the favourable outcomes of disease-specific and other 
health-related programmes (such as immunisation and Vitamin A supplementation) on 
reducing childhood mortality and strengthening health systems. A third factor was the 
failure of health care workers to recognise these conditions because of their common 
presentations. 
The World Health Organisation's Child Health and Development (CHD) department, 
in collaboration with UNICEF (United Nations Children's Fund), therefore agreed to 
develop a guideline that integrated successful disease-specific programmes such as 
the WHOs programme for the Control of Diarrhoeal Disease and the Acute 
Respiratory Infections programme into one. 74 The 3 main components of the 
programme were 75: (1) to develop a locally-adapted guideline on the integrated 
management of sick children in Falciparum malaria endemic countries with mortality 
rates of greater than 40 per 1000, thereby improving the case management skills of 
primary care health care workers (2) to through its activities, strengthen the health 
system, and (3) improve the care of children in and by the family and community. 
Case detection was to be based on simple clinical information, no laboratory features, 
and a response to empiric treatment. The clinical signs included in the guideline were 
to be easily recognisable by health care workers and sensitive in detecting disease. 
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The diagnostic infonnation was presented as algorithms, and the steps included in the 
guideline included assessment, classification, treatment of the child, and counselling 
of the mother. 
3.3.2.1 Development of the generic IMCI guideline 76 
The steps used to develop the generic guideline are as follows. After identification of 
the topic, the first step was to fonn a working group which collaborated with 12 WHO 
programmes and other experts or representatives from interested organisations. 
Thereafter, existing guidelines and treatment protocols of each related programme 
was infonnally appraised for its evidence-base and deficiencies. One example of the 
outcome of this process was the realisation that many programmes did not provide 
adequate outpatient counselling for mothers, and this was identified as a gap between 
current and optimal practice. After a number of meetings, the draft guidelines were 
integrated and refined, and were then circulated to experts for external review and 
comment. Based on the guideline, support materials were developed to be used during 
training. The training course was designed to combine classroom and clinical work. 
Concurrently, studies to validate the diagnostic and treatment recommendations were 
conducted to produce algorithms that were as accurate and simplified as possible. 
3.3.2.2 Assessment of the validity of the generic IMCI guidelines 
The accuracy of the diagnostic perfonnance of the IMCI guideline, in other words its 
validity, was in doubt because of the paucity of evidence on the accuracy of 
symptoms and signs to diagnose conditions included in the guideline, and because of 
the manner in which it was developed.76 This initiated a series of validation studies 
which served to test the accuracy of the guideline'S algorithms by comparing certain 
aspects of it to the perfonnance of experienced physicians with access to laboratory 
investigations and chest radiography.75 A secondary outcome was to detennine how 
the guideline could be improved. Studies in Gambia 77 and Kenya 78 were conducted to 
detennine the accuracy of the symptoms and signs used in the guideline in assessing 
and classifying disease (Table 4). The next 4 studies were conducted to detennine the 
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accuracy of the guideline after nurses underwent training in its use. 79 80 81 82 This 
served to infonn the next guideline revision. A final study was then conducted using 
the revised materials. 83 Table 4 provides an overview of the most relevant early 
validation studies. 
Table 4: Overview of the results of selected IMel validation studies* 
StudI setting Aim Results Results 
Weber et al77 To test IMCI n=440 
The Gambia diagnostic Disease: S~ns (0&) S12e!;; (0&) 
algorithms in an Pneumonia 81 89 
area with Dehydration 67 96 
seasonal Malaria parasitaemia (any level) 87 8 
malaria. Malaria parasitaemia (high level) 100 9 
Measles 100 99 
Reference Otitis media 31 97 
standard: Malnutrition 89 90 
paediatrician 
Perkins et To test IMCI n=440 
al78 diagnostic Diseaseiaction . S~S (0&) SP~!;; (0&) 
Kenya algorithm in a Pneumonia 97 49 
high malaria Dehydration with diarrhoea 51 98 
transmission Malaria 100 0 
area. Ear problem 98 2 
Nutritional status 96 66 
Reference Appropriate referral 42 94 
standard: Fever recognition 91 77 
paediatrician 
Simoes et To test a trained n=449 
aI'9 PRC· worker Disease· S~s (0&) SP~Q (%) 
Ethiopia usingIMCI Pneumonia 88 87 
algorithms. Diarrhoea with dehydration 76 98 
Malnutrition 85 96 
Reference Malaria 39 99 
standard: 
paediatrician 
Kolstad et To test the n=1226 
aiM performance of Disease· S~DS eta) SI2~Q eta) 
Uganda IMCI diagnostic Severe pneumonia 53 93 
algorithms Pneumonia 76 60 
Diarrhoea 91 88 
Reference Dehydration 25 99 
standard: Severe malnutrition and severe 19 97 
medical officers anaemia 
* PHC - primary health care; Sens: sensitivity; spec: specificity. 
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3.3.2.2 Implementation of the generic IMCI guidelines 
Implementation of the IMCI strategy comprises three phases. 85 In the first phase 
(introduction), the strategy is presented to key Ministry of Health and other 
government officials and interested parties with the intention of fostering an interest 
in the programme. If the strategy is agreed to, the second, or early implementation 
phase, is initiated. The Ministry of Health then starts plans for implementation and 
monitoring. It is in this phase that adaptation of the generic guideline to match local 
epidemiological patterns, health systems structure, processes, and cultural patterns is 
started. Policies, drug availability, health information systems, and communities are 
reviewed and engaged if needed. In the final phase (expansion), the intervention is 
rolled out to other districts; and the programme is evaluated by measuring outcome 
indicators. By 2004, the programme had been implemented in most African, South 
American, and Asian countries.86 
An evaluation of the programme in 5 countries has shown that IMCI improves health 
worker assessment, diagnosis and treatment of childhood disease, and results in early 
and appropriate management. 87 It is associated with lower costs per child treated, and 
improves global public health views and practices regarding child health. Barriers to 
the effective implementation of the programme are poor supervision, increased staff 
turnover, slow uptake of the programme, and low morale amongst health workers.88 
The IMCI programme has subsequently expanded and now includes guidelines 
targeting households, communities, and referral facilities. 87 
3.3.2.3 Local adaptation of the generic IMCI guideline 
Steps in the IMCI adaptation process are detailed in a comprehensive document.89 
These are (1) to initiate the adaptation process (2) to review current clinical guidelines 
and policies (3) to outline the adaptation process, and start a preliminary plan (4) to 
set up and facilitate meetings with the adaptation subgroup (5) to adapt the clinical 
guidelines (6) to circulate the guideline for comment and review. This process relies 
heavily on relatively informal consensus development methods but materials and 
checklists have been developed to ensure that the parts of the guideline and materials 
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that are adapted are standardised between the countries. In addition, the adaptation 
document lists which sections of the guideline are to be adapted. These relate to first-
line antibiotics, choice of complimentary foods, and the use of local tenns for 
symptoms and signs included in the guideline. Other adaptations are dependent on the 
local prevalence of HIV and malaria, and on local policies pertaining to Vitamin A 
supplementation. 
3.3.3 Integrated, syndromic guideline-based programmes modelled on the IMel 
strategy 
Following the successful development and implementation of the IMCI programme, 
the WHO Stop-TB strategy commenced the development of the PAL strategy. § This 
programme, as discussed in Chapter 1, was introduced to improve the case detection 
of tuberculosis, and also to improve the recognition and management of other 
respiratory illnesses in primary care in resource-poor countries. It was intended to 
provide a continuum of care by providing case management skills to health care 
workers for the recognition of disease in adolescents and adults who were already 
familiar with the IMCI programme.90 91 Development methods were the same as that 
for IMCI, and a number of documents detailing the outcomes of meetings held are 
available.92 93 94 95 96 97 However, explicit details of the development processes have 
not been published. One of the strengths of the generic PAL guideline is that 
systematic reviews on the treatment recommendations included in the guideline were 
conducted. 98 99 100 The IMAI programme is an expansion of the PAL strategy and 
addresses the management of other priority adolescent and adults diseases (diabetes, 
cardiovascular conditions, and HIV and AIDS), and is also currently being 
implemented in a number of countries.73 
§ PAL was previously known as the Adult Lung Health Initiative (ALHI) 
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3.4 Adoption of evidence-based guideline development methods by WHO 
In 2003, WHO published a document detailing methods to be used for the 
development of WHO guidelines. 101 This marked a shift from the use of primarily 
consensus-based development methods to the adoption of more evidence-based ones. 
It is suggested that WHO guidelines in general are to consider the most efficacious, 
cost-effective, affordable, and beneficial recommendations for populations as opposed 
to individuals with disease. The latter, addressing population rather than individual 
needs, is cited as one of the main differences between evidence-based guidelines and 
those guidelines developed by WHO. When comparing the methods proposed in the 
document to those used by the !Mel and PAL guideline developers there are many 
similarities, except that in the WHO document a strong emphasis is placed on 
ensuring that systematic reviews are conducted; that the derived recommendations are 
linked to evidence; and that the implications of these recommendation~ on costs and 
the health of the population be made explicit. It was recommended that the latter be 
done through use of a number of scenarios. The reason for the provision of a number 
of scenarios are to ensure that countries with limited resources are able to choose the 
best recommendations from amongst a number of possible recommendations given 
their local circumstances. 
3.5 The recent development of integrated, syndromic guidelines in developed 
countries 
Over the past two years, algorithmic integrated guidelines have been developed by 
medical societies in North America102 and Europe. 103 They have been developed to 
assist busy practitioners in general practice who have limited access to, or use of, 
diagnostic technology. They are both syndromic in that they are not disease-specific 
and.do not require a precise diagnosis. 
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The first, developed by the ACCp102 (American College of Chest Physicians) 
provides an empiric integrative approach to the patient with unexplained cough. 
Although there is extensive literature on assessing the causes of unexplained cough, 
the decision to develop an empiric approach stems from the fact that the most 
common causes of cough are attributable to a limited number of conditions, and that 
use of simple treatment algorithms avoids the need for expensive confinnatory 
tests.104 105 106 107 108 109 This empiric approach also results in high levels of treatment 
success. The algorithms provide approaches for acute, subacute, and chronic coughs, 
and all recommendations are graded. 104 
The second integrated guideline developed by the International Primary Care 
Respiratory Group (IPCRG) uses a syndromic approach to the diagnosis of common 
chronic respiratory diseases. 110 103 111 Cou~ wheeze, chest tightness, breathlessness 
or chest pain are entry points into the guideline. Its four main diagnostic algorithms 
address the diagnosis and management of conditions according to 3 age groups 
(children, adults, and older people). Clinical infonnation, based on validated 
questionnaires classifies patients into the most likely disease syndrome. Supporting 
papers are provided,112 113 114 and the evidence is graded according to a ranking 
system. A document proposing a course of action for its dissemination and 
implementation was also produced. 115 It was suggested by one of the authors that such 




Based on the literature reviewed in this chapter it appears that the two 'parallel' 
models of guideline development seem to be merging. Pioneers of integrated 
syndromic guideline development are adopting more rigorous development 
methodologies, whereas some evidence-based guideline developers have recognised 
the need to develop guidelines that take into account the overlap of symptoms and 
signs of numerous diseases, and the limitations of assuming that the guideline users 
know the diagnosis of the condition with which the patient is presenting. 
A locally-adapted syndromic approach integrating all priority respiratory diseases in 
South Africa is required. Therefore, in adapting the PAL guideline for South Africa, 
the development team set out as its goal to combine these methodologies as best as 
possible, given the local circumstances. 
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Chapter 4 : LITERATURE REVIEW: Diagnostic accuracy of 
symptoms and signs that predict respiratory disease 
4.1 Overview of the chapter 
This review evaluates studies of the accuracy and precision of history and clinical 
examination as methods for diagnosing obstructive airways disease. 
4.2 The role of clinical history and examination in diagnosing respiratory disease 
History and physical examination have been said to provide most of the clinical 
information required to make a diagnosis. 1 2 3 Sackete likened each component of the 
clinical examination (history findings, symptoms and signs) to laboratory tests in that 
their accuracy and precision can be quantified.4 The accuracy of a test refers to the 
degree of agreement between the test and the gold standard against which it is 
assessed. It is quantified by measuring its sensitivity, specificity, likelihood or 
diagnostic odds ratios, and the area under the receiver operating characteristics curve 
(ARUC).S 6 A test's precision refers to the probability that a particular clinical finding 
will be present in a patient with the target disorder under discussion. But unlike 
laboratory tests, little emphasis has been placed on determining the accuracy and 
precision of each component of the clinical history and examination to determine the 
disease under question. 1 4 This finding is supported by the absence of rigorous studies 
assessing the diagnostic accuracy of symptoms and signs to detect most respiratory 
conditions.6 
Some of the earliest work done to evaluate the value of the clinical examination was 
undertaken in the field of respiratory medicine. A systematic review of 21 textbooks 
and 29 articles yielded 40 and 32 different signs predicting COPD, respectively. 6 
None of these textbooks reported on the precision and accuracy of the signs, and only 
one of the studies was assessed as being methodologically robust.7 A series which was 
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first published in The Journal of the American Medical Association (lAMA) in 1992, 
called The Rational Clinical Examination was initiated to publish systematic reviews 
to identify history and examination findings that are useful in clinical practice. It also 
aimed to identify gaps in existing literature. I However, only 50% of the reviews 
originally commissioned were completed6 because of unavailability or low quality of 
supporting scientific evidence. 8 Of note was the absence of studies comparing 
findings made by a blinded independent observer to a 'blinded' reference standard 
amongst a large representative population of consecutive patients.6 This study design 
is considered to be the best way to assess the accuracy of a test.4 Reasons cited by the 
authors for the paucity of such studies are that they are usually difficult to design and 
conduct, particularly in primary care settings; that many investigators do not have the 
necessary statistical skills, for example, to do multivariable regression analysis; and 
that clinically the emphasis has shifted from skillful clinical examination to over-
reliance on investigations. Other reasons are that this kind of diagnostic research is 
generally not considered to be a priority, given the increased emphasis on more 
sophisticated investigations. Clearly the latter trend brings with it increasing costs, 
placing such tests beyond the reach of much of the world. 
4.2.1 Recognising respiratory disease 
Early and accurate identification of respiratory illnesses has important implications 
for treatment and prognosis. For example, in asthma, inhaled corticosteroids reduce 
the number of symptoms and exacerbations and increases patients' quality of life.9 For 
COPD, early recognition also improves patients' quality of life; 10 and the early 
institution of secondary preventive measures such as smoking cessation has been 
shown to reduce FEVI decline over time. I I 12 The prompt diagnosis and treatment of 
smear-positive tuberculosis reduces the number of infectious cases in the 
community. 13 And the early introduction of appropriate antibiotics in community-
acquired pneumonia is associated with improved prognosiS. 14 On the other hand, viral 
upper respiratory tract infections require only symptomatic treatment. Thus, 
distinguishing between these categories is important. 
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In the P ALSA guideline, knowing the accuracy and precision of common respiratory 
conditions diagnosed on the basis of history and examination is important. This is 
particularly relevant for the diagnosis of conditions characterised by airflow 
limitation, as diagnostic equipment such as spirometers are not available in primary 
care in South Africa The rest of this chapter therefore presents the findings of a 
review of the literature focusing on the identification of individual or combinations of 
history and examination elements that assist with the diagnosis of obstructive lung 
disease, asthma, and COPO. 
4.3 OBSTRUCTIVE AIRWAYS DISEASE 
4.3.1 Identification of obstructive airways disease among patients with cough 
As part of a prevalence study, Thiadens et ailS examined 192 patients (18-75 years 
old) not known to have asthma or COPO who presented to primary care in the 
Netherlands with a cough for at least two weeks' duration. The aim was to determine 
whether asthma and COPO could be diagnosed on the basis of history and physical 
examination alone. The reference standards used to diagnose asthma or COPO in this 
study are presented in Table 5. Subjects completed a modified Medical Research 
Council questionnaire, which contained questions relating to respiratory symptoms, at 
baseline and at 8 weeks. 
On univariable analysis of the presenting symptoms, an asthma attack in the past two 
weeks had the highest odds (odd ratio (OR) 7.2; 95% CI: 2.5-22.1), followed by 
breathlessness (defined as attacks thereof, being woken by it, or persistent symptoms) 
during the past two weeks (OR 4.2; 95% CI: 2.1-7.7), prolonged expiration· (OR 4.1; 
95% CI: 1.7-9.4), and wheeze (OR 3.5; 95% CI: 2.0-6.6). Of the items of past medical 
history, worsening of symptoms after exposure to specific allergens such as dust, hay, 
moulds, and animals were the highest predictors (OR 5.0; 95% CI: 1.9-13.7). Others 
were: symptoms provoked by non-specific stimuli such as pollutants, exercise, cold 
• Prolonged expiration on clinical examination was not defined in this study. 
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air (OR 3.7; 95% CI: 1.4-9.8), episodes of dyspnoea (OR 3.4; 95% CI: 1.7-6.7) and 
wheeze in past year (OR 2.9; 95% CI: 1.5-4.9). Symptoms not found to have 
significant odds were nocturnal cough over the past two weeks (OR 4.1; 95% CI: 0.7-
2.5), atopy in childhood (OR 1.1; 95% CI: 0.5-2.6), family history of asthma (OR 1.0; 
95% CI: 0.8-2.8), and nocturnal cough in the past year (OR 0.8; 95% CI: 0.4-1.6). 
Logistic regression analysis confirmed that the most significant multivariable 
predictors of obstructive airways disease were§: reported wheezing (p=0.02), reported 
breathlessness (p=0.01), symptoms provoked by allergens (p=0.02), prolonged 
expiration on examination (p=0.01), female sex (p=0.02), and pack years of smoking 
(p=0.01) (Table 5). Using these variables, a scoring system was derived with the 
highest accuracy for diagnosing asthma or COPD yielding at a cut-off value of 3 
(Table 5). At this value the PPV was 84%, and the NPV was 72% (76% of patients 
were correctly identified). Wheezing was a strong predictor of obstructive airways 
diseases, but a combination of variables, as opposed to a single variable, was shown to 
be most predictive. Of note, those individual items strongly predictive of obstructive 
airways disease (on univariable analysis) were not included in the logistic regression 
model, most likely due to their relationship with other variables (covariates). 
Reported limitations of this study were that the scoring system was not validated in 
another population to determine its generalisability; and that the small number of 
patients in the study with COPD precluded determination of variables that predicted 
either asthma or COPD. The reference standards were reasonably robust, except that 
patients with controlled asthma may not have been included. the scoring system is 
however easy to use clinically. 
§ Odds ratios for predictors arrived from multivariable predictors not provided. 
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Table 5 Summary of f"mdings for studies assessing history and clinical 
examination variables as predictors of obstructive airways disease. 
Source and study Inclusion/exclusion Reference standard Results 
design criteria 
Thiadens et all6 Inclusion· For asthma· N=192 
Netherlands • Ages - 18-75 • In the last year 1 Females: 62%. 
1998 • Cough ~ weeks episode of wheeze, Mean age: 44 years. 
cough, dyspnoea Asthma-39% 
Prospective Exclusion: for more than 3 COPD-7% 
(descriptive). • Asthma weeks, and 
Primary care • COPD • PD2o~15.6J.1ll101 Cm-oiIof3 indicat~s 
practice. 
• CVS methacholine or a 
QAJ2. 
• Pulmonary disease positive • Wheeze - 1 point 
Pregnancy. bronchodilator • Attack of or nocturnal 
response. dyspnoea - 1 point 
• Prolonged expiration -
ForCOPD· 1 point 
• IfFEVI <70% of • Pack years smoking -
predicted at nl25 points 
baseline and < 75% • Symptoms provoked 
after 8 weeks, and by allergies - 0.5 
• Reversibility <9% points 
andFEVI • Female - 1 point 
improvement 
<12%. 
Badgett et ailS Inclusion criteria: QAD: N=92 (343 physician 
USA • ~40, • FEV1<80% of contacts) 
1994 current/former predicted Female: 47%. 
smoker, or FEVIIFVC ratio Mean age: 56 years 
Prospective • Previous asthma, <0.7. OAD: 35% 
(consecutive). chronic bronchitis, 
Recruited by notices or emphysema. fredictors ofQAO· 
in hospital clinic. • Peak flow < 350Umin 
• Reduced breath 
sounds 
• ~O pack years 
Van Schayck et all7 Inclusion: Ilndia2DQsl:d QAO: N=201 
Netherlands • 35-70 years FEVI < 80% of Female: 62% 
2002 • smokers predicted Mean age: 47 years 
• Not on respiratory FEVI <80%: 17% 
Cross-sectional. medications. 
Random selection of QAO jf: 
patients visiting GP. 2 out of3: 
Questionnaire (self- • Chronic wheeze 
administered) . • Chronic cough 
• Chronic dyspnoea 
68 
4.3.2 Identification of patients with obstructive airways disease in high risk 
populations 
To determine the perfonnance of medical history, examination and peak flow 
measurements to identify obstructive airways disease (DAD) in high-risk patients 
(smokers; or those with self-reported diagnoses of asthma, chronic bronchitis, or 
emphysema), Badgett et al18 recruited 92 patients from a university outpatient clinic. 
Patients 40 years and older who were current or fonner smokers, or had self-reported 
obstructive airways disease were assessed. Table 6 lists the significant individual 
predictors of DAD and the positive likelihood ratios calculated from their report for 
purposes of this review. 
Logistic regression analysis identified 3 variables which significantly predicted the 
diagnosis of DAD. These were: peak flow measurements less than 350 Umin, 
reduced breath sounds, and ~ 30 pack years of smoking (Table 5). The presence of 
any of these variables yielded a sensitivity of 98%, specificity of 46%, and an area 
under the ROC curve of 0.87. The authors reported that although self-reported 
diagnoses of asthma or CDPD improved the perfonnance of the model they were 
excluded from it to ensure generalisability to those without previous access to care. 
Reduced breath sounds predicted DAD better than wheezing. 
Limitations of the study are that the model had not been validated in other 
populations, and that the studie's small sample size precluded defining predictors for 
each specified disease. The model is only applicable to populations aged 40 years and 
older. 
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Table 6: Statistically significant univariable predictors of OAD in patients ~40 
years at high risk oftbe disease (from Badgett et aI18). 
Univariable predictors Sens Spec PPV NPV LR+ 
(%) (%) (%) (%) * 
llistory variables 
Previous diagnosis of COPD (yin) 59 78 59 78 2.7 
Smoke (~30 pack years) 63 67 50 77 1.9 
Age (~50 years) 88 40 44 88 1.5 
Dyspnoea (Bathing, dressing or at rest (~4)) 47 78 54 78 2.1 
Steroid use 31 92 63 71 3.9 
Theophylline use 47 73 48 72 1.7 
Previous diagnosis of asthma 35 83 52 71 2.1 
Inhaler use 19 95 67 69 3.8 
Home oxygen 13 97 67 67 4.3 
Physical examination· 
Initial impression before examination only 41 81 54 71 2.2 
Wheezes present 6 99 88 66 6 
Reduced breath sounds 57 88 62 77 4.8 
Mean FE~ (~ 4 seconds) 77 49 45 79 1.5 
Final opinion after examination only 55 81 61 76 2.9 
Sens: sensitivity; spec: specificity; PPV: positive predictive value; NPV: negative 
predictive value; LR: positive likelihood ratio. 
* LR+ calculated for the purpose ofthis review. 
#FET: Forced expiratory time. 
Van Scbayck et al 19 aimed to detennine how well respiratory symptoms predicts 
airflow obstruction in current smokers; and whether selecting for age increases the 
probability of detecting smokers with airflow obstruction. Smokers aged 35-70 years 
(201 out of 651) were randomly selected from the databases of 2 semi-urban Dutch 
general practices. Eligible patients completed a questionnaire, and underwent 
spirometric testing. Undiagnosed OAD was determined if a FEV 1 < 80% of predicted 
was detected. Eighteen percent of patients met these criteria. 
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The only variable significantly related to FEVI < 80% was chronic cough (OR 2.50). 
A previous diagnosis of asthma or bronchitis, a history of allergies, tiredness, chronic 
dyspnoea and chronic wheeze were not found to be significantly related to airways 
obstruction. The combined odds for detecting OAD using 2 or 3 symptoms are shown 
in Table 7. The percentage of smokers with obstruction were shown to increase with 
increasing age. The chance of having bronchial obstruction also increased with age 
and was higher in those who coughed. The authors concluded that case finding by 
targeting smokers is a better option than screening all patients. Weaknesses of this 
study were the preponderance of females in the study population, and the limited 
sampling frame (two practices only). 
Table 7: Predictors of OAD in smokers 35-70 years (from van Schayck19). 
SYMPTOM ODD RATIO PPV NPV 
(95% CI) 
Family history 
• Asthma 1.03 (0.38-2.77) 18 
• Allergy 1.35 (0.49-3.70) 21 
Symptom 
• Tiredness 1.77 (0.77-4.06) 21 87 
• Chronic wheeze 2.15 (0.94-4.88) 27 85 
• Chronic dyspnoea 2.19 (0.98-4.90) 24 87 
• Chronic cough 2.50 (1.14-5.52) 27 87 
Number of 
symptoms(chronic cough, 
dyspnoea, or wheeze) 2.28 (0.93-5.60) 22 89 
• 1 3.02 (1.37-6.64) 29 88 
• 2 
3.01 (1.17-7.70) 35 85 
• 3 
• PPV -positive predictive value; NPV -negative predictive value. 
In summary, these 3 studies, suggest that wheeze (reported or chronic), increasing 
pack years smoked, and dyspnoea (chronic, or attacks thereof, or occurring 
nocturnally) are predictive of obstructive lung disease (observed in two of the three 
studies) (Table 5). Cough is a predictor in only one study, but was part of the 
inclusion criteria in the third. IS In one, female sex, symptoms provoked by allergies, 
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and prolonged expiration were also predictive and fonned part of a derived scoring 
system. 
4.3.3 Clinical examination features that predict the presence of airflow limitation 
As part of the JAMA Rational Clinical Examination series, Holleman and Simel20 
pooled data from 21 studies to detennine which clinical examination variables best 
predicted airflow limitation. Composite diagnostic characteristics of the history and 
examination findings of clinically robust studies were presented (Table 8). High 
cumulative pack year history had the strongest association with airflow limitation. 
Chronic bronchitis, chronic sputum production, and wheezing had a moderate 
association; and cough and dyspnoea had the weakest associations (Table 8). 
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Table 8: Findings taken from pooled data for 21 studies to determine the 
individual predictors of airflow limitations (from Holleman and Simell~. 
History Item PLR NLR Sens(%) Spec (%) 
Smoking history 
~ 70 pack years vs <70 pack years 8.0 0.63 40 95 
ever vs never 1.8 0.16 92 49 
Sputum production ~ y.. cup 4.0 0.84 20 95 
Symptoms of chronic bronchitis 3.0 0.78 30 90 
Wheezing 3.8 0.66 51 84 
Exertionaldyspnoea 
grade 4 vs 3 or less 3.0 0.98 3 99 
Anyvs none 2.2 0.83 27 88 
Coughing 1.8 0.69 51 71 
Any dyspnoea 1.2 0.55 82 33 
Examination Item PLR NLR Sens(%) Spec (%) 
Wheezing 36 0.85 15 99.96 
Barrel chest 10 0.90 10 99 
Decreased cardiac dullness 10 0.88 13 99 
Match test 7.1 0.43 61 91 
Rhonchi 5.9 0.95 8 99 





Sub-xiphoid cardiac apical pulse 4.6 0.94 8 98 
Pulsus paradoxus 3.7 0.62 45 88 
Reduced breath sounds 3.7 0.70 37 90 
. Accessory muscle use 0.70 24 100 
Excavated supraclavicular fossae 0.69 31 100 
PLR: positive likelihood ratio, NLR: negative likelihood ratio, sens: sensitivity, spec: 
specificity. 
• FET: Forced expiratory time 
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Calculating likelihood ratios for the combinations of findings that best predicted 
airflow limitation revealed that no single or combination of symptoms or signs 
excluded airflow limitation (Table 9). However, a patient with a history of never 
having smoked cigarettes, and no history of wheezing, or wheezing on examination 
has a markedly decreased likelihood of having airflow limitation «LR 0.18). In 
contrast, a patient with ~70 pack year smoking history, decreased breath sounds, or 
previously diagnosed COPD has a high likelihood of having airflow limitation. 
Table 9: Combinations of clinical examination items predicting airflow limitation 
taken from the pooled studies (from Holleman and Simell~. 
CLINICAL EXAMINATION ITEMS TAKEN FROM RELATION REFERENCE 
RELEVANT STUDIES TO STANDARD 
AIRFLOW 
LIMITATION 
Years of cigarettes exposure, patient-reported wheezing, LR+ - varies FEVIFVC and 
objective wheezing.21 LR- 0.18 FEV1 <Sth 
percentile 
Patient-reported chronic obstructive pulmonary diseases, FEV1 <60 
~ 70 pack-years of cigarette smoking, reduced breath S of predicted 
sounds. LR+34 or 
• ~ 2 findings present LR- 0.34 FEV1 IFVC 
• < 2 findings present22 ratio <0.60 
Dyspnoea, subjective wheezing, objective wheeziilg, R= -0.64 
accessory muscle use, excavation of supraclavicular 
fossae, and distension of external jugular veins.23 
Breath sound intensity, use of scalene muscles, objective Negatively FEV1 
wheezing, and rales during coughing.24 correlated with 
FEVI. 
Decreased breath sounds, objective wheezing, rales, and Abnormal 
prolonged expiratory time. FVC, FEV1, or 
• All 4 findings present LR+3.3 maximal mid-
• < 4 findings presenrs LR-O.44 expiratory 
flow. 
History by questionnaire, standardized physical 
examination FEV1 IFVC< 
• Any abnormal finding LR+1.4 0.70 
• No abnormal findin~s26 LR- 0.77 
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4.3.4 Differentiating between asthma and COPD 
Beeh et af7 also set out to identify items to distinguish between asthma and COPD. 
The aim was to find predictors that could be incorporated into a user-friendly 
questionnaire in clinical practice. Clinical data was retrieved on 546 patients from a 
specialist pulmonologist's database in Germany. The diagnostic criteria are presented 
in Table 10. Thirty eight percent had asthma and 62% had COPD. The following 
items were determined: age of onset of symptoms, smoking history, atopy, and 
productive or absent cough. Patient characteristics which were significantly different 
between asthma and COPD were age (33 years vs 55 years, p <0.0001), age of onset 
(31 years vs 54 years, p<0.0001), male sex (43% vs 60%, p=0.0008), presence of 
atopy (75% vs 14%), current smoking (28% vs 68%, p<O.OOOI), and cumulative pack 
years (0 vs 30 years, p<O.OOOI). Asthmatics were more likely to have dry (65% vs 
37%, p<O.OOOI) rather than productive (10% vs 45%, p<O.OOOI) cough. 
Regression analysis of predictors for COPD showed that as the pack year number and 
age of onset increased, the likelihood as measured by odds ratios increased. In 
contrast, age of onset less than 20 years and never having smoked increased the 
likelihood of a diagnosis of asthma. Table 11 lists the derived scoring system. The 
scores range from 0 to 15, with a high score indicating COPD and a low score 
indicating asthma. The mean scores for COPD (1O.5±0.19) was significantly higher 
than that for asthma (4±0.12; p<O.OOOI). Using a cutoff of 7, the questionnaire had a 
sensitivity of 87.6%, a specificity of 87.2%, and an area under the ROC curve of 0.95. 
Scores between 6 and 8 were observed in patients in whom the distinction between 
asthma and COPD was difficult to make (20% of patients). 
The authors' concluded that given the small degree overlap between asthma and 
COPD, spirometry would add little to the discriminatory power of the questionnaire. 
Limitations of the study design were that it was retrospective, and included only 
patients with established diagnoses of asthma or COPD. 
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Table 10: Summary of fmdings for studies assessing history and clinical 












































• FEVI <85%, and reversibility 
> 12% and ~00m1 after 
bronchodilator, or 
• Positive histamine challenge and 






Mean age: 33 yrs . 
Females: 57% 
COpD· 38% 
Mean age: 55yrs 
Females: 40% 
• Post-bronchodilator GOLD criteria predictors ofCopD· 
including symptoms, risk factor • Age of onset 
exposure. • Male sex 
QAD: 
FEV I < 80% of predicted 
m.e.o FEVIIFVC ratio below lower 
limit of normal for age, sex and 
height. (If these criteria were not met, 
the patient was assumed to have 
asthma). 
COPD without reversibility: 
• Post-bronchodilator FEVIIFVC < 
0.70, and 
• Reversibility < 200mL or < 12% 
of baseline FEVI. 
corD with revergibWty: 
• Post-bronchodilator FEVIIFVC < 
0.70, and 
• Reversibility ~OOmL or ~12% of 
baseline FEVI 
Asthma: 
• Post-bronchodilator FEVIIFVC ~ 
0.70, and 
• Reversibility ~OOmLor ~12%of 
baseline FEVI 
probable asthma· 
• Post-bronchodilatorFEVIIFVC ~ 
0.70, and 
• Reversibility < 200mL or < 12% 
of baseline FEV I, and prior 
diagnosis of asthma or chronic use 
of corticosteroids. 
probable asthma· 
• Post-bronchodilatorFEVIIFVC ~ 
0.70, and 
• Reversibility < 200mL or <; 12% 
of baseline FEVI, and does not 
fulfill criteria for probable asthma. 
• Current smoking 
• Absence of atopy 
• Productive cough 





• Pack years 
• BMI 
• Prior diagnosis of asthma or 
COPD or chronic bronchitis. 
• Chronic cough or phlegm 
N=597 
Mean age: 59 years 
Females: 62% 
COPD with reversibility: 29% 
COPD without reversibility: 11% 
Asthma: 7% 
Probable asthma: 38% 
Probable normal: 15% 
Predictors of CO pO (and scoring 
~ 
• Increasing age (40-49/50-59/60-
69170+) - 0/5/9/11 points, 
respectively. 
• Pack years (0-14/15-24/25-
49/50+) - 0/3/7/9 points, 
respectivel y. 
• Worsening cough (no) - 1 point. 
• Breathing related disability (no) 
-I point. 
• Breathing-related hospitalisation 
-6 points. 
• Worsening dyspnoea (yes) - I 
points. 
• Phlegm quantity> l5mUd - 4 
points. 
• Cold going to chest (yes) - 4 
points. 
• Medications for breathing (yes) 
- 5 points. 
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Table 11: Scoring system for the distinguishing between asthma and COPD 
among patients ~18 years* (from Beeh et a127). 
Item 















• Productive cough 














In yet another study (van Schayck et a128) the aim was to detennine which questions 
best predicted COPD in patients with OAD aged ~5 years old. Questions were taken 
from a number of sources including published questionnaires and the GINA9 and 
GOLDll guidelines. Data were retrospectively evaluated using infonnation from a 
population-based database (n= 1018). The definitions for COPD and asthma are 
presented in Table 10. The questions found to best distinguish between the two 
conditions were related to age, smoking status, BMI, pack years smoked, prior 
diagnosis of asthma, and chronic bronchitis or emphysema. Others were chronic 
cough (most days for 3 consecutive months and for at least 2 years) and phlegm (most 
days for 3 consecutive months and for at least 2 years). The presence of these items 
produced a sensitivity of 72%, specificity of 64%, PPV of 68%, NPV of 68%, and 
ARUC of 0.74. A major limitation of this study was the criteria used to diagnose 
asthma (Table 10). 
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And finally, Tinkelman et al29 aimed to detennine which symptoms best identified 
COPD among smokers ~40 years with no previous diagnosis of lung disease. The 
inclusion and diagnostic criteria are presented in Table 10. Each patient completed a 
self-administered questionnaire comprising 52 symptom-related questions. The 
predictors were derived from 70% of the sample (n=417), and then validated on the 
remaining 30%. The following were statistically different between those with and 
without COPD: phlegm in the morning (p=0.00l), phlegm quantity (p<0.0001), 
phlegm production for 3 months of the year (p=0.003), wheeze frequency (p<0.000l), 
non-smoker asthmatic in the family (p=0.002), age-related breathing difficulties 
(p<0.0001), fami~y history of allergies (p=0.042), reported past or present allergies 
(p=0.034), receiving treatment for allergies (p<0.0001), and reports that the patient 
tired more easily in recent years (p=0.019). 
The predictors derived after multivariable analysis and their corresponding scores are 
presented in Table 10. The following items were included in the latter model: 
increasing age; cumulative pack years smoked; worsening cough in recent years; 
breathing-related disability (problems interfering with work and limiting the patient to 
the house or bed); hospital admissions for breathing problems; worsening dyspnoea in 
the past few years; phlegm quantity; chest problems when the patient has a cold; and 
use of medications to help with breathing. The derived predictors yielded a sensitivity 
of 72% and a specificity of 83%, with a ARUC of 0.84. As part of a related study, 
Price and Tinkelman et al30 devised a scoring system for the derived predictors 
(Table 10).§ 
Strengths of the study were the large sample size and the consecutive data collection. 
Potential limitations were that the GOLD definitions of COPD could have 
overestimated the number of patients ~ 70 years with this condition, and the low 
response rate to the posted questionnaire. 
In summary, studies to detennine the best clinical items to predict COPD in patients 
with OAD regardless of the age of the patient suggests that increasing age, smoking 
§ The scoring system is presented as part of the data in the table. 
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status, cumulative pack years, chronic cough and phlegm production are most 
suggestive. In one study,29 breathing-related variables such as hospitalisation, 
worsening of dyspnoea over time, worsening of symptoms during a upper respiratory 
tract infection, and use of medications for breathing were additional predictors. The 
inclusion of breathing-related variables in the latter study could be attributed to the 
larger number of symptom-related items (52 items) included in their questionnaire. 
Sensitivities and specificities of the questionnaires ranged from 72%-87% and 64%-
87%, respectively. And areas under the ROC curve ranged from 0.74 to 0.95, 
indicating a high degree of accuracy. These results support the use of symptom and 
sign based questionnaires to aid in the differential diagnosis of OAD and in case-
finding for COPD. 
4.4 ASTHMA 
4.4.1 Clinical features in patients with asthma 
Wheezing and nocturnal dyspnoea are strongly correlated with asthma3! and wheezing 
is the commonest symptom in patients with this condition. A questionnaire-based 
(European Community Respiratory Health Survey questionnaire) 32 study, of 
respiratory symptoms as predictors of asthma, was conducted in Switzerland by 
Sistek et al.33 Randomly selected patients aged 18-60 years old were studied. Asthma 
was diagnosed if responses to each of the following questions were positive: (1) self-
reported asthma (2) physician-confirmed asthma (3) asthma attack in the last 12 
months. The prevalence of asthma was 2.3% (225 of9651 patients), and 14% reported 
a wheeze of any form (in the last 12 months; associated with breathlessness; in 
absence of a respiratory tract infection). 
Wheezing (wheezing alone (94.4%), wheezing with dyspnoea (87.6%), wheezing 
without cold (79.8%» was the most prevalent symptom in asthmatics (75%), followed 
by dyspnoea on exercise (82%), and nocturnal symptoms (chest tightness (67.4%) and 
dyspnoea (68.5%). The presence of chronic sputum production (43.8%), cough 
(42.7%), and bronchitis (24.7%) were least commonly reported. 
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Individual symptoms which best predicted asthma were wheezing (wheezing alone, 
wheezing with dyspnoea, wheezing without cold), nocturnal chest tightness, dyspnoea 
and nocturnal cough (Table 12). Chronic cough, sputum production and bronchitis 
performed worst at predicting asthma. Wheezing with dyspnoea had the highest PPV 
(23.9%) and a specificity of 95.1 %, compared to wheezing alone (12.4% and 97.3%, 
respectively). Wheezing with dyspnoea was therefore identified as the best individual 
symptom to predict asthma. Individual nocturnal symptoms and cough were poor 
predictors of asthma. The likelihood ratio for each symptom was calculated by the 
author of this thesis. 
Of the symptom combinations (as determined by multivariate analysis), wheezing 
with two of the three following nocturnal symptoms best predicted asthma: dyspnoea, 
chest tightness, and cough. The sensitivity of this combination of symptoms was 80%, 
the specificity (85.9%), the PPV (11.9%), the NPV (99.4%), and the Youden index, 
which is a measure of accuracy, was 0.66 (Table 13). 
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Table 12: Diagnostic characteristics of individual symptoms (from Sistek et 
aI33). 
INDIVIDUAL SENS SPEC PPV NPV YOUDEN LR+** 
SYMPTOMS INDEX* 
Wheezing 75 87 12 99 0.62 5.76 
Wheezing with dyspnoea 65 95 24 99 0.60 13 
Wheezing without cold 60 94 18 99 0.53 10 
Nocturnal chest tightness 49 86 8 99 0.63 3.5 
Rest dyspnoea 47 95 18 99 0.42 9.4 
Exercise dypnoea 69 76 6 99 0.45 2.9 
Nocturnaldypnooea 46 96 22 99 0.42 11.5 
Nocturnal cough 49 73 4 98 0.22 1.8 
Chronic cough 22 95 10 98 0.17 5.5 
Chronic phlegm 23 93 8 98 0.16 3.3 
Chronic bronchitis 13 98 14 98 0.11 6.5 
Sens: sensitivity; spec: specificity; PPV: positive predictive value; NPV: negative predictive 
value; LR: positive likelihood ratio. 
• Youden index=(sensitivity.specificity)-1. The closer the index is to one, the better the 
diagnostic value of the item . 
•• Positive likelihood ratio calculated for the purposes ofthis review. 
The authors' caution that the results of the study may be biased as it is an 
epidemiological study and may therefore not be generalisable to clinical practice. The 
use of self-reported, physician-confirmed asthma and a history of an asthma attack, as 
the reference standard, was said to be a relatively robust proxy for a definitive 
diagnosis of asthma, thereby increasing the certainty of a true diagnosis. A criticism is 
that patients without a recent asthma attack or doctor diagnosis could have been 
excluded, or that patients with a recent history of exacerbation may have had more 
severe disease, thus limiting the applicability of the findings. Due to the low 
specificity of bronchial hyper-responsiveness testing it was not used as a reference 
standard.34 35 
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Table 13: Summary of fmdings for studies assessing history and clinical examination 
variables as predictors of asthma. 
Source and 
study design 





































• 18-60 years 
• Current asthma 
Inclusion 
• 20-44 years 








• Patients with 
previous diagnosis of 
self-reported, or 
• Physician diagnosed 




• Self-reported, and/or 
• Physician-diagnosed, 
and/or 
• Asthma attack in last 
12 months. 
Current asthma' 
• Self-reported, and/or 
• Physician-diagnosed, 
and/or 
• Asthma attack in last 
12 months. 




predicted and ~O% 
fall in FEVI at 
maximum dose of 
hisiamine, or 
• FEVI<60% of 
















Wheezing with dyspnoea 
Predictors (combinations) of 
symptoms: 
Wheezing and 2 of 3 nocturnal 
symptoms (cough, dyspnoea, 
tight chest) 
N=1257 
Mean age: 35years 
Females: 37% 
Doctor-diagnosed asthma: 8.3% 
Predictors of asthma: 
• Wheeze with dyspnoea 
• Wheeze alone 
N=1527 
Mean age: not provided. 
Females: 58%. 
Items most stronely correlated 
with asthma: 
• Wheeze in the last 12 months. 
• Asthma attacks. 
• Chest tightness. 
• Recent nebuliser use. 
• Wheeze following exercise. 
• Dyspnoea at rest. 
N=1185 
Mean age: 64 years 
Females: 61% 
Newly-diagnosed asthma: 3.4% 
Predictors of asthma: 
• Any wheezing compliant, 
and/or 
• Attacks of shortness of breath 
and wheezing. 
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In a second study by Sistek et al36 aimed to assess the diagnostic accuracy of selected 
respiratory symptoms, and whether the presence of bronchial hyper-responsiveness 
(BHR) improved the predictive value of the symptoms. Data were collected by means 
of the ECRHS questionnaire. The reference standard definition is presented in (Table 
13). Of the 1257 subjects aged 20-44 years, 784 (62%) underwent BHR testing using 
methacholine, 8.3% had doctor-diagnosed asthma; and 30% wheezed in the last 12 
months. 
The most prevalent items were nocturnal symptoms (44%), nocturnal cough (36%), 
wheezing (30%), exercise dyspnoea (28%), and bronchial hyperresponsiveness (25%). 
The least prevalent symptoms were: nocturnal dyspnoea (7%), chronic bronchitis (8), 
and chronic phlegm production (13%). Symptoms predictive of doctor-diagnosed 
asthma were wheezing with dyspnoea, wheezing, BHR, and wheezing without a cold 
(Table 14). Chronic cough and chronic phlegm production were least predictive of 
asthma. For the purpose of this review, likelihood ratios for each item have been 
calculated. 
The combined symptoms of wheeze, wheeze with dyspnoea, nocturnal dyspnoea, 
nocturnal chest tightness, and exercise dyspnoea were the strongest and most 
significant predictors of asthma when adjusted for age, gender, ethnicity and current 
smoking. Adding BHR to each symptom significantly increased the specificity of all 
the symptoms, and significantly decreases the sensitivity for all symptoms except for 
nocturnal dyspnoea, chronic bronchitis, and chronic phlegm production (production of 
phlegm in the mornings in winter). But overall the addition of BHR adds little 
additional value to the diagnosis meaning that wheeze with dyspnoea and wheeze 
alone are the best predictors. 
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Table 14: Value of symptoms to predict asthma. All symptoms present in last 12 
months (from Sistek et a136). 
SYMPTOM SENS SPEC PPV NPV Youden LR+# 
index·· 
Wheezing 94 76 28 98 0.65 3.9 
Wheezing with 82 90 26 99 0.70 8.2 
breathlessness 
Wheezing or dyspnoea 77 87 43 98 0.72 5.9 
without an URTI 
Nocturnal dyspnoea 42 96 35 98 0.64 10.5 
Nocturnal chest tightness 75 85 47 95 0.37 5 
Nocturnal cough 60 66 31 98 0.61 1.8 
Dyspnoea at rest 43 93 14 95 0.26 6 
Dyspnoea on exercise 75 77 35 95 0.36 3.3 
Chronic cough 43 84 23 97 0.52 2.7 
Chronic phlegm production 26 88 19 94 0.27 2.2 
in morning in winter 
Chronic bronchitis 22 I 93 17 93 0.15 3.1 
Nocturnal symptoms· 83 59 22 93 0.15 2.0 
Sens: sensitivity; spec: specificity; PPV: positive predictive value; NPV: negative predictive 
value; LR: positive likelihood ratio. 
• Nocturnal symptoms refer to: nocturnal cough, dyspnoea, and chest tightness . 
•• Youden index = (sensitivity.specificity)-1. The closer the index is to one, the better the 
diagnostic value ofthe item. 
# Likelihood ratio calculated for the purposes of this review. 
Another study conducted by Bai et al37 set out to examine which questionnaire items 
from the shortened version of the IUATLD (International Union against Tuberculosis 
and Lung Disease) 38 questionnaire best predicted asthma and other respiratory 
'syndromes' in 1572 adults by determining which questionnaire items were highly 
correlated with each another. The correlated items were then examined to determine 
the 'syndrome' they represented. These syndromes were validated using history, 
examination and physiological factors (eg. BHR, atopy, lung function, smoking status, 
and body mass index (BMI)) associated with asthma and other respiratory conditions. 
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BHR was defined as a ~O% fall in the maximal dose of histamine (only perfonned if 
FEVI ~60% of predicted), or 2: 15% reversibility after bronchodilator testing (only 
perfonned ifFEVl <60% of predicted). 
Analysis of the questions identified four syndromes (asthma, cough, urgent medical 
visit, and breathlessness). Table 15 lists the questionnaire items (symptoms) which 
best correlated with each identified syndrome. Patients were placed into each group 
according to their symptoms, and a fifth group (nonnal) was added to the analysis. 
The question 'woken by cough' did not fit into any of the groups. Wheeze in the last 
12 months, asthma attack and chest tightness were shown to have the strongest 
correlation with asthma, followed by recent nebuliser use, wheeze following exercise 
and shortness of breath at rest. The authors therefore suggest that these items be 
considered in epidemiological studies. The increased prevalence of BHR in the 
asthma group supports the diagnosis of asthma in patients with these symptoms. 
\ 
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Table 15: Questionnaire items correlated with respiratory disease syndromes. 
(from Bai et aI37). 
Syndrome Questionnaire items Percentage in whom BHR 
demonstrated 
Asthma (33.8%) (if one or more Wheeze in last 12 months 77% * (and atopy p<O.OOl 
symptoms present, "regardless of Asthma attack when compared to the other 
cough or breathlessness status") Chest tightness groups) 
Recent nebuliser use 
Wheeze following exercise 
Chest tightness on waking 
Urgent medical visit (if one or Hospitalisation (included in asthma 
more symptoms present) (10.1%) Casualty department visit syndrome) 
(Over 95% of patients were also Urgent doctor visit 
in the asthma group, and therefore 
it was considered to be a subset of 
asthma.) 
Cough (7.7%) (if one or more Morning cough 4.2% 
symptoms present and negative to Cough for 3 months per year 
asthma) Usual cough 
Cough with phlegm 
Breathlessness (5.1 %) (if one or Breathlessness on waking 1.7% 
more symptoms present and Breathlessness on exertion 
negative to asthma and cough) 
Normal (53.5%) ( no positive No abnormalities reported 17.5% 
answers} 
4.4.2 Clinical features of asthma in patients 60 years and older 
Burrows et al39 conducted a study in newly-diagnosed asthmatics aged 60 years and 
older to describe their clinical features at the time of diagnosis. This longitudinal 
prospective study based on repeated questionnaires studied 1185 patients with no 
history of asthma or COPD and established a new diagnosis of asthma in 3.4% of 
patients. 
When comparing the newly-diagnosed asthmatics with the remaining study 
population, the combination of any wheezing and/or attacks of shortness of breath 
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with wheezing was the most prevalent symptom (63% vs 23%) and highly predictive 
of newly-diagnosed asthma (relative risk (RR) 5.1 (95% CI: 2.7-9.5). Wheeze (any 
form§) was the second most prevalent symptom (50% vs 20% in non-asthmatics) and 
strongly predicted a diagnosis of asthma (RR 3.8 (95% CI: 2.1-6.9). Attacks of 
shortness of breath with wheezing was only reported in 37.5% of newly-diagnosed 
asthmatics patients compared to 11 % of the controls, and it also strongly predicted the 
presence of asthma (RR 4.4 (95% CI: 2.4-8.2)). Chronic cough (20%), chronic sputum 
production (28%), and chronic cough and/or sputum production (28%) were least 
prevalent and poorly predicted the presence of asthma (RR 1.3 (95% CI: 0.6-2.9), 2.2 
(95% CI: 1.1-4.2), and 1.4 (95% CI: 0.7-2.9), respectively). 
Both wheezing (all forms) and attacks of shortness of breath with wheezing were the 
best single predictors of newly-diagnosed asthma using multiple logistic regression 
analysis. Other predictive history variables were: current allergic rhinitis (prevalence 
65% vs 36%; RR 3.1 (95% CI: 1.7-5.9) and "respiratory trouble before age 16" 
(prevalence 35% vs 15%; RR 2.9 (95% CI: 1.5-5.4). There was no statistical 
difference with regards to smoking habits, but significantly more patients with newly-
diagnosed asthma smoked < 10 pack years (p<0.05). 
Clinical features of the newly-diagnosed patients were also compared to those who 
were assessed as having COPD. No significant differences between the two groups 
were found except for initial wheezing, and reported allergic rhinitis without or 
without a positive skin prick test. Results show that symptoms started 8 years before 
onset of newly-diagnosed asthma if ~ 60 years old, and a rapid decline in lung 
function around the time of diagnosis suggests asthma. A limitation of the study was 
that BHR was not performed on the patients. Serum 19E levels were also analysed, but 
these were not reported in this review. 
In summary, wheezing with or without breathlessness and nocturnal dyspnoea were 
the strongest predictors of asthma regardless of age when detecting asthma in young 
and old. 
§ Wheezing (all fonns) includes wheezing alone or wheezing associated with: not associated with 
colds, dyspnoea, attacks of wheezing. 
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4.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) 
4.5.1 Clinical features predicting COPD 
Badgett et al40 claims to have conducted the first study to detennine which symptoms 
and signs best predict COPD. Ninety-two current or former smokers ~40 years old 
with self-reported COPD were recruited from hospital outpatient clinics. They 
completed a questionnaire, were examined by physicians blinded to the history, and 
underwent lung function testing. The criteria for moderate COPD diagnoses (16%) are 
shown in Table 16. 
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Table 16: Summary of rmdings for studies assessing history and clinical examination 
variables as predictors of CO PD. 
Source and study 
design 





Recruited by notices 




Straus et al41 
Multicentre; 25 






Primary care and 
referra1 settings. 
Straus et al42 
Multicentre study 











• ?: 40 years, 
current/former 
smoker,or 




• ~18 years 
• KnownCOPD 
• Spirometric COPD 
(FEVI and 
FEV 1 IFVC ratio 











• Suspected COPD 
Inclll5i on: 
• ;;50 years 
• Known COPD: 
• Spirometric COPD 
(FEVI and 
FEVIIFVC ratio 











• Suspected COPD 
Exclusion 
• Asthma 
• Medica1ly unstable 
Reference standard 
Moderate copp· 
• FEV 1 <60% of predicted or 
ratio <0.6. Ratio could not be 
0.8 or more with FVC less than 
80% of predicted. 
.corp: 
• FEV 1 below the fifth 
percentile. 
.corp: 
FEVI and FEVIIFVC ratio below 
the fifth percentile. 
Results 
N=92 
Mean age: 56 years 
Fema1es: 47% 
Predictors of copp: 
• ;;0:;70 pack years + 
reduced breath sounds 
N=309 
Mean age: 56 years 
Fema1es: 43% 
Predictors ofCOpp' 
• Self-reported COPD 
• 40 pack years 
• 45 years 
• Maximum laryngeal 
height:5:4cm 
N=16l 
Mean age: 64 years. 
Fema1es: 62% females 
predictors QfCOPP 
• Self-Reported history of 
COPD 
• Wheezing 
• FET ~ seconds 
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Freeman et al43 Inclusion: .cQfD: N=369 
UK • ~Oyears • FEVIIFVC < 70% and no Mean age: 61.7 years 
2005 • using respiratory reven>ibility. Females: 8% 
medications in 
Retrospective previous 2 years. MthIna: ~mlictors Qf CQ~Q: 
database analysis • History of smoking • Reven>ibility and clinical 
Primary care • Asthma based on impression • Increasing age. 
medical history but • Cough occasionally or 
not on medications NoQAD: more frequently. 
• FEVIIFVC ~70% of predicted • Dyspnoea on exertion. 
Exclusjon: and no evidence ofOAD. • Daily wheezing. 
• FEVI IFEV < 70% 




• Known respiratory 
diseases. 
Price et al44 Inclusion· CQfD without reversihili~: N=798 
Multic:entre • ~Oyears • Post-bronchodilator FEV I IFVC Mean age: 58 years 
UK, USA • No prior diagnosis < 0.70,and Females: 51 % 
2006 of OAD or not on • Reven>ibility < 200mL or < 
respiratory 12% of baseline FEV I. COPD with reversibility:: 
Prospective medications in COPD ~tb reversihili~: 29% 
Random mailing to previous year • Post-bronchodilator FEV I IFVC COPD without reversibility: 
primary care < 0.70,and 1\% 
patients. • Reversibility ~OOmL or ~ Asthma: 7% 
12% of baseline FEVI. Probable asthma: 38% 
.Asthma: Probable normal: 15% 
• Post-bronchodilator FEVIIFVC 
~.70,and fredi~OIS aiCQfD (and 
• Reven>ibility ~OOmL or ~ scorin~ system) 
12% of baseline FEVI. • Increasing age (40-49/50-
fmbahle asthma· 59/60-69/70+) - 0/4/8/10 
• Post-bronchodilator FEV I IFVC points, respectively. 
~.70,and • 8MI « 24, 25-29, >30)-
• Reversibility < 200mL or < 5/1/0. 
12% of baseline FE VI, and • Pack years (0-14/15-
prior diagnosis of asthma or 24/25-49/50+) - 0/2/3/7 
chronic use of corticosteroids. points, respectively. 
frobable asthma· • Weather affects the cough 
• Post-bronchodiiatorFEVIIFVC (yes) - 3 points. 
~.70,and • Sputum production when 
• Reversibility < 200mL or < you don't have a cold 
12% ofbaseJine FEVI , and (yes) - 3 points. 
does not fulfill criteria for • Sputum production first 
probable asthma. thing in the morning (no) 
-3 points. 
• Frequency of wheeze 
(occasionally or more 
often/never) - 4 points. 
• Reported allergies (no)-
3 :QQints. 
van Schayck et al18 Inclusion : .coeD: Mnltivariables: 
Netherlands ~5 years • FEVIIFVCbelowlowerlimit • Age 
2005 of normal (age, sex, height) • Smoking 
• Status 
Retrospective • Packyears 
Population-based 
• BMI sample • Prior diagnosis 
• Chronic cough or phlegm 
for three months. 
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The individual symptoms significantly associated with a diagnosis of COPD are 
shown in Table 17. Likelihood ratios have been added for the purpose of this review. 
Diminished breath sounds was the best univariable predictor of COPD (sensitivity 
65%, specificity 96%, PPV 77%, NPV 93%). 
Table 17: Significant predictors of COPD on univariable analysis (from Badgett 
et aI4'). 
UNIVARIATE ANALYSIS VARIABLES SEN SPEC PPV NPV LR+ 
(statistically significant) S (%) (%) (%) 
(%) 
History variables 
Age ~ 75 years 13 99 67 85 13 
Previous diagnosis ofCOPD (yin) 80 74 38 95 3.1 
Smoke 40 95 60 89 8.0 
Shortness of breath when bathing, dressing, or at rest 60 75 32 91 2.4 
Phlegm ~ ~ cup or morning in morning 20 95 43 85 4.0 
Theophylline use 60 71 29 90 2.1 
Steroid use 40 87 38 88 3.1 
Inhaler use 27 94 44 87 4.5 
Home oxygen 20 96 50 86 5.0 
Physical examination· 
Auscultatory percussion 32 94 50 87 5.3 
Cardiac dullness 16 99 69 85 16 
Reduced breath sounds 65 96 77 93 16 
Forced expiratory time ~ 11 seconds (mean) 12 99 57 85 12 
Initial impression 25 95 50 86 5.0 
Final opinion 51 93 60 91 7.2 
Wheezes 9 100 83 85 0.0 
• Not all variables included in study are included in the table. 
Combinations of history and examination variables which best predict COPD are 
presented in Table 18. When assessing the sequential addition of multivariate 
predictors for history variables alone, the only history variables entered into the model 
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were self-reported history of COPD and pack years history ~ 70 (Model A). When the 
blinded physical examination variables were entered into the model, then diminished 
breath sounds was the only significant variable to enter the model of all four 
examiners (Model B). Finally, a peak flow of < 200Llml was added to Model B and 
increased its sensitivity to 77%, and the area under the ROC curve (ARUC) to 0.90 
(sensitivity 77%, specificity 95%). Because of the small difference between models A 
and B, the investigators felt that peak flow measurements (Model C) in fact added 
very little to the history and physical examination variables and should not be used in 
the diagnosis of COPD. 
Limitations of the study are that it only tested moderate and not mild or severe 
disease; and no distinction was made between reversible and irreversible disease. A 
strength may be that the physicians' were not privy to history findings prior to 
examination and this may have reduced incorporation bias. According to the method 
of analysis, the ~ 70 pack year cut-off was generated to give the lowest 
misc1assification rate but this value is quite high. However, 13% of the sample had 
never smoked and 30% with an average pack year history of ~O years. 
Table 18: Predictive abilities of a combination of symptoms and signs (from 
Badgett et aI4~. 
MODEL VARIABLES Sens, Spec, LR+ ARUC 
{%i95%Cn (%i95%Cn {95%CI 
A Self-reported history of COPO 40 100 Infinite 0.80 
and pack years history ~ 70 
B Self-reported history of COPO 67 98 38 0.88 
and pack years history ~ 70, plus (58-80) (97-100) (22.5-infinite) 
decreased breath sounds 
C Self-reported history of COPO 77 95 16.9 0.90 
and pack years history ~ 70, plus (73-87) (95-97) (13.8-22.1) 
decreased breath sounds, plus 
Peak flow meter reading < 
200Umin 
Sens: sensitivity; spec: specificity; PPV: LR+: positive likelihood ratio; ARUC: area under 
the receiver operating characteristic curve. 
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A second study to detennine the accuracy of selected features (self-reported COPD, 
wheezing, laryngeal height, and laryngeal decent) in diagnosing COPD was 
conducted by Straus et al.41 This multicentre study assessed consecutive patients ~18 
years (n=309) with: (1) self-reported, or (2) suspected COPD, or (3) spirometrically 
confirmed COPD. About half (52%) had COPD as defined according to the reference 
standard (Table 16). The only variables significantly predictive of COPD on 
univariable analysis were: known COPD (LR+ 12.9), > 40 pack years smoking history 
(LR+ 19.1), age 45-64 years (LR+ 1.5), presence of wheezing (LR+ 2.7), and 
maximum laryngeal height :s 4cm (LR+ 1.5). Of these, only 4 items were included in 
the reduced multivariable model (wheeze not included). The likelihood of COPD in a 
patient with all 4 items was 220.5. Even at varying spirometric definitions of COPD 
these results were not shown to change much. 
The authors' argue that inclusion of self-reported history in the prediction rule reflects 
the role it plays in history taking and its accuracy in clinical practice. Even on its 
exclusion from the model, the utility of the other variables for detecting COPD in 
undiagnosed patients at presentation was the same. This study is one of the first to 
include a larger number of patients and clinicians (46 investigators), and to evaluate 
consecutive patients, thereby decreasing bias. But the model was not subsequently 
validated, thereby decreasing its generalis ability to other populations. 
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Table 19: Multivariable predictors (adjusted likelihood ratios) of COPD (from 
Straus et al41). 
Item All patients with Patients with known 
COPD COPD excluded 
LR+ LR- LR+ LR-
Self-reported COPD 7.3 0.5 
40 pack years 8.3 0.8 11.6 0.9 
Age ~5 years 1.3 0.4 1.4 0.5 
Maximum laryngeal height :s 2.8 0.8 3.6 0.7 
4cm 
All factors 220.5 0.13 58.5 0.32 
A third study also conducted by Straus et al42 aimed to determine the accuracy of 
self-reported COPD, smoking status, number of pack years smoked, wheezing on 
auscultation, and forced expiratory time (duration of forcible exhalation after maximal 
inhalation) to diagnose COPD in patients ~50 years old presenting in primary and 
secondary care. ROC curve analysis determined a cut-off of 40 pack years for 
smoking, and 6 and 9 seconds for forced expiratory time for inclusion in the model. 
Multivariate logistic regression analysis showed that the items that best predicted 
COPD were: self-reported history of COPD, audible wheezing heard on auscultation, 
and a forced expiratory time of greater or equal to 9 seconds (Table 20). The 
cumulative adjusted likelihood ratio§ for making the diagnosis of COPD if all three 
factors were present is 59. The reported strengths and limitations of this study are 
similar to those reported for their first study41 
§ The cumulative likelihood ratio is calculated by multiplying the likelihood ratios for all, or selected, 
variables included in the multivariable model. 
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Table 20: Multivariable predictors (adjusted likelihood ratios) of COPD. (From 
Straus et a142) 
DIAGNOSTIC ELEMENTS ADJUSTED LIKELIHOOD RATIO 
FACTOR PRESENT FACTOR ABSENT 
Self-reported history of COPD 4.4 0.5 
Wheezing 2.9 0.8 
FET ~ 9 seconds 4.6 0.8 
The second last study to be reviewed in this chapter was conducted by Freeman et 
al43 who determine the value of individual questions in identifying patients ~40 years 
with COPD in primary care settings. History and spirometric data were collected on 
all included patients, but reversibility testing was only conducted on patients who 
used medications, those who had asthma, and smokers with a FEVI < 80% (Table 
16). On bivariate analysis: age> 55 years, fonner smokers, reported cough, dyspnoea 
and wheeze were significantly associated with COPD compared to not having COPD, 
but no difference between pack years smoked was shown. Two multivariable models 
were evaluated: (I) a model containing variables with multiple responses (2) a model 
containing collapsed variables (Table 21). On multivariable analysis, the odds of 
having COPD were greater if older than 70 years, dyspnoeic when climbing stairs or 
on light exercise, and daily Wheezing. When the categories for each variable were 
collapsed, age ~70 years, cough, dyspnoea on exercise to rest were most predictive. 
When assessing the best combination of symptoms as measured by the area under the 
ROC curve, the model containing questions with multiple responses perfonned 
slightly better than the one requiring mostly 'yes/no' answers (ARUC: 86% vs 85%). 
The authors concluded that increasing age, occasional or frequent cough, dyspnoea on 
exertion, and daily wheezing were strong predictors of COPD among high-risk 
patients; and that their results supported the use of wheeze as a symptom to predict 
COPD. Limitations of the latter study were that they excluded smokers on 
medications, and used FEVI < 80% of predicted as the definition of airways 
obstruction. Results also suggest that the questions perfonn much better with 
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increasing severity of COPD. Other limitations could have been diagnostic 
misclassification leading to the inclusion of asthmatics, the retrospective nature of the 
study, and the high smoking burden that might have resulted in the exclusion of pack 
year history from the model. 
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Table 21: Multivariable predictors and the diagnostic accuracy of two models to 
predict COPD (from Freeman et aI4). 
ITEM AND ODD 
CATEGORIES RATIO· 



















Only with vigorous 
exercise 
On climbing stairs 











Area under ROC curve 85.9% 






















CATEGORIES ODD RATIO· 










Occasional or more often 
Dyspnoea 
None 
On any exercise or at rest 
Wheeze 
None or less that every 
day 
Every day wheeze 















Area under ROC curve 85.0% 
Sens: sensitivity; spec: specificity; PPV: LR+: positive likelihood ratio; ARUC: area under 
the receiver operating characteristic curve. 
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As p~ of the same study conducted by Tinkelman et al29 (reported above) in which 
the predictors to distinguish asthma from COPD were determined, Price et a)44 
assessed the symptoms that best identified COPD in smokers. Patients ~O years with 
no previous respiratory diagnoses, and those not using medications in the past year 
were enrolled. The diagnostic criteria used in the study were the same as that 
presented in Table 16. Each patient completed a self-administered questionnaire 
comprising 52 symptom-related questions. The predictors were derived from 70% of 
the sample (n=417), and were validated on the remaining 30%. The following were 
statistically different between those with and without COPD: age (p<0.0001), male 
sex (p=0.006), BMI (p=0.0004), smoking intensity as measured in pack years 
(p<0.0001), recent onset of dyspnoea (p=0.028), sputum production in the absence on 
an URTI (0.001). Regression analysis produced a model containing the following 
questions to predict COPD: age; smoking intensity; low body mass index, cough 
worsened by the weather, sputum production in the absence of a URTI, wheezing 
occasionally or more often, and no reported allergies. The derived predictors yielded a 
. sensitivity of 80% and a specificity of 72%, with an ARUC of 0.82. As part of a 
related study, Price and Tinkelman et a)4S devised a scoring system for the derived 
predictors which is presented as part of the data in Table 16. 
And finally, the same study reported above by van Schayck et a)28 (Table 16) 
compared predictors of COPD using patients assesseQ as not having COPD as the 
comparator. Results revealed that age, BMI, smoking status, number of pack years 
smoked, previous diagnosis of asthma, chronic bronchitis or emphysema, frequent 
cough, and duration of cough ~2 years; or frequent phlegm production (most days 
for 3 consecutive months) and phlegm production for ~ 2 years. These questions 
yielded a sensitivity of 71 %, specificity of 67%, PPV of 25%, NPV of 94%, and an 
ARUC of 0.75. 
In summary, a history of smoking, cumulative pack year history, a previous 
diagnosis of COPD, cough-related variables, and sputum production are the best 
predictors of COPD among patients older than 40 years. Only one sfudy42 was 
conducted in patients older than 18 years, and results supported the use of smoking 
history, cumulative pack years and age older than 45 years as predictors. 
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Chapter 5 : METHODS AND MATERIALS: Development of the 
P ALSA guideline and intervention support materials 
5.1 Overview of the chapter 
In this chapter, the methods used to develop the P ALSA guideline will be presented. 
It is important to note that although each development step is presented separately, the 
overall development process was iterative with each step informing the other and 
often occurring concurrently. 
The five phases were as follows: 
• Formation of a multidisciplinary guideline development group. 
• Review of relevant policy documents, guidelines and literature. 
• Qualitative research 
o Structured reflection and brainstorming. 
o Face-to-face interviews. 
o Focus group discussions. 
• Development of the printed guideline support materials and training 
programme (intervention strategy). 
• Piloting of the PALSA intervention strategy. 
These methods are discussed in more detail below. 
5.2 Formation of a multidisciplinary guideline development group 
The aim was to form a multidisciplinary guideline development group comprising 
members with a· wide range of experiences, interests, and skills. This group was 
assembled by EDB and MFZ. At the first meeting the aims of the P ALSA guideline 
and development process the roles and responsibilities of each member, the methods 
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to be employed during the development process, and time lines were discussed. The 
author of this thesis took the lead in the development process. 
5.3 Review of relevant policy documents, guidelines and literature 
5.3.1 Review of local policy documents 
The team reviewed available national policies and documents outlining primary health 
care in South Africa in order to determine the following: 
• The national framework and strategies for primary health care implementation. 
• Human and physical resource availability at local clinics and within the district 
health system. 
• The role, scope of practice (including prescribing provisions), and support of 
nurses involved in primary health care. 
• Organisational logistics relating to the district health system, for example, 
referral patterns and management structures. 
5.3.2 Review of relevant local and international guidelines 
Relevant international and national respiratory guidelines were reviewed. These 
guidelines were retrieved by electronic search (MEDLINE, web sites of well-known 
international respiratory societies, large international organisations, guideline 
development agencies, and departments of health websites), and by contacting local 
experts, frontline clinicians and managers. More infonnation on the details of these 
organisations will be provided in the chapter that follows. 
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5.3.3 Review of the medical literature 
Relevant published literature was reviewed to detennine local respiratory 
epidemiological patterns and to identify studies on the diagnosis and management of 
the respiratory conditions to be included in the PALSA guideline. The guideline 
development group chose not to conduct their own systematic reviews because of 
resource and time constraints, but instead considered those reviewed by others 
(secondary research). 1 Articles were identified through electronic searching 
(MEDLINE, the Cochrane Collaboration Database,2 evidence-based guidelines 
published by guideline development agencies) and through hand searching references 
in retrieved articles, and by contacting local respiratory experts. 
5.4 Qualitative research methods 
Qualitative research is one of the best methods to use for exploring opinions, attitudes 
and behaviors. 3 The qualitative methods employed in this ~tudy were used to (l) 
evaluate the generic PAL guideline (2) detennine barriers to the delivery of quality 
respiratory disease care, and (3) inform the tailoring of the guideline and its support 
materials to address identified barriers and to match local practices and resource 
availability. A variety of methods were employed, as methodological triangulation 
(obtaining information by using a variety of qualitative methods) has been shown to 
strengthen the reliability of qualitative research findings, and ensures 
comprehensiveness of the collected data.4 5 
Brainstorming is shown to stimulate generations of new ideas. Focus groups are 
useful for accessing varied beliefs, knowledge and attitudes from groups of 
individuals within a limited time period.6 It is also useful for facilitating generation of 
"-
ideas. Face-to-face interviews provide the advantage of allowing a topic to be 
discussed with a great deal of flexibility, with opportunities for clarification of issues, 
and opportunities for offering conversational' prompts, and for following up on new 
ideas.7 
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Brainstonning and feedback from the first focus group session were considered to be 
the exploratory phase of the P ALSA guideline development. In this phase, the generic 
PAL guideline was discussed, and recommendations for its adaptation were presented. 
This process also served to assess the acceptability and to inform the development of 
the first draft of the P ALSA guideline and its support materials, and to identify 
barriers to the delivery of quality respiratory disease care. The remaining focus group 
sessions, and the face-to-face interviews served to further inform the development of 
the P ALSA guideline and the intervention materials. Details of these methods are 
presented in the sections that follow. Figure 1 illustrates how the combination of the 
methods described in this chapter informed the development of the P ALSA guideline, 
its support materials, and the training strategy. 
Figure 1: Illustration of how the qualitative methods informed the P ALSA 
guideline and support materials development. 
PAL guideline 
Review of policies, 






Members of the guideline development group were asked to consider the concept, 
layout, presentation, and content of the PAL guideline, and to suggest ways in which 
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it could be adapted to the South African context. They were also asked about local 
barriers to the provision of quality respiratory care. This process was infonnal and 
relied on generation of ideas. The outcomes were recorded and analysed in the same 
manner and alongside that obtained from the remaining qualitative research 
(presented below). 
5.4.2 Focus group discussions 
The aims of the focus group discussions were the same as the overall aims of the 
qualitative research as presented above. Three focus group sessions were conducted in 
the Free State province (where the intervention was to be implemented) from 
December 2001 to July 2002. Participants in each group included nurse practitioners 
and doctors working in PHC, provincial tuberculosis coordinators, and clinical 
managers. Participants were chosen according to their rank (tuberculosis nurse 
coordinators), and/or level of involvement in patient care (nurses and doctors working 
in primary care), and/or their level of contact and training with nurses (nurse 
managers and trainers). Nurses and doctors working in primary care who had a wide 
range of experience in working in rural and urban areas were chosen.8 These criteria 
were communicated to provincial and local tuberculosis coordinators who chose the 
participants prior to the focus groups. This sampling technique was employed to 
ensure diversity of experience and opinions thereby minimising the potential for bias. 
Due to traveling constraints, most chosen participants worked in urban clinics, but at 
the time of the interviews many had previously working in rural clinics. The Free 
State province is however considered to be a rural province, and therefore most of the 
data are representative of conditions in these areas. 
Nurses and doctors were interviewed separately to reduce the potential threat of 
intimidation resulting from hierarchical differences that may arise between the two 
groups. Verbal consent from each member was obtained for their contributions to be 
recorded on audio or video-tape, and each participant's confidentiality and anonymity 
was ensured. For each focus groups session, two observers made hand-written notes. 
Interviews were conducted until saturation point was reached. To ensure reliability of 
the collected data, these were supplemented by the visual or audio recordings when 
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reviewed. Transcripts were repeatedly read and coded by three independent 
researchers (RGE, LF, BM), and emerging themes were identified from all the data 
sources. 
5.4.2.1 First focus group discussion 
Six medical doctors and 15 nurses attending this one-day meeting which was held at a 
city hotel in Bloemfontein in the Free State province in December 2001. At the start 
of the meeting, the objectives, as mentioned above, were presented to the participants 
and the PAL and P ALSA initiatives were introduced. Participants were then divided 
into two groups (doctors and nurses), and each group was moderated by a facilitator 
(MOB, BM). Thereafter, the groups reconvened for a plenary session to report back 
on the group discussions. 
Below are the questions asked of the participants: 
• To determine problems with managing lung diseases (cough and shortness of 
breath) in primary care. 
o What are the most commonly occurring lung problems/diseases in the province? 
o What are the problems associated with making an accurate diagnosis of 
respiratory disease in primary care? 
o What are the problems of choosing the most effective respiratory treatment? 
o What are the problems with communicating with patients and their compliance to 
treatment? 
o What are the problems with coordination and referrals (between clinics, GPs, 
district hospitals, etc.)? 
o What are the solutions to the above problems? 
• To assess the appropriateness of the PAL guideline 
o What do you think about these guidelines? 
o What format is best? (How do you feel about using a flow chart as a guide to 
diagnosis and treatment?) 
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o What do you think about the amount of detail (too much/too little)? Where should 
details be dropped or added? 
o What parts are not applicable to the Free State? 
o How can this be made to fit into the existing national tuberculosis guidelines? 
5.4.2.2 Second focus group discussion 
The second focus group meeting was held in April 2002 at the University of the Free 
State Community Health Department. The aims of this meeting were to (1) present the 
first official draft of the PALS A guideline to assess its layout and flow, content, and 
local applicability, particularly in respect of the diagnostic and treatment 
recommendations, and (2) to generate short (key) messages derived from the 
guidelines and thought by the participants to address key diagnostic or treatment 
barriers encountered in clinical practice. The draft guideline was presented page-by-
page by RGE. During the presentation an opportunity was provided for participants to 
comment. Comments were recorded by members of the team. Thereafter, the group 
was divided into two (doctors and nurses), with each group being facilitated by one 
moderator (EDB, BM). The rest of the team members (RGE, LRF, AB, MFZ, MOB) 
acted as transcribers or observers. Discussions were followed by a plenary session at 
which each group provided feedback and presented potential key messages. 
Below are the questions asked of the participants: 
• General comments on the P ALSA guideline 
o What do you think about the content of the guideline? 
o Does it cover all major diseases encountered in the province? 
o What do you think of the format, as opposed to the fMCf guidelines? 
o Will it be Simple to use, and are the algorithms easy to follow? 
o Does it have too much or too little information? 
o Will nurses be able to execute the instructions suggested in the guideline? i.e. 
find the guideline easy to follow. 
o Does the guideline add more responsibility to the nurses? 
o Do the drugs in the guideline also appear in the EDL? 
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o Are drawings/illustrations necessary for inclusion in the guideline? 
o What are your comments about this page (each page was discussed 
individually) ? 
5.4.2.3 Third focus group discussion 
The third focus group was held at the University of Free State's Department of 
Community Health Department in May 2002. The aims were to present and discuss: 
(1) a revised draft PALSA guideline (2) the number and type of guideline support 
materials required, and (2) the proposed implementation and training programme. 
After briefly presenting the progress in the PALSA guideline development process, 
the proposed training technique (academic detailing) was presented by MFZ and AB, 
and a short video detailing this method was shown. Thereafter, followed a general 
discussion addressing the above aims took place. 
Below are the questions asked of the participants: 
• Training approach 
o What do you think of this training technique (educational outreach)? 
o How can it be improved? 
• Guideline 
o What do you think of the P ALSA guideline? 
o Which materials would be useful in complementing/supporting the guideline? 
5.4.3 Face-to-face interviews 
Face-to-face interviews to determine the guideline content for correctness (evidence-
based validity), local applicability and conformity with local guidelines were 
conducted. These were conducted with key stakeholders in national (n=l) and 
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provincial (Free State) health management (n=I), and with respiratory physician 
specialists (n=5) in Cape Town, South Africa. 
Questions asked during the interviews: 
o What do you think of the P ALSA guidelines' layout, content and flow? 
o Do you think that is applicable to the local setting and local guidelines? 
o How can it be improved? 
5.5 Printed guideline support materials and training programme development 
After the second focus group discussion in April 2002 at which the P ALSA guideline 
was reviewed, group members (RGE, LFR, AB, MFZ) met regularly to develop (1) 
key messages (2) potential guideline support materials, and (3) the training 
programme. Support materials are any printed materials that enable the user to 
understand and retain key guideline recommendations. They should reflect the content 
of the guideline. Drafts of each were sent to the rest of the guideline development 
team for comment and were presented for comment at subsequent focus group 
discussions and at sessions at which the intervention was piloted. 
5.5.1 Key message construction 
Key messages are vectors of information that contain diagnostic, treatment and/or 
referral advice and serve as prompts or reminders. Its use is intended to aid 
information retention and ultimately health professional behavioural change. 9 They 
address identified, changeable barriers, take the form of short 'catchy' sentences that 
are easily memorised, and can be printed onto intervention materials. 'Changeable' 
implies that the barrier can be easily addressed within the policy, physical and 
financial resource limitations of the health system. Key messages ~n the PALSA 
project were based on evidence from published medical literature on the effectiveness 
of respiratory treatment, referral indicators, validity of signs and symptoms predictive 
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of individual respiratory diseases and syndromes, and both international and P ALSA 
guidelines, as well as information gained from the qualitative evaluation. 
An example of how the key messages were developed is shown in the following 
example for tuberculosis. Firstly, we identified barriers to tuberculosis care. One such 
barrier is that in most clinics the diagnosis of tuberculosis is the responsibility of one 
rather than all nurses because of verticalisation of the tuberculosis programme. 
Therefore, the overall clinic staff index of suspicion for tuberculosis is not high, and 
not all nurses are familiar with the recommended diagnostic procedures. The key 
messages therefore provide clear instructions on when to suspect tuberculosis and the 
appropriate action that must follow. These key messages are presented in the chapter 
that follows. 
5.5.2 Printed support materials 
The guideline development team met regularly to discuss which materials would best 
serve to support the guideline. After initial brainstorming and consideration of the 
outcomes of the qualitative research the group agreed to develop a desk blotter that 
could be kept on the nurse's desk in the clinic, and a flip chart that would contain a 
variety of different scenarios and which would serve as the main educational material 
during the nurse-led educational outreach session to the local clinic. A pen with one of 
three key messages printed on its side was also designed. After a series of meetings, 
the first draft of the desk blotter was conceived and compiled by LRF. Thereafter, it 
underwent a series of revisions. Only the guidelines, desk blotters and pens were 
provided to the nurses in the clinics. 
5.5.3 Educational Outreach 
Academic detailing - non-commercial, short, face to face, in-service interactive 
educational sessions by a trusted and trained outsider (also known as educational 
outreach) is an effective strategy for changing practice among physicians. lo II Well 
trained educators visit healthcare professionals to provide evidence-based information 
112 
on a specific subject in a concise and objective way through the use of key messages. 
The educator often provides reminders, pamphlets and/or other educational materials. 
In PALSA, the primary aim of this intervention strategy is to improve the nurse's 
adherence to the guideline recommendations and its support materials, and to promote 
the application and understanding of the key messages. A script was developed based 
on the materials developed, and served to 'tie' them all together. Nurses (tuberculosis 
programme coordinators) were chosen to implement the intervention. AB took the 
lead on designing the training programme with input from an experienced educator in 
adult education techniques. The guideline development group participated in the 
conceptualization of the training. 
5.6 Piloting the P ALSA guideline intervention strategy 
The intervention was piloted in three separate sessions. The first session (n=3) was 
held at a community health centre in an urban area in Cape Town in July 2002. It was 
attended by 3 clinic staff members who were invited to attend by the facility manager. 
The aims were to further test and refine the guideline, materials, and implementation 
strategy. This session was led by AB, and was observed by ROE, LRF, and MFZ. The 
next two sessions were attended by 4 participants each. Both were held at a 
community health centre in Thaba Nchu, in the Free State; were conducted on the 
same day by the same facilitator (LRF); and were held in succession. The intervention 
was presented as it was intended to be used in the clinics. Feedback was obtained 
regarding the training concept, and its content, duration, and relevance, as well as 
potential obstacles to its usefulness. After each pilot session, the development team 
met to discuss the training and the participants' feedback. 
Questions asked of the participants of the pilot sessions: 
• What is your general feeling about the PALSA training? 
• What are your comments on: 
o Time allocated for the training session 
o Venue for the training 
o Content of the training materials: the guideline, the deskblotter 
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o Relevance of the training on your daily work 
o The facilitator(s) 
• What are your general recommendations to the P ALSA researchers and FS 
Provincial Health Authorities on respiratory health care delivery in the province? 
5.7 Ethics approval 
Ethics approval for the study was granted by both the University of Cape Town and 
the University of Free State research ethics committees, and by the provincial 
departments of both these cities. Oral infonned consent was obtained from all 
qualitative research participants, and their anonymity and confidentiality were 
ensured. Each participant was infonned that participation was voluntary. 
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Chapter 6 : RESULTS: DEVELOPMENT OF THE PALSA 
GUIDELINE 
6.1 Outline of chapter 
This chapter presents details of the sequence and timing of study activities, the 
composition of the guideline development group, results of the review of policies, 
guidelines and the medical literature, and the analysis of barriers to respiratory care in 
South Africa which led to the process of guideline development through a series of 
interviews and working groups. Feedback on the PAL guideline and recommendations 
for its revision will also be discussed. Finally, it describes the completed PALSA 
guideline and the accompanying support materials for educating nurses in its use. 
6.2 Time frame of the P ALSA guideline development 
The P ALSA guideline was developed over a period of two years starting in 2001. 
Although the development process is presented sequentially, each phase of 
development did not occur in isolation. Table 22 illustrates the time frames for the 
different guideline development processes. 
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6.3.2 Roles of the guideline development group members 
The lead developer (RGE) was responsible for retrieving, synthesising, and presenting 
evidence from literature or from national policies in draft versions of the guideline. 
The latter were reviewed and discussed by the rest of the guideline development 
group. EDB and MFZ helped to review the evidence and develop the guideline. LRF, 
AB, BM, and MOB provided feedback on the draft versions of the guideline. RGE, 
LRF, AB, and MFZ participated in the development and piloting of the support 
intervention materials. All members were involved in the qualitative research 
discussion groups, and in developing the implementation strategy. 
6.3.3 Group decision-making 
Where evidence in support of diagnostic or treatment recommendations was lacking 
or inconclusive, or recommendations were considered by the team to be unsuitable for 
the practice setting, they were adapted through a process of discussion resulting in 
informal consensus within the group. All aspects of the guideline were considered in 
this way. 
6.4 Results of review of policy documents, guidelines, and medical literature 
6.4.1 Review of local policies and programmes 
The policies and programmes that provide the framework for primary health care in 
South Africa include the following: the National Health Plan, 2 the White Paper on the 
Transformation of the Healthcare System3 the Primary Health Care Package4 the 
Norms and Standards for primary health care and clinics in South Africa,5 the 
National Drug Policy,6 the Nursing Act,7 in particular Sections 3?A that specify the 
qualifications and limits of prescribing by nurses. These were considered in detail 
during the P ALSA guideline development process. 
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6.4.2 Review of guidelines 
Local and international respiratory guidelines relating to the diagnosis and 
management of respiratory conditions were assessed for content, local applicability, 
level of evidence and grading of recommendations (where included) and presentation. 
Table 23 lists the more prominent local and international guidelines reviewed. Of 
particular importance were the South African Essential Drugs List and Standard 
Treatment Guidelines and the handbook of the South African National Tuberculosis 
Control. 
Table 23: Local and international guidelines reviewed during the P ALSA 
guideline development process. 
International guidelines Local guidelines 
• Global Initiative for Asthma8 • South African Thoracic 
• Global Obstructive Lung Disease9 Guidelines for Asthma16 
• ARIA 10 • South African Thoracic 
• IUATLD asthma guidelinell Guidelines for COPD
17 
• British Thoracic Society Asthma • South African National 
guidelines 12 Tuberculosis Guidelines18 
• Scottish Intercollegiate Guidelines • Essential Drugs List and 
Network guidelines13 Standard Treatment 
• National Institute for Clinical Excellencel4 Guidelines
19 
• New Zealand Guidelines Network1s 
6.4.3 Review of literature 
Because the P ALSA guideline's content framework was narrow the search for 
evidence was relatively well-defined. Each diagnostic, drug and non-drug treatment 
recommendation was critically reviewed in the light of the available evidence. 
Appendix 3 lists the Cochrane reviews consulted. 
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6.5 Results of the barriers research 
Review of barriers to the provision of quality services for respiratory diseases in 
primary care led to the following observations which were derived from the results of 
the qualitative evaluation. Because of the similarities in the derived themes, the data 
from the various qualitative methods will be presented together. 
6.5.1 Knowledge and skills barriers 
Both nurses and doctors agreed that nurses received too little training (undergraduate 
or in-service) in physiology, pathology, and diagnostic procedures to fully understand 
the scientific basis for many guideline recommendations. The presence of more than 
one disease in patients led to confusion about which treatments to prescribe. One 
doctor stated that "Sometimes health workers, especially nurses show ignorance, 
uncertainty and reluctance to get involved too much and prefer to refer patients even 
when there is no need to." Nurses felt confident about treating, although not 
necessarily diagnosing, smear-positive tuberculosis, but lacked the skills required to 
diagnose other respiratory conditions when the sputum results were negative. The 
doctors and nurses reported that nurses did not know the value of administering 
medications such as oral prednisone for patients with acute exacerbations, and that 
they were allowed to prescribe cotrimoxazole to HIV patients. 
6.5.2 Difficulties in using guidelines 
Doctors commented that "Nurses are ignorant about guidelines". In contrast, nurses 
expressed dissatisfaction at the large number of guidelines and management protocols, 
and inconsistent recommendations between them. Limited knowledge about the 
existence, use and structure of guidelines were mentioned by both groups. Doctors felt 
that nurses were not able to use disease-based treatment guidelines like the EDL, and 
said that nurses tended to use symptom-based algorithms mechanistically and with 
little clinical judgment. This was reflected in statements like "They [nurses} lack the 
necessary knowledge and skills to adhere to guidelines. " Nurses on the other hand 
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reported that they were accustomed to using algorithms such as the tuberculosis 
diagnostic algorithm in clinical practice. 
Nurses were frustrated by the lack of logical flow in some of the guidelines and 
strongly supported the concept of a simplified guideline. They commented that 
"These guidelines [the draft PALSA guideline} are rather more direct. If a patient 
presents with a lung problem, you can treat promptly. You wouldn't mess up because 
they are easier to use, nicely tabulated and separation of conditions makes it easier to 
follow. Clear when to refer, when to prescribe antibiotics, what to give ... ". And 
"These guidelines are the same as the EDL, just that they are better designed and 
have more information. They integrate other conditions such as TE. " The absence of 
guidelines in some facilities, theft of materials, and non-adherence were commonly 
cited as additional reasons for poor diagnostic performance and ineffective treatment 
of patients. The reported limitations of the EDL was that it could not make multiple 
diagnoses, and assumed that the patients' diagnoses were known on presentation, or 
that all nurses were sufficiently skilled to make respiratory diagnoses. 
6.5.3 Professional barriers: Relationships and status of nurses within the health 
service. 
Nurses expressed frustration with physicians working within the public or private 
sectors who did not follow TB diagnostic protocols ("Doctors are using ESR readings 
to make a diagnosis [of tuberculosis}''), and failed to write referral letters explaining 
methods used to diagnose tuberculosis. "In most cases doctors tend to mistake severe 
chest pains for pleural pains resulting in them diagnosing pulmonary tuberculosis 
instead of pleural effusion. This can create serious problems in most cases. " Nurses 
were responsible for notification and documentation of cases and had to therefore 
explain irregularities to their managers. 
Nurses also reported being stressed by their relationships and communication with 
managers, their patients, and physicians who diagnose TB. They felt disempowered 
by managers who were autocratic and did not communicate effectively. One nurse 
cited a problem of a community tuberculosis awareness campaign, launched without 
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their knowledge. "Awareness campaigns normally result in an influx ofTB patients in 
clinics, a situation which is sometimes not budgeted for and can result in shortage or 
compromise on routine medication. " 
6.5.4 Organisational barriers 
Increased workload from overcrowded clinics left nurses feeling disempowered, 
frustrated and burnt out. "Work overload is another contributing factor. How can a 
doctor or nurse be expected to see more than two hundred patients per day and still 
be expected to do a good job?" Others reported that due to poor planning and 
prioritisation, nurses were required to attend off-site meetings when their colleagues 
were on leave, leaving clinics understaffed. Most clinics were equipped with the 
necessary diagnostic equipment and drugs, a finding that was supported by the 
national health facilities survey at the time.20 However, in discussion it was learned 
that not all facilities had supplies of oxygen, nor were they stocked with the full range 
of medications required in terms of the ED L for primary care. 
6.5.5 Patient barriers 
Nurses felt demoralised by factors such as poverty and migratory work practices that 
prevented patients from accessing regular care and adhering to treatment. This 
perception was supported by statements such as "We also need to consider the 
patients' economic status. You will find that a patient is not able to take medication 
properly because of poverty and hunger. TB medication requires one to eat nutritious 
food, which they cannot afford. ", and "The urban-rural migration of patients also 
contribute significantly to defaulting and/or non-compliance ... by patients. " Other 
contributory factors were perceived to be patients' cultural beliefs, fear of the 
stigmatisation of TB and HIV, and denial of the consequences of their high-risk 
behavior which compromised the care that nurses wanted to provide. "A lot of TB 
patients and their relatives still regard TB as witchcraft; they [the patients] are 
normally referred to us at terminal stages. " 
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6.6 Feedback on the PAL guideline and recommendations for its adaptation 
The feedback and recommendations obtained from the various categories of 
respondents for adapting the PAL approach and guideline for the Free State province 
were broadly similar. In the section that follows feedback on the PAL guideline 
concept, its layout and flow, its content, and recommendations emerging from the 
qualitative research for its revision are presented. 
6.6.1 The PAL concept: 
Integrated approach. Integration of tuberculosis with other respiratory diseases was 
very well received. Reasons cited by nurses for welcoming an integrated approach 
were that they often felt ill-equipped to manage patients who presented with common 
symptoms such as cough and shortness of breath; and that they were not always sure 
how to manage patients who continued to have respiratory symptoms when they had 
exhausted their diagnostic routine (including bacteriological testing) for tuberculosis. 
Conversely, other nurses felt ill-equipped to manage tuberculosis patients as their 
training in tuberculosis management was deficient because of the verticalisation of the 
tuberculosis control programme. 
Syndromic diagnosis and management. The use of symptom and signs to guide the 
user to make syndromic diagnoses was strongly supported by all. Nurses required a 
syndromic approach to correct the deficiency in their diagnostic skills - skills that are 
assumed at the entry point to most disease-specific guidelines. The PAL guideline 
also often assumed availability of diagnostic aids like chest radiographs or spirometry. 
Feedback on the layout and flow of the PAL guideline. Respondents liked the 
algorithmic or flowchart format, but felt strongly that it needed to be simplified. 
Comments on the layout and flow mainly related to the first page of the PAL 
guideline which, in the first focus group session, was reported to be an obstacle both 
for nurses and doctors being able to proceed to subsequent pages. These comments 
are discussed in the section that follows. Pages 4 to 6 of the PAL guideline which 
deals with the initial management of the patient are presented in Appendix 2. 
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Links between sections on the first page of the PAL guideline were not clear. Links 
between the sections Ask, Look, Listen and Classify on page 4 of the guideline were 
not clear (Appendix 2). For example, the questions are not presented in a sequence 
that corresponds to a standard approach to a patient (namely, personal details, 
presenting complaints, past medical history, comorbid illnesses, etc.). Another 
example is that most of the infonnation relating to the symptoms and signs in these 
sections are presented in the fonn of a question, but the relevance of each question 
and their relation to the action step that follows is not always evident or explained. 
For example, the third question in the Ask section assesses whether chest pain, if 
present, is new or severe. Neither of these terms are qualified. Yet, severe pain is a 
symptom of severe pneumonia or very severe disease, and pleuritic chest pain is a 
symptom of pneumonia. The duration of the pain (whether it is new or not) is not used 
as a 'sign' in the Classify section. 
Another example relates to difficult breathing (the second question of the Ask section) 
(Appendix 2, page 4). After establishing the presence of this symptom (which is not 
defined), it is not clear how the question relates to the Classify section. Furthermore, 
in the Ask section, further breathlessness questions are asked. Again, the link between 
these questions and the disease in question (asthma) is not made explicit. To establish 
this link requires background knowledge about these diseases, or a very good 
understanding of the guideline. While some of these difficulties can be attributed to 
the fact that the PAL guideline is intended for use by primary care physicians and 
nurses, the lack of flow was considered to make it cumbersome and difficult to 
follow. 
Use of the 'signs' in the 'Classify' section of page one of the guideline to diagnose 
the disease syndromes was not clear (Appendix 2, page 4). A comment was that the 
section Classify contained a heading which read Signs, yet symptoms were included in 
that section. Another comment from the guideline development group was that the 
Classify section did not easily encourage or facilitate making more than one diagnosis, 
which considering the frequent presence of co-morbidity in patients with respiratory 
disease (usually a chronic one), was considered by the group to be a serious omission. 
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Failure to establish an explicit link between the acute and chronic sections. The 
PAL guide does not clearly distinguish between acute and chronic disease 
presentations. For the chronic respiratory diseases, there is no explicit link between 
the acute and chronic sections that assists the user to consider asthma or COPD. This 
tends to perpetuate the view that these diseases cannot or need not receive the same 
emphasis as acute disease. It also perpetuates the perception that the only, or most 
useful function of primary care, is to identify and treat acute disease. Instead, the 
guideline presents these diseases separately in the 'chronic' section of the guideline. 
On the first page, patients assessed as having chronic disease are to be referred to the 
district hospital for assessment. 
The dosages of medications were often presented in a separate section. To 
determine the treatment steps and dosages for each disease the user has to refer to a 
different section to obtain treatment information. No instructions are provided on 
which section' and on which page the corresponding treatment is located. For the 
management of severe wheezing (Appendix 2, page 6) the user had to refer to the 
Treatments section in another part of the guideline (not included as part of appendices 
of this thesis). 
6.6.2 Content of the PAL guideline 
Disease mix. An obvious advantage of PAL is that the choice of diseases can be 
customised to a country's needs. For example, malaria which is not endemic to the 
Free State province of South Africa, did not have to be included. 
Knowledge, skills and scope of practice requirements of the PAL guideline user. 
Most functions required of the healthcare worker using the PAL guideline fell within 
the scope of local nurse practices, except for detailed auscultation, and use of and 
interpretation of spirometry. However, the PAL recommendations were not fully 
compatible with the South African National Tuberculosis Control Programme, and the 
Essential Drugs List (EDL). 
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6.6.3 Recommendations for local adaptation of the PAL guideline 
Recommendations for the layout and flow of the PAL guideline. It was 
recommended that the guideline should be as short as possible, and contain essential 
diagnostic prompts linked to action steps. The layout of the document should be 
simple and easy to follow - simple enough to eventually commit to memory through 
frequent use. Users required a guideline that was durable and could be kept on hand in 
the clinic room to guide their consultations. It was also clear that relevance to their 
clinical practice setting and ownership (through being consulted during its 
development) were important to users. 
Recommendations to improve the first (entry) page of the PAL guideline. Although 
the Ask, Look Listen approach had a logical appeal, these placed the emphasis on 
technique rather than on problem-solving. The latter was better served, especially for 
nurses, by providing a route map with simpler prompts that led to a syndromic 
diagnosis which in tum was integrated with treatment recommendations. 
6.6.4 Suggestions for local adaptation of the PAL guideline 
Separation of acute from chronic disease using a two or three week rule. Use of a 
two or three week rule to make an early distinction between acute and chronic 
presentations was suggested. Although this approach has disadvantages, it is useful 
firstly for identifying those that require acute care, but also draws attention to the 
presence of chronic disease and the need to consider tuberculosis in patients with all 
forms of chronic respiratory presentations. In PAL, disease is only considered under 
the heading "if known COPD", or if the symptoms have been present for more than 3 
weeks (Appendix 2, page 4). 
Assessment of patients with acute disease according to levels of disease severity. To 
ensure early recognition, treatment and referral of severe patients, the link between 
suggestive symptoms and signs and disease severity was to be tabulated. This 
assessment was to form the first step in the evaluation of acute disease. 
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Pneumonia versus lower respiratory tract infection. The tenn pneumonia was to be 
replaced by lower respiratory tract infection as pneumonia can only be confidently 
diagnosed with the aid of a chest radiograph, which is not available in many if not 
most first level facilities. Syndromic management of lower respiratory tract infections 
was to include possible pneumonia and bronchitis associated with sputum production 
and/or colour change. 
The re-classification of asthma into levels of control rather than categories of 
severity. The guideline development group felt that in accordance with the emerging 
trends in asthma management at the time (which have recently become more 
prominent),21 22 instead of basing treatment on the level of assessed asthma severity, 
treatment was to be control-driven. That is, the emphasis was to be on determining the 
level of control as the basis for initiating, increasing or decreasing asthma treatment, 
as would be the case in treating hypertension to achieve a target level of blood 
pressure. 
The role of spirometry in COPD and asthma. The role of spirometry in primary care 
for the diagnosis and management of COPD remains controversial.23 However, the 
guideline development team felt that inclusion of spirometry in the guideline would 
be a barrier to the diagnosis of asthma or COPD as lung function equipment is not 
available at this level. Instead it was suggested that infonnation gleaned from history-
taking be used to diagnose each condition. It was felt that the guideline should provide 
for referral to the next level of care of those requiring further evaluation. 
The need to consider tuberculosis in all patients with respiratory disease could 
receive more prominence. Since one of the main purposes of PAL is to increase case 
detection of tuberculosis, it was thought that prompts to consider tuberculosis could 
appear more prominently in the P ALSA guideline. This should appear at every 
decision node, including the management of acute disease. 
Tailor the HW and AIDS sections to the local context. It was advised that HIV and 
AIDS staging be included, together with HIV and AIDS screening questions, and 
instructions to offer VCT. 
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6.7 Feedback on the P ALSA guideline and recommendations for its revision 
In the section that follows feedback on the layout, and flow, and the content of the 
P ALSA guideline will be presented, and then the P ALSA guideline will be described 
in detail. The PALSA guideline is presented in Appendix 5. 
6.7.1 Feedback on the draft PALSA guidelines 
Layout and flow of PALSA guideline. The nurses who reviewed the P ALSA 
guideline were unanimous that it was user-friendly, simple, and more direct than most 
primary care guidelines. It was felt that most nurses, regardless of qualification, would 
be able to follow the algorithms. Diagnostic and treatment steps were clearly 
presented without ambiguity. One participant stated that it was lie/ear when to refer, 
when to prescribe antibiotics, what to give, like IMCI". Another stated, "These are 
easy to follow, even a lay person could use them". The use of colour and graphics 
were welcomed and added to its appeal. Incorporation of management steps into one 
section of the flow chart, as opposed to a number of related sections also simplified 
the guideline considerably. 
Overall content of the PALSA guideline. In terms of content, the nurses appreciated 
the integration of tuberculosis diagnosis and management with that of other 
respiratory tract conditions. They agreed that the medications and other treatment 
recommendations in the guideline were found to be consistent with current practices 
and available resources. 
The following recommendations made by focus group discussion participants were 
included in the P ALSA guideline: 
• The entry symptom related to breathing problems changed from 'difficulty 
breathing', to 'difficulty in breathing', and finally to 'difficult breathing' 
(Appendix 6, page 1). 
129 
• Dosages of inhaled corticosteroids, rather than the number of puffs were 
included to accommodate differences in the various metered-dose inhaler 
formulations in use (Appendix 6, page 13). 
• The type and dosages of the recommended analgesics were standardised. 
• The timing of referrals to doctors after initial diagnosis of asthma and COPD 
was reduced from three months to one month (Appendix 6, pages 13, 14). 
• Colour photographs of oral candidiasis were included as they were considered 
by the focus group participants to be useful for nurses and to patients as part of 
patient education (Appendix 6, page 9). Candidiasis was also added as a cause 
of sore throat as it is common in HIV -infected patients (Appendix 6, page 8). 
• VCT was replaced by VCCT (voluntary confidential counselling and testing) 
at the request of the nurses, an abbreviation not used elsewhere in South 
Africa (Appendix 6, page 20). Participants indicated that that use of the term 
VCCT was preferred in the Free State, the emphasis being on 'confidentiality'. 
At the time of these consultations anti-retrovirals were not available in public 
sector clinics. 
Changes to prescribing provisions requested by respondents. Focus group 
participants identified negative effects of certain policies and the difficulties of 
translating them into practice. For examples, nurses were not permitted to initiate, but 
could dispense repeat prescriptions and change the dosage of inhaled corticosteroids. 
This disadvantaged patients in rural clinics since it was difficult for them to access 
clinics with doctors. Consequently, most asthmatics did not receive inhaled 
corticosteroids. It was proposed that prescribing provisions for nurse practitioners be 
changed to include initiation of this class of drug. Other suggested changes in 
prescribing provisions are listed in Table 24. The guideline development group also 
motivated for circulars to be sent to intervention clinics to re-enforce the prescribing 
of cotrimoxazole prophylaxis for stages 2, 3 and 4 HIV positive patients. 
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Table 24: Prescribing changes successfully motivated for by the P ALSA 
guideline development team. 
Medications Previous prescribing regulation Amended prescribing 
provision 
Inhaled corticosteroids Nurses were not permitted to Nurses were allowed to 
initiate inhaled corticosteroids. initiate inhaled 
They were, however, allowed to corticosteroids. 
issue repeat medications, or 
change the dosage of inhaled 
corticosteroids. 
Oral corticosteroids Nurses were not permitted to Nurse could prescribe a 
prescribe oral corticosteroids for stat dose and short course 
patients with an acute for patients with asthma 
exacerbation of asthmaiCOPD as or COPD exacerbations. 
stat dosages or as short courses. 
Broad-spectrum antibiotics The antibiotic to be prescribed for Amoxicillin 500mg orally 
for tuberculosis suspects tuberculosis suspects with 2 three times a day for five 
with negative sputa. negative sputa was not days was standardised to 
standardised. be the drug of choice. 
Recommendations made by the national tuberculosis co-ordinator. The national 
tuberculosis co-ordinator provided feedback and suggested that the cut-off for 
suspecting tuberculosis be reduced from three to two weeks. This pre-empted a 
change in national policy that was under discussion at the time. The Free State 
province became the first to embrace this change. 
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6.S Description of the P ALSA guideline 
The P ALSA guideline addresses the diagnosis and management of acute asthma and 
COPD exacerbations, lower and upper respiratory tract infections, asthma, COPD, 
chronic bronchitis, tuberculosis, the diagnosis and staging of HIV and AIDS, and 
cotrimoxazole prophylaxis. 
6.S.1 Flow and layout of the PALSA guideline 
Figure 2 depicts the concept behind the P ALSA guideline. This will be discussed in 
more detail below. 
Figure 2: Figure illustrating flow of P ALSA guideline 














Entry point to the PALSA guideline. An outline of the flow of the PALSA guideline 
is presented in Figure 2, and the guideline is presented in Appendix 5. Cough and/or 
difficult breathing serve as the entry point into the guideline. Difficult breathing is 
defined as the presence of breathlessness at rest or on activity, wheezing and/or tight 
chest. 
Acute versus chronic presentations. If symptoms are new or worsening, or there is 
uncertainty about the underlying respiratory diagnosis, then the duration of the main 
presenting symptoms is elicited. A two-week cut-off distinguishes acute from chronic 
disease (Figure 2; Appendix 5, page 6). A diagnosis of stable chronic disease is 
assumed in patients who report no worsening of symptoms, and/or no uncertainty 
regarding the underlying diagnosis. The guideline was also intentionally designed to 
make both acute and chronic diagnoses at the same visit in each patient. For example, 
a diagnosis of an acute exacerbation can be made in a patient who has underlying 
poorly-controlled asthma or COPD. The guideline is also designed to make more than 
one diagnosis, for example, community-acquired pneumonia in addition to pulmonary 
tuberculosis (Appendix 5, page 5.). 
6.8.2 Acute conditions in the P ALSA guideline 
Determining disease severity. Patients with acute presentations are assessed using the 
disease severity table (Appendix 5, page 2.) By assessing the degree of breathlessness, 
mental state, use of breathing (accessory) muscles, breath rate, heart rate, and 
haemoptysis the presentation is assessed as being either severe, moderate, or mild. 
The purpose of this table is to ensure that patients requiring urgent assessment, 
treatment, and/or referral are identified as early as possible and managed 
appropriately. 
Acute exacerbation of asthma or COPD. Patients with respiratory complaints for 2 
weeks or less, and whose symptoms are considered to be severe and are associated 
with wheezing or tight chest, are diagnosed and treated as having an exacerbation of 
asthma or COPD (Appendix 5, page 2). In the PALSA guideline no distinction is 
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made between asthma and COPD exacerbations as it is often difficult to distinguish 
clinically between the two conditions, and because the recommended initial 
management of these conditions in the EDL is the same. If the acute exacerbation is 
assessed as severe, initial management by a nurse is to position the patient for ease of 
breathing; administer 40% face-mask oxygen, or oxygen at 4 Umin via nasal 
cannulae; to call for an ambulance, refer to a doctor; administer beta2-agonist from an 
MDI via spacer or by nebulisation; and to give a stat dose of oral prednisone 
(Appendix 5, page 4). Moderate or mild exacerbations are treated with betaragonist 
therapy (via spacer of nebuliser) administered every 20 minutes for one hour, and 
with a stat dose of oral prednisone. After one hour, the patients' condition is re-
assessed. If no change, beta-agonist therapy is repeated and the patients are re-
assessed within one hour. If worse, subsequent management is the same as for a 
severe exacerbation. If better or asymptomatic, the patients may be discharged. The 
discharge plan ensures that compliance and inhaler technique is acceptable and that 
appropriate medications are prescribed with instructions to return if the there is no 
continuing improvement. It includes provision for a follow-up visit to confirm the 
diagnosis of underlying obstructive airways disease, and patients are encouraged to 
stop smoking, and criteria are provided to prompt patients to return if there is no 
clinical improvement. 
Lower respiratory tract infections. In patients with respiratory symptoms for less than 
2 weeks and evidence of severe respiratory distress on examination, the presence of a 
temperature of greater than or equal to 38 degrees Celsius categorises the condition as 
a severe LRTI (Appendix 5, page 2). Patients with mild or no symptoms are assessed 
as having either an obstructive lung disease exacerbation or LRTI (or tuberculosis, 
suppurative lung disease, or upper respiratory tract infection), depending on the 
associated symptoms (Appendix 5, page 5). Patients are further categorised as being 
at high or low risk of a severe LRTI. The former includes patients with co-morbid 
disease such as diabetes and HN infection or AIDS. These receive immediate 
antibiotics and are referred to the next level facility, while patients at low risk are 
treated at home. The guideline directs that patients with symptoms of LR TI be 
considered for tests for HIV infection and tuberculosis. 
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Upper respiratory tract infections. Patients are assessed as having an upper 
respiratory tract infection (URTI) if they have respiratory complaints for 2 weeks or 
less, and the following symptoms: runny nose, sore throat, pain and/or tenderness over 
sinuses, or an ear problem (Appendix 5, page 6). Although URTIs do not typically 
present with cough or difficult breathing they constitute a common cause of 
respiratory symptoms and are therefore included in the guideline. UR TIs covered in 
the guideline are the common cold, pharyngitis, tonsillitis, sinusitis, otitis externa and 
media. Allergic rhinitis and oral candidiasis are also included. 
Rhinitis. A common cold is diagnosed in the presence of a mild sore throat and/or 
fever. Patients are reassured that antibiotics are not necessary. The only EDL and 
guideline provision for such patients is oxymetazoline (0.05%) nose drops prescribed 
for no longer than 1 day (Appendix 5, page 7). Allergic rhinitis is diagnosed in the 
presence of sneezing and itching for four weeks or more, on more than 4 days each 
week (i.e. on most days). 0.9% saline nose drops and chlorpheniramine is prescribed 
for both conditions, but patients with persistent (symptoms ~four days a week) are 
referred to the next level facility for corticosteroid aqueous nasal spray. 
Acute sinusitis. Viral sinusitis is diagnosed in the presence of a clear nasal discharge, 
mild pain over sinuses, and/or post-nasal drip. Patients are reassured that antibiotics 
are not necessary. Treatment options include: bicarbonate of soda or 0.9% saline nasal 
solution, oxymetazoline nose drops, and/or paracetamol (Appendix 6, page 7). 
Bacterial sinusitis is diagnosed in the presence of symptoms for 7 days or more, 
severe symptoms regardless of duration, pussy nasal discharge, and/or facial or dental 
pain and tenderness. Treatment options are the same as for viral sinusitis, but include 
antibiotic treatment (amoxicillin). Patients are referred to the next level if a tooth 
abscess is suspected, there is swelling around the eye or facial swelling, and/or failure 
to respond to medication after 10 days (Appendix 6, page 7). 
Acute pharyngitis, tonsillitis, oral candida. A diagnosis of acute pharyngitis is made 
if the throat is reddened but there is no purulent material ("red without pus"). Patients 
are reassured that an antibiotic is not necessary. Treatment options include salt water 
mouthwash and paracetamol (Appendix 5, page 8). Bacterial tonsillitis is diagnosed 
when the throat is red and there is pus or white patches on the tonsils or tonsillar area. 
135 
Treatment options are the same as for acute pharyngitis, except that antibiotics are 
included (phenoxymethylpenicillin, or erythromycin if penicillin-allergic patients). 
Patients are referred if they have marked difficulty swallowing, inability to open 
mouth (suggesting a quinsy), and/or more than four documented episodes a year 
warranting referral for assessment for removal of tonsils. Oral candidiasis is 
considered if white patches are present on cheeks, gums, tongue and palate. Treatment 
includes nystatin lozenges or drops. The nurse is instructed to exclude HIV infection 
in all such patients. A separate page in the guideline provides photographs of the 
various appearances of oral candidiasis. 
Acute and chronic ear problems. If skin of the outer ear is involved, an antibiotic 
(flucloxacillin, or erythromycin if penicillin-allergic) and paracetamol is prescribed. If 
there is ear canal involvement, then the above-mentioned treatment is also prescribed, 
but, in addition, the ear is dry mopped. Patients are referred if in addition to the above 
they are known to have diabetes, or the condition does not respond within two days. 
Acute otitis media is diagnosed if middle-ear pathology is observed or suspected for 
less than 2 weeks duration. The recommended treatment includes the following: 
antibiotic (amoxicillin, or erythromycin in penicillin-allergic), paracetamol, and dry 
mopping of the ear. Patients are to be referred if no response after 5 days, swelling or 
tenderness of the skin behind the ear, and/or persistent pain. Chronic otitis media is 
diagnosed if pus from the ear is present for two weeks or more. No treatment other 
than dry mopping and paracetamol is recommended. Patients are referred if there is no 
improvement after four weeks, a foul-smelling discharge is present, a large hole in the 
eardrum is observed, hearing loss, and/or pain. Colour pictures of the various ear 
conditions and instructions on how to dry mop the ear are provided (Appendix 5, page 
11). 
6.8.3 Chronic conditions in the P ALSA guideline 
Patients are assessed as having chronic disease if they have respiratory symptoms for 
two weeks or more or are known to have chronic lung disease. The first objective is to 
confirm or exclude the presence of asthma or COPD. Other chronic conditions 
addressed in the guideline are chronic bronchitis, tuberculosis, and HIV and AIDS. 
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Distinguishing between asthma and COPD. The absence of lung function equipment 
in primary care facilities and the erratic availability and limited knowledge on the use 
of peak flow meters by nurses necessitated the use of the syndromic approach to the 
diagnosis of asthma and COPD and led to the exclusion of peak flow meter readings 
from the guideline (Appendix 6, page 12). Table 25 lists the symptoms and history 
questions used to distinguish asthma from COPD. For asthma, the questions related to 
the age of onset of symptoms, history of atopy, family history of asthma, variability of 
symptoms, triggers or aggravating factors, and response to bronchodilators. For 
COPD, the questions related to the onset after the age of 35 years, deterioration of 
symptoms over time, onset and frequency of breathlessness, and a smoking history of 
15 pack years or more. 
The guideline instructs the nurse to default to a diagnosis of asthma should diagnostic 
uncertainty exist. If only one feature of asthma or COPD, no significant history of 
smoking, but a positive history of hypertension, ischaemic heart disease, and/or 
diabetes, then a cardiac or non-lung causes of breathlessness is to be considered. 
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Table 25: Table listing the symptom and history variables used to distinguish 
asthma from COPD in the P ALSA guideline. 
Ask if: Ask if: 
• Symptoms started during childhood • Symptoms started later in life 
or early adulthood. (usually after the age of 35 years). 
• History ofhayfever, eczema and/or • Symptoms slowly worsened over a 
allergies. long period oftime. 
• Family history of asthma. • Long history of daily or frequent 
• Symptoms only during attacks with cough and sputum production 
periods of normal breathing in (usually starts long before the onset 
between. of shortness of breath). 
• Symptoms are usually worse: at • Short of breath for most of the day, 
night; in the early hours of the rather than at night or during the 
morning; during an upper respiratory early hours of the morning. 
tract infection or when the weather • History of heavy smoking ego More 
changes. than 20 cigarettes / day for 15 years 
• Symptoms improve or disappear after or more. 
using inhaler. 
Asthma. The aims of asthma treatment are clearly stated in the guideline (Appendix 6, 
page 13). This are defined as minimal (ideally no) daytime or nighttime symptoms, 
minimal or no asthma attacks, minimal need for 'quick relief medications', and no 
limitation of daily activities. The nurse is also instructed to identify the patient's 
current level of asthma control by enquiring about the following: day and night time 
symptoms. Table 26 lists the levels of control as presented in the P ALSA guideline. 
Well-controlled 'asthma is diagnosed if daytime symptoms are present for less than 2 
times per week, and if nocturnal symptoms are reported for less than 2 times per 
month. Poor control is diagnosed if daytime symptoms are continuous and nocturnal 
symptoms are reported to be frequent. 
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Table 26: Table listing the levels of control of asthma as presented in the P ALSA 
guideline. 
LEVEL OF WELL- MODERATE POOR CONTROL 
CONTROL CONTROLLED CONTROL 
Daytime symptoms < 2 times / week 2 - 4 times / week Continuous 
per week 
Night time symptoms < 2 times / month 2 - 4 times / month Frequent 
per month 
Treatment is prescribed according to the level of control (fable 27). If the level of 
control is good (well-controlled), then the patient uses an inhaled bronchodilator when 
necessary, and a dosage of 200-400J.1g inhaled corticosteroids daily. For poorly-
controlled asthma, the dosage of inhaled corticosteroid is increased to 800-1600 J.1g, 
theophylline is added, and a short-course of oral antibiotics is prescribed. These 
medications are the only treatments available for asthma in the primary care sector. 
Pharmaceutical management is according to a step-up or step-down system, and 
patients are to be reviewed every three months. If complete control is achieved at the 
three month visit, then medication is continued and is maintained and the treatment 
may be stepped-down at the next visit (that is, after 6 months of control). If control is 
poor, treatment is stepped up, and the nurse should consider adding a short course of 
oral steroids. The patient is to be re-assessed within one months time. 
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Table 27: Table listing the treatment options according to the level of asthma 












2 puffs when needed 
200-400 micrograms 
per day 
MODERATE (if MAXIMUM (if 
moderate control) poor control) 




May be required 4-6 
times per day. 
800-1600 
micrograms per day 
1 tablet twice a day 
40mg orally (once 
daily) for 14 days to 
gain rapid control. 
COPD. The aim of COPD management is to encourage patients to stop smoking, 
improve symptoms with inhaled bronchodilators, and to recognise and treat acute 
exacerbations. Table 28 lists the criteria used to diagnose COPD disease severity 
(Appendix 5, page 14). 
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Table 28: Table listing criteria used to diagnose disease severity as presented in 
the P ALSA guideline. 

















Treatment for all disease severity levels included inhale bronchodilators (salbutamol 
or ipratropium bromide) and theophylline, except for moderate disease. However, 
antibiotics (amoxicillin, or erythromycin if penicillin-allergic) plus a short course of 
oral steroids, and diuretics are prescribed for patients assessed as having infection and 
right heart failure (ankle oedema), respectively. 
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Table 29: Table listing the treatment options according to the level of COPD 
severity as presented in the P ALSA guideline. 
Level of Mild/moderate Severe COPDwith COPDwith 
severity COPD COPD complications infection 
Bronchodilators 
Inhaled 2 puffs when 2 puffs when 2 puffs 4 times 2 puffs when 
salbutamol needed needed a day needed 
Inhaled 2 puffs when 2 puffs 4 times 2 puffs when 
ipratopium needed (up to a day needed (up to 
bromide 4 times per 4 times per 
day) day) 
Theophylline 1 tablet 2 times 1 tablet 2 1 tablet 2 times 1 tablet 2 times 
per day times per day per day per day 
Amoxycillin 
500mgtbree 












for 14 days 
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Chronic bronchitis. Chronic bronchitis is considered in patients with chronic cough 
with or without sputum production and no breathlessness (Appendix 5, page 15). The 
guidelines identifies those at risk of having this condition as heavy smokers, patients 
with known lung damage, and those exposed to heavy occupational dust or domestic 
air pollution. Other suggestive features are daily cough with or without sputum 
production for months or years with onset of symptoms in middle or old age. 
Treatment includes avoidance of the suspected cause, if any. The guideline advises 
that patients with these symptoms who do not have a history of smoking be referred 
for assessment of other forms of lung disease. 
Tuberculosis. Increasing the suspicion of tuberculosis among nurses is considered to 
be one of the main benefits of the guideline. Users are therefore encouraged to suspect 
tuberculosis at several decision points, regardless of the duration and severity of the 
symptoms. Tuberculosis is suspected in the presence of the following: cough for two 
weeks or more, unintentional weight loss, loss of appetite, night sweats and fever, 
haemoptysis, and in known HIV or AIDS patients (Appendix 5, page 16). Additional 
instructions are provided on the timing and choice of investigations, and/or referral to 
a higher level of care for other diseases and provision for follow up is made. 
Instructions are provided on how to collect sputum, how to investigate the 
tuberculosis suspect, and an treatment recommendations. 
HW and AIDS. Page 20 of Appendix 5 lists the features suggestive of HIV infection 
or AIDS. The guideline provides a brief description of YCCT, follow-up of HIV 
positive patients, co-trimoxazole prophylaxis; and WHO staging (Appendix 5, pages 
20-22). 
6.9 Description of the support materials and educational outreach methods 
Although not the primary focus of this thesis, providing a description of the 
intervention support materials and their development is vital'in understanding how the 
guideline informed their development, and how they informed the development of the 
guideline. Providing a description also serves to increase the understanding of the 
reasons for conducting such comprehensive research during the development of the 
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guideline. However, detailed descriptions and discussions on each component are 
beyond the scope of this thesis. The final support materials are presented in 
Appendices 6 to 7. Appendix 13 details how the interventions relate to one another 
and the barriers each one addresses. 
Selection of key messages. The P ALSA key messages can be classified into 4 
categories (Appendix 13): (1) directives in words - phrases that contain a diagnostic 
or treatment recommendation (2) visuals - cartoon-like visual prompts which give 
instructions or serve a reminders (3) questions - a phrase asking the user about a 
diagnostic or treatment recommendation, usually starts with "Did you know?" (4) 
gimmicks (treatment wheels) - special aids that serve to simplify the management 
decision process. The key messages included on the pens for the nurses were: 
• Cough ~ 2 weeks ~ think TB 
• Inhaled steroids control asthma 
• HIV+ & symptomatic ~ cotrimoxazole for healthy life 
Printed support materials. Based on the outcomes of the focus group discussions, the 
intervention development team agreed to include a desk blotter (Appendix 6) and flip 
chart (Appendix 7) as part of the printed support materials. Other materials were a pen 
with the key messages printed on the side, a placebo inhaled corticosteroid metered-
dose inhaler (for demonstration of correct technique), a commercial spacer, and a 
spacer constructed from a plastic bottle used for soft-drinks. 
Desk blotter. A colour A3-sized, laminated desktop blotter containing graphics and 
consisting of 5 panels was developed (Appendix 6). Each panel addressed specific 
disease diagnoses and/or management strategies identified from the focus groups, to 
be areas of knowledge gaps,. The key messages were incorporated into the desk 
blotter. The blotter was to be used by the nurse as a quick-reference tool and for 
patient education. In Appendix 13 the information included in the desk blotter has 
been tabulated and linked to their corresponding key messages and source barriers. 
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Flipchart. The flipchart was designed for use by nurse trainers and was intended to be 
the focus of the educational outreach sessions (Appendix 7). This A3-sized 
freestanding booklet consisted of 7 pages and served as a stimulus for discussion 
around specific disease or management scenarios, and for introduction of the key 
messages (Figure 1). The first few pages allowed for discussion on recognising severe 
and non-severe disease, with specific emphasis on recognizing and treating the 
seriously ill respiratory patient. The last few pages dealt with the diagnosis and 
management of non-severe respiratory disease and smoking cessation. The discussion 
points are detailed in the script that accompanies the materials during the educational 
outreach sessions (Appendix 8). 
Educational outreach. The educational outreach training aimed for combining the 
content of the guideline and materials using the key messages with reflective, 
experiential learning, role-play, and non-judgemental feedback. A detailed description 
of the educational outreach methods will be reported elsewhere.24 
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Chapter 7 : METHODS AND MATERIALS: Validation Study 
7.1 Aim of the PALSA Validation Study 
The primary aim of the P ALSA validation study was to test the diagnostic accuracy of 
the P ALSA guideline by comparing the diagnoses made by a primary nurse care 
practitioner using the guideline with those made by a respiratory physician who had 
access to special investigations like chest radiography and spirometry. A secondary 
aim was to determine which symptoms and signs best predicted respiratory disease 
amongst the study participants because of the paucity of medical research to support 
the use of syndromic algorithms in the South African primary care settings, and to 
establish whether the P ALSA diagnostic algorithms needed to be refined accordingly. 
7.2 Study design 
The validation study was a prospective cross-sectional study with consecutive 
recruitment of patients presenting to a primary health care centre with respiratory 
symptoms. The study took place between November 2002 and December 2003, and 
was planned and coordinated by ROE, who also served as the lead study investigator. 
7.3 Study population 
Eligible patients were identified by the study nurse from among those presenting to 
the triage nurse in the waiting room of the study site by asking, "Do you have a cough 
and/or difficulty breathing?" Those 15 years and older who responded positively were 
eligible for inclusion unless they refused to participate or provide written consent, 
were known to have severe psychiatric problems or required urgent care. 
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7.4 Study site 
The Retreat Community Health Center, a local primary healthcare facility, was chosen 
as the study site. This facility provides a 24-hour accident and emergency service, as 
well as an outpatient clinic that operates on weekdays only. It services seven middle-
to low income suburbs and about 9000 patients are seen at the clinic each month. 
Twenty percent of these patients are seen in the Accident and Emergency Unit. 
Patients of all ages are seen at the clinic except neonates and pregnant women. The 
Centre provides services in radiology, community psychiatry and social work, and has 
a phannacy. A full-time voluntary HIV and AIDS counselling and testing service is 
also offered to patients. Emergency services are contacted telephonically in the event 
of an emergency requiring transport to the local district hospital. Patients who present 
to the clinic for an acute complaint are triaged immediately by nurses and are sent the 
emergency department. The rest are attended to in the outpatient department of the 
clinic after presenting to the triage room. A limited set of investigations are permitted 
at this level. Bloods and sputa for tuberculosis testing are sent to a local laboratory. 
Lung function testing is not available at this level of care. 
7.5 Assessment of subjects by the PALSA Nurse 
One nurse (SN) with over 20 years of nursing experience in a variety of clinical 
settings including primary care was the designated study nurse. Her duties were to 
recruit patients, obtain consent, and make 'PALSA' diagnoses using the guideline for 
each patient enrolled in the study. Each morning she screened patients as they arrived 
at the clinic for unscheduled or scheduled (follow up) appointments, and collected 
their clinic folders. Consecutive patients, 15 years or older, who answered 'yes' to the 
screening question were considered to be eligible to participate in the study. On 
occasion, patients were referred directly to the study nurse by the emergency unit. 
clinic doctor or nurse because they were deemed suitable for inclusion. 
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After obtaining consent the nurse entered the patient details onto a screening log and 
took a brief history as required by the P ALSA guideline. A copy of the consent forms 
can be viewed in Appendix 9. She then measured and recorded the height, weight, 
blood pressure, temperature, pulse, respiratory rate and oxygen saturation for each 
patient (Appendix 1 D). Enrolment of patients for the study took place between D7H3D 
and 16HDD during weekdays only. Using the PALSA guideline she could make up to 
3 diagnoses. The list of P ALSA diagnoses can be found in Table 3D. She was 
instructed not to deviate from the algorithms as presented in the guideline, nor to 
record diagnoses based on her clinical experience. Instead she was to rigidly apply the 
answers to the algorithms, and record the 'guideline' diagnosis. This was done to 
ensure that the diagnoses as suggested by the guideline were accurately reflected in 
the final results. Thereafter, all patients were sent to the radiology department for a 
postero-anterior chest radiograph. She was blinded to the results of the radiographs 
and the assessments made by the primary care and respiratory physicians. 
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Table 30: PALSA diagnostic categories 
Acute mild/moderate COPD/asthma exacerbation 
Acute severe COPD/asthma exacerbation 
Asthma - moderate 
Asthma - severe 
Asthma - well-controlled 
COPD - complications 
COPD - infective exacerbation 
COPD - moderate 
COPD - severe 
Chronic bronchitis 
Common cold 
Acute otitis media 
Chronic otitis media 
Outer ear furuncle 
LRTI - high-risk 
LRTI - low-risk 
Intermittent allergic rhinitis 







Non-P ALSA diagnosis 
7.6 Assessment of patients by a primary care physicians 
After the nurse's assessment was completed, patients were seen by one of two 
primary care physicians (RGE, TvR) who were blinded to the nurse and respiratory 
physician diagnoses. Both primary care physicians each had over 6 years postgraduate 
clinical experience. The physicians took a comprehensive standardised medical 
history and performed a physical examination that included all systems relevant to the 
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guideline and any other medical conditions present. This information was recorded in 
duplicate onto a structured record form. One copy of the record form was left in the 
patients' folders, and the other copy with the exception of the page containing the 
primary care physicians' diagnoses were filed for the respiratory physician to review. 
A copy of the structured record form used is provided in Appendix 11. The physicians 
performed flow volume loops before and after inhalation of 400~g of salbutamol 
administered from a pressurised metered dose inhaler, using a PMl Spirometer (Erich 
Jaeger®, Germany). Training of the physicians to perform these manoevres were 
undertaken by a qualified respiratory technologist over a period of one week prior to 
starting the study. 
The primary care physicians systematically recorded the patients' clinical details, the 
results of spirometry and chest radiography. Their diagnoses were made without the 
assistance of the P ALSA guideline. The results of these and the chest radiograph of 
each patient were reviewed by the physician., and if considered necessary, additional 
investigations (sputum, blood or other tests) were requested. They recorded their 
levels of confidence in each diagnosis made, using a 5-point Likert scale (1 
representing the lowest level of confidence, and 5 the highest level of confidence or 
certainty). In all subjects in whom even a low level of suspicion of tuberculosis was 
recorded, sputum specimens for examination and culture were obtained. In 
accordance with the South African National Tuberculosis Control Programme, 1 
sputum was only obtained for examination for tuberculosis in patients who were 
suspected to be infected. Thus, not all patients had their sputa tested. In most 
instances, the first sputum was taken at the study visit, and a second on the following 
day. Details of the algorithm followed by the respiratory physician, which is the same 
as that adhered to by the South African National Tuberculosis Control Programme can 
be found on page 16 of Appendix 6. More details of the methods used to test for and 
examine the sputa will be discussed later. 
Further patient management was performed according to usual clinic procedures and 
standards of care. Up to four guideline diagnoses could be made in each patient. 
Patients requiring referral or further care were sent to one of the following: the 
medical officer at the clinic, to a district hospital or specialist clinic in the local 
academic hospital, or to the local tuberculosis clinic. No laboratory results were 
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available to the study physicians at the initial visit, but a follow-up visit was arranged 
for those requiring further follow-up, discussion of results, or investigation (for 
example, after a trial of therapy). Patients requiring respiratory specialist attention or 
in whom the respiratory diagnoses was uncertain were referred to the respiratory 
clinic at the local academic hospital. 
7.7 Assessment of patients by a respiratory physician 
Two qualified respiratory physicians (RD, AH), who were both blinded to the nurse 
and primary care physicians' diagnoses independently reviewed each patient's data. 
This evaluation was done off-site and patients were not present. They had access to 
the structured record sheets containing information regarding the presenting 
complaints, history and examination findings, as well as chest radiograph films and 
printouts of the lung functions, but not their diagnoses. They could record up to four 
diagnoses for each patient onto a structured record sheet. Diagnoses were accorded a 
P ALSA diagnosis and if none applied they were assigned to the 'non-P ALSA 
diagnosis' category (Table 30). 
The GINA and GOLD guideline parameters were adhered to for diagnoses of asthma 
or COPD, respectively. These parameters, however, merely acted as diagnostic 
guides, as their final diagnoses were informed by their clinical judgment based on 
clinical information and investigations. For example, the assessment of levels of 
control of asthma was informed by spirometric results, but the final assessment was 
based on clinical judgment taking history and examination into account. A P ALSA 
diagnosis of mild/moderate COPD was based on GOLD stages 2-3, and severe COPD 
on stage 4 COPD. High-risk LRTI was assessed according to the likelihood of 
mortality according to age, concomitant disease and disease severity. Low-risk LRTI 
were diagnosed in patients who could be treated as outpatients, or those who in the 
opinion of the respiratory physician did not require antibiotics. 
Severe acute exacerbations included patients who required urgent treatment and/or 
needed to be referred for further management. Mild/moderate exacerbations included 
patients who according to their symptoms or history required immediate but not 
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necessarily urgent treatment, and/or in the opinion of the respiratory physician could 
be managed in the clinic. 
7.8 Investigations 
7.S.1 Chest radiography 
A postero-anterior x-ray film was taken at the clinic's radiography department. A 
Shimadzu x-ray machine was used and films were developed immediately in the 
Kodak. processor. X-rays were repeated if the quality was not thought to be acceptable 
to the radiographer or the doctor. The films were then taken directly to the primary 
care physician by the patient for assessment. 
7.S.2 Spirometry 
All lung function tests were performed on one of three Jaeger PM2 spirometers 
(Fredrich Jaeger, Germany). This apparatus employs a digital gas volume sensor for 
bi-directional measurements of airflow enabling performance of flow volume loops. 
The PM2 sensor was cleaned and disinfected once a week as recommended by the 
manufacturer. Calibration was performed daily using a 3-Litre calibration pump, and 
disposable mouthpiece incorporating a microbiological filter was used for each 
patient. All lung function tests were performed daily between the hours of 08HOO and 
16HOO. Patients were asked to refrain from smoking, drinking hot or cold beverages 
and from using an inhaled bronchodilator prior to testing, where possible. However, it 
was not possible to ensure that all subjects withheld bronchodilator therapy for four 
hours prior to testing. Therefore some values were potentially 'post-bronchodilator'. 
The majority were not. 
Forced expiratory manoevres were performed with the patient seated with a nose clip 
on herlhis nose. In accordance with American Thoraci,c Society recommendations 
these were repeated until 3 satisfactory expiratory flow volume curves had been 
obtained. The PM2 quality-assurance steps provide prompts when curves are 
satisfactory and do not permit the next step until the requisite curves are obtained. 
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Four hundred micrograms of inhaled salbutamol was then administered via a metered 
dose inhaler using a Volumatic® spacer device. A post-bronchodilator blow was 
performed ten to fifteen minutes later. FEVl, FVC, and FEVIIFVC ratio were 
presented in liters and percent of predicted. Reversibility readings were presented in 
milliliters and percentage. The study doctor reviewed the results immediately, and a 
copy of the test was placed into the study file for review by the specialist. 
7.8.3 Blood pressure measurement 
Blood pressure was measured using the COLIN Press-Mate Advantage® apparatus 
that measured blood pressure non-invasively and automatically and recorded it in 
units of mmHG. The appropriate cuff size for the patient's arm width was placed 
around the upper arm. The measurement was displayed on the monitor and the result 
was automatically printed along with the oxygen saturation result. The manufacturer's 
instructions for use of this apparatus were adhered to throughout the study. 
7.8.4 Pulse oximetry 
Oxygen saturation was measured using the COLIN Press-Mate Advantage® 
apparatus and recorded as a percentage. A non-invasive Dura-Sensor DS-IOO®, 
which is a reusable finger probe for adults weighing over 40kg was used. The 
measurement was displayed on the monitor and printed out along with the blood 
pressure result. The manufacturer's instructions for use of this machine were adhered 
to throughout the study. 
7.8.S Temperature 
The temperature (in degrees Celcius) was measured using a glass-mercury 
thermometer placed under the tongue for at least 3 minutes. The pati ents were 
instructed to not drink any warm or cold fluids before this measurement. 
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7.8.6 Heart Rate 
The heart rate (beats per minute) was measured manually. The exact number of radial 
pulse beats in 60 seconds was measured. 
7.8.7 Respiratory Rate 
The respiratory rate (breaths per minute) was measured by counting the number of 
breaths taken by the patient in 60 seconds. 
7.8.8 Sputum collection 
A first specimen was collected immediately and a second specimen the following day. 
• Instructions were provided to patients on how to optimally produce sputa (Appendix 
5, page 16). At the clinic, the smears were refrigerated, and later transported to the 
laboratory on the same day that it was collected to ensure viability of the sputa. The 
sodium citrate method was used to process the smears which were stained using the 
Ziehl-Nielsen method and then examined for acid fast bacilli (AFB) by one reader. A 
positive smear was reported if at least one AFB was visible per 100 immersion fields. 
Sputa were cultured on a slope of LOwenstein-Jensen medium and incubated at 37°C 
for about six weeks. Bacteriological confirmation of tuberculosis was accepted if two 
sputum smears collected on different days were positive as reported above, or one 
culture was positive with or without a positive smear. 
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7.9 Statistical Analysis 
7.9.1 General analysis 
After data collection, data were entered and cleaned by 5 data capturers. Each entry 
was double-checked by ROE to ensure correct capture. Where missing data related to 
information retrieved from history, an independent person reviewed the nurse's 
handwritten notes to determine whether she had recorded the data. Where the data 
related to information that could be easily obtained from the patient and that was 
unlikely to have changed significantly from the time the study was conducted, an 
attempt was made to contact the patient to obtain the information. Data were analysed 
using Stata 8® statistical software. 
Descriptive analysis was conducted to describe the data distributions, to examine 
outliers, and to determine whether parametric or non-parametric methods should be 
applied to subsequent univariable analysis. Inter-physician agreement was measured 
by determining the kappa statistic. Interpretation is as follows: 0-0.20 means slight 
agreement, 0.21-0.40 means fair agreement, 0.41-0.60 means moderate agreements, 
0.61-0.80 means substantial agreement, and 0.81-1.00 means 'almost perfect 
agreement".2 
7.9.2 Sample size determination 
Prevalence of PALSA conditions among patients with cough and/or difficult 
breathing at Retreat Day Hospital as diagnosed by an experienced generalist 
(December 1999, Summer season) is shown in Table 31 and Table 32. 
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Table 31: Estimates of prevalence of respiratory diseases likely to be encountered 
in the study. 
Chronic Obstructive Pulmonary Disease 
Upper Respiratory Tract Infections 
Asthma 









Table 32 lists the proposed prevalence distributions of the P ALSA diagnoses. 
Table 32: Likely prevalence distributions of the P ALSA diagnoses 
ACUTE 
Severe 
Acute obstructive lung disease 
Lower respiratory tract infections 
Moderate 
Mild obstructive lung disease 
Lower respiratory tract infection 
CHRONIC 
Chronic obstructive pulmonary disease 
Moderate 
































The sample size of 2000 was intended to provide reasonably precise estimates of 
sensitivity, specificity, positive and negative predictive values, for a range of key 
diagnoses (Appendix 4). For example, for a relatively mre diagnosis such as 
tuberculosis, which has a predicted prevalence of 3% in this setting, if the sensitivity 
of a nurse using P ALSA to diagnose tuberculosis, compared to a specialist, was 70% 
then the corresponding 95% confidence intervals was predicted to be 58-82%. The 
sample size of 2000 was said to provide reasonable estimates of chance - corrected 
agreement between P ALSA doctor and the specialist expressed as a kappa statistic 
(Appendix 14). For example, for a condition with 4% prevalence and a kappa value of 
10%, the 95% confidence interval for the kappa will be 5-15%. For a prevalence of 
15% and a kappa of 60%, the 95% CI for kappa will be 55-65%. 
7.9.3 Analytic methods to determine diagnostic accuracy of the guideline 
Studies detennining the diagnostic accuracy of tests, compare the results of one or 
more tests with a reference standard. 3 The sensitivity, specificity, positive and 
negative predictive values, areas under receiver operating characteristic curves, and 
positive and negative likelihood ratios for each index test compared with each 
reference standard (respiratory physician diagnoses) were calculated. 95% confidence 
intervals (CI) for proportions were calculated based on binomial distributions. 95% 
confidence intervals for areas under receiver operating characteristic curves were also 
detennined. These were calculated for broad disease categories (asthma, COPD, 
exacerbations, LRTI, URTI) and levels of diseases severity or control diagnosed by 
the nurse and were compared with those diagnosed by the respiratory physician, 
except for diagnoses of suspected and confirmed tuberculosis where the primary 
reference standard was considered to be the primary care physician. 
The nurse and physicians were allowed to make three and four diagnoses per patient, 
respectively, as it was estimated that these were potentially the most number of 
concurrent diagnoses made in one consultation when (1)·using the guideline (nurse) 
(2) considering concurrent respiratory and comorbid diagnoses (Physicians). Thus, 
when analysing the false positive and negative results we analysed each potential 
diagnostic category. We wanted to have a more accurate reflection of concurrent 
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disease presentations. For the nurse using the guideline the primary diagnosis was 
defined as the first diagnosis that the guideline 'led' the nurse to. This does not mean 
that the secondary of tertiary diagnoses were less important. For the specialist, the 
primary diagnoses was the condition that he/she thought to be the reason for the 
presentation. Any additional or comorbid conditions were recorded as secondary, 
tertiary, or quartenary diagnoses. 
7.9.4 Analytic methods to derive predictors for each disease 
Continuous measurements (pack-years, heart rate, respiratory rate) were categorised 
according to the PALSA guideline criteria, and according to cut-points obtained from 
published literature or from noting obvious inflection points on receiver operating 
characteristic (ROC) curves. The relationships between each diagnostic element and 
the reference standard diagnosis were tested using chi-square or Fischer's exact tests, 
depending on distribution of data. Data for each question included in the structured 
record sheet were examined for a relationship with each outcome. Categorical 
variables were also reduced to single items and each one was examined independently 
by univariable analysis. 
Criteria for including a variable into the reduced multi variable model was a risk ratio 
(RR) of> 2.0 or less than 0.5, with a sample size of more than 100, and p-values of 
less than 0.05. However, variables not showing significance, but which were thought 
to be important in multivariate analysis were included. As far as possible we adhered 
to the rule of including at least 10 outcome events for each independent variable 
included in the model to reduce overfitting of data. 4 Stepwise multiple regression 
analysis was performed using the Spiegelhalter Knill-Joness technique to determine 
which combination of symptoms and signs best predicted each disease Variables were 
excluded from the models if not independently associated with the reference standard, 
and if their odds ratios were less than 0.5 and more than 2, aiming for a parsimonious 
model of powerful predictors. Independent (mutually-adjusted) associations between 
each predictor and the reference standard diagnosis were then expressed as likelihood 
ratios instead of odds ratios. This entailed adjusting crude likelihood ratios with 
shrinkage factors obtained by logistic regression for potential confounding by other 
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related variables, as described by Spiegelhalter and Knill-Joness• The adjusted 
likelihood ratios of different predictors can be multiplied by each other because they 
are independent. Confidence intervals for adjusted likelihood ratios were estimated by 
non-parametric bootstrapping of logistic regressions, with 2000 replications, and 
using the bias-corrected percentile method. 
This analysis was conducted for each disease, except URTI, as the number of patients 
with respiratory physician diagnoses of this condition was too small. For asthma and 
COPD, 3 separate analyses were perfonned to reflect clinical practice and to infonn 
future guideline revisions. The categories were for patients: (1) ~15 years (2) ~15 
years with respiratory physician diagnoses of obstructive lung disease (asthma or 
COPD) (3) ~O years with respiratory physician diagnoses of obstructive lung 
disease (asthma or COPD). Only for tuberculosis was the primary care physicians' 
diagnoses used as the reference standard. 
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Chapter 8 : RESULTS OF THE VALIDATION STUDY 
8.1 Overview of the chapter 
This chapter presents the results of the assessment of diagnostic accuracy of the 
PALSA guideline for asthma, chronic obstructive pulmonary disease (COPD), acute 
exacerbations, tuberculosis, and lower and respiratory tract (LRTI) disease. The 
following will be considered. 
• The accuracy of the guideline as used by the nurse in diagnosing conditions 
included in the P ALSA guideline using the respiratory physicians' diagnoses as the 
reference standard. For tuberculosis, the nurse's diagnosis of suspected 
tuberculosis will also be compared to the primary care physicians' assessment of 
suspected and bacteriologically-proven tuberculosis. 
• How frequently and which conditions were misclassified by the nurse using the 
guideline by examining the false positive and false negative diagnoses, thereby 
determining the diagnostic and treatment implications of the nurse making an 
incorrect disease classification. 
• Which symptoms and signs best predict each condition in patients with cough or 
difficult breathing, by estimating their crude and adjusted likelihood ratios, 
respectively. For asthma and COPD, to estimate these separately for the following 
patient subgroups: (1) all patients (2: 15 years) (2) patients 2: 15 years with 
obstructive lung disease (asthma or COPD) (3) patients 2: 40 years with obstructive 
lung disease. 
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8.2 Patient characteristics 
8.2.1 Patient sample 
Of the 1400 patients enrolled into the study a total of 1392 were eligible for analysis. 
A flow-diagram illustrating the flow of patients in the study according to the 
Standards for Reporting of Diagnostic Accuracyl (STARD) is presented in Figure 3. 
Reasons for exclusion were as follows: 6 absconded, 1 was screened twice and 1 was 
unable to give an adequate history. 
Figure 3: Disposition of study subjects (ST ARD diagram). 
Excluded patients (n=8) 
1----------tJoi· Absconded n= 6 
LEVEL 1 Nurse 
n=1392 
LEVEL 2 - Primary care physician 
n=1392 
LEVEL 3 - Respiratory physician 
n=1392 
• Screened twice n= 1 
• UnfitlProtocol violation n= 1 
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Table 33 lists the patient characteristics of the study population. There was a 
predominance of females (63%), the median age (range) was 48 years, and 806 (58%) 
were between the ages of30 and 60 years. 
Table 33: Age and sex distribution of study population. 
Variable 
Age 
Mean age (SD), years 




Sex, n (%) 
Females 
Males 








The symptoms resulting in patients' inclusion in the study were cough and difficult 
breathing (in 71 %), cough alone (in 19%) and difficult breathing alone in 10% (Table 
34) Tight chest (50%), wheeze (45%), and sputum production (35%) were the most 
commonly reported additional symptoms, whereas symptoms of upper respiratory 
tract infection were a less common presentation in this study. 
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Table 34: Relative frequency of cough or difficulty breathing in patients entered 
into the validation study (n=1392). 
Screening question Number(%) 
Cough and difficult breathing 986 (71) 
Cough alone 264 (19) 
Difficult breathing alone 142 (10) 
Tight chest 690 (50) 
Wheeze 630 (45) 
Sputum 490 (35) 
Night sweats 180(13) 
Weight loss 163 (12) 
Increased sputum production 129 (9) 
Runny nose 121 (8) 
Pleuritic pain 102 (7) 
Sneeze/itchy nose 54 (4) 
Haemoptysis 53 (4) 
Blocked nose 50 (4) 
Fever 43 (3) 
Sore throat 35 (3) 
Sinus pain 12 (1) 
Discharge from ear 8 (1) 
Painful ear 6 (0.4) 
Hearing loss 1 (0.07) 
Tooth pain 1 (0.07) 
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8.2.3 Previous respiratory conditions 
More than two-thirds (69%) of patients reported a previous diagnosis of one or more 
associated respiratory or related disease (Table 35). Asthma (43%) was the most 
commonly reported respiratory disease, followed by COPD (20%) and TB (15%). 
Data detailing the medications that each patient used at the time of the study is not 
provided in this analysis. 











Interstitial lung disease 
Lung Cancer 
Cardiopulmonary lung disease 













* Some reported more than one previous respiratory diagnosis. 
For each disease the denominator is 1392. 
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8.2.4 Previous non-respiratory medical conditions 
Table 36 lists the past medical conditions reported on presentation. Cardiovascular 
disease, including hypertension was present in 38%; allergies, including allergic 
rhinitis in 16%; and metabolic conditions, including diabetes mellitus in 10%. 
Table 36: History of non-respiratory medical conditions in patients in the 

















* Some patients reported more than one previous medical condition. 
For each disease the denominator is 1392. 
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8.2.5 Smoking history 
The prevalence of a history of smoking (current or former) was high. Just over three-
quarters (76%) of the population had a history of smoking, and the majority (47%) 
reported ongoing tobacco use (Table 37). Seventeen percent of patients admitted to 
having previously used cannabis, with 92% reporting its use for years. 
Table 37: Smoking status of the study population. 
Smoking status (n = 1390)# Number (% of total population) 
Never smoked 330 (24) 
Ex-smoker 407 (29) 
Current smoker 653 (47) 
Smoking history (pack-years) (n = 1386)* 
<20 930 (67) 
20-39 277 (20) 
>40 179 (13) 
Duration of cannabis use (n = 237) 
~~ 3m 
Weeks 1 (1) 
Months 10 (5) 
Years 182 (92) 
# Data on smoking status unavailable for 2 patients 
* Data on smoking history unavailable for 6 patients 
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8.2.6 Spirometry 
The mean spirometric values are presented in 
Table 38. For the first 19 patients, the data for spirometric testing were lost due to a 
technical error. For 25 patients, ATS criteria were not met. The mean FEVI was 66% 
predicted and the mean PVC was 75% predicted. The mean FEVIIFVC ratio was 
87% and the mean number of patients with a change in FEVI of ~15% and ~OOmL 
after bronchodilator testing were 30%. 
Table 38: Spirometric values of the study sample (n=1348). 
Spirometry values 
FEVI (% predicted), mean (95% CI) 
FVC (% predicted), mean (95% CI) 
FEVIIFVC ratio (%), mean (95% CI) 
Reversibility, t (%) mean (95% CI) 
Number of patients with reversibility,t n (%) 
Airflow limitation, n (%) 
FEVIIFVC ratio <70% 
FEVI < 80% (% predicted), mean (95% CI) 
t ~FEVI ~ 15% only 









Table 39 lists the mean FEVI and FEVIIFVC ratios for each disease category as 
diagnosed by the respiratory physician. 
Table 39: Spirometric values for each disease category. 
Disease classification No. MeanFEVl Mean FEVIIFVC 
(% predicted; 95% CI) ratio (%; 95% CI) 
Asthma 489 62 (60·64) 81 (79·82) 
Well·controlled 49 78 (70·87) 92 (89·96) 
Moderately controlled 180 65 (61·68) 84 (81·86) 
Poorly· controlled 260 57 (55·60) 76 (74·79) 
COPD 353 45 (43-47) 69 (67-72) 
Mild/moderate COPD 225 56 (53-58) 77 (74-79) 
SevereCOPD 107 26 (25·28) 57 (53·60) 
COPD with complications 21 24 (20·27) 54 (46·62) 
Acute exacerbation 287 54 (51·56) 76 (74·78) 
Severe exacerbation 90 42 (38·46) 71 (67·76) 
Mild/moderate exacerbation 197 59 (56·62) 78 (75·81) 
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8.2.7 Respiratory diagnoses made by the nurse using the guideline 
The most common diagnoses made by the nurse using the guideline were asthma 
(38%), followed by suspected tuberculosis (37%), COPD (29%), and acute 
exacerbations (26%). URTI was diagnosed in only 7% of patients (Table 40). 
Table 40: Respiratory diagnoses made by the nurse using the guideline 
(n=1392).* 
Nurse (guideline) diagnoses 
Asthma 
Suspected tuberculosis 
Chronic obstructive pulmonary disease 
Acute exacerbation of asthma/COPD 
Lower respiratory tract infection 
Chronic bronchitis 
Upper respiratory tract infection 
Allergic rhinitis 











8.2.8 Respiratory diagnoses made by the respiratory physician. 
The respiratory diagnoses made by the respiratory physicians are listed in Table 41. 
Asthma was the most prevalent condition (36%), followed by COPD (27%), acute 
exacerbation (21 %), and LRTI (20%). Tuberculosis was suspected in 19% of patients. 
These served as the reference standard against which the diagnostic accuracy of the 
nurse using the P ALSA guideline was judged. 
Table 41: Respiratory diagnoses made by the respiratory physician (n=1392).* 
Respiratory physician diagnoses 
Asthma 
Chronic obstructive pulmonary disease 
Acute exacerbation of asthmaiCOPD 
Lower respiratory tract infection 
Suspected tuberculosis 
Allergic rhinitis 
Cardiovascular disease, including hypertension 
Other lung conditions 
Metabolic diseases (including diabetes mellitus) 
Chronic bronchitis 
Upper respiratory tract infection 














8.2.9 Inter-observer agreement between the respiratory physicians 
Table 42 illustrates the agreement between the respiratory physicians for 200 patients. 
Agreement between the physicians for all conditions were satisfactory. Kappa values 
for asthma, COPD and acute exacerbations ranged from 0.66-0.70. For suspected 
tuberculosis and LRTI, these values were less satisfactory (0.57). 
Table 42: Levels of agreement between the respiratory physician diagnoses 
(n=200). 
Respiratory Agreement, 0/0 Expected Kappa Standard 
physicians agreement, % Error 
dia2llosis 
Asthma 85 51 0.70 0.09 
COPD 84 53 0.66 0.09 
Acute exacerbations 88 61 0.70 0.09 
Suspected TB 85 65 0.57 0.09 
LRTI 85 65 0.57 0.09 
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8.3 Asthma 
8.3.1 Accuracy of the nurse using the guideline in diagnosing asthma 
Table 43 lists the diagnostic accuracy of the guideline in the hands of the nurse in 
diagnosing asthma (n=533), using the respiratory physicians' diagnoses (n=508) as 
the reference standard. More than three-quarters of patients were correctly diagnosed 
by the guideline (sensitivity 77%). The guideline's performance was good with an 
accuracy, defined as the area under the receiver operating characteristics curve 
(ARUC), of 0.81 (Figure 4). The positive likelihood ratio value indicates that a nurse 
using the guideline was 4.83 times more likely to make a correct diagnosis in patients 
who are also thought to have, as opposed to those thought to not have, asthma by the 
respiratory physician. 
Table 43: Diagnostic accuracy of the nurse using the PALSA guideline in 
diagnosing asthma with respiratory physicians' diagnosis as the reference 
standard. * 
True positive, n 392 
True negative, n 744 
False positive, n 140 
False negative, n 116 
Sensitivity, % (95% CI) 77 (73-81) 
Specificity, % (95% CI) 84 (81-86) 
PPV, % (95% CI) 74 (70-77) 
NPV, % (95% CI) 87 (84-89) 
LR+ 4.83 
LR- 0.27 
ARUC (95% CI) 0.81 (0.78-0.83) 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive 
likelihood ratio, LR-: negative likelihood ratio, ARUC: area under the receiver 
operating characteristics curve. 
* Nurse diagnoses (n=533). Respiratory physician diagnoses (n=508) 
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SympitlllU' lnwrcd by CII"'torIIDCTI1 ihlll\lh 
NOCtlIl1Ial lll!htnc:u of dim 
"'I1I,ly h,$IOf)' of asthma 
Inil)" couilh 
Dillyorr~um~ 
Nocturnal 5hort_ o{brealb 
I»))'tl~ 11&111_ of chcsl 
llilflCUll """''' ~ 2 ... eels 
Nocturnal COIIlb 
WlIcc« 011 *loCUIIMIOII 
NOC'Iurnal.l\eI:«: 
Couab~! "uU 
SymplOll11 IIllJlrml by rcspIllIIIOf)' tract 101«110111 
I>3)ttmC " 'ba:.fc 
SyDlplomI Ingzcmi bycmoclOll 
Dadyor frIlqlOC'Dl fpUI\lm produaM)ll 
'1151"'1 of ha)"ncr 
S)"IllpiOOll s.!o ... ly ...-orr;mc:d ()\"eI" limo: 
Short ot bmltb Ibr moM otthe 41y 
I;.1IO ... n 1IIeJ111:¥ 
COIIib and sputum. ~JOII ~ tbcou:& ~of~ 
S)'lllplon"l~ Ir1&FR'd by apoII,n: 10 a11c:rpca 
"''''~ Nnl'l'" IlWd I brto;:bodibmr Ixftft 
1I111"'1ofCOI'D e ...... _ 
Nllmba ofc,~_ •• bo1ooaI pel" )oar 
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8_' .4 Aaal~'il} or biJlo!,} ud namiDatlon predklon ur u lhma 
Tabll' 48 lisl! IlK' Sijplllklllll uni\ ariab]~ "" .. dieters of asthma in ~ticnlS ~ 15 }Tlm 115 
measured by their crude lIkehhood 1'lI1105. In this o!)C calcpr. 0hSC1 or ~)mploms 
~fon: the a .. o(: of:W )'ClU'5 flK~ 6.28} .• p~'ioU$ diagl105i5 uf llS!hlna elR T 579}. 
nlic'lPCS tlR. 5,011). lICasonnl \lInallon of s)mptDlm (lR+ 513). !b)-clHlay 
"'"nablli ty 0 1 symptoms (lK ~ 4 J4J. In~nng UrS)'TTIpIOO1S by C'ITK)I.i~ (LR'" 4.0S). 
n:spirotury tmet In fC<.1lon5 (lR4 ~ 16J or em lr'OOmcnI3] fllC10cs (lR + 3. 16) "c:T'C' mosI 
pr~"t! lcll\' e l)a)1Imc ... +teenns (1..R. 1 1M) and chest lightness IlR" 2.85) "'ere 
moocrnlcly pmhCII 'c. II§ \O.CT"C ooctul'1llll Jymploms (\O.beenn; (lR~ 2.6M. !ihonness 
or bn.alh (LR. :UW). cheSl IIGJllneu (LR - 2,]4}). wh«nng 011 aullCulwion (LR-
2 . .HI. lind any ~o:d ,,'II("l:l.1n& (LR-t 2.60). A :m1Oklllg histOl)' of <: 20 p."ld: )'NN 
\O.lIS ooly lohghtly pn."t!ICI!\": o f asthma (LK, 1.40). Ahbough th&:- onKt of symptoms 
bl:fort' lhe a .. ~ of 2() )"tOal"ll WI"-- lhe SlfOf'lSCSl predictor. It haoJ a low !ICIlSlli\11)' (oHO'.) 
bUI hlah spetllicu) (930 .). ,\ ~\'iOU5 dllllj1lOSIS of IlSlhma and sca5llnal \ .. nallOn of 
S)mp'OffiS had good J('flJllIVIIIC:S (84· ... 8S" ... ) lind S]J\."CI lid,ics (95' ... IU" oj. 
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Table -18: Uni\"llriable prediclO l"S of a51hl1l~ in paljc lIl ~ <! 15 ~ can olel " -jlh cough 
Mnd dirticulty breathing. 
"ariablcs Se il S. Spet.". C rude likl'lihood 
% rallo~ 
lR+ lR-
Onset ofs)mptonls Mfore the age of20 years ," " 6.18 0.62 Previous diagnosis of asthma '4 85 5,79 0.1 S 
Seasonal ,'ariation .1f S)l11ptOtrui 85 " 5. 13 0.18 Past m~ical history of allergies 34 OJ 5.08 0,70 
Day to day variabIlity of S)l1lpt()1nS 8S 80 4.14 0.15 
S)lllptOms triggered hy emOTions 4' 89 4,05 0.62 
HIstory ofhayfever 42 " 3.14 OM OnSe1 ofdyspnoca is l-pisodic 54 86 3.75 0.54 
Daytime "'hcczing " 86 J.65 0.58 History of allergies 20 04 H7 0,S5 
S)mpl0m~ trigg~n-d by environmental factors 64 " 3.16 0.45 Symptoms tnggcred by respiratory tract 54 83 3. 16 0.55 
in f("(:li Ofl.'l 
Family history of asthma " 7S 2.'" 0,48 Daytime tIghtness of chl-sl 00 79 2.85 0,51 
Noctumal ... hce7jng 57 7S 2.66 0.54 
Symptoms tnggcrcd hy weather 75 71 1.61 0.J5 
History ofwheel-ing 75 72 1,60 0.36 
S)TIlpto=tic response to inhaled 89 64 2.50 0.17 
t<ronchodilator 
Whtezing(audiblc or on auscuh3lion) " 77 1.35 0.59 Nocturnal tightness of chcsi " 73 2.34 0,49 History of lightness of chest 77 OS 2.10 0.}5 
NoclUmal shoT!n~"SS ofhreath " 71 1.09 0.55 Symptoms worsened s[ow[ y O"l'T IUIIC 21 55 I."" 0.47 
NO! shoT! ofbrcatb for most ofth~ day 18 " !AI 0.43 Smoking history of less than 20 paek years 83 " 1.40 OAI Cough anJ spulum protlu~tion did nol " 62 1.37 0.40 prcccd~ onset of shortness ofbrcath 
Ft:male " 57 1.3-1 055 History Qfdiflh:uh b~aJhing " 26 US 0.23 No pre"ious diagnosis ofC'O!'D J 77 1.26 0.15 
No past history of tuben:ulosis 9 S3 1. 11 0.49 
No leg oL-dcma m el\llImnallOn J 91 1.07 0.31 
Cruckles heard on auscl.lItahOn 4 87 0.32 1.10 
'83 
8.3.4.1.2 Multi"ariahle analys is o( prcdirlOrs of as thma: ~1 5 yea rs 
Table 49 li sts the sigmfieant multinmable prlxhctors of asthma in patients 15 years 
Ill1d older as detcnmncd by logistic regression analysis after adjustment for non· 
dcvc.,ldence. A previous diagoosi~ of asthma (LR+ 2.27). ollSet of 5~1nplOmS before 
the age of 20 years \LR+ 1.73). WId !Ill audible wheeze or whcc:ze on auscultation 
(LR+ 2.20) were most prcdieti\e. Reponed 5)1nplom3tic response to bronchodil31(or 
thempy, nocrumal dyspnoea, s}mptoms triggered by emotions. no worsening o f 
symptoms over time. and no previous diagnosis o f COI'D were only moderately 
prl'(]ict,vc (LR+ 1.47·1.32). lfall 9 items i'<lriabks) were prcsem in 3 pat ient :::: 15 
years with cough or difficult breathing then the (cumulatIVe) likelihood of a diagnosis 
of asthma would be 81.8. In contrast. if all 9 variab les were absent the pallent would 
hal e II vcry slim likelihood of being asthmatic (LR· 0,01), Ill1d asthma can be I'inually 
ruled out 
Table 49: Muhiuriable prl.'dic lors for the diagnusi$ or asthma in p~ tie nts :: 15 
rears (N~IJ54). t 
Likerhood ratiu 
lliagnl>Sli~ clement Faclor 95-1. C I Faclor 95-;. CI 
ercst,,1 IIlt S"'''I 
Previous diagnosi ~ of asthma. 2.27 1.6'J·3.01 0.5} 042·0.67 
Onset ofsymptoms before the 1.73 1.39·2.08 O.KI 0.9()..0.90 
age uf 20 )I'ars , 
Audible, or wheeze on 1.10 1.72·2.76 0.61 0.52-0.72 
auscul!atiol1. 
Day 10 day variability or 2.22 1.50-3.16 0.55 0.37-0.66 
s)mptoms. 
Noclurnal shonncss ufhreath. ! 31 1.14·U! 0.82 0.73-0.92 
Symptoms triggered by 1.10 1.01·1.17 0.93 0.87·0.99 
emotions. 
Rcsponsl.' to bronchodilator 146 1.02·2.16 0.57 0.41..0.76 
No wor.;t'!l1l1g o fsymptom$ (/VI;1 1.46 1.02·2.16 0.55 0.52..().75 
time. 
No erl'vious di3!;!!0~is .. fCOPD. 1.47 1.16-1.84 OA2 O.2()"0.l!3 
CUlTIulatll'c LR~ (1111 9 Items) 81.R 17.7·41.3 O.UI 0.0 1-0.21 
t 38 Patients had specialist diagnoses of asthma and COPD. there/ore c-:dud~'(] from 
the multI "ariale anal )sis 
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Tht' cut-<lIT (or n dlQ/PIOOIS of asthma In patients ;>: I S years is > S iTsbh: SO). 
Therl'Jore. Ir 4 or more Symptoms IIrt mcluded in the .leril((1 mod.:!. then IlSlhmll eun 
be: tba!lJlOktl Wllh a sen,<;uivuy of 86"'. und spe.:ii1cny of 87" •. Figure S demonslrnl<:S 
Ihe Ik."CUl'3ty orlht dmlttl prediClion rult (ARUe 0.93) oompured 10 me uccumcy of 
the nurse \li1l1g lhe lJIIiddl~ (A RUC 0.81). 
'hbl.., 50: C UI-poial of d{'rind mullh'uriable model for predic ting a)thma. 
Cu i on St'm,ilhil ), Sprcirldl)'. COrTtd l~ CR+ I. R_ 
polnl (Y.I (%) C lanififfi. 
% 
'" 100 0 Jj 1.00 ., 100 I Jl 1_0 I 000 
" 100 " " 1.16 000 >J 98 60 JJ 2.44 0.03 
'" 93 " 8) 4.21 1.00 '" " 87 87 6.47 0,1 (i ><i 75 91 .. 9.7-1 O.n 
.7 53 97 81 19.5 0.48 
'" " 96 " 56.4 0.7-1 >9 7 100 " 0.91 
Figur{' 5: Pt rforlJ\;iln{'t or nurse u$ing 11K- ~uidc11nc computd 10 thr dHh'l'd 
lin-diction rull' ror pa tients ~5 rears (ARUC) for I dbl!no~b or .$thma. · 
• chronu5thn- nur.;c dilllPlVSI.'d IIslhmB: fIlISlhmu - d"lil ed predl~1lon modd 
I" 
I. .' .J.? Prrdk",,.., "f INI""II: ~ 15 }YII" .. 'it" ,,..,IImll or COPD 
8.:\.4.2.1 Uni .-. rlllbll' II nlllYII) or p~kl.,n or :11)1"",11: p;lllknl~ .. illl n lll"," Dr 
COI' I). 
Anal>'I! of the uOl, .... lIble prcdlt:lOn fOf astbm.II In pa.w;:nu ~ 15 >"ars "'llh 
ubsIOl.:t I'l' IIIfIII dl5Je~ 1\. .. eakd • number of, anallles strotlgl) pn'(iICli\'c of MIluM. 
T~blc SI These "'ere: omcI of .),mplOms before the "4.'<' of:!O )ea1O (LR+9,9). /I 
PfC"IOIU dlugnosi. (If ;IIl,lhml (U"S 11 ), • hl~OI')' of h.yfl:'o-..... ~ LR 0-6.9S). ~"uo"ull 
"1II"i1l11Ofl of )'llIptoml ILR·~ 14) •• hlilury or alll-TpCS (lR~","9). Uil)' \() ~) 
~~nllbihly of Iymptoms fLR+4 J3 I 
1'.h'~ 51: Lnh-.ri.bI~ prrdkt~ of .,111'111"1,, padr"h .. h~ ot"ll'\I l"Il\ ........ f.Ill ......... 
,."hllli or corm. 
0.-""1'1,,1"',, Srn .. -_ Sprr. -. CMUm. 
I.M ... \.M • 
OnRl of.)mploms bcf~ the ".,'eof ' 2 .. 9'" 0,4'11 
2() )"a.rs 
I're. I"US dIDgn0>5IS of .. tun. " .. 11.71 0,17 History ofhlyfl:'o er " '" (i 95 0,62 Sc:tSOn.I,.,.hon " " '" 0,19 11I5tOl')' of 1I11&:fWcs 20 ., ,,' o 8~ 
DlI} to dlly 'Ml"mlll)' of symptoms 88 110 ,4-\J O,IS 
1\(1 ... lXStI1lng tl f ~mptoml O,'&:f tllTIC " 21 3,70 027 Srnolmg hislOr)' orles! thlln 20 J!oX'~ 8J " 1.17 0.1] "' .. Family hiSloryof asthmD '" RO 317 0,47 '01 Won o'brellth for most of the " " 2" 0.2S d., 
;"'0 rough and 5JlUlUm p-OOUCl ion " 29 2.90 0.1 1 precl"ded 
FClllalc " " 2 19 Oj7 1\1.' pn""IWS UliKflOlIS of CO I'D J " 2, IS 006 Illstory of tlghllll:SS of chest n " ,60 0 .. S)mptomPI.e lI:spOnsc 10 ulhllled " " 150 0.28 bronchodil:llor 
:-'0 hlshlry uf (!UlnObis usc " 67 1 .. 13 0,3.1 \\ 'hcc1~n1! (uu.hblc Of on " " 1.22 0,82 ,luscuIUthOn! 
• Sens: S('nSW' 'I); Spec: spco;:l lklt)' 
• .1 .... 2.2 1\1 Ulli"uiahlt an.ly," or pnd/clon Ill' I •• hma amon~ Pilltllt, "lIh I.,hm. or 
COt'" 
'86 
\1uhl\an3blc IOglSlu,: rq;re5SlOll analYliIs shoI\ai thaI a prcvious diagoosl~ of asthma 
II 11 slrong predictor (lR ' ~ .03) of rcspm:llory diSC3SC 10 paucnls .2: IS yean; with 
obslfUcthc lung diseuse. foUolloo by no report of gmd11:11 \\OrSe111ng of S)1l1plOmS 
01 CT umc (LR + 217) (Tablc 52). Other rrcthctors 01 obsb1JcU\ c luns dlscase lITC a 
pack ycn history of < 20. day to day \ .... ~,hty of symptom!>. \\h ... "t7Jng. and fcmale 
,;c); (LR + (42). The eumU]Phlc LR' IS 511. II/1IJ 1he cumuJtIIlVC ntgalllc hkchhoo.)d 
TallO is 0.01 
Tahll- 5 ~ ; ,\ dj ll ~l cd like lihood Ml tios for the diagDosiJ of asthma in pa t icnl ~ \\ IIh 
IISI hona or COI'O. (N=ItIJIII. t 
Adju"ed like lihood ra tio 
llill l! lIos tlc d cmcnl Faclor 95-/_ C I .·. ctor 1)5-/_ C I 
IlrC!}e l1t Hhsent 
Pre, lOW dia~is of of 03 3.0}·5. IS 0.21 0. 1(H}.28 
HSlhrna. 
No wOTSI.'Iling of 1-17 1.62·2.91 0.46 0.35-0.6 1 
symptoms OICl' ume 
Poclo. )'i:3I" hiSlOt)' uf <20 1.80 1.3 1·2.48 0.48 0.36·0.7 
><= 
Day 10 d~y ,·unabihtyof [7] I 3702.22 0.49 037-067 
S)1l1plOms. 
AudIble. or whce-« on 1.48 1.08·200 U.71 0.56-0.94 
a~hs"on 
Female 142 l.OS·[ 85 0.10 0.53-0.95 
Cumw31ile lil.:diOOod " nZ·I05 I OO[ OO I·O.ZO ral10 (all 6 ilC1t\$) 
t )8 palicnl5 \\ nh sp!.'Ci:aiJst diagtlO$o..'S of IISIhma tmd COPD. IlnoJ SS4 patlent~ \\ lihulll 
usthrna or COPD .... en: C'Ildudal from \he muhi .. .,lde analysis-
The ~III-off roo the PrW!ChOIl rule is 2:4 (scnsitivllY 8~ .. specificity 9)-_. and lhe 
LR-t is I! 9) (Table ~3). The ARLC WII.Icr lhl: run·c i$ OQS Figure 6 sho .... "'5 !h3llbc 
dcnvcd rule IS supenor 10 lite guiddmc algonLhm as u..aJ b)' the nurse: IARUC 0 86). 
IS' 
Tahle 53: C ut -point of derived nlulli>'arinble model for prcdiCiing asthma In 
p:llil'nt wi th OhM rueli>'e air" a~ s disease. 
C ut off Scnsitivit}·. Specificity. CorreeUy LR+ LR-
,>oinl ("I.) ("/.) Classlfkd. 
I'"I,,} 
"" 100 0 59 1.00 ., IIJ() 22 OS 1.17 0.00 
>1 " 55 80 1.19 0.<14 '" 9-1 76 86 3.89 0.08 '" 87 9J 89 11.93 0.14 '" 64 98 7S 34,3-1 0.36 ,. 2J 99 " 75.82 0.77 
Figure 6: Per fonnllll ce of nu rse using Ihe guideline eompn rtd In the derived 
prediellon rule for patients ~ 1 5 years " ·j.h ob$lructh'e airways disc,flSc ("RUe) 
for ~ dJa;!nosis of a5thl1l9 . 
• ChrollDSlh - num: diagnosis of asthmn: asa-{lcri> ",d pr~-dicli"n mndel 
8.3.4.3 l'N!dictor.. 'if uSlhmu: "2./0 y eul"1' "';fh U,,/r"' 11 ." COl',) 
Ii. 
8.3..1.3. 1. Ulli''flriubll' IIJlIII)·.~is of fJreuimm; of II.II/mlll UI/IOlIg pIllieli /)' ';!.JO J"t'ltr.l 
",;,11 u.,·II,mu fir COPO 
Unil'ari:Jble pn."'(\ictof<; of flSlillna in patients ?: ~o years with IISthma or corn are 
l:>resented '" Table 5-1 . Onset of symptoms b<:fore th" ase of 20 year.; (LR-8.67). a 
previuus diagnosIs of IISthmu (LR+6.83), season"1 I'ariutiw\ f!.R+-I.60). day to day 
variability of SymplOms (LR . 4.17). no gradual worsC11ing of symptoms oYer ume 
(LR-3.82), :.nd smoking less than 20 pack )'I:urs (LR -! 3A2) were the strongest 
[In.-dictors. rho: absence ofa brom:hodiialOr ri:!;ponse I"inually ruled OUI usthma (LR· 
0.20) 
Tabk 54 : Unh'a riable predie(o~ of aSlhma ill palienl~ "ilh ob!i l r llclil"e airwa~'s 
disease (as lhma or COI'D) in p;uienu onr 40 ~'ears Dlld older. 
[)cSU iplioll Seils. Spc:e. CR UDE 
~. % CR + CR -
Oru;ct of symptoms hf-fore the age or 20 years " " 8.67 0.' 
Pre"ious diagnosIs of aslhma 85 88 6.83 0]1 
Sca.'iOnal variation 87 " 4.60 0. 16 
Day 10 day ," ~nabLlily of symptoms 88 19 ·U7 015 
No worsening of symploms OVe!" lime 26 " .1.82 0.32 
Smokin,l; history ofl css than 20 pack years " 76 3.42 0..22 
NOl sllon ofbrealh for [JI{lSI of the day 22 " 2.83 0.30 
f('male " jj 2.3) 0.37 
No cough and sputum production pnxeded 17 28 2.30 0.24 
No previous di~gnosi$ of COPD , 44 2.18 0.Q7 
S)mptomatic response to inhaled bronchodilator 9J J4 1.4} 0.20 
• Scns: 5L'f15Itivity: Spec: specIficity 
'"' 
8.3..1.3.1 Mllfl;I'tIr;ubf~ ullufJ"I;.~ vI prt'dkltlrl flf u." hmu u"'''''g fUllil'm,· 'i:!.JO ) 't!Uf7; 
W/11r Itv/""u Ilr COPt) 
The best predictors for the diagTlOllis of asthma umong pldientg 40 years and older 
wnh Ob>trud;ve 1I111g drsea"e are: a pn:\h)U~ diagnosIs of a:.thma (LR+ 41-1), no 
grndual won;cning of symptoms o'er lime lLR+ 2.26). I <: 20 pad ),ear h,MOf)' of 
e'garc1te smoking (LR-1.87). and day to day \'amsb lll1Y of S)'lllplo.ns (LRllle) 
(Table 55). If aJl "" hislory ,'lIIiablcs were present In a p3liet1\ <'! 40 years wuh 
obstructive airways disease. then a diagnosiS o f 8SThma would Ix: 40 tim~ mor" 
likely. On the "on'r:lI'), If the Hems were ah,ent 'he patient would unlikely to h:we 
aSlhm~ (LR· 0.01). 
Tabl~ 55: Adjus ll"d likdibood ratios for I_h~ diagnosis of utl-Ima In palieDu owr 
4U yea" "ilh as thma or eOI'D, (N- 56J).t 
AdJuSlrd likelihood nlio 
Diag:noslk rkmenl FlClor 95"/. CI Flclor 95"/. C I 
"ncr ", _bor nl 
Pr"'10us diagnOSIS of asthma. 343 2.52-1.59 0.23 0.16-032 
No wemming of symptoms 2.28 1.63-3,1l 0.50 0.38-0.66 
0"'-" lime 
Pad year history of< 20 1.86 1.37-2.50 0.46 0 .33-0.68 
)'I:ars 
Day 10 day ,0000abillly of [.83 1.39-2.40 OAiI 0.3 1-0.64 
~ymploms. 
Fl:lTlak 102 1.08-2. 14 0.69 051-0.94 
CumUlali\c likelihood mILO " 216-8J.3 0.02 0.01-0.03 
(all 5 Items) 
t 38 pa!lr:l1ts wilh s])(:Ciuli$1 diu~n"lrI.':o uf IL'othm;r and COI'D. S~ palj"nli wi'hou, 
as,tuna or COI'l), Ulld 237 youn~cr than 40 Ye:lrs wcre e~eludl.'(] from the multivariate 
analysis. 
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F()T thl' derived pl\. ..dil1iun modd (Table 55). a cut-off 01' <: J out of tbe four ill'1TlS 
would ylc!d 11 5ell$i1lVUY of 90%. a spc<:!licny of 86%. and an ARUC 01'0.95. nle 
LR+ would be 6.5-1 ITablc 56). A cut-off of ::!: -I "',Quid h1l'rcasc the likelihootJ ratio. 
but d~(,' the sensitivity to 78°1". Figure 7 illUSlIlItcs the hig,hlT ARUC of th(,' 
derived multiv8riable Pfediclion model (ARUC 0.95) compatul to the accuracy of the 
nUm! using the guideline lARUe 0.87). 
Table 56: C ut-point of ticri' cd mul\ivariabl r modcl for predicting :.Istbmll in 
I'li licnts ~ll ~ fa rs "il b obst rlldin ai,..., a)'s diw:.lsc. 
C UI off Scnsi ti vit)·. SJlC!~ ili ti ty, Corre~try LR+ LR-
point ( % ) (%) C lassi rlt'd. 
l~·l 
>Il 100 0 61 1.00 
>1 98 '" 76 1.62 O.M '" 96 68 " 3.02 0,55 '" 90 86 " 6.54 011 "" 78 91 " 28. 11 0,22 '" 43 99 65 92.82 0.57 Flj!urc 7: rHformanc~ of nu rse using th l" !!.uidclinc comparl"d to thc de ri ved 
pr~diction rule for palicnts 2:-10 ~'ears willi obstructh'l" ain'a),1 di M'a~c (ARUe) 
for :.I diagllosis of asthma . 
• chmnasth - nurse diagnosis of astJun.~: aa-Ocrivcd algorillun model 
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SA Chroll k Ob!olrucli' C Pulmonary Disease (COI'D) 
IIA.I ,\ ccuraey of Ihe nursc using guiddlllf.'S ;n di:l gnos ill~ COrD 
The overall IIccuracy of Ihe b'Uidelin;' 10 diagnMing COI'D (n-404). uSing Ihe 
n:spiratory phYSicians' dia!;OOses as lh .. reference standard \n~368) 1'.';1$ salisfhctury 
Crable 51). Its scnsi thity was 77";0.. specificity was SS'ID. and area under the ROC 
cul'e was 0.84 (Figure ll). 
Table 57: Diagnostic accuracy of nu rse usinj: Ihe PALSA guideline in diagnosing 
COI' O \\ ilh I he rCS(lirnlory (lhysichlns' di:lgnosCll as th ;' r l'f;' rf.'nce ~ Iantlard. * 
True puslti~cs. n 283 
Trul."" negatives. n 903 
Fal!\C posilj\"~'S. 1\ 121 
False nl'gallv~'S, n S5 
Sensitil"iLy. % (95% e l) 77(72-8 1) 
Specificity, % (95% e l) 88 (86-90) 
PI'V. % (95% e l) 70 (65-74) 
NI'V. % (95% CI) 91 (l!9-93) 
LR+ 6.50 
LR· 0.26 
"RUe (95% cn 0.84 (O.S(H).85} 
rrv· positivc pr~-dicti\"c \"alue. NPV: neglltlve predictive value, LR+: positive 
likclihnoJ ratio. LR-: negative likel ihood rmio. ARUe: area under tile rcc.:i~l'T 
opcrallllg charal';1t:nstics Curve . 
• 'J Ul"lle diagnoses (n=.104). Respiratory physician diagnos<:s (n= 368) 
Flgurt II; UiajtnOilit a«un",' of Ihe nunc: us! IIjt 1 he jtultldlnt 10 dlal!lI()~t COJ' D 
.. II h 1 ht rtSplnlof) sptcialisl..' t1ia!tllO$t\I as rhe ",rennet ~I. n.lartl (A MI Te). 
'" 
&-1.1.1 FQf~ ",,_,-ifi.·, diug"" Ji~ of co PO 
Asthma WIl3 the most oommon false posit]\'", Ih llgll<)S IS. r~'Presentil1g 46~. 133 "f tlte 
primary !IIld 23 of the addition ~1 diagnoses) of the 112 (30"~; IOO"i.-PPV) false-
poS!!"!: dIagnoses orCOI'D mllde by the nurs.c (T abh' 5S) Otller common pnmary 
mlsdiugnoSt:s were LR1 1 in 16 (1 3.2'\--.). a ... 'Ule e~aetthallon~ 111 1<) (16.0".). ~hronic 
broncllllis in 13 (10.7%1. and uther lung colldillOns in 1J (10.7"'.) parienl~. PDl lcnl$ 
wnh Iilhl lli<)nal diugnoses of asthma had LRTI ( n~ 1 6-2. (12.S~.)). cw-dio\'llSCular 
discase In-I6-2. (l 2.S0o»). and tuberculos is (11 .. 7-1 . (I-U" .)! :lS lheir pnm;tr) 
diagnoses. 
Tnhle 5H; Faist f1osi l i\'(' dilignosH (CO I'Dj.* 














dlagllo~ n (¥.) 






7 U ,S) 
I (OS) 
I (O.S) 
I iO 8) 
I (08) 
121 (100) 
,\ ddi lionlll uthma 
dial!nlm.·ji mad~ iii 
sec:ondnf'J . rcrlilll'1. or 
qual~maJ) dia!!nU5e5 h~ 
tltt- spcc:hlisr.· (n) 
18 , 
1 
• TIle 5['l'<:Ioh5t ph}-SlClhn roul..! mllke I mllXlmum offuur dlUi!OO'SCS ~ p3h~'tl1 
t For the lolal 1lW1lber of asthma diagnoses add lhe IlSIhm9 diagnosn made by the 
specnllsr us secolwbry. ten laT) 01' quaternary d131!1Kl5CS (n- 23). 
'" 
&,/.1.1 f"uA~ " I'garin' diug,,,,!<is o/COPO 
FIIIsc-negari\(' di:tgJll))otS ("~ IOO· ... PV~ made by Ihe nurse instead of COPD 
Included lubcrcu losn In 32 (38",). 3CtI1<: euCCTblauoru m Ht {ll··.). asthma on 18 
121 00). and 3§ a S<!ttlnd:tfy dlll~is. asthma In a funlw.'I" 21 (46·.m 1(101) sigmf)ing 
Ihe d~ of O\C1"Lop bct\\ccn ItSIhma III1d COPD (Table .59). MilSl IIddllIonal asthma 
diag:noscs \lere mJide for p3!Jcnts with luhi.'l"tUIOl!'" (10 (31' .)), acute e.ucerbauons 
(1 0 (56'.)). and only 1 (2S'.) ror URTI. 
Tahle 59: False negal;,·" dlaT,; !lDSU ICOI'O)." 
Diagnostic ~at~orlci "rlmllr) nu rs~ dr~gmuc$. Addl1lopal {8e<:ondary or 
II (y.) tHliary) aSlh lllq 
dl ~l1.n G!iflS mnlie ~. the 
nursc". In) 
TBS 32 1380 . , 10 
Asthma 18 (2'-0) 
Acute ellllCcrlmion 18(21 0 0 ) 10 
LRTI S (9"',) 
Chronic bronchItIS -4 (5~,) 
CRT! -4 (50.) 
'lon-PALS"" I II· .J 
Total " " 
~ The nu~ could maJ.:e II TllI!."<imUOl of three di:!.gI1C)!>CS po;"!" patiCflI 
... DIagnosis not cI~ifiilble b) Ihe PALSA I:tuidcltne 
t For lilt 100aT numOC" of II$thma Jla~ .,1\1 IhI: add;lI"n;d D,thmu dingtlOSC!! 
made b) lhe nurse (n .. 21) 10 the \Dial number of pnmary dillgtlOkS 
'" 
8.4.2 ,\ec:unI(T o f Iht g uid eline in dN~rmlning I~HI~ of COP!} 5C'tri l ~ 
~ gUld~hlk! pc:rformcd mu£'h bc1lcr Itt di~gnosing o;.e,'cr~ COPD thllll mildlmodl'fDIC 
COPD (Table 60). Ilo\\e\'l.'r. for both mildimodcflllC COPD and SCVt'fC disease. ~ 
posi lhc nUl'>': dioglluSIS rules in the ~"'lodiliOl1. /) .... iOIl 10 the high sJl'Ccilici lY 
{spcI.-lfiClric:s 9)". nnd 87' •. respcdl,elyl 
Tablr 611: Distriblltion of dlagnuse$ for ettch le>r l of IIsthm~ di5c~sc rUl1trul 
(~- 13'l2 ). 
Levels ofst,vtmty 
COPD 
True poS[[l\'CS 82 
TrucncJYll l\ CS 1072 
False posi lh'cs 84 
False I1cgalj"cs 1 54 
ScnSill\ily 195'. CI) 35 (29 .... 1) 
Spccifidly {95'. ('"I) 93 (91-94) 
PPV (9S·'. e ll 49 (42-57) 
NPV /':15- . CI) 87 (S5-89) 
LR -+ 4 .78 
LR - 0.70 













PP\': f'OSlt,'iC Pfrol~ll\e \'aILle, NPV_ ncgatin: prcdicJi \'c valuc_ LR+: posiu\"c 
hLchhood rahO, LR-. neg;..II\'e hLehllood fatiO. ARUe: afC3 undlT the receiver 
operanng dlDf1ICllTISI1CS ~·Uf\'C. 
1% 
1104.3 l'rN'lI lencr or cUnical cn mlnation rCli l uru In plIllr nlt wi ln CO I' D 
The pn. .. al<.'fl(:CS or cllI\l~aI eXU1Oill31iuIl fC31Ures in p:!hffits with COI'D an: prCS<'llted 
bcl()\\ (Tnblc 6 1) st~ty four percenl of pllli.."IS were m3le: no. reroned aslhma 
prC\lOU'ily Mnst rqxn1ed diOieul t hrcalhiny ami 31", hllll 1&'<1 mandrax 
(methllqu3lonc-mllled "ilb cannabis), Da)'IIII1C dyspll()l!a, bu t 001 clIe\ll hghlnes:> ()J 
"heel&: IO&:rC' frequenll), n.1!Of'IN 10 most palu:ots SurpriSIrlWy. 61°'~ rtpOrted a 
~ponsc 10 Inhaled bc:u-agl)llIStS, .sl~. had ne\et had an acute ~xacetbalion wilh 3~0. 
reponing bdwecn I 300 S per yeal \ \ 'tM:e .. c ,,(1:1 hc:tnl III -17· ... of pallenls on 
clllImina!ion 
,,, 
T.ble 61 : I'rn ah:nct' of ~-"'I'I ... ",~' in I)Dl i~ l1h "illl rn pir.llury phy,kian 
diagn~u of COPD (n-)6fj). 
Difficult brentl1lJlg .. fany duratIOn 
Cough of any dunu.ion 
Symptoms slowly woJJCDCd oVCT lime 
Da, lyor frequent cough 
D~}'ime shonness ofbn.'alh 
Shari of breath for most of the day 
Cough IIOd sputum production pn.'I:~-dcd the onstl 
shonncu of bn:ath 
Dftlly or m.-qUt'Dl sputum proouel10n 
Male 
RCSPORSc 10 a bronchodlllltor 
1-1il;lory of COI' I) 
Dally cough 
Difficult breath::!: 2 ~'l"IC1:s 
Nocturnal cough 
Cough ~ 2 .. web 
Wheeze on aU$l."Ultahon 
Nocturnal shonness ofbftnth 
Nocturnal tightness of l:hCSI 
N\Ktumai wh0e7.e 
Df.>1ime lightncss of chest 
Dagga USC 
NC'o"er used II bmnehod,lulor belOn:: 
Oay 10 duy "Drillbihty 
Doytlme whlleZe 
History of IISthma 
Scll5(>Dul ,'al'iDbilily 
FlUm]y hlslOt'y ohsthma 
Crcplllltions 
1 h!ilory (lfhayfC\lt'!" 
Known ul lagi~'$ 
Sumber of o:xacl'fbillons per year 
1-5 per year 











































8."'" ,\ n l l~ sl~ or hlslol1' =and eun1in:l.lion prediclors or COPD 
/t ./.;I, I P"dirron a/COPD: ~ /j )"l'ars 
Table 62 lislS Ihe significaJ1l univanable pl'l.'\Iictors of COPD in p~lio:nlS 2:1 S yc:a~. A 
prt:\10US dl0snuSIS of COrD WIIS the strongest prcdiclor ( LR - )-1,48). fo llowed by 
C\)u!lh ~nd sputum preceding onsel Ilf dyspnoca (LiH 4.I IJ. 2:20 pack year smokmg 
hlSlnr)' ILK .. 4 .07), lind dyspnoea for most of Ihe day (LK· ) 44; V~nabl($ 
mlldCTalciy prediclh c of COI'O were symploms worsening .slowly over lime ( tR..-
).33), hislor)' of c~nnnbis usc (LR· 2.84). male se... tLR- 2.J8). and prel'iulbly 
dj~gno~cd lubcrculosis (LR" 1.31 ). Inlcrcsllni;lY. dai ly frequent Sputum productIOn Of 
~'Ough {LR+ 1.83 ~nd I AS. rcspccll\'elYI "~e nOl strong predicton>. The ,,~ce of 
fculurl!S typically iUggeslil c of asthma (aJ lerwcs. family hislol) . hayfnerj '" ere only 
mi nunaliy predictive o f COPO t LR' 1. 1 (}.1.361. 
'" 
T.h~ 62 U",j'lIrillblC' prf ll intln vf COl'!} in pil litnt 's ~IS ,rll" fil II " ilb C'ou~b 
Mnll IIlffiC'ull) b rtllhin2-




PrC'\ious dilliOOSIS ufCOf'D " 
,. 14 01 9 ()A 7 
Cough and spulum prodlK'TlOn prrccde:d 1i " 'I' 036 Smoking hlslory of 2()p1ck yean. or Il1(lf"e " " 4.07 0.32 "lion ofl:tualh for \l1()!;1 01 the da) n " 3.'" 036 Syml'l0UI) .... IW'SC\IL'oIi ~lo .... l)' O\'t'f 1\111(' ,. 76 3.33 028 
II lSIor)' of cnnnabis IISC' JJ " 2.8., 0,76 Mille " 7J 2JS OAS f'1\':\'lou~ly dlallJloOSC'd lubm:ulo~i~ " " 2.J I 0 .... Onset ors)"nlptom~ IIACT lhe age uf 40 year, " on 200 033 D1Iily Of frequent sputum p"xlu~l1on " '" 1.83 0" No prlC\'l(1U~ IIiDgno!i!j of asthma 10 ~2 173 0.20 
No dQ)' to day \'pnohiluy ofs),mplUms 2U " 
,,,. O.4U 
No seasonal \'onallO" " lJ U6 0.38 Dally I» frequent CQugh " ., lAg 0.s2 No fOlUi ly hlMor), of asthma 20 " 1.36 (1.48 No hislOI) ufhyh:~"r , 7J 1.28 0,23 
Hhwry of difficult bre:llhlng " 2.1 1.21 (1.30 Nu historv of allerglcs , " 1.10 O.3S • Sens: St'ns ltwlly: Spec: ~pa:liieIIY 
1J.4.-I.1.1 Ill1lri •• riQJJ/~QftlllrJ!J ofprtllictDnfor COPD: ~j yell", 
T .bl~ 6~ li5U the Slgtllfi'*'t l1lulu,an!lble p!l!dIClOfl of COPD III patlc:t1t~ C!: I S ),c:"" 
1I1d. As for the 1In1 • .,ablC IIMlysu (T.bll: 61).. ~'ious diagnosis of eOI'D was the 
WOfIFSI predlClOl' (LR+ J J6). A SfI1OI,:mg ~k )'UIf hlSiory o( C!0)'e'lfS (LR ~ 2,071. 
hiSioty II f CannabiS UjC- iLR+ 1.191. pm'jolls diagnosis ofwbcrtulosis (LR' 132). 
and J.I\!\\ wQNellln. o( symptum! o,er linle (LR+ 1.56) lIeTe Included m the model 
CWllulot!n:: pu!llll\c IIkehhood mllu If all 9 symptoms W('ft pr~1 is 61.J. A 
CUI1lUmUle negal.'e lI~r .. 1l1lO\1d mlio of 0.02 ,'inually rules OUI COr D In palimt!! 
Wl1ho,lUllhHe fcatlln."j.. 
r .hl t 6.1: Mullhll tluhlr I'n dk l Ort uf corD In pl l H-1I11 ~ 15 ) 'flI" old ",i,h 
(ouJ:h and dlmcult) hrta lhlnJ:(N- I.lS-').t 
Adj u.lrd Iikdillood nlliK 
U1~~ no>'lf r l f tn ( n l ~·.CI IJf' ~.I. CI Fulor ",. CI 
)lreo.rnr ~lKflll 
I'r cviwli dill~'lIW1i 01"<':01>0 , ... 2."4-4 .&5 0$1 o J7.tl.b7 
l'l d y,m biSlO!)' of itO )'\'.lI", 2.07 11>4·:!.5S 0>5 0 4S~.67 
IU_oryO(C1II=bli Ille ..,. 0,%-1.68 0.8'3 0.1:,'1·1-0) 
Imi1.1usl)' dl.lJl!'l'5<"d and I~rd TO 1.32 1.18.1."6 '" O..JI.tl64 S)"II1p101'N 110.01), VourxllC:d OI"'tr lime: ,.>6 1.1J·2 12 0.74 O. 6().(l. 92 
C~;:h aIId 1pU1I.m ~aon pro:.:v:tkd "' 1.10.1 55 .. , 04J..().34 
OIlS(! of dyipnoo 
Onset ofsymptoms aRe.- 1M ate or.ao '" U7.27) 0." 0.76-&. \13 ,..,.. 
Pnxmlllllnllpb:1I1 of difflCllll 1.25 1.07·1.44 0.65 o 411~.1I9 
""""'"' -..:0 pl"CI"1IIUS d:i2pom of 1I!Itim .... ,., I IG-I 12 0.» OJ5.Q'Kl 
AU \I i!cms liD 35.G- 0.02 (1.01.1),03 
119.1 
-t 38 PIIlICl1IS had SJlCCutllSi dla;no5C$ ur 11.51111114 lind ('01'0. l hcn:r~XI! c~I! IUI[cd from 
!he mull:i,'arilllC ana!}o.is 
20' 
The cUI-ofT for a diagnosis of COrD in Ihis eale~'OI')' is ~5 (Table (4). This value 
yields u scnsil1vily of 79"0 and specificily of 86%. Figure 9 Ct11nparCS the ARUC of 
the nurse using Ihe guiddine (0.841 to thai of the derived pn.>d,Clion rule lA RUe 
091 ). 
Table 64: C UI-point of deri-'ed predkiion multh"ariable modd for predicling 
COI' I>. 
Cut off S~" s lth' ity Specinelty Correctl) L"+ L"-
point t%' tv.) Class ified 
(°/·1 
"" 100 000 24 1.00 ~I 100 I " 1.01 0.00 '" 99 30 " IA2 0.01 '" 97 59 " 2.38 0.", '" 88 78 " 4.03 0.15 ,,; " " 86 6.35 0.13 '" " " 87 10.48 034 ~7 " 97 " 15.61 0.52 ". 16 99 79 18.61 0.84 
;,9 , 99 77 -10.33 0.% 
Fignr~ 9: rHformance of nurse usinc the I! uidciinc comp~rcd to Ih r derind 
prediclion rn Ie for patients :!: 15 years (,\ It Uel for a diagnosis or corl>, 
"chroncopd nursc corD diagnosis: a-derived prediction model 
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6../ • ./.1 f'rlod;r lvl'$ of COPD: ~ J 5 yru~' ,,';flr us/lrrrru fir CDI'D 
&../../.1. J l.I11;''Griubl, 1II1I1IJ·.~il· of pra/Clon< of Cop" unltJII!l /Wri/'rI/.'· .. ·;th IIMhrrru 
,II" COPD 
The bc-st IIIdivK!LIOI[ unl\'ariable predrC1.~rs u( COPD rn pblitnlS "'lib obsInK"Li~'e lung 
disease IS a p!"C'\10US dmgnosls ,,(COI'D (LRT 16,2). oough and spuTUm prodllC1101l 
precailllg dyspnoc:8 (LR ; -1 .67). dY5pllocu for most ufthc: doy (LR+ -I .OS). 5~mplom$ 
slowly worsenillg on"T time (LR+ 3.67), 00 S}mplomallC' n:spo:JlbC 10 IIlhalcd 
I>ronchodilillor (LR t 3.60). onsel of '}"I1Iph'ms oller Ilk- "ge or -10 ~lIrS tLR ' 3.57). 
and u~e ufcannabis \ LR+ 3.02) [Table 65 1 l'Te\ious tubtTcul~ n .Rr 2.92). male 
StA I LR" 2.7.3). 00 reportC'd wtl<.'e7.ing (LR~ 2.29). and no lustory of light ehest (LR;. 
2.26) were nlO.xknllt"'t) ~iCli\e. Tht"' ~ \,( inlhl iduQJ feruuTI:$ 'rillcally 
suggestIve or IlSIhn"1 (bayfe\·er. aUergil.'S. family h,-'IIilI)' of Il'il[una, Uiopy) 1·!Ttua[[y 
ruJ~ OUI COPD mthiJIl.':llcgory 
Table 65 lnl'-arillbit prtdklon of COI'I) In pD I I~ "I:S <,: I ~ yU" "ilh oMtrll~tht 
lung dl~,t (a"bma or CO I'I)). 
l)~crlpdon Srns. ";. Sp« .• ,. CRUUE 
lU' lU-
No dllY 10 da) "uri~bl l il)' of ')1nl'lu lnS 20 " 657 0.23 Previous d iagnoS I$ orcol'!) " 91 6.:!Q 0'-Nu SC3SOnBI vllriatlon " " 5.36 O,.z I 
No previous diDllll,,~i5 of IlSlhllll 10 " S.J8 0.12 
Cough lind ~pUIUIil produetioll proc.aIcd 71 8S 46' OJ, 
SmoUng history of20padr r(!1IIli or m .. re 74 .. '60 0.31 
Short of brcath for most of thc day 72 " , 0' OJ5 S}mptoms worsened 5101'.Iy o'er IIITlC " " 36' 0.21 No ~YlTlptomatie ~flO~ 10 inhaled 60 II 360 0.61 
bronchodilator 
OnSCI ofsymptoll1llfter!he 1ge of 40 81 11 H7 0.25 
yC11'I 
History 0 1 cannabis use JJ " 3.02 0.76 Pre· .. ioI»ly diagnosed lubn-culosis " " 2.<)2 0.82 \Ialc .5 7' 1.7.' 0.-
f'o ruSIOf)' of '" I'IeelIJli 41 " 2.29 057 1'.\1 hl~lory of hghlnc:ss of dlcsI " lJ 2 2t'1 0.63 
1\0 family hlslfIf) Ilf aslhnuc '0 " 2.13 OJ2 S)mptOrtU nollnggrmJ by 30 36 2 00 '" ClwUT>nmmllll tact0t5 
No history of hayfC"Cf 6 " 1.62 O.H 1\0 repor1ed da)1IHlC: .... hCCllng 23 SO 1.56 0.45 
Symptoms not Ingsered by cmotKHIS 11 56 I." OJ8 
1\0 1u5lory o f allerlad 5 SO 1.20 022 
r-o hi~1(1)' of Itopy " 118 0." 
• Sens: §CIlSlllvny; Spec' spcccfiaty 
6.J.4.1.1 lIultil"llrillbl" "lUtI)"'/.' lif IIr!·Jirl"r .• ,,/ COPI) ,m,m'Il/ltIti"m., ,,"tlt ,n,hmlJ 
,,, COI'I) 
'u pre"o'ioll~ I.haJ,;llQ>ii of IISlhmu (lRI ·t OO). n prc\1OUS dipW'uISIs of tubemalOSii 
(lk * 2.021. no "--ported vMabi lny of symptoms (l.R l.()()). and slow worsening of 
'I)"mpltlnu O\ Cf" ume (LR 1.&4) were indudcd in the ml~ IlUXkl (Table 66). Ifall 
1 unns wae absent. the UkdthoOO ofllavin; COPD would be wry low \LR· 0.02). 
The cumu1 ~the LR Yt1l5 w:ry hid! III 129.1 
Tah!" Ii6 ' hllthltTiubl" prell iclOn IIf C.O PO III pallel)!) ~ 1 5 run- " llh 1I 'lhma 
or eopo. (~~800).. 
Adjusted Ilktlihood ra llo, 
J)ial!llo§lK- rif lllt'1I1 Faclor 9!'% CI FafH!r 95%CI 
pr_ nl almal 
'10 previous dl:lgoosis of "SIbnu '09 2.99-5.11 0.18 O.;!2·0.l1 
S)1Ilploms sl0Yt1y"~ ,.84 1.311-2.4'- 0 ... (}4()'0.11 
(wcr time. 
'n day 10 day ,-.nabil ilyof 2.00 1""·2.72 0,58 () 4(>·0 1f1 
I)mploms. 
Pack yar htslOl")' ()(~ 2Q )'e3n 1.91 1·41·2,73 (J,59 0,4(...0 77 
OnJd oh)"mplUlftS after !be IF '''' 1,20-1.96 0,51 0 ... 1.(.1 7<) 
Ilf~ )ean.. 
\Iale ' 40 1.01· 1,89 0.12 o ~1-0. 91 
l'TI:\ious tii.goo&i, of 2.Q2 1()+.396 091 0,85-0 99 
ILibemiiosis 
AJ111Il'tt1S present 129,1 52,l·3 19.0 0.02 0,01.(.103 
t 38 palimlll .... i1h 'f'C'CioliJl dingoo,,":s o'wma :and COPO. and 554 p.dienllo Itt I1houl 
IlSlluna or OPO wen: I."-xdudrd rrom the n.uu\:an .. te ~)'5I" 
The Ix-st CL1t-oIT for dctl-.::ting pillients with COPD IlITHlng pat ients ::-: 15 yetlrS \\ith 
oough or diffieLlIt breathing is ~ (scru;iti\'it~ 82~o. spt'Cificily 92%. LR+ 10.7) ( f able 
67) The predkllon fll ic p<-'I"fonns ,et'y well (A RUC 0.95) c(lmp3red to the nLlr;;c using 
the guideline (ARUe 0,84) (FigtIn' 10), 
Tahk 67: C UI-pt.oinl of dcri"ed pred ic lion model for predk lin,: COPD in palients 
" jlh o~lructi , e lung di~l'~ se. 
C Ui orr Scnsirh-ily. Spcei fi cily. Corn'cll), CR+ CR. 
poin l (%) <-I.) C lassml'd, 
<-I.) 
2Jl 100 0 41 100 
>1 100 35 62 l.53 0.00 
'" 99 H S3 3.-17 O.DI '" 93 SO 8Q 6." 0.07 2>1 " " " 10_71 0.19 >5 67 97 85 12 .-1~ 034 
2j\ 44 98 76 19.70 0.56 
>7 8 99 62 1).29 0_91 
Fii,: urc III Performance of nu TSI' using t h ~ l1. uidc1 inl' compared to Ihl' dc rin d 
prt'il icr ion rule for I"' rlcnl.s ~IS yran "lth obsl ru ~ ll\'e lung di$taSl' (A RUC) for 
~ diugnosis of COI'O 
*chruneopd - num: diagoosis; 6-dt-rivcd prediction mood 
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&-I. -I.J Pr .. dirt"r3 ,,/COI'D: "'- .10 j"l'url >l-ilh "I'I/w ,U 'I( CON) 
8.4.4.J.1 l ·n i,"/triub/~ unwJ'$is 0/ p ... ·dk",r' ,,/ COPD u""'" K p",it"/lJ.I ~4(1 )·I'I.rl 
with /I.\'tlt",,, IIr COPD 
The irKIividual univariablc. symptoms most predictive of COI'O in patients ::.0 yean 
wuh ObslrtK..1ivc: lung disease were-; a pre,ious diagnosis ofCOPD (LR+ \·1.8). no 
l":J.nability of symptoms lLR+ 6.82). 110 scllSOnJI VlIriatlOn of symptoms lLR+ 6.2·1). 
00 pm·ious diagnosis of asthma lLR ... 5.83). 00 symplorlUltic l"CSflOnsc to 
bronehodilnlol'll (LR+ 5.13), II smol:ing pack year h,!O!ory of ~o (LR~ 4.(4). and 11 
hl!Jtory of cough and sputum production pnxeJing onset of dyspooca (LR ... 3.34) 
(fable: 68). As in the malysis for the JlTC"iow; 2 categories. the @sencc of features 
typicol1y suagesth·c of asthma rules 001 COPO. No previous dlnsnosis of asthma was 
a strong posi tive: pn.'IIit1or (LR + 5.83), and the PI"I.'S('fICC of II. p!'e\'ious dIagnosIS of 
asthmCl, strongly ruh:d out eOI'D in this CIlto:gory of p;lticnls (LR- 0.15) 
107 
T able 68: Uninlriahle prcdiclOr~ of COP!) in pliltco is ~O rears l\ ilh obSlructiH' 
lung dlscast" (asthma or COPO). 
Descr iption St"us. "(. Spec. y. C R UDE 
CR+ CR-
Previous diagnosis of COPO " " 1484 0 .... No doy 10 day vnnal)llity OfS)TllplomS 21 " 6.82 0.24 
No seasonal variation 19 13 6.2-1 0.22 
No previous dillgnosi$ of a51hmll " 15 5.83 (US Nos}mptomOlic response 10 inhalccl 66 7 5.13 0.71 
bronchodilalor 
Smoking bislOry of20 pack years or more 75 84 4 .6-> 0.30 
Coush und sputum produ~tion pn:ceded 72 83 .. 1.17 0.]4 
OnSCI of symptoms nlh-r the: agc uf 40 yem~ 79 79 1.74 0.17 
Shon ofbrcath for most of the day 72 78 3.14 0-" 
Symptoms worscned slowly over lime 81 74 1.10 0.16 
Male: 68 75 2.68 0.43 
Breathless on e:.lllfninullon 53 77 2.27 0.62 
No lIislOry of II lI~ezing 36 28 2,27 0,51 
No lIislOry oflightn~ss ofchl'St 4 1 " :U5 0.57 
'10 fnm ily history () r asthma 17 )9 2.1-1 0,28 
S}mptoms not triggl-rcd by environmental 34 34 [95 0.51 
factoN 
No 1I;~lory of hnyfc"cr 7 " l.S1 0,17 
Nu daytime tightrll'SS of chest " 50 1.52 0.48 
Symptoms nOltriggcrcd by l>JllotlOns 21 54 1.49 0.44 
No daytime I,hl'CZing 14 9 1.46 0.35 
No history of allergies 3 77 US 0.15 
" Sens: sensitivity. Spcc: specificity 
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&.4.4.J.1 MII/,jo"llriub/t' unuJ)'"i~' 'if IlrrJicr"r., lif COl'!) IUI"'"~ parl,'III' ~O Fur, 
" 'j,1I u..,flmQ or COPO 
The best predictors for this Calegory BJC shown io Table 69. N(1 previous diognosis of 
astluna (LR+ 4.4 1). 00 day-!o-day variabili ty (LR+ 2.13). slow W()ISColflg of 
s)mptoms over time (loR. 2.12), ood a C!20 pack yclIr hiSlory of cigareuc !ImOkio,S 
(LR 1- 2.07). The cumulative LR'!" IS 81.7, 
Tahle 69: ~lulth'lIrihtJle predictors of COl'!) io patil'11I5 C! oil) ~'ca rs "ilh 
uh~ rruc' '' 'c luog disu se (asthma or COPD). ~·-Sb3) . t 
,\djusted likdibood ratios 
DlM(:n oo:t lr dcm~ut f "clur 9$0;' C I Factor 95.". C I 
presenT absent 
No previ(lUS dll1gll05is of asthm(l. 4" 3.11-6.08 0.28 O.1I"{).38 
No day to dllY vtuillbdlly or 2.1 J 1.46-2.99 0.S7 o -l)..(). 7S 
:;ympIO/TW. 
S)mplonu ~Iowly worsened OVCI' 2.12 "(:I1-1.MI 0."'1 0.]7-0.58 
tIme. 
Pad; )'UI" hIstory of 0!:20 )'C"I'S 2.07 1.40-2.92 0.56 0.U·O.76 
Mole 1.'18 1.08·2.02 06-1 0,4>0.92 
Rc:por1ed wh0C7.ing IJ. 1.01·1.79 0.71 0.-19-0.98 
All 6 items present 81.7 38.J.11-'J 0.02 0.01-0.04 
l' 38 p:lIJ~rus .,.,ith tpc."dllhSI dillgtmCli of asthma and COPD. SS oi palieru5 .,.,.ithou! 
astiuna ill' COPD. JlIId 2]1 )'OUIIgcr than 40 yeaf'J.,.,-ere u:duded fium tht' mulu\1Iriate 
lI.Ilol)'Sl$, 
The cut-off for Ihe derived multivmiablc prt:d iclion model above is ;<:3 (Tahle 70). 
Thert:lorc, if 3 OUI of the 6 items nrc present, the sensitivity is 93% .• pccitidly 86%. 
the lR+ 6 . ~5. and the ARUC is 0.94. The model p<.·1foml. bclleT than the nurse using 
the guidclioc (ARU(" 0.94) (Figure II). 
Table 70: Cut-point ofd crh·cd predic tion rule for predicting COI' D in pa tients :<!: 
40 yea" " ilh obst rueli'·f "in' a~·5 disease. 
C UI orr ~nsiti \"il)' Spedfidty Corrcctl}' LR+ LR-
point i"/·) W.) CI:,s5ificd 
,ole) 
"" 100 0 J9 1.00 .1 99 " 53 UO 0,01 '" 99 '" 77 2.75 0.02 >J 9J SO 89 6.85 0.08 
". 78 92 87 10.36 0.23 
>S " 97 80 ISln 0.46 >6 20 100 69 0.79 
Figure II " crrorman cc of nu"e using Ihe guideline romparNi 10 the dcrhcd 
I)r{"diction rule for pati{"nts :<!:40 years \, ;Ih obstrucl;n lung t1i sc ftsc (ARUe) fur 
a dhlgnusis M CO I'O 
~chroncopd nurse diagnosis: c-dcti\'cd prcdict10n model 
'" 
8.5.1 ,\ ce u r:l t~· of the n"'"lie using guideline In dbgnoslng acute Hace.· ha l i o n ~ 
The l1U~e using the guideline (0 .. 363) perfunned very ""cdl in diagnosing 
l:lIaccrbalions o f a;;thma ur COPO Wiing the respil310ry physician as the reference 
sllIndnrd (n~293) [fable 71). Its sen.sith·ity was &0" ... ;;pc..:ifh::lIy was 88'~ positJve 
likelihood mtio ""115 6.89 and tbe 1II"C8 wuicrtbc ROC curve was 0.84 (Figure 12). 
Tallie 71: i) illgllos t ic 9ccuru r,. of the nurst u.sin; the PALSA guideline in 
d ; a ~no s inlt " cllte ua~rrbalion s u ~ ing the respir:Hory phys icians' dill !;1I0Sh as the 
refl'renct st Bocian\. * 
True positives. n m 
True ncgati~cs, n 971 
FoJ!iC po';livcs. n '" Fslse negatives. D " s.en~il1\ily.·{, (9~% Cl) RO (7S.8~) 
Specificity, "I. (95% CI) 88 (86-90) 
PI'V, % 19S% el) 6S (6(}.70) 
NPV, % (95%CI) 9-1 (93-96) 
LR+ 6.89 
LR· 0.22 
,\RUe (95·'" e l) 0.84 (0.82·0.87) 
PPV: pos:nivc pn:dtctll'e value. NPV: n~gatlH pn:d icdvc value, lR+: JIOSltiW 
liJ.dihood ratio, LR-: ncpuvc likelihood ratio, ARUC: area undcr the rc:<."'!iver 
opaatinS ebal"acl~"'Slics curve. 
"Nurse diagnos.:-s (n~363). Resp ir.llory physician diol:lloses (n=293) 
t' l!:lI rt 12 : l)iagnO!<t k ~~~un~~ oflht nUrsC' using Ihc guiddin~ 10 diaj!lIose aCUlt 
nUfr".tion~ .. ilh Ih~ r e!l piralOI1 tp«iaiisis' diagnos" u Ih~ rdcrl' n~t 
!illlnd~rd tARUq. 
Table n lists the distribution or the- fol se nrgtt!l\'e diagJ"lOSd for COrD AnalYSIs of 
fuJ.\IC f1OS 'h ~t \>cUlt eJlaccmMion dlasn05C.'~ by Ihe nO~ u:sinll tht .sutddint 
demonstnned dun these flilhenb ~'ed • pnmary ~II"3IQ1")' pll)'S1Cian dingnosis 
OS".; lOO".·rrv) ofl.RTI In )7-. ~47) of Ctit'S, of !Htbma In 2] •• (29). orCOPD In 
I ~·. (18). of c:lnho\"lW(uhu' disease: In XO. 110), lind of OIbtr lung tli5tascs In I ~I 
( I J) rJII. .. :nt5 ..... lth undcrl)"mg :l."Sth m:l (.a6 (}6. 'll uniI COrD (21 (21 ".)). would hove 
benefited from treatment f(]l" at! lCute nllCetbauon. anti ..... ere al ]ellSl rtCOgI1'$~'(! as 
hIInng un (lbSlnK1"e lung disnse.. Hov,I!\t1". patltTlUi with LRTI. canlioc dl5e:lse or 
lIlher forms ofl ung dlSlellSe. represenllng 56·, orlhe rlll"",poSl!ilies would nOl. 
In tooll more thM bnlr (57"-0) had ob;;tructiv~ lunS d lS(":ut. Of the IISlhmu dir'gMscs. 
:n~, (29) Wt~ pri lt1.ll)' diugtlOlleS unrJ 17 1I 7) were lIdditionnl dillgn05CS ()6". ID 
IOIU!) Foc CDI'D. 14% (18) V,all pnmury and 7". ~y) \I.·ere addWonul dil.JPlOs.:s. In 
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aildihon. th.: fH11'liC cJlllI.SIlicd the following dingnoSd as acute C!xucabarions: LR TI 37 
(47). canlJac distase S·" (10). chronic brOllchllis 2'~ (3 ). common cold 2% OJ, 
a1ler\:ic rhml\i~ I". (1). $uspec1cd tuberculosis 2~~ (3), and i nf~tioo 1% (I ). 
T able 72: IliJ trihul ion of Il.'spiralol)· ph~'s ldan diagnoses" made when Ihe nurse 
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• lbe 15J>lraIDr) pb)"Stt"1aD ,.111 pmnmed 10 mak~ • ,nn,mu,,, of fl"JUf ~ pcr panem. 
t For Lhe '0Ill1 numlla or IlMhma dillg~ add dM: :sddiliunOll aSlhnlll di~.l. made I') 1110: 
m.pITllory ph)'5iciln (1t""17) to 'M 10lIl1 IIumbcT of pnmllf)' dilpll)!CS (n-N). 
i rOf 11M: lOIal number ofCOPD d~ add Ihe addiuon.1 001'0 di;!g!~ ITIlMk II) 11M: 
~pmtury ph»lCi.m 111""'""9)10 lIlO: II.JlIlI number of primary daaiJlO$$ (II'" 18). 
llJ 
6. 5. 1.1 Fulsf' "f'f.:uti.'t! diugllo .• -iv 'if orllte eXON'rhUlit.".-
Of lhe 58 (6%.: IDM.-NI'V) I'JlicrIIS wi lh false-negative diagnoses, 860 -0 (SO) had 
ob~U\Jcti'c lung disease: 5()Oti. (29) had asthma und 360 • (2 1) had COPO (fable 73). 
Other d ial7lOSCS Ifi lhis category were: common cold 50 0 (3), LRTI 10 (6), suspcclcd 
lubc:n:ul()~is 21°. (12) and oon·PALSA diagnoses 1°0 (I). 
Tabl~ 73: Oiagnose5 made h~' the nu rs~ in palienls with respiralOry physician 
diagnoses of ~I':U tl': c~ .I':~rh.tion clinical $~ ndromc (fa Lse negali'-'s). 
OlagnOSlic Prima!) nuru AcidilionJl I (iCconda!)' or tHlia!) 
u tl'1,i;o ries djagno~cs. n (0/. ) as thma/COI' O diagnoses RllIdc hy Ihc 
nursc" 
ASlhmat COPDt 
A~thma 20 (34·.)t 
COl'O 16(28): 
Common cold 3 (5) 1 1 
LRTI 600) 2 
Nun-I'ALSA 1 (2J 
TBS 12 (21) • 4 
Total 511(100) 9 , 
• rho: ".me "",Id mal. •• ma~lm ...... l>fd.r •• d ........ ("!Of piOIJcm_' 
t For ,hi: UKaI number of ~hma d~ adoJ die ... 11;1;11011.( Mlma doa&!'''"' madt II) die IIIIfW 
(,,-9110 lhc ,~allWmber 01 pmnary d.lII:JIOUI' (n·.!Oj. 
; r ... the "",.1 number of coro d~~ a.J,J ,he :><idiho.,.1 COI'D d~ m ..... II) ,he nu,," 
(n-5, 10 lhc '~al number of ,..unary d.~ (. - 16). 
2(4 
Table 7J hMS the pn!\ru~'I1CCS ,.( the SymptORl( u.socimtcd with nu ld modcl1lt ~ 3lId 
~"'cre enccmal!on!l. Of the I uriablcs IIsl"d to dl:'1~'fTTllne tile dl.SCaSC S(:",enl~ of the 
ao.:utt e:u.:crbation. (01)' Kcessory muscle use lind I'I.'SplrlltOI') r:1l~ i!: 30 "'t'\'C ~ 
r~uenlly :t5SVCilllcd wnh ~cre eltaCmllon, The frcqlll."tKlCS of the n.'mlIll1il1g 
vuriables that dClmTlll1C di~:lSO: sC\mty WeT(! low fur broth d l ~'\I.:t II/ld thCfl.'foru 
rrIIKt li l ely d id not OOI1to l)Ule nlllch to tach d insnosiJ,. FlIl1hC'l1ll(ln:. the fn:q\.M.'I1C)' of 
ttt.: ~)lI'ptOms and SIgnS thai lH.Ij;i;CS1 acUIC dlsea<e: arc SImilar hc:fwet.'fl the IWI'I 
~ ... m ty dllbllicatwn5, 
Table 7J: Frt(IU ~ n c)' d ls lrlh.ulon or s~ mplom~ II~JOCill'~1 " Ji ll mJldJmuticrll te 
Mud sel'tn e.\ll ~~ rhatlo ll s. 
Vori ::lhlcs M IIdlno(l(lcnlll." S CI'H C 
t uccrhat lOIl t.\ IIct r b.t iOIl 
(,,- 202). 0 ('Y. ) /n- 9 1). n W.) 
Cough '5 2 Ileeks 162 (S~.) 76 (84~01 
DifIieull breathing ,5; ~ \\'cc ~s 160 (79";') 76 (Mo/.) 
Bn:ol hltSSncs..~ ", hI Ie lR Ikmg 7(3'.) 6(7"0) 
Bl'Clth 1l$.~m:ss '" 111 Ie watlmg 96 (2]'.) 28t31·.) 
Promm~'1\llIeecssory muscle WoO: 18 {fr'.l J2 (35 0,.) 
Hl1Cmoply!i~ 6 P"".) 1 ( 1"0) 
C,mtUsion t to,S'.) I (1'0' 
Aj!l lnlioo 1 (0.5°,.) I ( 1°.) 
lIelln I1Ile ~ 120 .3 (1".) 5 (5".) 
R~'Sp!TlIlury nlill ~ ]O 7 (3"'i) 21 (23°~.J 
Tighl ChC)l 164(Sl-.) 8{)(8S-;,) 
HlslOf)' of whe<!u 165 t8':!-.. / 79 (S1".) 
"'h~lC on lIuscuhll!IOO 'uudible 129(64".) 79 (81'~1 
2lS 
8.5.3 A nalysis o f h iS lOry and ~XIlFllin ation pr~dl ctt)rs of acu Ie E;>.ac{'rbat ion$ 
8.5.3. I Un ;,'Qriub/t! unoly.,; .• uf pr"uicI"r .• · uf 11 m,,, ". .• ·u/;l!rbuli"" .< 
The univariable predictors tha! best predict aC lI\e exacerbations are a history of atOpy 
(LR+ 320). wheezing (audible or on auscultation) (LR- 1.6&), reported whec/.ing 
\LR+ 2.37). reported episodic dyspnoea (LR+ 229). and report~'ti \analton of 
symptoms (LR- 2.16) (Tllble 75). A prCSCnlalion llf cough (LR- I.OS), and no cr"JcJdes 
heard 011 auscultation (LR+ 1.08) were only shghtly predict;\c. bul the ncgali\e LRs 
were 0.35 and 0.38. respectively. 
T a hle 75 Uni \"uiabl ... pred ictors of 3n acute Hacerhation. 
De..'\e riplion S ... ns. 'V. Spec, -I. CRUDE 
LR ' I .• R 
History of atopy " 96 3.20 0.9 Wheezing (audible or 01) auSCU l! aIH)II) 69 " 2.68 0,41 History ofwhcc7jng 8J " 1.37 0.20 Episod1e dyspnoea on prc!;CntatiolJ 66 71 2.29 OA1 
Seasonal variation " 68 2.10 0.44 Pre\ious diagnosis of asthma 68 69 2. 15 0,47 
Usc of bronchodilator more than tW1ce a day 40 81 2. 15 0.74 
History of previous eucerbalions 23 37 1. 11 0.36 
S)1nptoms triggered by tC$(1iratory tra~t " 76 2.10 0.65 infections 
History of lightness of ChL'St 83 60 2.05 0.28 
Day ttl day van ability of symptoms 73 64 2.02 0 . ..\2 
Symptoms triggered byel1viroml1ellla l factors 57 70 1.90 0.0 I 
Symploms lnggcred by weather 1 62 1.86 0",\7 
Symptoms lriggered or worsened by exercise 56 " 1.82 0.63 H istor), of difticu ll breathing 96 B 1.25 0.16 
Symptoms triggered by cmotiolls 37 81 1.20 0.7S 
Presenting complaint of cough " 12 1.08 0.38 No ,,"3c~ lcs heard on auscu ll ulion , 88 1.08 0.35 
.. Scns: :i{miti\ ity; Spee; spcci lici ty 
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8. 5.3.1 Mllff;''Uriubl.: 1IIIal)'.'·i~· of predictor .• ' of a",,'e l!.~aC<'rbu'i"" .• • 
Only 4 items WtTl' included in the mulllvariable nw:>dcl (Table 76). Rl-portl~! wheeze 
WitS the strongcst prooiclOr of an acute exacerbation (lR-..- 2.15). Th.:- absence of\ht:Se 
4 Items ( LR- 0.08) \'il1ually ruled out an acute exaclmation. 
Tablr 76: l\Iulli"ariable prrdicfOrs or an aeutr exal'Hbalion. 
Uiagnosl ic clem .. "1 ,\ djustrd tikdlhood ra l;o$ 
Faclor prescnl Faclor abscnl 
History ofwhcczing 2.15 1.62-2.89 0.6<) 0,48-0.73 
Wheezing (audible or on auscultation) 2.06 1.77-2.40 0.52 0.43-0.62 
Iilstory of tightness of chest 1.35 l.J 3-1.56 059 0.42=0.81 
No crackles heard on auscultation 1,07 1.02-1.11 0.44 0.20-0.79 
All 4 il\!ll1S 6.38 5.06-7.80 0.08 0.Q3-0.1 ~ 
l1le ARUC of the derivoo prediction rule is 0.82. with the lieS! eut-off for the 
pn.."diaion of an acute cMc~.,bation in a patient ~ 15 )l'3l"S presct1ting wilh cough or 
ditlicuh bn:lIthlOg being ~ 3 of the "clinical femures prescnloo below. The sensitivity 
:1I1h;~ cut-<)ff i ~ 83%. and the gpecificity;$ 66% with & LR+ of2.5 (Table 71). Figure 
13 compares the accu11lCY o t" the nurse nnd deri\ed prl"iliction rules. Th~"e is \'cry lillie 
dltTcrcncc bClwe!-'n the IWO. 
Table 77: Cut-point or dHind prediction rule for predicting acutr 
nac('rhations. 
Cut off Srnsitivity. Sprcifidty. Corrcetlr CR. l.R-
poilU , 0;_) W.) Clas~ ifird 
Co;.) 
"" 100 0 11 1.00 ., 99 1 " 1.07 0.04 '" 97 " " 1.89 0.63 >J 83 66 10 2.46 0.25 
'" " 88 80 4.35 0.54 
217 
Figllr~ LJ: Cnmllarisou of Ihe a~cuncy of Ihe l1urs~ using Ihe guideline and the 
derh ed predicllon rule (A R UC) for MClIle uacerhlltions. 
-acutooldn-flU"'c diagnoSIS o f acule ~XIICC.-balio"; a-dm, ~'(\ prediCtion model 
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11.6 Tuherculosis 
S.6.1 Ilist ri bu tion of ~ us peetcd amI bacleriologica ll~·-pro ' en diagno~t'!i llf 
tuberculosis. 
figure 14 lists Ihe distnbUlion of tuberculosis diagnoses in the study. The primary 
CIlf"C physician suspected 365 (26~"') patieilts of having iubcmJlosis. Of these. si.xtccn 
(70"/0) were unablc 10 produce sputa and 7 (30%) did nOi Ti-1Um their sputa samples. 
Of the remaining 341 to r whom sputa were rCiJucsted. 40 (12%) were proven to havc 
tubm:ulosis · 24 {57%) h.w smear-posi tive tuberculosis. 5 (21%) had smear and 
(:ulturc-positivc tuberculosis. 10 (14%) had culture-positivc tuhcr.::ulosis {lnly. and 
(2~,.) had smear-negatil'e tuberculosis. 
figure 14; Distribution or t ubl'rculosi~ diagoMes (s u ~ pec t('d and 
bac tc rill ing ically-pro' en) In thc s tudy. * 
Nurse d lagnollis o f suspeCCI!"d T 6 
I N"1 392 
ST. ". 
N - 5 16 N .. S76 
Primary CIIra physic ian 
I -
d;a9"ocic 01 auap ect.d TB 
N"1 392 
m ST. -j 
N"365 N"1027 
• Un"l>le to OOUoion 
Sputa (n_16) 
• Oelaultltd follow 
g ~ 
up (n_7) 
Respira tory specialist 
"-
diagnosis 01 suspected T6 
ST. 
N_ '392 
"" Na260 N - '135 
• STB. ~uspcclcd lUl)~rcu lnsts 
'" 
8.6.2 Accuracy of guideline in diagnosing tuberculosis: primary care physicians 
as reference standard 
The diagnostic accuracy of the nurse using the guideline as compared to the primary 
care physicians' diagnoses (Table 78) was as follows: sensitivity 76%, specificity 
77%, PPV 53%, and a NPV of90. 
Table 78: Diagnostic accuracy of nurse using the P ALSA guideline in diagnosing 
suspected tuberculosis to primary care physicians' diagnoses as the reference 
standard. 
True positives, n 276 
False positives, n 240 
False negatives, n 89 
True negatives, n 787 
Sensitivity, % (95% CI ) 76 (71-79) 
Specificity, % (95% CI) 77 (74-79) 
PPV, % (95%CI) 53 (49-58) 
NPV, % (95% CI) 90 (88-92) 
LR+ 3.2 
LR- 0.31 
ARUC (95% CI) 0.76 (0.74-0.79) 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive 
likelihood ratio, LR-: negative likelihood ratio, ARUC: area under the receiver 
operating characteristics curve. 
* Nurse diagnoses (n=516). Respiratory physician diagnoses (n=365) 
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8.6.3 Level of primary care physician confidence in the suspicion of tuberculosis 
Of the 40 patients proven to have tuberculosis, the non-specialist assigned a level of 
certainty of 5 in 23 (58%) patients, whereas 1 (3%) and 3 (8%), respectively, were 
assigned values of 1 or 2 (Table 79). The certainty of diagnosis values for non-
specialists was not significantly different from those of the specialists. 
Table 79: Confidence of primary care physicians' in their diagnoses of suspected 
tuberculosis in proven and unconfirmed tuberculosis. 
Levels of Tuberculosis suspected, Tuberculosis 
certainty not proven, n (%) suspected and 
confirmed, n (%) 
1 28 (97) 1 (3) 
2 73 (96) 3 (4) 
3 79 (93) 6 (7) 
4 58 (89) 7 (11) 
5 64 (74) 23 (26) 
Total patients 302 (88) 40 (12) 
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8.6.4 Accuracy of the nurse using guideline in diagnosing bacteriologicaUy-
proven tuberculosis 
The sensitivity of the nurse using the guideline to detect patients with proven 
tuberculosis was 90%, specificity was 65%, PPV was 7%, and NPV was 99% (Table 
80). Of the 4 patients not suspected of tuberculosis by the nurse, 1 had cough and 
difficult breathing, wheezing and tight chest for 1 day, another had these symptoms 
for 4 months, and yet another had cough and difficult breathing with pleuritic chest 
pain and new sputum production for 1 week. The fourth patient reported having only a 
cough and night sweats for 4 days. Two patients had previous diagnoses of asthma, 
and 1 of asthma and tuberculosis. 
Table 80: Diagnostic accuracy of nurse practitioner using the P ALSA guideline 
in diagnosing bacteriologically-proven tuberculosis (n=1392). 
True positives, n 36 
False positives, n 462 
False negatives, n 4 
True negatives, n 867 
Sensitivity, % (95% CI) 90 (76-97) 
Specificity, % (95% CI) 65 (63-68) 
PPV, % (95% CI) 7 (5-10) 
NPV, % (95% CI) 99 (98-100) 
LR+ 2.6 
LR- 0.15 
ARUC (95% CI) 0.78 (0.73-0.82) 
p.PV: positive predictive value, NPV: negative predictive value, LR+: positive 
likelihood ratio, LR-: negative likelihood ratio, ARUC: area under the receiver 
operating characteristics curve. 
* Nurse diagnoses (n=516). Respiratory physician diagnoses (n=342) 
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8.6.5 Accuracy of guideline in diagnosing tuberculosis: using the respiratory 
physicians as reference standard 
The respiratory physician assessed 262 (19%) patients as having suspected 
tuberculosis. The diagnostic accuracy of the nurse using the guideline compared to the 
respiratory physician diagnosis of suspected tuberculosis was as follows (Table 81): 
sensitivity 73%, specificity 71%, positive predictive value (pPV) 37%, negative 
predictive (NPV) 92%, and area under the ROC curve of 0.65. The primary care 
physician identified 152 more patients for tuberculosis screening than the respiratory 
physician, 6 of whom were later proven to have tuberculosis. 
Table 81: Diagnostic accuracy of nurse practitioner diagnosis of suspected 
tuberculosis, compared to respiratory physician diagnoses of suspected 
tuberculosis (n=1392). 
True positives, n 189 
False positives, n 327 
False negatives, n 71 
True negatives, n 805 
Sensitivity, % (95% CI) 73 (67-78) 
Specificity, % (95% CI) 71 (68-74) 
PPV, % (95% CI) 37 (32-41) 
NPV, % (95% CI) 92 (90-94) 
LR+ 4.5 
LR- 0.67 
ARUC (95% CI) 0.65 (0.62-0.67) 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive 
likelihood ratio, LR-: negative likelihood ratio, ARUC: area under the receiver 
operating characteristics curve. 
• Nurse diagnoses (n=516). Respiratory physician diagnoses (n=262) 
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8.6.6 Prevalence of symptoms and signs: suspected and diagnosed tuberculosis 
Table 82 details the most common symptoms in patients proven to have tuberculosis. 
Cough (100%) followed by difficult breathing (70%), new sputum production (63%), 
loss of weight (50%), and night sweats (50%) were among the most common 
presenting symptoms. 
Table 82: Prevalence of symptoms among patients confumed to have 
tuberculosis (n = 40). 
Symptom Proven Doctor Specialist 
tuberculosis suspected suspected 
(n=40) , n (0/0) tuberculosis tuberculosis 
(n=36S), n(%) (n=262), n(%) 
Cough 40 (100) 97 (27) 97 (37) 
Difficult breathing. 28 (70) 77 (21) 73 (28) 
New sputum production 25 (63) 54 (15) 43 (16) 
Loss of weight 20 (50) 45 (12) 41 (11) 
Night sweats 20 (50) 44 (12) 43 (12) 
Pleuritic chest pain 11 (30) 16 (4) 19 (7) 
Increased sputum 6 (15) 13 (4) 13 (5) 
production 
Haemoptysis 5 (13) 13 (4) 14 (5) 
Sputum colour change 5 (13) 8 (2) 7 (3) 
Fever 2 (5) 3 (1) 5 (2) 
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8.6.7 Analysis of history and examination predictors of tuberculosis 
Three independent features interrogated in the multivariate model predicted the 
diagnosis of tuberculosis. In decreasing order these were pleuritic chest pain, weight 
loss, night sweats (Table 83). The presence of all 3 items increased the likelihood 17-
fold. The features associated with the diagnosis of suspected tuberculosis by the 
respiratory physician were haemoptysis, weight loss, night sweats, previous 
tuberculosis, pleuritic chest pain, absence of difficulty breathing, and absence of 
wheeze. 
Table 83: Independent and combined likelihood ratios for predictors of 
suspected or diagnosed tuberculosis: logistic regression models. 
Reference Predictors LR+ (95% CI) LR- (95% CI) 
standard 
Tuberculosis Previous tuberculosis 2.6 (1.9-3.5) 0.75 (0.67-0.84) 
suspected by Haemoptysis 4.8 (2.2-10.3) 0.91 (0.86-0.96) 
respiratory Night sweating 2.8 (1.8-4.2) 0.77 (0.68-0.87) 
physician* Weight loss 3.5 (2.3-5.6) 0.75 (0.66-0.84) 
Pleuritic pain 2.5 (1.5-4.1) 0.90 (0.84-0.95) 
No difficulty 1.6 (1.2-2.1) 0.88 (0.80-0.96) 
breathing 
No wheeze 1.2 (1.1-1.4) 0.70 (0.53-0.92) 
All 7 predictors 594 (232-1821) 0.22 (0.17-0.29) 
Tuberculosis Pleuritic pain 2.9 (0.2-4.79) 0.82 (0.63-0.99) 
diagnosed by Night sweats 2.9 (1.0-4.63) 0.81 (0.67-0.96) 
primary care Weight loss 2.0 (1.0-4.6) 0.76 (0.54-0.97) 
physician** All 3 predictors 17 (5.9-29.4) 0.50 (0.36-0.65) 
* area under ROC curve for model=O.85. ** area under ROC curve for model=O.74 
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8.7 Lower Respiratory Tract Infection (LRTI) 
8.7.1 Accuracy of the nurse using guideline in diagnosing LRTI 
The guideline perfonned well at excluding LRTI (specificity 94%, NPV 85%), but 
had a low sensitivity of only 33% (Table 84). The positive likelihood ratio was 5.39 
and the area under the ROC curve was 0.64 which is not high enough for a condition 
that requires specific therapy, namely antibiotics. 
Table 84: Diagnostic accuracy of the nurse using the PALSA guideline in 
diagnosing LRTI, using the respiratory physicians' diagnoses as the reference 
standard* 
True positives, n 92 
True negatives, n 1045 
False positives, n 68 
False negatives, n 187 
Sensitivity, % (95% CI) 33 (27-39) 
Specificity, % (95% CI) 94 (92-95) 
PPV, % (95% CI) 56 (49-65) 
NPV, % (95% CI) 85 (83-87) 
LR+, % (95% CI) 5.39 
LR-, % (95% CI) 0.71 
ARUC (95% CI) 0.64 (0.61-0.66) 
PPV: positive predictive value, NPV: negative predictive value, LR+: positive 
likelihood ratio, LR-: negative likelihood ratio, ARUC: area under the receiver 
operating characteristics curve. 
• Nurse diagnoses (n=160); respiratory physician diagnoses (n=279) 
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8.7.1.1 False positive diagnoses ofLRTI 
The primary respiratory physician diagnoses when the nurse incorrectly diagnosed 
LRTI (44%; lOO-PPV) were acute exacerbations in 30% (20 patients), COPD in 13% 
(9), other lung conditions in 13% (9), asthma in lO% (7), and cardiovascular disease 
in 10% (7) (Table 85). 
Table 85: Distribution of primary respiratory physician diagnoses made when 
the nurse using the guideline incorrectly diagnosed LRTI (false positive 
diagnoses). 
Diagnostic categories Primary respiratory specialist 
diagnoses, n (%) 
Acute exacerbations 20 (30) 
COPD 9 (13) 
Other lung conditions 9 (13) 
Asthma 7 (lO) 
Cardiovascular disease 7 (10) 
URTI 6 (9) 
Suspected TB 6 (9) 
Allergic rhinitis 2 (3) 
Metabolic conditions 2 (3) 
Total 68 (100) 
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8.7.1.2 False negative diagnoses of LRTI 
Table 86 lists the distribution of the diagnoses made by the nurse instead of LRTI 
(15%; 100-PPV). Most patients were suspected of having tuberculosis (51 %). Twenty 
three percent would have been treated for acute exacerbations, and only 10% were 
thought to have an URTI instead. 
Table 86: Distribution of diagnoses when the nurse using the guideline missed a 


















8.7.2 Analysis of history examination predictors of LRTI 
8.7.2.1 Univariable analysis of predictors ofLRTI 
Table 87 shows that the univariable clinical features most predictive of LRTI in this 
population is a history of fever (LR+ 4.18). Although the presence of cough is only 
mildly predictive (LR+ 1.13), the absence thereof strongly rules out LRTI (LR- 0.09). 
The absence of reported difficult breathing (defined as dyspnoea, tight chest, or 
wheezing) (LR+ 3.59), reported pleuritic chest pain (LR+ 2.08), and sputum 
production (LR+ 2.06) were also significantly associated with LRTI. Of note, in the 
univariable analysis, the colour of the sputum was not a predictor. 
Table 87: Univariable predictors of LRTI 
Description Sens, Spec, Crude 
% % LR+ LR-
History of fever 8 98 4.18 0.94 
No difficult breathing on presentation 55 12 3.59 0.63 
Pleuritic chest pain 13 94 2.08 0.93 
Sputum production 60 71 2.06 0.57 
No history of wheezing 23 49 1.57 0.45 
No history of tight chest 31 46 1.50 0.56 
No previous diagnosis of asthma 19 56 1.45 0.43 
No wheezing (audible or on 17 61 1.37 0.44 
auscultation) 
No previous diagnosis of COPD 6 81 1.16 0.34 
Cough on presentation 99 12 1.13 0.09 
* Sens: sensitivity; Spec: specificity 
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8.7.2.2 Multivariable analysis of predictors of LRTI 
The multivariable predictors of LRTI included in the reduced model are presented in 
Table 88. History of fever (LR+ 4.20) and the absence of difficult breathing on 
presentation (LR+ 2.26) were still the strongest predictors of LRTI. Sputum 
production (LR+ 1.80) was mildly predictive. No reported asthma or COPD, and the 
absence of wheezing (LR+ 1.18) were only slightly predictive. But the absence of 
cough (LR- 0.17) virtually rules out the disease. The presence of all 7 items in an 
adult patient presenting with cough or difficult breathing increased the likelihood of 
LRTI 32-fold. Sputum history and a history of fever were included in the guideline 
algorithm. 
Table 88 Multivariable predictors of LRTI. 
Adjusted likelihood ratios 
Diagnostic element Factor 95%CI Factor 95%CI 
,l!resent absent 
History of fever 4.20 1.84-8.78 0.94 0.90-0.98 
No difficult breathing on presentation 2.26 1. 78-2.86 0.74 0.66-0.82 
Sputum production 1.80 1.53-2.13 0.63 0.53-0.73 
No previous diagnosis of asthma 1.24 1.15-1.35 0.52 0.38-0.68 
No previous diagnosis of COPD 1.20 1.11-1.30 0.41 0.24-0.63 
No wheezing (audible or on 1.18 1.07-1.30 0.64 0.48-0.84 
auscultation) 
Coucl1 on presentation 1.06 1.03-1.09 0.17 0.05-0.42 
All 7 items ~resent 32 13.6-76.3 0.01 0.00-0.03 
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A cut-off of ~5 has the most acceptable sensitivity and specificity (Table 89). Figure 
15 shows that the derived prediction model performs better at detecting LRTI in this 
population than the nurse following the guideline algorithm (ARUC: 0.79 vs 0.69). 
Table 89 Cut-point of derived multivariable model for predicting LRTI 
Cutoff Sensitivity, Specificity, Correctly LR+ LR-
point (%) (%) Classified, 
(%) 
~1 100 0 20 1.00 
~ 100 2 22 1.02 0.00 
~ 94 27 40 1.28 0.21 
~ 83 62 66 2.20 0.27 
~ 65 84 80 4.12 0.41 
~ 25 96 82 6.74 0.77 
~7 1 99 80 11.96 0.99 
Figure 15 Diagnostic accuracy of the nurse using the guideline, compared to the 
derived prediction model (ARUC) for LRTI. * 
* lrtin - nurse LRTI diagnosis; lrtia - derived prediction model 
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8.8 Upper Respiratory Tract Infection (URTI) 
The performance of the guideline to detect URTls is presented in Table 90. A total of 
35 URTI's (TP (21) + FN (14)) were diagnosed by the respiratory specialist in this 
study. This is less than anticipated and limits the scope for analysis and conclusions 
regarding this category of disease. Therefore no formal analyses are presented. 
Table 90 Diagnostic Accuracy of guideline to diagnose URTI. 
True positives, n 21 
True negatives, n 1280 
False positives, n 77 
False negatives, n 14 
Sensitivity,% (95% CI) 60 (42-76) 
Specificity, % (95% CI) 94 (93-95) 
PPV,% (95% CI) 21 (14-31) 
NPV,% (95% CI) 99 (98-99) 
LR+ 10.6 
LR- 0.42 
ARUC (95% CI) 0.77 (0.69-0.85) 
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8.9 Summary of results of the validation study 
The guideline perfonned best at predicting acute asthma or COPD exacerbations, 
COPD, and asthma (sensitivities 77%-80%; specificities 84-88%, ARUC ~0.8l). It 
perfonned relatively well as a pre-screening test for tuberculosis (76% and 77%), 
using the primary care physician as the reference standard. For the diagnosis of 
bacteriologically-proven tuberculosis, the guideline in the hands of the nurse 
perfonned well (sensitivity 90%, specificity 65%), and only 4 patients were missed by 
the nurse. The guideline perfonned moderately well for diagnosing conditions which 
have milder symptoms, and/or those with a high degree of overlap of their symptoms 
(well-and moderately controlled asthma, mild/moderate COPD). Overall, the results 
for the individual disease syndromes fall within the following ranges: sensitivities, 
33%-80%; specificities, 71%-94%; PPV, 21%-74%; NPV, 85%-99%; LR+, 4.83-
10.6; LR-, 0.2-0.71; ARUC, 0.64-0.84). 
False positive and false negative diagnoses for all diseases were at a minimum, with 
most diagnostic misclassification restricted to conditions that had clinical similarities, 
in particular for asthma and COPD. Detailed analysis of URTIs was not possible as 
the total number in the sample was too small. 
The predictors for asthma in adults with cough or difficult breathing were: onset of 
symptoms before the age of 20 years, audible or auscultated wheeze, a previous 
diagnosis of asthma, day-to-day variability, symptomatic response to bronchodilators, 
nocturnal dyspnoea, symptoms triggered by emotions, no worsening of symptoms 
over time, no previous diagnosis of COPD (cut-off of any of;::: 4 items yielded a 
sensitivity of 86% and specificity of 71 %; LR+ 3). In adults with OAD the predictors 
of asthma were: a previous diagnosis of asthma, no worsening of symptoms over time, 
a pack year history of ~ 20 years, day-to-day variability, audible or auscultated 
wheeze, and female sex (cut-off of any of;::: 4 items yielded a sensitivity of 87% and 
specificity of 93%; LR+ 12). For patients;::: 40 years with OAD the predictors of 
asthma were: a previous diagnosis of asthma, no worsening of symptoms over time, 
and a pack year history of ~ 20 years, onset after the age of 40 years, female sex, 
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reported wheeze (cut-off of any of ~ 3 items yields a sensitivity of 90% and 
specificity of 86%; LR+ 6.5). 
The predictors for COPD in adults with cough or difficult breathing were: previous 
diagnosis of COPD; pack years smoking ~ 20 years, cannabis use, previous diagnosis 
of tuberculosis, slow worsening of symptoms over time, cough and sputum 
production preceding onset of dyspnoea, onset of symptoms after the age of 40 years, 
dyspnoea on presentation, and no previous diagnosis of asthma (cut-off of any of~ 5 
items yielded a sensitivity of 79% and specificity of 88%; LR+ 6). The predictors for 
patients ~15 years with OAD were: no previous diagnosis of asthma, slow worsening 
of symptoms over time, no variability of symptoms, pack year history ~ 20 years, 
onset after the age of 40 years, male sex, and a previous diagnosis of tuberculosis 
(cut-off of any of~ 4 items yielded a sensitivity of 82% and specificity of 92%; LR+ 
11). And finally, for those ~ 40 years with OAD were no previous diagnosis of 
asthma, no variability of symptoms, slow worsening of symptoms over time, a pack 
year history of ~ 20 years, male sex, and reported wheezing (cut-off of any of ~ 3 
items yielded a sensitivity of93% and specificity of 86%; LR+ 11). 
For LRTI, predictors were: a history of fever, no difficult breathing, sputum 
production, no previous diagnosis of asthmaiCOPD, no wheezing, and cough on 
presentation (cut-off of any of ~ items yielded a sensitivity of 83% and specificity of 
62%; LR+ 11). 
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Chapter 9 : Discussion 
9.1 Introduction 
The approach adopted in the development of the P ALSA guideline appears to have 
been successful judged both from the perspective of the target group, being the nurse 
practitioners and their managers. Its validity as a guide to syndromic diagnosis and 
management of respiratory diseases and tuberculosis has also been demonstrated. In 
developing and assessing the P ALSA guideline, qUalitative and quantitative research 
methods were combined. The qualitative research and review of relevant literature 
and documents informed its development, whereas the validation study served to 
validate the processes and outcomes oflocal adaptation by quantifying its accuracy. 
The P ALSA validation study is, to our knowledge, the first one of its kind to 
determine the accuracy of a locally-adapted guideline for diagnosing common 
respiratory conditions in adults presenting to primary care in a developing country. 
This study set out to test how close the guideline came to the alternative, a respiratory 
physician with access to special investigations. Its results confirmed the P ALSA 
guideline's overall satisfactory performance as a diagnostic tool for detecting acute 
and chronic obstructive airways disease and LRTI; and as a pre-screening tool for 
patients with suspected tuberculosis. The P ALSA guideline can therefore be viewed 
as an adequate solution for primary care with the potential for leading to earlier 
diagnosis and treatment of important respiratory conditions. Supporting nurses to 
provide early and more accurate treatment is a much better option in settings where 
patients would otherwise be required to wait until they could be transported to, or be 
seen in doctor-staffed clinics. 
The analytical approach adopted in this study has been pragmatic, in that results. were 
viewed not only from the perspective of 'correct' or concordant diagnoses, but also 
from the perspective of whether the potential benefits of early and correct diagnosis 
might outweigh the potential harmful consequences of an initial incorrect one. 
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Although complicated and speculative in parts, this detailed assessment of false 
positives and false negatives provides some reassurance that the nett result is positive. 
Ideally, this also needs to be tested in a pragmatic field study with examination of 
both process and health outcomes. It is also worth noting that although the respiratory 
physicians' diagnoses were considered the 'gold' standard, even they demonstrated an 
element of diagnostic uncertainty as evidenced by the moderate concordance between 
them for two conditions in this study (kappa values of 0.57). 
The P ALSA guideline's successes however are not unqualified, as several 
shortcomings are evident both in the approach used and in the tool itself Some of 
these have been or will be addressed in future revisions of the guideline and training 
programme. Others will remain a weakness, and must be viewed as the 'cost' 
consequence of oversimplification of diagnostic processes, and of having to rely so 
heavily on nurses to perform functions which optimally should be performed by 
physicians. The latter deficiency is implicit in the use of integrated management 
programmes like PALSA and IMCI, as they owe their existence to the systematic 
problems in the distribution of health care in poorer countries and the need to address 
these. On the other hand, the exercise of researching the extent to which these 
problems can be overcome, and the need to offer the highest level of care to those 
who have no other health care alternatives, is both a humanitarian obligation and a 
challenging academic exercise. 
Results of the randomized controlled study conducted in the Free State province, 
confirm the effectiveness of the PALSA guideline when implemented using the 
educational outreach strategy. 1 Approximately 1000 patients ~15 years were included 
in both the intervention and control arms. Inhaled corticosteroid prescriptions were 
significantly higher in the intervention group (13.7% vs 7.7%; OR 1.90 (1.14-3.18) 
and were thought to be appropriate as more patients with inhaled corticosteroids 
reported a clinical response to bronchodilator therapy (85% vs 73%). A significant 
increase in tuberculosis case detection (6.4% vs 3.8%; OR 1.72 (1.04-2.85», despite 
only a modest, non-sigriificant increase in sputum testing in the intervention group 
(22.6% vs 19.3%; OR 1.22 (0.83-1.80» was shown. Patterns of referrals to higher 
levels of care also improved significantly. Antibiotic prescribing rates however were 
not different between the two groups, but were said to be low overall. And no 
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differences in co-trimoxazole provision were shown. This finding was reported to 
reflect the erratic supply of this drug at the time. 
Some aspects of the development and validation studies require further discussion, 
and these will be presented below. 
9.2 DEVELOPMENT OF THE P ALSA GUIDELINE 
Local adaptation of existing international or national guidelines for local use, recently 
coined trans-contextual adaptation by the ADAPTE Working GrOup,2 3 has been 
shown to improve the uptake and ownership of adapted guidelines.4 5 6 7 This area of 
guideline development research is relatively new,2 and the group calls for 
standardisation of guideline adaptation methods, and presents a potential framework. 
At the time of the development of the P ALSA guideline, no formal methods for 
guideline adaptation were published. Therefore, those proposed for de novo guideline 
development were employed and adapted for use by the PALSA guideline 
development group. When compared to the adaptation steps proposed by the 
ADAPTE group, many similarities are noted. These relate to those PALSA methods 
used to: form a multidisciplinary development group; define and assess the clinical 
question; search for and externally review other guidelines; tailor the guideline to 
local circumstances; and to ensure adequate adoption and endorsement of the P ALSA 
guideline. 
A major deviation of P ALSA from methods used to either develop or adapt existing 
guidelines is that in the P ALSA guideline, recommendations are evidence-based but 
are not graded to indicate how they are linked to their supporting evidence. This 
process is regarded by evidence-based guideline developers to be a very important 
step in the development of valid and explicit guidelines.2 4 8 The decision to not 
employ this particular method could therefore be a potential weakness in the 
development of the PALSA guideline's recommendations. The reason underpinning 
this decision, however, was that qualitative research revealed a lack of understanding 
and knowledge of basic processes of care. Therefore it was assumed that inclusion of 
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a grading system might have not been effective in this setting. However, this is an 
assumption and must be tested in future studies. Knowledge support was however 
provided by the P ALSA developers to the target users, as they were encouraged to 
submit 'frequently asked questions'. These were compiled and sent to the trainers on a 
monthly basis. The aim was to provide a scientific basis for those recommendations 
requiring clarification. This practice eventually lead to the compilation of a 
Frequently Asked Questions booklet. The inclusion of a grading system in the P ALSA 
guidelines, and/or the provision of a detailed document showing exactly which 
evidence supports each recommendation are considerations for future revisions of the 
guideline. 
Another deviation from methods proposed by evidence-based guideline development 
groups was that the P ALSA guideline developers did not use formal decision-making 
processes to develop the final recommendations. These methods could have aided in 
improving the transparency of the developers' judgements 9 10 and in how local 
policies and practices were applied. 11 12 
9.2.1 The use of qualitative research for developing the guideline and its support 
materials 
Integrating qualitative research into the development of the guideline, its support 
materials, and the chosen interventions provided detailed information about the 
acceptability and feasibility of its introduction into primary care in South Africa. 
These methods provided a depth of understanding of the local context and health 
practitioners' attitudes that mere review of the literature could, and often did, not 
provide. It also helped to identify barriers to the delivery of quality respiratory care 
locally. Futhermore, it served to determine how the PALSA guideline could be 
tailored to and integrated into current practices. In addition, areas needing 
improvement were highlighted (for example a change in the prescribing provisions for 
nurses) and served to inform changes in local policy: The deliberate emphasis on the 
use of qualitative research is considered to be a major strength in this study. The 
importance of the these methods in the development of multicomponent interventions, 
otherwise known as complex interventions, such as the one presented in this thesis 
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was emphasised in a document published by the Medical Research Council in the 
UK.13 This document provides a framework for the development and evaluation of 
randomised controlled trials for complex interventions. It reports that qualitative 
research helps not only to inform the development of each component of the 
intervention, but also helps to more easily determine which component has 
contributed to the success or failure of the intervention as determined by the 
randomised controlled trial. 
9.2.2 Limitations of the qualitative research methods 
The focus group participants were chosen to be representative of those working in the 
setting in which the intervention was to be implemented. Inclusion of predominantly 
urban based health professionals could have therefore under-represented or excluded 
discussion of problems encountered by those working in rural areas. However, a 
prerequisite was that the participants have experience working in rural areas. 
Conducting more focus groups could also have provided more data, but the research 
team agreed that data saturation was reached as no new ideas emerged during the last 
focus group discussion. Patients were excluded from the qualitative evaluations and 
their inclusion could possible have provided more information. However, given the 
time and resource constraints, and the fact that the intervention was specifically 
targeted at nurses, a decision to not include them was made. Division of nurses and 
doctors into separate groups when conducting the focus group interviews was 
intended to increase the participation of members with shared work experiences and 
qualifications, and to reduce the effect of hierarchy on the groups' dynamics .14 
9.2.3 Barriers to the delivery of respiratory disease care in South Africa 
The main barriers to providing respiratory care were related to knowledge and skills, 
interprofessional relationships, and organisational issues. These findi~gs are 
confirmed by the results of a number of other studies conducted in South Africa over 
the last two decades. IS 16 17 18 19 The existence of gaps and weaknesses in the training 
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and practices of nurses were also confinned in a study evaluating the work practices 
of primary care nurses working in community clinics in South Africa.2o 
Other studies confinn the huge impact of organisational and interprofessional issues 
on nurses in primary care in South Africa, for example, a study in two local health 
districts showed that most nurses denied having had adequate managerial 
supervision.21 One study conducted in the early-1990s reported that although most 
nurses actively participated in their daily activities, many reported very low levels of 
job satisfaction in comparison to most other professionals, but that despite this, their 
self-esteem was high. 22 Assessment of nurses' perceptions of the process of 
introduction of free health care revealed that the timing and degree to which they were 
involved in the introduction of health care policies directly influenced their 
involvement in helping to implement them.23 In addition, most nurses felt excluded 
from the process of policy change and reported that resources were often insufficient 
to facilitate policy implementation. Finally, Thipanyana et al24 reported that about half 
of the nurses worldng in primary care in two rural areas in South Africa reported 
heavy workload, and about three-quarters showed that clinic staffing ranged from 
average to poor. Together the results of these studies confinn the deficiencies so 
evident in South African primary care, and serve to further support the development 
of interventions to assist nurse practitioners. 
Research on the barriers and facilitators to care in South Africa is lacking, and it is 
hoped that as the PALSA initiative expands, the group will conduct more studies in 
this area and will continue to design interventions to address them. Furthennore an 
effort will be made to, through consultation with policymakers, use past and future 
research to specifically address identified organisational and interprofessional 
barriers. 
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9.3 THE PALSA VALIDATION STUDY 
9.3.1 Characterisation of the test population 
The perfonnance of any diagnostic test is dependent on the population mix and local 
disease prevalence in which it is validated?5 The mix of respiratory diseases and co-
morbid illnesses in the validation study is consistent with that found in a 
predominantly middle-aged adult population in South Africa.26 27 The prevalence of 
past respiratory diseases, in particular, asthma (43%) and COPD (20%) was high, and 
15% of patients had a history of previous tuberculosis. The latter, although high, is 
typically representative of the popUlation that attends the study clinic, and reflects the 
high prevalence of tuberculosis in Cape Town which was estimated to be 638 per 
100,000 in 2002.28 The prevalence of cardiovascular disease was also particularly 
high (38%), with 10% of patients reporting a "metabolic disorder", usually diabetes 
mellitus. In most, this represents Type II diabetes, as obesity and the metabolic 
syndrome including insulin intolerance are common in this community. 29 
Furthermore, the presence of multiple diagnoses on presentation seem to have further 
complicated the diagnostic process. 
The first version of P ALSA had little on HIV and AIDS. The reasons for this were 
three-fold. Firstly, when it was developed, anti-retrovirals were not available for 
patients in the public sector. Secondly, the provincial health authorities were in the 
process of developing guidelines for HIV diagnosis and management, and did not see 
these as part of a respiratory treatment package. Thirdly, it was considered 
overambitious to include HIV care in the first version, at least until the strengths and 
weaknesses of the approach had been tested. However, the almost immediate success 
of PALSA, in terms of its uptake and acceptability, prompted the expansion of the 
guideline to include HIV care (called PALSA Plus) even before the results of the 
randomised controlled trial were available. 
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P ALSA Plus is currently being implemented and tested in two provinces in South 
Africa. In the version presented in this thesis, we included only the diagnosis of HIV 
infection and HIV-related respiratory complications. The prevalence of HI V infection 
in the suburbs served by the Retreat clinic in 2001 (estimated from anonymous testing 
of antenatal blood specimens) was 5.9%.30 Although HIV testing was available at the 
clinic at which the study was conducted, it was not included in the design of the study. 
9.3.2 Impact of the demographics and use of diagnostic categories in P ALSA 
South Africa's burden of tuberculosis is amongst the highest in the world, and the 
contribution of respiratory tract infections and obstructive lung diseases is high. 31 
Although each condition was considered separately from the perspective of its 
diagnostic and management evidence-base, in the PALSA guideline they were also 
grouped according to whether or not they were acute or chronic. Furthermore they 
were grouped according to their degree of disease severity and shared symptoms and 
signs. This process resulted in the identification of 5 disease syndromes which were 
further divided into 26 potential 'diagnostic categories' for which separate distinct 
treatments were available. 
9.3.3 Diagnostic accuracy of the PALSA guideline 
The PALSA guideline's performance for diagnosing each disease compares 
favourably with that of other diagnostic questionnaires and algorithms, many of which 
consider only one or two conditions rather than the several in the P ALSA guideline. It 
performed particularly well at detecting more severe conditions, or those with easily 
detectable clinical signs, for example wheezing in acute exacerbations and obstructive 
airways disease. Its performance for detecting respiratory tract infections was less 
satisfactory. Thus, in accordance with the IMel validation studies,32 3334 3S results for 
conditions (such as pneumonia in children) which are easier to diagnose because of 
more obvious or specific clinical features seem to have higher sensitivities and 
specificities. Reported performances of other respiratory screening tools,36 37 38 394041 
42 span a range of sensitivities from 23% to 86% and specificities between 40% and 
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100%. The derived predictors for obstructive lung disease and the results of the 
literature review, confirm that those history and clinical items included in the 
guideline were sufficient for making a diagnosis given the absence of spirometry. The 
performance of the guideline is best described disease by disease, and will be 
presented below. 
9.3.3.1 Diagnostic accuracy of the guideline in diagnosing asthma 
The P ALSA guideline as used by the nurse performed well for the diagnosis of 
asthma (sensitivity 77%, specificity 84%). This compares favourably to the results of 
a study reported by Sistek et al,43 in which the sensitivity and specificity of wheezing 
in combination with two out of three nocturnal symptoms (cough, dyspnoea, tight 
chest) were 80% and 86%, respectively. Sensitivities and specificities of symptom-
based questionnaires to diagnose asthma in children ranged from 23% to 86% and 
from 55-100%, respectively.39 40 This satisfactory performance can be attributed to the 
design of the guideline which included several ways of ensuring that asthma is 
considered and diagnosed. The guideline also provides an opportunity for 
distinguishing between asthma and COPO with a default to asthma if diagnostic 
uncertainty. A positive outcome of weighting the diagnosis towards asthma is that 
inhaled corticosteroids are introduced at an earlier stage, thereby reducing the 
possibility of exacerbations and even deaths from asthma.44 4S A process of review 
within one month provides the opportunity for treatment to be stopped if ineffective or 
considered unnecessary. However, even in COPO, a trial of inhaled corticosteroids is 
considered an acceptable option as their use is associated with reduced exacerbations 
and hospitalisations in some patients.46 According to the guideline the physician can, 
at the one month visit, decide whether to stop them or continue their use. Experience 
in resource-poor settings is that inhaled corticosteroid use is so low, that over-
treatment is unlikely to reach wasteful proportions, as their cost is likely to be offset 
by savings of resources spent on treating exacerbations, including hospital 
admissions.47 48 
The numbers of asthma or COPO cases that were either missed or misclassified by the 
nurse were small which suggests that the guideline was reasonably successful in 
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making the distinction between the two diseases. The guideline also appears to have 
two contrasting tendencies. The first was to diagnose (or default to) asthma instead of 
mild/moderate COPD; and the second was to diagnose severe COPD instead of 
asthma. The potential harm of incorrectly treating an asthmatic as COPD according to 
the guideline is that inhaled corticosteroids would be delayed for a period of one 
month until the patient is reviewed by a physician. Some of these patients may have 
had mixed disease (asthma and COPD) and may have benefited from asthma 
management. 49 50 
Several patients with LRTIs were diagnosed by the nurse as having asthma. Definitive 
diagnoses were not made for patients classified as LRTI, therefore the exact nature of 
the infection has not been reported. A possible explanation is that many of these 
patients had post-infectious cough due to postnasal drip or wheezing secondary to 
post-viral airways hyper-responsiveness. Post-infectious cough and wheezing 
typically continue for weeks after an upper respiratory tract infection and this time 
period falls outside the 2 week PALSA guideline cut-off for ac~te disease. 51 The 
observation that post-infectious cough is the most common cause of cough lasting 
between 3 and 8 weeks has led the American College of Chest Physicians to include a 
category of subacute cough in their clinical practice guidelines for the empiric 
management of cough. 52 They recommend that obstructive airways disease only be 
considered when post-infectious cough is excluded. Other diagnoses to be considered 
in the subacute category are pneumonia and acute exacerbation of chronic bronchitis. 
These findings have resulted in consideration of inclusion of post-infectious cough 
and post-viral wheezing in future revisions of the PALSA guideline. 
More problematic is the tendency of the guideline to label patients with 
cardiovascular disease and other forms of lung disease not represented in the P ALSA 
guideline as asthma. Cardiovascular disease was misdiagnosed as asthma by the nurse 
using the guideline in 15% of the cases. This finding is not surprising since nurses are 
neither trained nor expected to diagnose such conditions. Negative effects of this are 
possible delays in diagnosing heart disease, and treatment of these diseases with 
respiratory medications. The high prevalence in this community is grounds for 
altering the guideline to enable chronic heart disease to be distinguished from chronic 
lung diseases, and once again emphasizes the importance of local adaptation of the 
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guideline. Delay in diagnosing other lung conditions such as diffuse parenchymal 
lung disease, occupational lung disease (other than asthma) and carcinoma of the 
lung, while not ideal, is inevitable in this setting. These conditions frequently require 
radiology and physician input (often at specialist level) and, in some, biopsies and/or a 
trial of therapy. The overall prevalence of other forms of lung conditions not included 
in the guideline in this sample was low (2%), and the guideline made provision for 
referral of symptomatic patients not meeting the diagnostic requirements for the other 
conditions and those who did not improve on therapy. A small number of patients 
with asthma (11%) were diagnosed as suspected tuberculosis and would have 
undergone sputum testing, and then referral to a physician in the event of negative 
results. This small percentage of patients was unlikely to place a heavy burden on the 
tuberculosis programme, and the consultation with the physician might have resulted 
in their asthma being diagnosed. 
9.3.3.2 Accuracy of the guideline in determining levels of asthma control 
The guideline performed very well in diagnosing asthma as a syndrome, and at 
correctly identifying patients who did not fulfill criteria for each level of asthma 
control (specificities 87%-94%, NPV 89%-97%). However, it performed less 
satisfactorily at correctly classifying levels of asthma control as assessed by the 
specialist (sensitivities 27%-58%, PPV 17%-51%). As the level of control increased, 
the sensitivity of the guideline to make an accurate diagnosis increased, but at the 
expense of the specificity. These results highlight the difficulties in determining levels 
of disease control in the absence of more comprehensive questioning and lung 
function testing. Despite these poor results, further analysis of the levels of asthma 
control for each diagnostic category suggests that many patients may not have 
received the correct dosage of inhaled corticosteroids that matched the level of 
control, but would have received inhaled corticosteroids, albeit too high or too Iowa 
dose. Possible reasons for this are faulty training, and/or oversimplified categories of 
control. Assessment of the frequency of day time and nocturnal symptoms were the 
only criteria to determine control in the PALSA guideline. 
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Currently evidence-based recommendations for asthma management aim to assess 
asthma control, rather than levels of disease severity at each visit. 53 54 55 56 One reason 
for a change in classification is that asthma symptoms do not always correlate with 
the degree of asthma severity. 57 58 When the National Heart Lung and Blood Institute 
published their guidelines in 1991,59 asthma severity was proposed to be assessed at 
the first visit with the assumption that the patient was treatment-naive.S3 Asthma 
control however changes over time60 61 and should therefore be assessed at every 
clinical encounter. 62 63 Assessing and managing the patient according to asthma 
control therefore has the added advantage of ensuring tailoring of treatment for each 
patient and makes the link between the current medication and level of control more 
explicit. 64 65 This allows for pharmacological treatment to stepped-up or down 
according to assessment of symptoms and other factors. 
Six factors determine asthma control: asthma symptoms, sleep disturbance, use of 
rescue medication, limitations of daily activity, patient and physician overall 
assessment, and lung function. s2 Asthma can be well-or completely controlled. Well-
controlled asthma is defined as having: (1) symptoms S2 times per week (2) use of 
bronchodilator for ~ 2 times a week (3) no nocturnal or early morning symptoms (4) 
no limitation of daily activities (5) normal FEV1 or PEFR, and (6) patient and 
physician assessments of well-controlled asthma.S2 Complete or total control implies 
(2) symptoms, and/or (2) bronchodilator use for ~ 2 times per week (3) no limitations 
of daily activities (4) no nocturnal or early morning symptoms (5) normal lung 
functions, and (6) physician and patient assessments of complete control. Treating 
asthma by determining the level of control will therefore be the new approach to 
asthma management and this is currently being promoted by GINA (personal 
communication Professor Eric Bateman). The revised P ALSA Plus guideline has 
included a more comprehensive assessment of the level of asthma control, as adapted 
from a more recent publication. 53 Further research into the added value and feasibility 
of peak flow meter measurements in primary care in South Africa is needed to clarify 
its utility for nurses. 
9.3.3.2 Clinical predictors of asthma 
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Categorical distinctions were made when assessing predictors for asthma for ease of 
comparison to studies reported in the medical literature, and to determine whether the 
diagnostic criteria for asthma and COPD should be refined. On univariable analysis, 
onset of symptoms before the age of 20 years and self-reported asthma were the 
strongest predictors for all three categories. Some authors argue that inclusion of self-
reported diagnoses of asthma or COPD in a prediction model limits its generalisability 
to other populations, and is reliant on patient recal1.43 Others argue that it is a 
component of the clinical examination and should be included.66 In agreement with 
the latter argument, it was included in this analysis. The only items present in each 
multivariable model were a previous diagnosis of asthma, and no worsening of 
symptoms over time. Reported wheezing of any kind did not perform as well as 
audible wheezing at predicting asthma. The strong predictive ability of the latter 
variable in this study could be a reflection of the inclusion of patients with acute 
exacerbations. 'History of wheeze' which referred to ever having had a history of 
wheezing, on the other hand, was most likely excluded from the model due to 
correlation with other variables (covariates). Reported wheezing with or without 
nocturnal symptoms or breathlessness has previously been reported to strongly predict 
asthma in a number of studies.43 67 68 69 Exclusion of audible wheezing from the ~40 
years obstructive lung disease model could have been due to the increased prevalence 
of wheezing in patients in this category, suggesting that wheeze is not useful at 
distinguishing between asthma and COPD in older patients with obstructive lung 
disease. Wheezing was shown to be a predictor of asthma, 43 68 69 of COPD,1° and of 
obstructive airways disease71 in other studies. Reduced breath sounds have also been 
shown to be a strong predictor of asthma72 but this variable was not included in this 
analysis because most nurses in primary care do not have auscultation skills. 
However, the excellent performance of 'audible or auscultated wheeze', prompts 
consideration of its inclusion in the next version of the PALSA guideline. 
Other studies reporting on predictors to distinguish between asthma and COPD among 
patients ~40 years, confirm that decreasing age, absence of smoking history, low 
cumulative pack years, and no report of worsening of dyspnoea over time are more 
suggestive of asthma.36 42 Only one also reported wheezing (in the absence of an 
URTI) to distinguish between the two conditions in patients ~45 years.36 Cough 
and/or difficult breathing, defined as breathlessness on rest or activity, wheezing, 
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and/or tight chest, were entry points into the guideline. Although studies have shown 
that asthma is one of the commonest causes of chronic cough (which mayor may not 
be associated with dyspnoea and wheezing),73 and that up to 36% of patients may 
have these symptoms simultaneously,74 cough was not a strong predictor. 75 The latter 
was probably due to these symptoms being common features of other respiratory and 
cardiovascular conditions. 
Most of the studies discussed above however were not population based, were 
retrospective, and did not prospectively validate their findings. In this study all 
relevant history and clinical items were incorporated into the structured record form 
not just those presented in the guideline. This was intentionally done as to determine 
whether items not included in the guideline would prove to be predictive of asthma. In 
support of the P ALSA guideline, results suggests that the guideline items are 
sufficient for diagnosing asthma in the absence of spirometry, as no new items other 
than that found in the guideline were included in the multivariable models. 
9.3.4 Diagnostic accuracy of the guideline in diagnosing COPD. 
The diagnosis of COPD is usually confirmed by spirometry.46 An accurate diagnosis 
is however important from a public health perspective as the incidence of COPD 
secondary to tobacco use is rising steadily in South Africa and in developing countries 
throughout the world.76 Despite the absence of spirometry, the guideline performed 
very well (sensitivity 70% and specificity 88%). This compares favourably to the 
results of two studies to determine predictors of COPD among patients ~o years,42 72 
which yielded sensitivities between 67% and 80% and specificities between 72% and 
98%. 
Features in the guideline prompting the nurse to diagnose COPD are cough and/or 
shortness of breath, wheezing or tight chest which started in later life (usually after the 
age of 45 years), and slowly worsening of dyspnoea over time. Other suggestive 
features are a longstanding history of cough and sputum production usually before the 
onset of the shortness of breath, dyspnoea for most of the day rather than in episodes, 
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and a smoking history of 15 years or more. As is the case in asthma, an opportunity to 
diagnose COPD in those with acute presentations is also presented. 
In general the number of COPD diagnoses which were missed or misc1assified were 
small. The most frequent false positive diagnosis was asthma. Given the small 
numbers of patients falsely diagnosed, and that newly-diagnosed patients are 
eventually to be seen by a physician for diagnostic confirmation, the costs of this 
misc1assification can be speculated to be minimal. The misdiagnosis of COPD as 
tuberculosis is partly understandable, particularly in patients with a chronic bronchitic 
element, or in those who had systemic features of COPD such as wasting and loss of 
appetite. If the tuberculosis diagnostic algorithm is adhered to, patients shown to not 
have tuberculosis on sputum bacteriology testing will inevitably be referred to a 
physician for definitive diagnosis. Only 9% of COPD patients were thought to have 
LRTI which could have lead to inappropriate antibiotic prescriptions in this group, 
and could have delayed the diagnosis of COPD in these patients. 
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9.3.4.1 Clinical predictors o/COPD 
The predictors of COPD regardless of age and underlying obstructive lung disease 
were as follows: no previous diagnosis of asthma, slow worsening of symptoms over 
time, a ~20 year pack history of COPD, and onset of symptoms after the age of 40 
years. These results are consistent with those of other studies.42 36 77 78 Other 
predictors (for COPD among patients with obstructive disease regardless of age) were 
male sex and absence of day-to-day variability. Auscultated wheeze was an 
independent predictor of COPD among patients ~ 40 years with obstructive lung 
disease. 
In contrast to other studies, a previous diagnosis of tuberculosis and use of cannabis 
were strong predictors of COPD in this population. In Cape Town, cannabis is 
reported to be the most commonly used illegal drug,19 with the prevalence among 
high school children estimated to be 7%.80 In a recent population survey in a low-
socioeconomic urban community in Cape Town, 11.3% people reported having used 
cannabis. 81 Many cannabis smokers also combine this drug with methaqualone, 
known as 'white pipe,.80 The relationship between cannabis and lung injury and 
airflow limitation has been well described,82 838485 although epidemiologic evidence 
of its link to COPD is speculative.82 Cannabis use is also associated with an increased 
prevalence of cough, sputum production, wheeze, exercise-induced dyspnoea, and 
nocturnal symptoms.82 84 
Tuberculosis was another independent predictor of COPD. The association between 
tuberculosis and airways obstruction have been shown in a number of studies 
conducted in South Africa.86 87 In a paper by Ehrlich et al, the authors report that 
recognition of tuberculosis as a risk factor for airflow obstruction has not been widely 
acknowledged and call for more research to determine the exact pathophysiology 
underlying this condition.88 In another study conducted by Ehrlich et aI, a history of 
tuberculosis was the strongest predictor for chronic bronchitis, which confirmed 
findings of another South African study showing increased frequency of cough and/or 
sputum in previously treated tuberculosis patients.89 Further research is needed in this 
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area as tuberculosis prevalence is high in South Africa. Failure to recognise the role 
that it plays in the development of chronic airways disease will only serve to further 
increase the local burden of respiratory disease. 
9.3.5 Accuracy of the guideline in diagnosing acute exacerbations of asthma or 
COPD 
Overall, the guideline performed best at detecting exacerbations of obstructive lung 
disease (sensitivity of 80% and a specificity of 88%). This might be explained by a 
number of factors, namely that the clinical features constituting this diagnosis are 
usually reported as being of sudden and of recent onset, and that most patients usually 
report a history of chronic obstructive airways disease on presentation. Because of the 
similarities in the acute presentations and initial treatments of asthma and COPD, 
P ALSA makes no distinction between them. 
Not surprisingly, LRTIs were frequently misdiagnosed as acute exacerbations. This 
means that these patients would have received inhaled beta-agonist as initial therapy, 
and not antibiotics. This perhaps is the most serious consequence of imprecise 
diagnoses, but is probably unavoidable within the constraints of clinics without 
physicians to check diagnoses, or those without radiology services. It is to be hoped 
that some of these patients will return if initial treatment fails to result in 
improvement. In addition, the diagnosis of LRTI includes bronchitis with purulent 
sputum. 
A number of patients with chronic presentations of asthma and COPD were assessed 
by the nurse as having acute exacerbations. In the guideline an opportunity is 
provided to assess for underlying asthma or COPD. We therefore assume that the 
patient would have received the appropriate therapy as part of their long term asthma 
control. One reason for the difficulty in distinguishing between the acute and chronic 
disease presentations could have been the rigid definition that designates an 
exacerbation of longer than 2 weeks duration a chronic rather than an acute event. 
Important conditions that the guideline incorrectly diagnosed as acute obstructive lung 
diseases exacerbations were cardiovascular disease and other acute and chronic lung 
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diseases not included in the guideline. These patients might in some instances have 
received inappropriate and possibly harmful prescriptions of oral corticosteroids. 
The most common diagnoses made by the nurse instead of acute obstructive airways 
disease exacerbations were chronic presentations of asthma or COPD. Treatment 
would however have included inhaled beta-agonist therapy for all, inhaled 
corticosteroid therapy for asthma, and a short-course of oral corticosteroids for 
patients assessed as having uncontrolled asthma or infective exacerbations of COPD. 
In most cases this would have been helpful if not ideal. 
9.3.5.1 Clinical predictors of an acute exacerbation 
Not surprisingly, reported wheeze, audible wheeze or wheezing on auscultation, 
reported tight chest, and the absence of crepitations on auscultation were indicators of 
an acute presentation. Exclusion of crepitations from the model did not change its 
accuracy, therefore the presence of the first 3 variables have a reasonably good 
accuracy at detecting acute exacerbations, particularly in our setting where nurses are 
not skilled at auscultation. Inclusion of reported wheeze and tight chest in the model 
yielded an accuracy of 0.76. 
9.3.6 Accuracy of the guideline in suspecting and diagnosing tuberculosis 
Identification of patients with possible pulmonary tuberculosis who require sputum 
examination is one of the major objectives of the PAL and PALSA programmes. One 
of the aims when developing the guideline was therefore to increase primary care 
nurses' suspicion of tuberculosis amongst patients presenting with signs and 
symptoms of respiratory diseases and to prompt bacteriological screening. 
Identification of such patients was thus not strictly a "diagnosis" but rather a 'pre-
screening' test for employing a diagnostic method, namely sputum examination. Even 
the specialist diagnosis may be regarded as a screening 'method' rather than a 
definitive diagnosis, as bacteriologic confirmation is necessary. The diagnostic 
accuracy of the guideline in the hands of the nurse was assessed against the non-
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specialist's diagnosis, and then against bacteriologically-confinned tuberculosis. 
Because sputum testing was only perfonned on patients suspected of having 
tuberculosis by the primary care physician, these results are more useful for showing 
that the nurse identified all or most of the patients whom a doctor with access to 
radiology and a more detailed history identified as tuberculosis suspects. 
The fact that the nurse using the guideline demonstrated a high degree of accuracy 
when compared to the specialist and primary care physicians, validates the syndromic 
'diagnosis' for identifying patients requiring screening for tuberculosis. High 
sensitivity is achieved at the expense of specificity. Thus, while it is unlikely that a 
'positive' case is missed, the low specificity results in additional effort and 
expenditure on false positive patients. In the case of tuberculosis, this results in 
additional use of resources for sputum examination. This is reflected in the ratio of 
suspected to bacteriologically-confinned cases which for the nurse using the guideline 
was 13:1, compared with 9:1 and 5:1 for the primary care and respiratory physicians, 
respectively. These values compare satisfactorily with the ratio for high prevalence 
populations of 10: 1 recommended for high prevalence countries. 90 
While the perfonnance of the P ALSA guideline was satisfactory in the population in 
which it was tested, it is recognised that the effiCiency of a screening test is influenced 
by disease prevalence, which in this study was 3%. If the tuberculosis prevalence had 
been higher, the yield from screening would have been higher. Conversely, in lower 
tuberculosis prevalence settings the yield from screening would be lower. The current 
guideline therefore appears appropriate for primary care conditions in South Africa.91 
9.3.6.1 Use of the two-week cut-off 
According to WHO, a tuberculosis suspect is defined as an individual with a cough 
for 3 weeks or more.92 The 3 week cut-off for classification of a tuberculosis suspect 
has been shown by many studies to be a robust indicator for screening for 
tuberculosis93 94 95 Recently a study conducted in India compared the detection of 
smear-positive cases among out-patients with cough ~ weeks or ~ 3 weeks.96 Using 
~ 2 weeks yielded a case detection rate of 481 per 100 00 new adult out-patients 
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compared to 328 per 100 00 patients for ~ 3 weeks cough. Using this criterion also 
resulted in an increase in the number of patients with chest symptoms (1371-2210) 
and an increase of 46% in the detection of smear-positive cases. More than a third 
reported cough for ~ 2 weeks, but less than 3 weeks. A third of patients also reported 
cough on direct questioning, which reinforces the importance of active case-finding 
among patients presenting to health facilities. 
In this study restricting screening to those with a cough for 2 weeks or longer would 
have resulted in failure to detect one-fifth of the confirmed cases. In an Ethiopian 
study in a high tuberculosis and HIV burden area, tuberculosis in patients with a short 
cough duration (1 to 3 weeks) was associated one or more of the following: weight 
loss; absence of response to a short course of antibiotics; and/or living in overcrowded 
place.97 Thirty-five percent of such patients had tuberculosis. Teklu et al98 noted that 
more than 5% of tuberculosis cases seen at a chest clinic have respiratory symptoms < 
2 weeks with cough being the most common presenting complaint. The validation 
study reported in this thesis confirms that in high tuberculosis prevalence settings, 
there should be a high index of suspicion of tuberculosis in all patients with cough, 
even in those reporting a shorter duration of cough. 
9.3.6.2 Clinicalfeatures predictive of suspected tuberculosis 
The symptoms included in the PALSA algorithm (namely, night sweats, loss of 
weight, and pleuritic chest pain) were shown in multivariable logistic regression 
analysis to be predictive of suspected and diagnosed tuberculosis. Interestingly, the 
absence of breathlessness best predicted suspected tuberculosis. Other than cough, the 
presence of haemoptysis, weight loss, pleuritic chest pain best predicted tuberculosis. 
Many studies confirm that cough, weight loss, night sweats, and haemoptysis are most 
commonly associated with tuberculosis.99 100 101 102 
Identification of predictors of tuberculosis in patients with smear-negative 
tuberculosis is also important, as making diagnoses in these patients is often 
difficult. l03 In two studies, cough and sputum production,104 and cough alonelOI were 
shown to be the only significant predictors of smear-positive tuberculosis when 
255 
compared to smear-negative tuberculosis, respectively. Although additional studies 
show that absence of cough is associated with smear-negative tuberculosis,I03 others 
report that cough with or without sputum production is a commonly associated 
symptom in smear-negative patients with or without HIV infection. lOS 104 
9.3.7 Accuracy of the guideline in diagnosing respiratory tract infections 
The guideline's poor performance in diagnosing LRTI is of concern since this 
condition is an important cause of morbidity and mortality in primary care. It 
performed well in excluding patients who do not have a LRTI, but had a low 
sensitivity, meaning that many patients who required an antibiotic failed to receive 
one. The most common incorrect diagnoses were acute exacerbations of asthma or 
COPD, upper respiratory tract conditions and suspected tuberculosis. While 
suspecting tuberculosis is a reasonable alternative, and likely to increase detection of 
active TB, it may result in delayed antibiotic treatment. On the other hand, the 
requirement for two sputa to be examined in suspected TB would mean that patients 
would re-attend on two successive days, providing a further opportunity for the 
diagnosis to be corrected. In addition, the guideline makes provision for an empiric 
'trial' of amoxycillin in symptomatic sputum-negative patients, meaning that many 
patients with suspected TB would have been adequately treated. In addition, many 
patients may well have presented with viral conditions and might have recovered 
spontaneously. 
9.3.7.1 Clinical predictors of LRTI 
In this study, features predictive of LRTI are cough, reported fever, sputum 
production, dyspnoea, no obstructive airways disease and no wheezing. Assessment of 
the type of LRTI each patient had (eg. bronchitis, pneumonia) was however not 
possible, as no definitive investigations were made to determine the underlying cause. 
Very few patients with severe LRTI were included and most patients had mild acute 
bronchitic illnesses, therefore the prediction model can be specUlated to be more 
useful in distinguishing between upper and lower respiratory tract conditions, than in 
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aiding in the diagnosis of pneumonia for example. Systematic recording of chest 
radiograph abnormalities by the physicians were not done, therefore assessments of 
which of the patients with LRTI diagnoses had radiographic infiltrates. This can de 
done as a post-hoc analysis. A review of the clinical features that best predict LRTI 
concluded that no individual or combinations of symptoms and sign predicted LRTI, 
and that chest radiography be considered in the event of diagnostic uncertainty. 106 
A number of severity scores have been developed to predict the clinical outcome of 
patients with community-acquired pneumonia, 107 108 109 but their application in other 
settings such as primary care in resource limited areas requires prospective 
validation. 110 Many of these scores require the undertaking of investigations not 
available to most nurses (for example, chest radiography, blood testing). The CURB108 
and CURB-65,109 on which the PALSA guideline'S management of patients at high 
risk of severe disease from pneumonia is modelled, contain 4 clinical features that are 
easily measurable by nurses (confusion of new onset, respiratory rate of~ 3D/min, and 
systolic or diastolic blood pressures of < 90 and ~ 60, respectively). The CURB-65, 
adds the variable of age ~ 65 years to the score. Although blood pressure 
measurement by the nurse was not included in the PALSA guideline, it was included 
in the data collection form and thus also in the analysis. None of the severity 
predictors included in the guideline significantly predicted LRTI in this study 
population. This is most likely a reflection of the definition ofLRTI used for analysis 
(i.e. the lack of a definitive gold standard) and of the large number of patients with 
milder disease clinically. 
Because of the small numbers of patients diagnosed with upper respiratory tract 
infections, detailed analysis was not possible. In comparison to the PAL multi-country 
survey, much smaller numbers of patients were seen in this study. This could be 
attributed to health care utilization patterns in poorer communities in South Africa 
whereby patients with mild URTIs do not present to busy primary care clinics because 
of long waiting hours. The latter is however merely speculative. Future guideline 
revisions will continue to incorporate UR TIs, but an attempt will be made to condense 
these conditions to comprise a smaller section of the guideline. 
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9.4 STRENGTHS AND LIMITATIONS OF THE VALIDATION STUDY 
Diagnostic accuracy studies are important to determine how well the results of a test 
agree with that of the reference standard. III However, a number of factors influence 
the internal and external validity of the results. Below these factors will be evaluated 
in the light of the validation study. 
9.4.1 Strengths 
Study design and study population factors, such as demographic features, disease 
severity, disease prevalence, and selection of participants can affect the outcome of 
diagnostic accuracy studies in one of two ways. First, they are potential sources of 
variations in the study's estimates of the test performance, and second, they can 
influence the generalisability its findings. III Thus, one of the main strengths of the 
validation study's design is that the index test (the guideline in the hands of the nurse) 
was evaluated prospectively using consecutive patients. This design reduces bias 
resulting from under- or over estimation of disease. Additionally, the study patients 
closely represent the same population to whom the guideline will be applied, and the 
primary care clinic represents the setting in which it will be tested. These factors 
provides the same level of diagnostic uncertainty as would be expected in real-life 
clinical practice.25 
Another strength of the study is that the eligibility criteria were broad (subjects aged ~ 
15 years with cough or difficult breathing), thereby reducing spectrum bias. 112 
Potential for spectrum bias was further reduced by the wide range of diseases and 
disease severities seen in this study, as sensitivity measures are often higher in studies 
with a larger proportion of patients with severe disease. These broad inclusion criteria 
do however have the potential to increase the likelihood of false-positive and false-
negative diagnoses due to the larger number of patients with milder disease and co-
morbidity.1I2 113 Test bias (when the result of the reference standard is known when 
interpreting the test result) and diagnostic review bias (when the results of the test are 
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known when interpreting the reference standard) were reduced by blinding of 
investigators to each others' diagnoses. 1 14 The reference standard in this study was 
relatively robust and appropriate - a blinded specialist physician with full access to 
clinical features and diagnostic tests - which according to Bossuyt et alllS is defined as 
the 'best available method for establishing the presence or absence of the condition of 
interest'. The reference standard was in fact a composite measure of clinical judgment 
informed by a number of tests. Another strength is that the primary care physician saw 
the patient immediately after the nurse did, and no treatment was applied in the time 
between the nurse and the primary care physician seeing the patient. These features 
reduce both disease progression and treatment paradox biases, respectively. 
9.4.2. Limitations 
One of the main factors limiting the study's generalisability was that although patients 
represented a wide clinical spectrum, they were from one clinic, and were seen by 
only one nurse, 2 primary care physicians, and 2 respiratory physicians. Inclusion of 
more clinics and investigators may well have resulted in different results. The 
generablisability of guideline's use by different nurses is better tested in a pragmatic 
randomised controlled design, such as that performed by in the Free State province 
and reported above. I 
9.4.2.1 Limitations arising/,.om patient selection 
Patients were recruited primarily from the clinic triage area, and less frequently from 
the emergency room. Due to limited study staff, only a maximum often patients could 
usually be seen by each investigator every day, and this meant that sampling mostly 
occurred during the first half of the day. Patients presenting with more severe disease 
to the emergency room, or those presenting at times when active recruitment did not 
occur could therefore potentially have been missed. 
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9.4.2.2 Limitations due to patient-related/actors 
Interpretation of the questions asked of the patients, or of the answers received by the 
investigators could have been incorrect, misunderstood or misinterpreted, leading to 
incorrect recording of infonnation. An important potential reporting bias could relate 
to the infonnation gained on cannabis use, as cannabis smoking is illegal in South 
Africa. It is therefore possible that many patients may have under-reported its use. 
9.4.2.3 Limitations due to nurse-related/actors 
Testing of the guideline relied on the skills and interpretation of the nurse, which 
could have resulted in biasing of results (under-or over-reporting of PALSA 
diagnoses). She was however instructed to strictly adhere to the guideline. But use of 
her clinical judgment as influenced by features not included in the P ALSA guideline 
cannot be excluded. As mentioned before, another important potential source of bias 
was the involvement of only used one nurse. Calculating inter-observer variability 
was therefore not possible. An important limitation was that intra-observer variability 
testing was not conducted in this study. Errors in the application of the guideline by 
the nurse, or in the interpretation of the results could have had a major influence on 
the estimates of the tests perfonnance. However this study, being pragmatic in nature, 
aimed to assess the application of the guideline by a nurse working in primary care, 
and this was achieved. The use of only one nurse could have possibly reduced the 
impact of variability introduced by different guideline users, as it was the diagnostic 
accuracy of the guideline rather than the perfonnance of the nurse that was under 
study. Prior knowledge of respiratory disease could have biased the nurse to favour 
those diagnoses over different ones. 
9.4.2.4 Limitations due to primary care physician-related/actors 
Systematic errors in the taking of the clinical history and examination of the patient, 
and the execution of the spirometric measurements could have resulted in infonnation 
bias in the primary care physicians' recording and interpretation ofinfonnation. Intra-
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and inter-observer variability was not tested for between them, thereby influencing the 
reliability of the clinical infonnation presented to the respiratory physician. Another 
important source of bias relates to the reference standard for tuberculosis. Data 
reporting which medications patients use have not been reported in this study. This 
infonnation was made available to the respiratory physician, who perfonned lung 
function testing on all patients irrespective of their treatment status and current use of 
medications. The use of inhaled bronchodilator before spirometric testing may have 
biased the results and resulted in under-detection of reversible airways disease as have 
been discussed above. 
9.4.2.5 Limitations due to respiratory physician-related/actors 
An important limitation of the validation study was that the respiratory physician did 
not examine the patients in person, but were provided with clinical infonnation 
instead. Once again, this situation was unavoidable as the costs and practicalities of 
employing a specialist physician to participate in a study such as this one was not 
feasible. The availability of clinical infonnation could be perceived to bias the 
findings of spirometry and chest radiography. It was the intention of the investigators 
to provide the respiratory physician with as much clinical infonnation as possible so 
that the final composite diagnosis reflected usual clinical practice. Of course, under-
and over-diagnoses of these respiratory conditions cannot be excluded as further 
supplementary investigations, such as bronchial hyper-responsiveness testing, skin 
prick testing, serum 19E testing, and sputum or blood cultures, were not conducted. 
The reference standards used to diagnose obstructive airways disease were based on 
the clinical judgement of the respiratory physician. Re-categorisation of the GOLD 
and GINA guideline definitions could have under-or-over-estimated the number of 
patients with these conditions. Reliance on clinical judgement to determine other 
causes of respiratory disease may have also contributed to the reference standard not 
being robust. However, in the clinical setting in which this pragmatic study was 
conducted, the physicians' diagnoses were considered feasible. Because this was a 
cross-sectional study, patients were not followed up to determine the accuracy of the 
physician or nurse diagnoses for purposes of diagnosis for this study. 
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9.4.1.6 Limitations due to the use due to the reference standard for tuberculosis 
For the investigation of tuberculosis, only those suspected by the primary care 
physician were investigated by means of sputum examination, thereby introducing 
partial verification bias. Given the resource availability, testing of all patients in the 
study was not feasible and therefore bacteriological diagnosis of tuberculosis was 
used at the reference standard. This study's aim was to examine the performance of 
the first stage of a 2-stage screening process; the nurse using a guideline (pre-
screening) against the generally accepted approach of a primary care physician who 
has access to sputum testing and a chest radiograph. Bacteriological screening is 
considered by the author to be the second stage of the screening process. The 
availability of chest radiography may have been useful in assisting the primary care 
physician with suspecting tuberculosis. This is supported by the association of the 
certainty of diagnosis of the primary care physicians with positive sputum results, 
suggesting that it is unlikely that those that they viewed as not requiring sputum 
examination had active tuberculosis. The increased association of radiographic 
changes with smear-positive tuberculosis has been well described. 116 In further 
support of the physicians' abilities to correctly identify tuberculosis with the aid of 
chest radiography are the results of a recent study. 117 In that study chest radiographs 
as a screening tool for tuberculosis was shown to have a sensitivity of91 % in patients 
with cough ~ 3weeks and/or haemoptysis. However, in other studies a small 
percentage of symptomatic patients with normal or atypical chest x-rays have also 
been shown to have culture positive tuberculosis, II 8 105 119 104 and these results are of 
particular importance in high HIV settings. 
9.4.1.7 Limitations related to derivation of the predictors for each disease 
Factors that improve the validity of predictors derived using multivariable analysis 
arel2o: (1) prospective data collection, and (2) deriving the set of predictors (the 
'prediction rule') from the population in which it will be applied. In this study, one of 
the factors limiting the direct application of the prediction rules to other populations is 
that they have not been prospectively validated in other settings in order to test for 
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their reproducibility or sensibility (whether is makes clinical sense to the user).120 To 
address this the study sample could have been separated into a two sub-populations. 
The first population could have been used to derive the predictors, and the second, for 
performing prospective validation. However, a criticism of this approach is that 
validation of a split sample means that the results may still not be relevant to other 
populations, and that further testing may therefore be necessary.120 
9.5 Policy implications of the guideline development and validation study 
Given the difficult and fragmented origins and evolution of health care in South 
Africa, large disparities in the provision and distribution of health care still exists. 
This, and the essential process of healthcare reform has placed a strain on the already 
overburdened health care system. Provision of simplified interventions, like the 
P ALSA guideline, that works with, rather than against the system, can therefore be 
considered to be useful. 
The P ALSA guideline, its development, and its validation have important policy 
implications at various levels. The methods used to develop the guideline serve to 
inform policymakers about current gaps and deficiencies in the health system and in 
the delivery of health care. As evidenced in this study, in-depth consultation with 
frontline clinicians, such as the nurses, provided an opportunity for the P ALSA team 
to address a 'policy' barrier (nurse prescribing provisions) which ultimately led to a 
policy change. 
Another example of how the guideline has already affected policy is evidenced by the 
Free State department's insistence on expanding the PALSA guideline to include anti-
retroviral therapy and management of HIV/AIDS patients when national government 
first proposed the launch of this programme in 2003. The decision to expand the 
guideline occurred even before the results of the trial were analysed. What this 
implies is that the intervention clearly targeted a health system need, and on face 
value was thought to be the best option for implementing integrated care. This is a 
testament to the programme's success. The expanded guideline, the PALSA Plus 
guide, now also includes treatment for sexually-transmitted diseases and is being 
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implemented in the Free State and Western Cape provinces with the revision methods 
modeling that used during its development. The Western Cape government has 
recently approached the PALSA Plus team to assist with the development of a chronic 
disease guideline that will integrate hypertension and diabetes mellitus. Plans have 
also been proposed by the National Department of Health to roll the intervention out 
nationally, and the guidelines are currently being revised to include nurse-initiated 
anti-retroviral therapy in the Free State. Furthennore, the training strategy has been 
modified based on qualitative work done to evaluate its impact on nurse trainers. The 
underlying principles are the same as that reported in this thesis, but it has been 
expanded to more explicitly incorporate adult education techniques. 
The South African Tuberculosis Control programme welcomed the request by the 
P ALSA Plus team to revise the existing tuberculosis algorithm to include the 
management of smear-negative tuberculosis and to integrate the diagnosis of 
tuberculosis with the diagnosis and management of HIV and AIDS. These algorithms 
have already been revised in collaboration with the Western Cape Department of 
Health and the University of Cape Town, and have been endorsed for use in both 
provinces. More barriers research work and evaluation by means of a pragmatic 
randomised controlled trial are ongoing to inform the further development and 
implementation of these guidelines. 
9.6 Priorities for future research 
The results of the validation study will be circulated to relevant role-players, 
stakeholders, and policymakers. Given the paucity of research in the area of guideline 
development, adaptation, and validation in developing countries the results of this 
study will be submitted for publication in peer reviewed journals. One such study has 
already been accepted for publication. 121 These results will be particularly informative 
for the implementation of the PAL initiative in other countries. 
Clearly, more work in the area of diagnosis of respiratory disease based on clinical 
findings need to be done. The predictors derived for each disease need to be validated 
in another population and setting. The weaknesses identified in this study will need to 
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be addressed in order to increase the validity and generalisability of its findings 
should future research in this area be undertaken. 
9.7 Conclusion 
This study shows that a locally-adapted integrated syndromic guideline, tailored to 
suit local practices and needs is an acceptable and feasible strategy for improving 
nurse practitioner care in frontline facilities in South Africa. This study also shows 
that it is possible to develop a valid guideline for use in resource primary care 
settings, through inter-professional consultation and assessment of local 
circumstances. The P ALSA guideline development and validation studies, as well as 
the chosen implementation and evaluation strategies can be considered to be a model 
for development of integrated syndromic guidelines in other developing countries. 
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Appendix 4: Stati sti cs tables used to calculate the 
sample size 

TABLES USED FOR STATISTICAL PLAN PRIOR TO CONDUCT1N G THE PALSA 
VAltDATlOH STUDY 
Thesample sIZe ",hn 10 (tor senlllMty, the IlUmbet of positIVe pallent, ~1I.r19 to llie goid 
SlanaartJ lest or (lor speci1icny) 1M roumbef of negllllVe casel on gok!lla'l(IlI'lI 
• fOf posIlIYe predIctIVe vM.Ies lample IafI refer. 10 !he numbet .... h. POIllb .. JCr~ I. 
• For l1fI{IaIl\Ie predictIVe ~IIIU", IIImple sQe relers to me rtiJrTlber W'II\. ~U~ JCr..wlg 
." 
A1ph .... 0.05; Pow, ... 90% 
Sample ,Ize needed lor IIn81e nmple to u tlme" senlltlvlty (01 Ip.clncll~ 1 





P"llENT Wmt OIFACULT BREATHING ANDIOR COUGH 
Cl""soly «CIC>IO!IlO 10 sympiOnlJ 1 
S¥"1Q\Qn'l$ - :2 'tI'!JOks. A$SE.SStJ:ENT AMlINITTAL J.'JI, .. W,GMENT 2 
I',1I1hcIt 1' M1m&n1 01 litO WIIeoun) pa~ __ AST}j~.tA cope EXACERBATIQ.'Il :I 
OotehaogQ plan 101 1"'= v.tlMl.ng p!lloefIl...no Ivls ,eSP<:If1deCI \0 1!!!:alfOOf!\ 4 
I'Ul\!'oef lurMlIlIIl'lI 0I1lwptlllO!fll Wllil IIIYe< and,or JIi'ifJ on bf~ and cougt1tflg: LOWER AESPIRATORYTRACT INFECTION 1) 
uweR RESPIRATORV TRACT INFEC'TlONS 
Ml.1Iy 11\ palleo>l IMIn un'Y1)Ioc;..ed nose RHINITIS 6 
M~1Iy 11\ ~hlll\l IMltl pall! and 0' -.eo1de;.I(,>SS 0\I'ef S>O.J!'i<!S: ACU1l: SINUsmS 7 
MoIrtly III p3hBII\ Wlltl s.OIB ttl'<)II1 ACUTE PHARYNGmS. TO:":SIlUflS, ORAl CANDIDA U 
Miltly III pahfll'll WIlli e:\l pmbIem, ACUTE AND CHRONIC EAR PFIOBLEMS 10 
Dry moppII'lO Inll BlIf 11 
SYMPTOMS :- 2 WEEKS 
Diill)lmll~l OIl~I'lJctL\I(I lurq rtl5e:l5& 12 
Ma"llgom~1O\1 01 ohron«: 3~111mSI 13 
MIl"n~olI1\&11\ 01 dl,ol'O(: Ot)BlIllClI~e puln~n8l) cisease (COPD1 I-I 
Glllol1i c CQu\II' Wllh 01 ",tholll 5P\lllIIn I.lla.:luctjon. n.o blealhlessnoss CW'IO NIC eRONC~ITIS 15 
TUBERCULOSIS \T8 1 
Dhl~llcs'110 1 B 16 
Spull.lrn 'iI!I~ln 11 
follow-up plan \01 R&gIll1OU ann 18 
Faiow.up Plan !of Reg!lMl1 Two 19 
HIVIAIOS 
~11lQ HIV,AlDS 20 
Fofow·~ 0( the ~II(JWII HIV-POSlWII lX1~enl 21 
Who 1$ -"glble Ia! iorlg-Islm colnmo~:uole (BaClnml p!uptl)Ia~IS'> 22 
,-.... 
Meek .. h>!;to,y 
Prl'Sent>~~ !>f"",,l<lms 
Purpose of the '-"$II 
IIlhe purpose ot IhlS villi lalo Irll!'!1 and assess; 
Wof~"nlnll of ~ymp\Q"l$ Of 
II continued treatment 01 known lur'lg dlseose with; 
• No worsenmg 01 symp!Oms 
NIlW symptoms 
It lIfl$Ure of d iagnosis 
Symptoms present < 2 _ktI 
Go 10 pagll 2 
. , 






(GoIO page 151 
• No nil '" symptoms 
• No u/IO&rtaiflly aboul do~r(lsrs 




(Go 10 page 12) _----I 
Asthma 100 10 pape 13) 
• COPO (Go 1O?a1Jtl 1-1) 
· TB (Go to PfICIIt t 6) 
· HIVlAIOS (Go 10 p;tge 2Q) 
:SENT.ASSESS SEVERITV 
MILU 
20· 19 P'J' IM l\II(l 
100- 119001 mlmllo 
Sl!'JQ(f W&.!l~lng 
ASK. LISTEN: 
,~ 1"-111,· .fl)lm • 
• , clnl:nJc: 
oII.,'''OU ..... ~1fw,'V' 
_~ ... (COPO) 
• • :><.,11;>110,," 
.. 
Ou 1.1 . ...... . 1 
ASK. MEASURE: 
~'"""IW1Il .. ",,", "" 
"'~~ttt.>o '" """'>:I"""J ..... .;. ."'~,,~ 
1l'''',''.QoJt! 
~(I~ LRll. 10 
'" II/I'pwall ..... lung <1,"-
FURTHER TREATMENT OF THE WHEEZING PATIENT; 
ACUTE ASTHMA,COPO EXACERBATION 
• <I pulls b4)1;htgonlS\ vill SpdCel every 2{) millules lor one hour then reassess. 
OR 
Nebullse US rrlQ bcla·a~nisl every 20 mrnules lor one hour then massess • 
• GIve 1 dose 01 oral prednisone 40 Illg stat 
REASSESS SYMPTOMS AFTER 1 HOUR ....... --~-------,r---------~ 
BETTER OR NO SYMPTOMS 
OBSERVE FOR ONE MORE HOUR, 
THEN FOLLOW DISCHARGE PLAN 
ON PAGE4 
REPEAT ABOVE TREATMENT AND 
ASSESS WITHIN ONE HOUR 
II warscnillll at ~ym~1I0m$ . ltealllS 
s",~e", and rei¥< 
II no response Wlm!l1 two hOI,l($ , ' 9 Ie, 
FOLLOW TREATMENT PLAN FOR 
SEVERE PATIENT ON PAGE 2. 
. trolUWllt'MldoS(lllnd hCIQUonq 01 rnell'llaJed OIoncnodllD.lOI 10 II ma><murrr 01 2' puffs 4 times a lilly. 
' 11 \he IJilIJ01nt t5 a.tready on 1rV!aled CQItIC(lSlefokt$: cned<. CQlT!pinn.ce (are mQdM;Qloon5 l<IJ<en IWICG ;'1 day ..... OIy day) 
",heek 1nI1/lk1. l6CMique (life lhe lnhaIe.s use<! cor.QClI/) 
' 11 poor OOfI'IpIInra II/'IdiOllecllrnQUe .llSIruc:I pallen\ on <;OlreQ "'''0 u-s.111'e 
. GlVe <l0m0 01 poll<)lllSOflll ora~y Ie-nee I1mlyll,,, 1 days 10 p:JlferllS 'MII'I IMlollowlng; 
.Hi$lO.y 01 roocnI eme,gen;:y viSll$ len IIsthma. 
-Wonwnlng 01 ilSll'Ima Symptoms io The monIhs 0' w"h pr.o.r 11>9 orosUl ollho acute !Iliad<.. 
·HlJlOry 01 previous ho$pIInl 01 tnan&IVecrue uok ~ lor IISlllma. 
· 11 loa paloOni ,epMS a emq, Wlth ..... w Of 10Cf0,olse<! Sl)UUJ.m ptodochco ;'1re'or cl'lar1goe'o spou.m co\ol.lr Iytll\ow Q'HfI) IIfIIlo'o, leve, 
ftdd Amo.<yCIDifl 500mg \tlI1lQ hOles .. dily lot 7 d~ys OR II peoic"~f1·alle!gk;. Eryth,omycil1500rng kM.Ir Urn" ill llIIy 101 7 dIIys 
· 1I 1I'Ie UlldeIl)"lnu Iu/lg CQroJihon Is unknown, 0<.> 10 pa~a 12 10 Imke (1111;.-.;>"'_ 
' Encouragtl ~ 0.111(1,."" 10 SlOp smoking cig;orSlies. popes or dagua. 
' Book laIIo .... uP \/iSn t.Qlo.tI madtcines alII aXpecled to run ouL 
TELL PATtENTTO RETURN IF: 
.Syrnotom$ 01'1 WOI$e. 
· No!!)eU(Ir 1Iheu 0 course 01 o,al pr8dol50,," hag bven coroplel/)(l. 
FURTHER TREATMENT OF THE PATIENT WITH FEVER AND/OR PAIN ON 
BREATHING OR COUGHING: LOWER RESPIRATORY TRACT INFECTION 
IS THIS PATIENT AT HIGH RISK OF SEVERE NOT AT HIGH RISK OF SEVERE RESPIRATORY 
RESPIRATOR Y INFECTION? INFEcnON? 
;::: GO y&arS old 
Flail wiU, ~usp!)Clcd AlPS I Bod leM alll<lme 
Known- lJ.J<19 diw,,~e I Encourage Iligll fluid mtakc 
He~'1 disease / No Smoklllg 
u vordisease • TIOa) pa in -'lr>:! fever with parauw.mol 1·2 I<lb lels 4 limes a 
Diabeles Mellilu. da~, , If n~w or IrrcrlilJWtl S~lum proc!Utlron 1In1r\ wlo:Jw cnange. 
prescribe ArrloryClillr' 500ma oral ly Ih'M times II day lot 7 
da~s OR II penicll lln-aJlOt(l1c. Ef)'lh1o'nyc1n 500mg orally 6 
hourty for 7 days. 
, Look lor signs at HIli/AIDS (Go 10 P'l>le 20) , A sk about symptom s 01 Ta jsuch ><s loss ~I weigh!, ni(fll 
Immedlawly (llVe I g'<o"1 Amoxyc.Rm o,ally 5W1><1(5) (Go 10 page 16; 
0' 
II ponLcll l l~-a ll erQOc , ErythromyCin 500trto;l. orally Reier 11: 
A~D 
, Get~ng wOl se, or nO 'oopOl1s,; 
REFER TO NEXT LEVEL FACILITY OR CLINIC ' Stdl flOt c0I1"lolc1y bolt(!, with in 7 dil~S. 
DOCTOR 
"""1" ... _ .... ,' .... ~- _c_ O 
Ask about associated 
Mild sore throat 
Fev!!l 
Consider: Common cold 
REASSURE PATIENT THAT 
ANTlBIQTICS ARE NOT 
NECESSARY. 
Consider oxyme!awUne 0.05% 
no~e dfOP~, 2 dfop~ in eoch noSh'll 
ev.:.')' &-a hCl; tS In< no longer than 
\ day. 
II: 
Symptoms on most days IOf ?.) weeks, ask aoout 
Sneez,n(l 
I1chlng 
Conside.' Allerg ic rhlollls (haytever) 
o.w~ saline rlOS(l drops. 
Chbrphe~frllmin" 4mg 3·.! 
I,mes it day when fl!lC".!ssa,y 
Beware: Sid~"",flf!C\ Is 
sedation. 
0.9"/. s."lilne flOse d1ops. 
CMkllplll.miramloe 4mg 3·4 
limes it day ",hOlO McassaJY 
Beware: SkJ&.eJlocl is 
sedat1{ln. 
, Reter to nexllevelladlity lor 
slerold tUlsal W'"uy. 
MILDLY ILL PATIENT WITH PAIN ANDIOR TENDERNESS OVER SINUSES: 
ACUTE SINUSITIS 
, CI"Hr nasal d<S(;haf'J" • Sympll)"'5 2 7 days. 
• Mlk:lI:<ain ewer sinllses . Sever", symptoms leg~rdless iJl duration. 
• POSH1a~1 (lnp . Pussy nas,,1 discl'1arOI!. 
Face 01 locth lX,'~ lied terlde'ne~s . ""_. Vital sinusiUs Cons>:!e!" Bacterial sinusitis 
REASSURE PATIENflHAT Af/T1BtOTICS AilE NOT 
NECESSARY. , A"""Yelll", 5OOrr.(l ~'a ll t Ihrea'''Ms a (.lay fm \0 days 
0' 
II p~"ic!lIIn·<llla'9'c . ~Nij C<Jtrlmo""al~ IO .. c~"nl 2 
Iable\, 180 '400"")1 two:::s ~ d~y to r 5 o~ys , 
InSlruct p~llen\ to mli 112 leaspoon salt- I leaspoon 
bk;3,bo""t~ DI sod! In :;O(Jmlluk"",<ym water, Smft "I' 
~OC~ ""$Ir~ every 4-1) 11OO'~ 
1~Sl1Ucl P"li~"t 10 m" , 12 le""l'W" ."It. 1 I""spoon 
bo:::a,bon;l.le ~1.oOa,~ 5(lOmilukIiWilr f'\ waler Snifl u~ 
eac~ ""sln l every 4-6 hours. 
00 0" 
0,\1"1. SOOn.HT1 CllkH,Oe C'DPS In eactl "OClrll avery 4·6 
hoot';. 
0.9"';' SodIum c/1kmde crrops " e~ch nostr,l ev~,y 4·6 
I",u",. 
O~ymetuu rn~ 0.05% nose d,~. 2 dtor'" ,n eacll 
!lost,. ,,ve<y &-a hou!s lor no longer lhM 5 d<,y" 
O.ymc!Jwilo" 0.05"4 r"IOS8 Orops.? arC?> If! Mell 
r"l¢s~" eva')" G-.9 I,Wr:s lor no lonllet 1I1i1~ 5 day • . 
Pa ' ",,'C1itrTl<l1 1·~ \itolcts 4 times a (J,lY. Pa ,aC<'lamol 1-2 \~b"I' 4 limes a day. 
Rete' it: , Tooll1 JtJSC1"i~S "J5p<!"C!e-d. 
• SweWl1g around ey" <l( lace. 
• Failure 10 !espooo 10 memcallOn alter 10 days. 
RED THROAT 
WITHOUT PUS 
Consider : Phary ngitis 
REASSURE PATIENT THAT 
ANTIBIOTICS ARE NOT 
NECESSARY. 
sari waler moutllWlIsh (112 
leasp:xm sail in II gl.as~ 01 warm 
"Noler). ('-.argle 1,,",00 (I day. 
ParfliXtlamolt-2[sblels 4 ['mes 11 
,",y. 
RED THROAT, WITH 
PUS OR WHITE 
PATCHES ON TONSilS 
Consi(kw 8 3<:l lIl1al lonslllllls 
I S~ll wale' mouthwash 1112 
lilaspoOrl s.aH In a glass 01 worm 
wat&). GaI,O!c twfco a day. 
ph(lnoxymeillylpe"k~tln (P\ln VKj 
SOOmg orally every 6 hollrs for to 
days. 
OR 
II pe'~ciI IIJNIIle!glc. gNU 
Erythromycin 250mg I> hourly 
bela,,, meals lor 10 days. 
Paril()etamolt-2 lablets 4 limos a 
day_ 
Reter it ; 
, 5ev",'e swallow,ng problerm. 
101abllrty \0 op~n mouth. 
More than 4 doQlmented 
(fpiSodes per y!>ar. 
WHITE PATCHES ON 
CHEEKS, GUMS, 
TONGUE AND PALATE 
ConsiOOf' 0 ",1 candida (thrush) 
Nyslal rn lozenges 100 000 IU _ 4 
timtls a day lor 10 days. 
OR 
Nystalrl1 tOO 000 iUlml 1-2ml 
4I1m~sadaylo' 10 days_ 
Exclmfu HIV inlecOOf1. 
(Go 10 pag9 20) 
Rei'll II : 
No re5pQM9 10 Nyslatin Within 5 





E;IIamine the checks 
00 
II oonloll"'.~I",,\I'c. ~"'~ 
~'yth<,,"'ydn ~~3'''~e 
2".Almg 4 I,,,,,,,, ~ doy I~' 
~ Ua)'-
~",~!;)n\Q! 1· 2 1 ,ll)1el~ 
4 Ii,,,,,,,,. any I", PiIi"-
G" .. H,oj'P"ci l ,n ~~O"'9 
.. ~ . ¥ 41J",,? , ~tI3Y 
~ 
II P'J.,,,, l ln ,"",r~ g"" 
E'ylnrom),(:,m 5tN",1 9 
2SO~lg' 1o",", ~ d~y for 
days 
;:<l. A,ooJjc ~d. , alo~oI. 
6 ~0<.Jrlv fOt 5 <lays 
"''1 m<lI' eal 
(Go 10 ""111" II 
P ..-_\.1-n0' I - 2 lab''''' 
4 t,,- 8 d<ly 1(> Pd'''-
ReIer iI: 
Di, ool;;. 
II flO 'e"P'l""~ will>" 
4d I .. s 
c.y mOf ,m. 
IG-J IQ fl.'1l" \ t I 
~prn, t;il ln •• k rgIC , ~". 
Il • ..:tr;m Z IilOIoKs 
leQ .'~OOmgl twee a day 
I ~' 5 d;>fb 
p R'ac@tan,d 1.~ tai:llets 
4 "f1,,", a di\)' tor pain 
Rc(e, il: 
No ,etpoo1'" of'~r 5 d'ls 
Swcll.n~ ""d l (>rldoerrt<"~ 
of .ldn 100<1 ;"0 ~" ' . 
PerJj<t~nl ~," , 
Tl>!l &at "" " 1",..,. 11"'," ,I 
" 
P",a""lo'nol 1-21~~ Ie:s 
~ 11rM!; ~ tmy jt>! ~,'Ii" 
/letor II : 
No;> 'mcro"",, >enl afl~( 4 
""',, Foul smellnQ di, dm'(I<> 
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DRY MOPPING THE EAR 
Demonstrate method to pollen! . 
Roll a p,ece of paper lowel into a wick. 
Illsen wick into ODr and lemovo once Il ls wo\. 
Repeal 4 limes a day unlll ear IS dry 
Inscrt acellc acid ear drops IllIXlicoloo (QO 10 page 10) . a drops In affected ear. 
Never leavo the WICk or any QlMr coleel inside ,he eal. 
" . "
Chronic Olllls Media 
~~~~~~: help with tho dlllgIlOsl'.;;;;;;;-;·";;;;;;;;'C;; 
Ask II: 
Sym"'Otnl.,.,~ed ~""I1""l<t1ood '" "'"''''' l'lddlloood 
l-Iu0'Y 01 I'III , ! ....... -.;:.'naNl<l.'OI.~ 
~ ... "Itv ''''ot)' 01 .. m~ ... 
6l"''''''''''' O'W """lIltlvo:I<o ."jill ~ 01 normAl "'NIl"",,! In 
~-
s~ ... at. , ....... '1' '"ore.- III rtQI1I. bll,.. .'1 1'1(>, •• '" tile 
ft'IOInl....., ; 11uI1~ On IQ>er '"'"""1<0", ~a" 1111""'"" or wh", Il>II 
""",1,* _''''_, 
TREAT AS ASTHMA. 
REFER TO DOCTOR WITHIN I MONTH 
Go to page 13 
~--~----~--~-­Ask if: 
S)",p1o", •• ....,MI ..... In 111ft ( .... u;>IIy lofI ... tt.. _ c>I 35 ~"",,) 
SymgtO, ... $IOWI\' " .rw>C6 """ • 1:ri"Q ~". I"" •. 
lor'll II"""" 01 <WIV '" ~_ o::>t>;Jh 3I"d op<.(um p!Q\!",tk:n 
(us wly 01_ ~ bo>IDlO I .. """ .. 01 slul",," of bearh), 
S/'Iof1 ot ",,,,'I'> 11>' m¢II! 0'I1h& "'Y. fame. than ;!J rrift 01 <l<J M'\I II,. 
~~1 tIo\.oS Dll~ momI"" 0,.,.,. 
"'~l"'y o! ~ $~ e; mO!OII\¥l2Q d~tlM I d.1y toc'~ 
,MO' or '_I 
TREAT AS COPO. 
REFER TO DOCTOR WITHIN 1 MONTH. 
Go 10 page 14 
(It un'UfO. Irenl ilS allhmll) -II .:. 1 leshne ot II$IhmII. arid no S1go~K:am hrstory 01 $mOk1O(l . con:;.rde< a CIUClac or 1"On-lung ~use d bloathleS5llC$s. especially ~ 
~ted hyperlenslon, .schaemic hear1I1is9a$1I af'd.'ol l1Iabeles tn(lll~u&. 
MANAGEMENT OF CHRONIC ASTHMA 
"; , " 01 1I!11ealures 01 ~sthm;l. 
, I Mtnlmal (Or.Ieally no) tiaylJ mil ami rlIghl lime :;;ymplorn& 
" M,ninml or no e~aoo,bations (~~!hm il. alti!d<:s) 3) Minimal nOOl1 101 qulck·relief 1T>{.'(}K:~lions ., No Um,l:otlons I.'f dally aclillille$ 
ASSESS CONTAOL OF '" 
, 
LEVIOL Of' CONT ROL IoIOOE"ATE COI/TllOl POOR CONTROL - -
I 
D'yllm. Hmp!"''''' J>e' _e~ <.{ Imes! W"~~ ;>-4. tim .. I "' .... r;.",1.O'JOU' 
Nivh1 firM '~mp!o,n. p., "'''''th ~: t;me~ I morrt~ ;>.4 lirr .... '">?nIh F''l{j<ji~t 
LEVELS OF TREATMENT LOW (If well.conltollod) MOOEf{Al E (~ m<><loor:>! .. . "",,,01) MAXIMUM lit poor c.onlrol) 
IrII,..O<I .... n""""..,. 2 P'Jff~ ""'~n ~ ;>."" ,1. w~~~ n~  ;> \l'IJ ~$I'Al" ~ 
f,I.'Y ~ fV<lUnd 4.{; !,mo. pe< dny 
In il,,¢<! cOf\lo»t.mId. 2QO.-.\OO """'''9''''''' I d;oy 600 mk;rogram. 1 d~ &lO-!600 '" ~'''II'&n\$ 1 "~y 
SIOw-'$'I,,,,,,,, t!'l«>phylh ... ~ . . \ ",~I twl"," ~ u"Y 
I Docb'., ""''''_; 
0.,. In"""""" . ~ 1)"'0 Q"'~Y ((II>;" <SI"y ) !O, 14 '~'YI to ~n 'Allid (Q(1 ~oI 
I REVIEW EVERV :) MONTHS I 
IF COMPLETE CONTROL AT ANY LEVEL OF TREATMENT IF POOR CONTROL AT ANY LEVEL OF TREATMENT 
Ca<llmoo Cllfrenl rrloolr:;ation. 
, 
Inr;tone to !1e~IIe"Qi t>f Ir8.1ltmont Istep·up) 
At ne ~1 visit. 'OOlK:e Ire03tlll<><1110 PU:V10U S leWI (Mep·do wn) CO! I';OC~ adding ploon lSQ'W 40)TIQ 0' all y !)!1Ct! dilll~ fo' 7 cliYS 
II COfItml is sll~ ,omplete and raaSS05S Itt 1 month. 
Schodulu next app<lmllT!(!nl. ... I Rete' It " !~l .'. :::..~ .. '."'.-
• !' / 
11le aim 01 COPO management Is 10; 
, , , 
EflCOOl~ pal_IS 10 Slop ~ ¥l orool 10 PO:iI"lI:IIIl ~nlng 1;)( dGease. 
Improve SymplOms willi Wlaled broflChod,l;llOr$. 
Recognise aflCI treal acute 'lx..eerbalOOfl$ early. 
ENCOURAGE Tll€ PATIENT TO STOP SUOI(ING 
A.~ ldQ<til~_~""1C:tJo<n> .-<11"""' ...... 
AdvlM S!<ongIy uvo ~'G p!I6eroI \0 <pi. 
Au..... 0&'.."...,,.,., 10 _ a ~_'I>I. 
10 ... 1.1 ~ 1Iw ~11Q qtL 
Atlal>ll" ~~con1aCt. 
MODERATE SEVERE 




Inl\.olooa .... bUIIIt'lOI ? ~~. __ .- I': ru.r. _ _ 2 D<rfIs. ~roos a my 
l ....... phyHI ... 
j 
REVIEW EVERY 3 TO 6 MONTHS 
Io=ta ..... ~ Jll''''''''' 1)1 cobJo 
~ 'C )'Clk'''.!g-'' 
Almxy<:lll iro SiXl"'il OIY.~ 
1..- a <!:oy lor 7 (3)'11 
"" ~ """"tn-aI\oI{jo; 
~nyQ<o~~ 
lou 1,,-10< 7 o.rll.-
Usu~lIy ill heavy smokers. or Ihose wilh lung dlimagR. 
Oally cough with or wilhoot s?Utum prc:dJ~tso n 101 months w y"ars. 
Usuatl)' bo<Jm s In Tlllctjla or old a!)e 
Heall'f Q<;Cupatlonal \dust. m11S5. irldo,J,II Y) OT 1l001MtJC ai r pOS~tiO!T (rndoOT 1","5 or gas stoves) exposure ill some. 
Treatment 
THE MOST EFFECTIVE TREATMENT IS TO REMOVE THE CAUSE! 
A ll pa\lsms shorJd be ailvlooj \0 SlOp smoll ing. 
It po~ble. avoill Ooroosuc pollulLon. occupalio!'l3l exposure and substance abuse \e(l, daggal 
Reier: 
II no hlSioly 01 <;n1ok lng. 
SUSPECT T8 WHEN : 
Pa!>\Hl! rtlpo<li COvgro IOf 2. 2 ~t<I<l;. 
Ul'intentllma! weigh! loss.. 
loss of appoti~. 
Ntg\l\ Sweilt.s and lever. 
Blood·sta lned spulum 
!\Mwn HIV-posi!lve or AIDS ""Mnts 
METHOD OF SPUTUM OOLLECnON 
Palienl: 
Must Slalllj In 3 well--
ven i\ta led ,oom or 
oUlslde. 
Take <~ dwp b<e~1h . and 
rough forcibly. 
Nurse: 
I MuSt '10\ stand In IrQ/lt 01 
patJilnl dur;n-g Ihe 
IlIocl!dufi'. 
I Rgplace and sect/ 'e the 
tid Immooi<ltely 
I W~sh h"nds aflor 
jl~ndlin'g ~1 f116n. 
I Place 5pQdmlin In bail 
,ullj S!tl'e In trldge I'I!lja 
awaWng oo lle-ctJon 
TB SUSPEClED 
~ 
NEW, OR PREVIOUSLY PREVIOUS TB TREATED FOR 
CONFIRMED TB TREATED l!. 4 WEEKS 
FOR "" 4 WEEKS ___ ==::!.':' ___ =:::I 
T&31 spulUm; l..aOel !)Ollkis cerore dl~pe",ing !Mem to patlanlS. 
Day 1: For Add-Fasl Bacil li 
(AFB·~) . 
Doy ~ : Earty nl(lmi11{1 sputllm. 
at home, for AF5·s. 
Day 1: For AcId·Fest Bac~1I 
(AF8'S). 
Day 2: TWo ear ly roomfng 
sput/l, /II ~orrl!;!. 
• \ fa, AFS'$ 




Acnve T8 CONFIRMED 
Nol.,1y and 'eijisler palle,l!. 
SPUTUM RESULTS 
active HI 0/ 0/1>0, eo<>dl t lo~ ""lui.!,,!! 
• , <>JIll • • 
11 fleW casu, or Pfev!Ovs conl ,rmeQ T8 lrealmeOI 10'" 4 woek!. legister as NEW CASE: SPUTUM-POSITIVE PULMONARY T8 ~nc:t stat! 
!he 1 ~Ier'lSl\fe phaiUl 01 REGIMEN 1 (Go 10 page 18) 
11 pi'1VlOUS r9 lrealme'l1 10 r ~ 4 weeks. reg/slet as RETREATMENT PATIENT: SPUTUM-POSITIVE PULMONARY TB. and GlarllIle 
1!11C1<So'\1 pl\il.5e 01 REGIMEN 2. (Go 10 PiI98 19) 
Olle< HIV IeSIIO 11M pall1lnt~. (Go to paga20) 
SeIecl DOT supo!f\'ISOI. 
• 
INITIAL TREATMENT FOR REGIMEN ONE 
• _, to - • 
START INTENSIVE PHASE 
R,f'IIT'C<e>nlls()r.lUX!!Pyr .. ~'~f>;Jt'l'lbuloi 12OI6Or~ .11"'«' :; lID) ... .... e..I<) 
AI tiM: end 012 MONTHS ot INTENSIVE heaU",," •. lake 2 891M 101 AF8 .. 5<:hfilule follow-up. 
====~ 5\1u18 AF6_ MS- $p.Ila AF8. AFa- OR SfJUI8 AFS. AFS. 
Conlloue 'lII_ve phiIsD lot 1m; ... lI1OI'1I1 
"'I the end of 3 MONTHS. repeal 2 .puu lor AFB. 
~1oIo"UD. 
Sputa AFS. AI'S- 1::::::;i"~UAF8'AFB-O~R~S·,"·" A~F~8·.·A~F~8~.~· .... ,. ........ 1j 
Thke &p.I1U'T11<1t o.J/I".,tllIl"C1 senu ..... ,y 
ScI\e(JuIe lo/Iow"Up. 
II 5USceplibie. t;tlnrwlI)(! (I 1115.$(;;101 ,&1., 10 MOA uniL 
" ~~A""'~==;~~~ 
Spuu AFS- AF8- Of unablo: \0 Pl'oduce 5iluh~m. Spu\lll ,l,FB. AFS- 01'1 Sput! AF8. AFS. 
Slop trHlmolnl ..-d ,.go.1er ,u CURED. Reg$ler 3$ TREATMENT FAILURE. 
~oe!rom TB dItroc T.v... mullJI1'I lor cul~e aro ~tly 
Rt.I., HlV~# .... p.tl .... ~ 10 !he oen-'" 00 .. : 10< Ro-legI$ler lIS" AETAEATMENT paliffi1. snd ",lei 10 1oIIow-vp pbn 
'UI'" mao~i"_ rot R~ 2. 
TREATMENT PLAN FOR REGIMEN TWO 
- - -, . ----....~~~~ --., - - ---. 
START INTENSIVE PHASE 
RitMl"lJicifli!s()llla.id 'Py'<.VJn~nliOe1El~.lmtlutQll~(J16(1i30012001l19 (Ylve~ 5 tl<lys J wee~1 PLUS 
,s,leptomydo Illi¥en 5 days a weekl inlralTIuSCllt'l!ly. 
THIRD MONTH 
Ritllmp oCini isonlaz.:!IP,'r;)zlnam>;1ei Etlmml;>utQi 12o;6(jIJ0(1200rng (glvQn 5 clays a WIl<ilK) QNL V 
Inillal . If: 







Rei", to MDR !lInt 
Sputa AFB+ AFB· OR Sputa AFB+ AF~,~.~····"!I~,,~~::::;;::::::::::::~",=::;::::'::::::-' 
Repeal sputum lor culture arld SBn&lhvlly \0 
Schoclul<J fo llow-up 
START CONTINUAllON PHASE 
Aitllmp icinilwnlarid \50i l00mg ~ E!h~mb'ltoI 400miJ 
RiiampicHlllsoniazid JOC/ I50mg _ EthambulQI40Qrng 
'0' 
'" StO{lI~aTm(l<JI ~nd'~ ilSOJRED. 
Disch.a,go Irom T6 cli ruc. 
I Reier ~l lV,poSJ1Lve pIllltlms 101M general dinlc tor man<l1l8In6!ll . 
.: 50 kg ~50 kg 
3 tab lets. 2 (<lolets 
2 tab1ets + J tao lets 
Take sputum lor cUliure lind s"nsil ivity. 
Aoler 10 MDR un't 
HIV/AIDS 
SUSPECT HIV/AIDS IN ALL WITH THE FOLLOWING: 
m 
, f'Ir:.cuo"l'" """" ,;0<",,, hili><!."... 
M,,~ _'00. QoaI """""*' 
SIo.., oog ..... p<rs Z<ntJl< 
~_""'QI'IIi;>s.9. 
!,.Ine~ I""" 101 > , ,....... 
~ ~aM<1'I!!Ied ,rrI..,WM 
LOOK. FOfI 
P ~nesH"",,",,' ~r($, 
l.<>na N$lO<y 01 (to "h:>/);) 
' ''''''1 ~I ~~ In 11'11'-,, 01; tIoho"o UO' 1<111. V~"roI. """I "" ""II 
~"'" wnl'<'IJI ~ eoncloml 
VIIllo __ .n 1t>&!l"IOUaI. ......", 't'" oc,""cr.<!d 0I1 .. <n ~, """""V D~ (ORAL 'rnAUSHiCANOIDA). 
p",,,,.A ~ ... th bO>leM, aort,r.allo 0"'" pIIrI 01 tile I>ody (HERPES ZOSTER). 
~~ 0' I""", (>0''''''' '" motJb (KAPOStS SAROO ...... )_ 
E~ of _", 100., m "'""III'< 
GoruloIIbfs '" ~
DO YOU SUSPEC1' HIVIAIDS '1 
I DOES THE PATIEIfT REOUEST ilN IlIV lEST? 
INFORU ABOUT VOLUNTARY CONFIDENTIAL COUNSELUNG AND TESTING (VeeT) 
Edui;;3Ie pal .... .,.,.... HlV AlOS, ""'~ O! "~~"" 1tI:I< I<OCI<><J 
E~~VCCT 
Who W. pOn",m ~'" ~~ _l'IIIlell<", 
ltDl ~ .. """'~1<:Iy """""'~". 
11'01 -.,~ II. ...... ,"'*""'-
HOW _ ts _ . 
"""" __ atO iii"'<'" 
I..,." "'" ~ """""'-
n 1l'O''''''' "II'''" ID Ita .... veer. ,., .. ',, 'he t.oy cou_, 10< '"'irIIJ. 
I. loy _"'Of IJ ""I.""I~. r.~ , ...... all~ IKili.y .. "... WlsH'I!Iia ovabblo. 
FOLLOW-UP OF KNOWN HIV-POSITIVE PATIENT 
1-....................... ".'v. ' •. O"" ... v.' ...................... ... 
EstabKsh a rela\lollslup wilh lhe pali1tn1 and encourage regular loIIow-up. 
Respect h,&fh&r rlgh110 conlident~~I~. 
Reier 10 lhe lay counsellol' &hoold 1110 p;)blln1 require turlllef CQ\.Inselhng. 
Encour<lge s.a1er'$II~ prilCliOl:!$. 
PrOVIde medea! cafe al each w.:n 
Look 101 and Ileal HIV·,eIall)d clseases. 
Go 10 page' 
Recommendations lor lM ~ 
p,eventM and Irealflwnl 
01 OWO'turlslie and HI"-
related (/isea&9s 1fl1ldU11 
~;::==~H.IV NeOA~':'V~'=:::-__ ....:; 
Encourage sater se~ prac tices. 
~ 
.... 4 
WHO IS ELIGIBLE FOR LIFE-LONG COTRIMOXAZOLE (BACTRIM) PROPHYLAXIS? 
(2 SINGLE STRENGTH TABLETS (80/400MG) PER DAY) 
All HIV-In lvcted T8 palic,lls CO\llmo'<lloIB (Sacu lm) prophylaxiS IS s!~rw<J at a higher-
le""lloo:;l li ty. 
Al l SYlr~'I(l<nati<: H IV [l<ll >ents (Wo!ld Health Otgamsa/J(ln (WHO) 
skogll :):,3.4). R.e(~r ooklw. 
ADAPTEO FROM THE WORLD HEALTH ORGANISATION (WHO) CLINICAL 
STAGING FOR HIli INFECTION 
STAGE' 
W,thoUI symplams. 
Acute Ylr nl llll1<)ss !o llo lVlfl(l HIV infection. 
PN8lsten! s~.ullen gIJnds.: :): em and symmet rICal 
STAGE 2 
UninlenliQ"al wB~~lloss. 
Mloor mouth ond Skill oorl(:iIlions (d<y skin, moulh Ulce rs. IUi">go l 
naji ,nloolons). 
Herpes ZOSIeJ .... 'Ih ln the last 5 ye¥s. 
Recu rr enl uppet re spl r:.lo,y Ir~! inlocl<)ns i€g . ~nuSllIs). 
STAGE 3 
Signillcant unintentional ",,,>gnt loss. 
Diarthooa lor rn or" II'an a month . 
FIlV!,if IDr mare Ih~n a mOl1til. 
Oral th".lshicarKllda. 
PulnlOna,y 11> ,n 1M 12151 year, 
$evOr':: pnOurllon,a or olher boc.1Dr ,<\1 Inledlons. 
Vagin al CJrxlili 10' 1'10rO lilan 000 m onll1 , Of IlOo r TOnp.;"'&!! 1(1 
lilefi>p~. 
STAGE 4 
CMron lc vlCl\lht iDSS p lus diarmoea <;If lever 
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Appendix 6: The PALSA desk bloner 
• First page of Appendix 6: Desk blolter with side 
panels closed . 
































































COUGHING ::0 2 weeks 
~ Send SPUTA for TB 
)0 -r est tor HIV bcC<lUSC 
~\ 
TIII~ common In IIiV rati~ntl 
/ 
"/ COTRIMOXAZOlE 
rr.OPHVI AXI~ .1"'(Tl"~'I"t"\ 
COlllplicatioll5 and PJ'olollQs 
life in IIIV 
-
r Diagnose I nT11n piltlcnt~ w ith 
cough, difficult breathln9. 
, paIn 011 coughing/hredthlng , 
I and fever 
It SI?V<::, c I~EFER 
If new 0 1 plJluknl ~pUtllll1 
pre~(ribe AMOXI GllLlN for 7 ddYS 
FOUOW - UP in one weell 
!sooner if getting worse) 
Diitgnose URTr in patienlS 
wIth it bloc/wd or runny 1l"~c, 
sore throat and mild fever 
but NO difficult brcnthing 
or chest p.iln 
Prescribe SYMPTOMATIC 
~TRE"T"E"T ooly 
rAntibiotlcs only if 
pus on tonsils, fn ears 
or nmial s~cretlun:. J 
Diagnose ASTHMA In patients 
with wheeze, 
difficult brearlling and cough 
';;;'--l. Prescribe INHALED STEROIDS 
::: I&refcrl 
Dlitgn ose COPD in patients 
wilh Wlh::cLo..:. 
difficult breathing ,md cm.gh 






Appendix 8: The P ALSA educational outreach 
training script (to accompany the guideline, 
flipchart, and desk blotter) 

PALSA TRAINING THE TRAINERS 
SCRIPT FOR TRAINERS 
refer to FLIPCHART 
FLIP I: Respiratory illness are very common in primary care. 
Here's a typical scenario of a busy primary care clinic. You've got patients streaming 
through, while others are seated and awaiting nurses' help. Many of these pts. present 
with difficult breathing (SOB, wheeze, chest-tightness) and! or cough. These are 
TYPICAL respiratory symptoms that nurses CAN RECOGNISE in clinics. 
How do you identify ADULTpts. who have respiratory illness? 
COUGH + DIFFICULT BREATHING are the 2 most common symptoms. 
Refer Page 1 guidelines manual 
Nurses should .... SUSPECT respiratory disease in all pts. who present with difficult 
breathing and! or cough. Most, and certainly all serious cases, present with cough and 
difficult breathing. 
FLIP 2: Respiratory illness affects 1 in every 3 patients. 
FLIP 3: 
You've have patients in the waiting room .... The one's in blue .. these patients are 
presenting with signs of difficult breathing: 
SOB, wheeze, chest-tightness and! or cough. 
As you can see respiratory illness is very common. It affects 1 in every 3 pts. 
Recognise SEVERITY FIRST! Very sick pts. require YOUR immediate 
care. 
Now that you've identified patients who have difficult breathing and! or cough in the waiting 
room you would need to assess the severity of their condition. This would mean that severely 
ill patients are attended first, and referred. 
Severity should be assessed in all patients upon arrival. This patient in red you see here [refer 
to page ... ] - requires immediate attention. He requires oxygen and must be referred. When 
nurses triage, severely ill pts present in two ways. 
Respiratory distress, wheeze, shortness of breath~ pt. in a state of panic, 
Tight chest seeks nurse's attention at consultation room 
Moribund lying down, looking a little wasted, quiet, sleepy, 
probably sweating, confused ~ hardly noticeable 
How DO you identify SEVERE respiratory Illness? 
What are the most common indicators used to assess severity? 
Nurses are capable of identifying severe resp. illness in the waiting room by looking 
for key indicators. They should do a quick clinical assessment from observation. 
refer Desk blotter 1 LHSFLAP 
If the patient is 
• breathing rapidly: ~ 30 breaths per minute 
• breathless at rest or while talking 
• overusing neck muscles 
• hot: temperature> 38°C 
• agitated I confused 
• coughing blood 

you prescribe treatment AND refer. 
Refer Page 2 guidelines manual 
How would you treat a pt. with severe respiratory illness? 
i refur Desk blotter 2 RHS FLAP 
Treatment of pt. with severe respiratory illness: 
Give O2 to ALL pts to restore breathing. 
Ascertain whether the pt. has a bacterial infection or suffering an acute exacerbation. 
How would you do this? Do a quick physical examination. Observe if pt. is: 
REFER! 
• Wheezing / tight chest! Asthma / COPD ~ give 131 agonist (nebulise /4-
8puffs via spacer) every 20' + Prednisone 40 mg (po) stat 
Refer Page 3 guidelines manual 
• LRTI !Pneumonia / T ~ 38 0 C ~ Give antibiotics: 
Amoxycillin(lg)/ Erythromycin (500 mg) po 
Refer Page 5 guidelines manual 
FLIP 4: Now that you've attended to the severe pt. return to the patient 
presenting with chronic respiratory symptoms. 
Diagnose and treat 
How would you know if a pt. has pneumonia? or TB? URTI? or LRTI 
How are you able to differentiate between upper and lower respiratory tract infection? 
What are the key signs that nurses should look for? 
How do you differentiate between upper and lower respiratory symptoms? 
Overview of 4 respiratory diseases 
We have outlined the 4 common respiratory diseases that nurses are most likely to encounter 
in their clinics. We've provided the most common indicators to help nurses make a diagnosis 
and provide the appropriate treatment. 
Suspect TB in all pts. with 
• Cough for >2 weeks 
• Night sweats, fever 
• Weight loss, loss of appetite 
• Blood stained sputa 
• 1llV+ 
Sputa Collection: How do nurses collect sputa? 
Nurse + pt. stand in well ventilated room - perhaps outside. Nurse does NOT stand 
in front of pt. 
Pt. rinses mouth, takes a deep breath + coughs forcibly into sputum jar. 
Nurse replaces and tightens the lid. 
Nurse washes her hand under running water. 
2 

Sputum labeled and stored in fridge for collection 
Label bottles on the days that sputa were collected 
Schedule folloW -up 7 TB can be curedl 
HIV is common in TB pts 
Nurses should encourage pts. to TEST for HIV because .... 
Co-trimoxazole Prophylaxis = 2 tabs (80/400) daily .J, complications; prolongs life. 
Prophylaxis eligibility 
manual 
• HIV infected TB pts. 
• Ox. of pneumocystis carinii pneu monia 
Refer Page 
• Symptomatic HIV stages (WHO staging 2,3,4) 
22 guidelines 
Suspect 1 THINK about HIVI AIDS in pts. with 
• TB 
Refer Page 6 guidelines manual 
• Oral thrush =white patches, scratched off with difficulty 7 bleeding (Pg 6) 
• Herpes zoster= painful rash with blisters confined to 1 part of the body 
• Recurrent URTI = colds, flu 
• Long Hx of diarrhoea> 3 wks + severe wt. loss 
• S1"ls 
• Painless swollen glands 
• High risk sexual behaviour 
Encourage VCCT 7 completely confidential + voluntary 
Teach about HIV/AIDS, methods of transmxn, avoidance of high-risk 
behaviour 
What the test results means? 
Who does the test? 
How testing is done? 
When, how results are given 
If Pt . agrees 7 refer to lay counsellor I to health facility 
Follow-up of HIV + 
Encourage follow-up care, safe-sex practice 
Respect confidentiality 
Refer to lay counsellor 
Medical care @ each visit 
Look for signs of: Oral thrush 
Asymmetric large swollen glands 
Refer Pages 6 -10 guidelines manual 
Diagnose URTI if 




• sore throat 
• mild fever 
NO difficult breathing + NO chest pain 
Pts. with flu have MYALGIA; those without it have a common cold 
Most colds + flus last for 3-5 days. 
Treatment NO pus = NO fuss? NO antibiotics 
Most URTls = viral ~ NO antibiotics! Antibiotics are only effective for bacterial 
infections and make NO difference for colds and flus 




Refer Page 6 guidelines manual 
Antihistamine: chlorphenlramine 
NaCI nose drops 
Refer ~ steroid nasal spray 
SINUSITIS Refer Page 7 guidelines manual 
Mild: Post nasal drip, clear nasal discharge Oxymetazoline, NaCI drops 
Severe: pussy nasal discharge Amoxycillin 1 Co-trimoxazole 
faciall tooth pain Refer ~ swelling around eye 
symptoms> 7 days tooth abscess 
PHARYNGITIS 
red throat without pus 
red throat with pus, white patches 
on tonsils (=b/tonsillitis) 
CANDIDA (thrush = white patches in mouth) 
EAR 
Inflammed linfected outer ear: 
discharging + swollen 
ear canal 
Bulgingl perforatedl pussy eardrum < 2wk 
Chronic 
Ask trainers: 
Refer Page 8 guidelines manual 
salt water m/wash; paracetamol 
Pen VK I Erythromycin 
Nystatin 
Refer Page 10 guidelines manual 
Flucioxacllli nl Eryth romycl n 
acetic acid ear drops+ dry mop 
Amoxycillin 1 Co-trimoxazole 
dry mop, refer 
What would you do If there is pus discharging from the ear? 
What simple approach would you use to get rid of pus from the ear? 
Dry mop 
Roll piece of cotton wool into wick 
Leave in ear; remove once wick is wet 
Repeat 4x daily until ear is dry 
Never leave wick 1 objects in the ear 
Asthma + COPO 
Refer Page 12 guidelines manual 
Most often symptoms for both conditions are quite similar and it is difficult to tell them 
apart from each other. To help nurses differentiate between them they should take a 
4 

medical history to arrive at a more definite conclusion. 
Diagnose ASTHMA if pt.has: 
• recurrent WHEEZE 
• difficult breathing AND cough 
Ask if :Symptoms started in childhood? / adulthood? 
Family history of asthma? 
Intervals of normal breathing? 
Symptoms worsen at night, early hrs. of the morning? 
Symptoms improve / disappear after using pump? 
Symptoms only present at work? 
Treatment: INHALED S"rEROIDS + inhaled bronchodilator 
Beclomethasone = Viarox®, Beclate®, 
Budenoside = Inflammide®, 
Diagnose COPD if: 
• persistent WHEEZE 
• difficult breathing AND cough 
• history of smoking 
Asthma (recurrent) COPD (persistent) 
Starts in childhood /early adulthood Starts in adulthood (>35), worsen over time 
Hx of hayfever,eczema, allergies, family Hx of heavy smoking (> 20 cigarettes/day) 
hx 
Symptoms only during attacks with SOB for most of the day. Daily cough 
periods of normal breathing Sputum prodn. starts long before SOB 
Worse at night; early morning; 
during a cold, weather changes; 
when@work 
Poorly controlled asthma if pts. are 
• awakened at night frequ ently because of asthma 
• using a bronchodilator frequently> 4xdaily 
Treatment: Oral Prednisone 40 mg dally x 14 days 
Check pts. inhaler technique. Recommend SPACER 
Shake MOl 
Fit MDI into spacer 
Breathe out 
Press down the pump once 
Immediate inhale from spacer mouthpiece 
Hold breath, count to lO 
Breathe out 
Rinse mouth 
Spacers carry a static electricity charge that causes drug to stick to the spacer wall. 
WASH spacer once a month (not everyday) using washing up liquid and allow it to 
drip dry. 
COPD Refer Page 14 guidelines manual 
COPD pts. have a history of cigarette smoking. Encourage pts. to stop smoking! 
Document tobacco use 
Detennine willingness to quit 
Suggest ways to reduce smoking 
Schedule follow-up visit 
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Assess severity of breathlessness during activity 
Infection (sputum =purulent, / 
color change to yellow /green) 
Ankle oedema (RHF) 
LRTI pneumonia 
Diagnose If 
• Cough + Difficult breathing 
IDhaled salbutamol/ipratropium 
bromide 
AmoxycilUn / Erythromycin 
+ Prednisone 40mg 
Refer ~ Diuretics 
Refer Page 5 guidelines manual 
• Chest pain on breathing I cough 
• Fever SEVERE ~ Refer 
Treatment 
Newl or t sputa prodn +colour change: AmoxycilUn / Erythromycin 
NO Smoking 
High fluid intake 
Paracetamol 
Follow-up after 1 wk 
Exclude TB: cough ~ 2 weeks, loss ofwt, night sweats, blood stained sputum, mv 
FLIP ••. SMOKING worsens lung diseases. More people stop smoking if 
encouraged by a health care professional. Smoking makes all 
respiratory conditions worse. 
6 
Nurses + Drs who encourage patients to quit smoking actually do 
sol Quit smoking today. 
Remind pts. about the hazards of smoking on every visit. 
• identify and document all tobacco use at each visit 
• strongly urge pt. to quit 
• determine willingness to quit 
• help the pt. to quit 
• schedule follow-up contact 
III 
Appendix 9: Consent forms for persons > 18years 
and < 18 years 

INFORMED CONSENT (!> 17 YEARS) 
PATIENT INFORMATION AND WRITTEN CONSENT FORM - PALS A 
VALIDATION STUDY (PATIENTS 12 YEARS AND UP TO AND INCLUDING 17 
YEARS OF AGE) 
Screening Number: § ___ _ 
Study Number: ___ _ 
Patlenfs Initials: ____ _ 
Your child is invited to participate in a researcn project. Before you agree to allow your child to 
participate you need to understand what it involves. 
Purpose of study 
Researchers from the UCT Lung Institute and Medical Research Council are studying patients who 
present to the Community Health Clinic with a complaint of difficult breathing and/or cough. 
The reason for doing this study is to test a new clinic plan to improve the treatment of respiratory 
diseases. We aim to see how well nurses can diagnose respiratory diseases using this new guideline. 
Do I have to participate In this study? 
Your child's participation in this study is voluntary. If you agree to allow him/her to take part, we require 
of you to sign this form. You are free to withdraw him/her from the study at any stage and this will in no 
way affect the way in which your child will be treated in the clinic today. Likewise, should we feel that 
further participation in the study would not be in your child's best interest we will withdraw him/her from 
the study. 
What will happen to me If I participate? 
The process may take longer than usual (usually less tan 2 hours). First, your child will be seen by a 
nurse who will record information about his/her medical history and current condition. She may record 
your child's temperature, and will examine him/her. Thereafter, your child will be escorted to another 
cubicle where he/she will be examined by a doctor. Information regarding medical history and their 
current condition will also be recorded. His/her blood pressure, temperature, weight, height, oxygen 
levels in the blood and lung function will be measured. In addition a chest x-ray may be done. If blood 
tests are considered advisable the reasons will be explained to you and your child and your further 
consent will be requested. 
What are the possible drawbacks or discomforts In participating In this study? 
Drawing of the blood samples may cause some discomfort. His/her stay at the community health centre 
may be longer than would have expected it to be. 
What are the possible benefits of partiCipating In this study? 
The information that we obtain from the study will help us improve the diagnosis and treatment of 
respiratory diseases by nurses at primary health care in South Africa. 
Will the Information remain confidential? 
Should you agree to allow your child to participate in the study all his/her records will be viewed by the 
study investigators and by a specialist physician. Their information will not be viewed by any other 
persons or parties not involved in this study. All the information will be safely stored on a computer and 
at the study site. At no time will anyone be able to link the information stored on the computer to your 
name. 
Contact details of the study staff 
Should you have any questions about the study, please ask any of the following research team. 
Name ________________________________ __ Phone Number ______________ _ 
Name ________________________________ __ Phone Number _______ _ 

INFORMED CONSENT (:5: 17 YEARS) 
WRITTEN INFORMED CONSENT FORM FOR PARENT OR LEGAL GUARDIAN 
Screening Number: § ___ _ 
Study Number: ___ _ 
Patient's Initials: _____ _ 
I ..................................................................................................... .. 
(Name of Patient and parent or legal guardian in block letters) 
have read and understood all the information given to me about my child's participation in this study and 
I have been given the opportunity to discuss it and ask questions. I voluntarily agree to allow my child to 
participate in this study and understand that I will receive a copy of this consent form. 
Signature of Parent or legal guardian Date 
Printed name of Parent or legal guardian 
Signature of Patient (if possible) Date 
Printed name of Patient 
I have explained the nature and purpose of the study to the Patient and Parent or legal guardian named 
above. 
Signature of Prlncipallnvestlgator or delegate Date 
Printed name of Principal Investigator or delegate 
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INFORMED CONSENT (s 17 YEARS) 
WRITTEN INFORMED CONSENT FORM FOR PATIENT REPRESENTATIVE 
Screening Number: ~ ___ _ 
Study Number: ___ _ 
Patlenr. Initials: ____ _ 
I •...................................................................................................... 
(Name of Patient and parent or legal guardian in block letters) 
have read and understood all the information given to me about my child's participation in this study and 
I have been given the opportunity to discuss it and ask questions. I voluntarily agree to allow my child to 
participate in this study and understand that I will receive a copy of this consent form. 
Signature of patient representative Date 
Printed name of patient representative 
Signature of Patient (if possible) Date 
Printed name of Patient 
I have explained the nature and purpose of the study to the Patient and Parent or legal guardian named 
above. 
Signature of Principal Investigator or delegate Date 
Printed name of Principal Investigator or delegate 
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INFORMED CONSENT (~ 18 YEARS) 
PATIENT INFORMATION AND WRITTEN CONSENT FORM - PALSA 
VALIDATION STUDY (PATIENTS 18 YEARS AND OLDER) 
Screening Number: ! ___ _ 
Study Number: ___ _ 
Patient's Initials: _____ _ 
You are invited to partiCipate in a research project. Before you agree to take part you need to 
understand what it Involves. 
Purpose of study 
Researchers from the UCT Lung Institute and Medical Research Council are studying patients who 
present to the Community Health Clinic with a complaint of difficult breathing and/or cough. 
The reason for doing this study is to test a new clinic plan to improve the treatment of respiratory 
diseases. We aim to see how well our nurses can diagnose respiratory diseases using this new 
guideline. 
Do I have to participate In this study? 
Your participation in this study is voluntary. If you agree to take part, we require of you to sign this form. 
You are free to withdraw from the study at any stage and this will in no way affect the way that you will 
be treated in the clinic today. 
What will happen to me If I partiCipate? 
The consultation process may take a little longer than usual (usually less than 3 hours». First, you will 
be seen by a nurse who will record information about your medical history and current condition. She 
may record your temperature, and will examine you. Thereafter, you will be escorted to another cubicle 
where you will be examined by a doctor. Information regarding your medical history and current 
condition will also be recorded. Your blood pressure, temperature, weight, height, oxygen levels in the 
blood and lung function will be measured. In addition a chest x-ray may be done. If blood tests are 
considered advisable the reasons will be explained to you and your further consent will be requested. 
What are the possible drawbacks or discomforts In participating In this studY? 
Drawing of the blood samples may cause some discomfort. Your stay at the community health centre 
may be longer than you would expect it to be. 
What are the possible benefits of participating In this studY? 
The information that we obtain from the study will help us improve the diagnosis and treatment of 
respiratory diseases by nurses at primary health care clinics in South Africa. 
Will the Information remain confidential? 
Should you agree to participate in the study all your records will be viewed by the study investigators 
and a specialist phYSician. Your information will not be viewed by any other persons or parties not 
involved in this study. All the information will be safely stored on a computer and at the study site. At no 
time will anyone be able to link the information stored on the computer to your name. 
Contact details of the study staff 
Should you have any questions about the study, please ask any of the following research members. 
Name ________________________________ _ Phone Number ______________ _ 
Name ________________________________ _ Phone Number ______________ _ 
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INFORMED CONSENT (~ 18 YEARS) 
WRITTEN INFORMED CONSENT FORM FOR PATIENT 
Screening Number: ~ ___ _ 
Study Number: ___ _ 
Patient Initials: ___ _ 
I ...................................................................................................... . 
(Name of Patient in block letters) 
have read and understood all the information given to me about my participation in this study and I have 
been given the opportunity to discuss it and ask questions. I voluntarily agree to take part in this study 
and understand that I will receive a copy of this consent form. 
Signature of Patient Date 
Printed name of Patient 
I have explained the nature and purpose of the study to the Patient named above. 
Signature of Principal Investigator or delegate Date 
Printed name of Principal Investigator or delegate 
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INFORMED CONSENT (~18 YEARS) 
WRITTEN INFORMED CONSENT FORM FOR PATIENT REPRESENTATIVE 
Screening Number: ~ ___ _ 
Study Number: ___ _ 
Patient Initials: __ _ 
(Name of Patient) 
has understood all the information given to him/her about this study and has been given the opportunity 
to discuss it and ask questions. This patient has voluntarily agree to take part in this study and 
understands that he/she will receive a copy cl this consent form. 
Signature of Patient Representative Date 
Printed name of Patient Representative 
I have explained the nature and purpose of the study to the Patient named above. 
Signature of PrincipallnvestJgator or delegate Date 
Printed name of Principal Investigator or delegate 
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Appendix 10: Nurse record form 
PATIENT NO"rES FOR PALSA NURSE 
Weight __ _ Sats: __ _ 
Height __ _ BP: ---
Temp: __ _ Pulse: __ 
RR: ---
Known Medical Conditions: 
1) __________________ __ 
2) __________________ __ 
3) ______________ _ 
4) _________________ __ 
Current Medication: 
1) _______________ _ 
2) _______________ _ 
3) __________ _ 
4) _________________ __ 
5) _________________ __ 
6) _________________ __ 
History, symptoms and signs: 
Comments: 
Screening no: __ 
Studyno: __ 
Initials: __ 
Occupation: _______ _ 
Gender: 
~--------Smoking History: _____ _ 
Appendix 11: Doctor record form 
Appendix 12: Specialist record form 
FINAL DIAGNOSIS 
(This form is to be completed by the Specialist Physician. File in the 
SPECIALIST PHYSICIAN'S FILE.) 
SCREENING NUMBER: S ___ _ STUDY NUMBER: ___ _ 
PATIENT INITIALS __ _ DATE: __ '-_/2 0 0 
FINAL DIAGNOSIS: 
PRIMARY PALSA CATEGORY: ____________ _ 
CERTAINTY OF DIAGNOSIS: 1 ---------------------------5 
SECONDARY PALSA CATEGORY: ____________ _ 
CERTAINTY OF DIAGNOSIS: 1 -----------------5 
TERTIARY CATEGORY: ____________ _ 
CERTAINTY OF DIAGNOSIS: 1 -----------------------------5 
aUARTENARY PALSA CATEGORY: ____________ _ 
CERTAINTY OF DIAGNOSIS: 1 ------------------------5 
PROPOSED MANAGEMENT PLAN: 
COMMENTS: 
REVIEW NEEDED: YES 0 NO 0 
REVIEWED BY DR/PROF __________ _ 

Appendix 13: Table listing key messages and 
barriers 
Diseases and Corresponding key messages Barrier Source data Form of Key 
Addressed messages 
TBandHIV 
Coughing ~ 2 weeks. Knowledge Brainstonning, Directive in 
Send sputa for TB. focus group words 
test for HIV because TB is common in HIV discussions 
patients. 
Cotrimoxazole prophylaxis delays symptoms and 
E!:olongs health}' life in HIV ~atients. 
Sputum collection Knowledge Focus group Visual: (cartoon 
and skills discussions or other gra~hic} 
Suspecting HIV/AIDS in patients with TB Knowledge Focus group Visual (cartoon 
and skills discussion or gra~hic} 
OBSTRUCTIVE LUNG DISEASE 
Diagnose asthma in patients with recurrent wheeze, Knowledge Brainstonning, Directive 
difficult breathing and cough. and skills focus group 
Prescribe inhaled corticosteroids (and refer for Physical discussion. 
doctor follow-up). resources 
Diagnose COPD in patients with persistent wheeze, 
difficult breathing and cough (and a history of smoking. 
Prescribe bronchodilators (and refer for doctor 
follow-u~. 
Instructions on how to use a spacer Knowledge Brainstorming, Visual: (cartoon 
and skills focus group or other graphic) 
discussion, lit. 
Spacers should be used with inhaled steroids because they Knowledge Brainstorming, Question 
increase drug delivery to the lung and reduce oral thrush and skills focus group prompt: ("did 
discussion, lit. }'ou know .. ?") 
Dose-puff converter Knowledge Brainstorming, Gimmick: 
and skills focus group (Special aid) 
discussion, lit. 
Asthma diagnostic guide KnOWledge Brainstorming, Gimmick: 
and skills focus group (Special aid) 
discussion, lit. 
RESPIRATORY TRACT INFECTIONS 
Diagnose LRTI in patients with: cough, plus difficult Knowledge Brainstorming, Directive in 
breathing, and/or pain on coughinglbreathing and or fever and skills focus group words 
If sever, refer. discussion, lit. 
In new or purulent sputum prescribe amoxicillin 
for 7 days. 
Follow-up in one week (sooner if getting worse) 
Diagnose URTI in patients with: 
Bocked or runny noses, and/or 
Sore throats, and/or 
Mild fever but 
No difficult breathing 
No chest pain 
- Prescribe symptomatic treatment only [antibiotics only if 
EUS on tonsils, in ears or nasal secretions.] 
Instructions on how to treat colds and flu Knowledge Brainstorming, Visual: (cartoon 
and skills focus group or other graphic) 
discussion, lit 
Reinforcing the differences between colds and flu Knowledge Brainstorming, Question 
and skills focus group prompt: ("did 
discussion, lit. ~ou know .. ?") 
Reinforcing that antibiotics are not to be prescribed for Knowledge Brainstorming, Question 
colds and flu. and skills focus group prompt: ("did 
discussion, lit. ~ou know?"~ 
